2013N172718_04 CONFIDENTIA L
The GlaxoSmithKline group of comp anies 200331
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: A Phase I, Open -Label, Dose -Finding Study of [COMPANY_004]2636771 
Administered in Combination with Enzalutamide (Xtandi) in 
Male Subjects with Metastatic Castration- Resistant Pros tate 
Cancer (mCRPC)
Compound Number: [COMPANY_004]2636771
Development Phase: I
Effective Date: 27-JAN-2017
Protocol Amendment Number:  04
Author (s):  
 
Copy right 2017 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited.
[COMPANY_003]
[COMPANY_003]
2013N172718_04 CONFIDENTIA L
The GlaxoSmithKline group of comp anies 200331
2Revision Chronology
GlaxoSmithKline 
Document Numb erDate Version
2013N172718_00 2014 -MAY -22 Original
2013N172718_01 2014 -SEP-08 Amendment No. 1
Amendment 1 incorporates changes to Section 5.2, Permanent Discontinuation of Study  
Treatment(s) for clarification as requested b y the Medicines and Healthcar e products 
Regulatory  Agency  (MHRA) in the [LOCATION_008]
2013N172718_02 2015 -FEB-26 Amendment No. 2
Amendment 2 was completed to include the following changes:
Allow [ADDRESS_367682] within the study  to 
ensure sufficient time for completion of pre -screening and screening assessments
Clarify  and define the 14 -day treatment with enzalutamide monotherapy  prior to 
the addition of [COMPANY_004]263771 as the “Enzalutamide Run -In Period”, that the 
Enzalutamide Run -In Period is to follow completion of pre -screening and 
screening rather than be concurrent with screening, and other administrative 
changes needed as a result of defining the Enzalutamide Run -in Peri od (e.g., 
specify  collection of adverse events [AEs] during the Enzalutamide Run -In Period 
and that enzaluitmide will be provided during the Enzalutamide Run -In Period)
Added an assessment for genetic research
Add parath yroid hormone assessments at baseli ne and in the event of Grade 2 or 
higher h ypocalcemia or hy pophosphatemia 
Add updated standard GlaxoSmithKline protocol language for specific AEs (i.e., 
liver chemistry  stoppi[INVESTIGATOR_3418]).
Removed androgen receptor antagonists from the list of prohibite d medications 
and other changes to lists of medications to avoid or use with caution
The remaining changes are largely  administrative, and intended to provide additional 
clarification or to correct inadvertent errors
2013N172718_03 2016 -JUN-24 Amendment N o.3 
Amendment 3 was completed to update the risk assessment section and to include 
additional requirements for monitoring of renal events.  Optional pharmacodynamics 
paired biopsies as well as clarifications around biomarker assessments were added to the
Time and Events tables for the Dose Escalation and Dose Expansion Phases.  Additional 
2013N172718_04 CONFIDENTIA L
The GlaxoSmithKline group of comp anies 200331
3language was added to clarify  that:
Subjects with disease progression defined b y PSA progression alone or for the 
worsening of an isolated disease site that is not clini cally  significant are not 
required to discontinue treatment in the study ,
The decision to terminate the Dose Expansion Phase will take into account all 
relevant factors, including but not soley  based upon the statistical methodogy  and 
futility  criterion.
Other minor clarifications were also added.   
2013N172718_04 2017 -JAN-27 Amendment No. 4
Amendment 4 was completed to include the following: 
Additional requirements for monitoring of events related to calcium results. This 
includes revisions to the Tabl e & Events to clarify additional laboratory  testing 
requirements
Clarification of secondary clinical activity  endpoints and update to associated 
statistical section(s)
Revision of clinical activity  population to allow analy ses to occur using a 
combination of dose escalation and dose expansion populations
Revision of dose escalation and dose expansion wording to move into dose 
expansion with a MTD or lower dose level and to clarify  that multiple dose levels 
may be examined in the dose expansion phase to est ablish RP2D after dose 
expansion phase
Adjustment to Week [ADDRESS_367683] timing of disease 
assessments for this visit after actual 12 weeks on combination treatment
Revision to reflect current indication for enzalutamide throughout the d ocument
Clarification of study  populations
Clarification of bone progression definition
Other minor clarifications and corrections of inadvertent errors were also added
[COMPANY_003]
[COMPANY_003]

2013N172718_04 CONFIDENTIA L
200331
5SPONSOR INFORMA TION PAGE
Sponsor Legal Registered Address :
GlaxoSmithKline Research & Development Limited
Iron Bridge Road 
Stockley  Park West, Uxbridge, Middlesex, UB11 1BU, [LOCATION_006]
Telephone:  
GlaxoSmithKline Research & Development Limited
[ADDRESS_367684]
Collegeville, PA [ZIP_CODE], [LOCATION_003]
Telephone:
GlaxoSmithKline Research & Development Limited
Five Moore Drive 
P.O. [ZIP_CODE]
Research Triangle Park, NC [ZIP_CODE]- 3398, [LOCATION_003]
Telephone:
In some countr ies, the clinical trial sponsor may  be the local GlaxoSmithKline affiliate 
compan y (or designee). Where applicable, the details of the Sponsor and contact [CONTACT_23957].
Sponsor Medical Monitor Contact [CONTACT_301145] -
hours 
Phone/ 
Cell/
Pager 
NumberFax 
Number[COMPANY_004] Address
Primary 
Medical 
Monitor, 
MD, PhDGlaxoSmithKline
[ADDRESS_367685]
Collegeville, PA [ZIP_CODE], [LOCATION_003]
Regulatory  Agency  Identifying Numbers:
Investigational New Drug (IND) No: [ADDRESS_367686] No: [ADDRESS_367687] to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
[CONTACT_132026]:
Investigator Phone Number:
Investigator Signature [CONTACT_1782]
2013N172718_04 CONFIDENTIA L
[ADDRESS_367688] OF ABBREVIATION S................................ ................................ ........................... 12
PROTOCOL SYNOPSIS ................................ ................................ ............................... 16
1.INTRODUCTION ................................ ................................ ................................ ....32
1.1. Metastatic Castr ation -Resistant Prostate Cancer ................................ ........ 32
1.2. [COMPANY_004]2636771 ................................ ................................ .............................. 33
1.2.1. Clinical Safety, Pharmacokinetic Data, and Clinical Activity 
of [COMPANY_004]2636771 ................................ ................................ ........... 33
1.3. Enzalutamide (Xtandi) ................................ ................................ ................. 34
1.3.1. Clinical Safety, Pharmacokinetic Data, and Clinical Activity 
of Enzalutamide ................................ ................................ ........... 34
1.4. Summary of Risk Management ................................ ................................ ...35
1.4.1. Risk Assessment ................................ ................................ ......... 36
[IP_ADDRESS]. [COMPANY_004]2636771 ................................ .............................. 36
[IP_ADDRESS]. Enzalutamide ................................ .............................. 38
[IP_ADDRESS]. Potential Overlappi[INVESTIGATOR_70034] ................................ ..38
[IP_ADDRESS]. Risk of Drug -Drug Interaction ................................ .....38
1.4.2. Benefit Assessment ................................ ................................ .....39
1.4.3. Overall Benefit:Risk Conclusion ................................ ................... [ADDRESS_367689] AWAL OF SUBJECTS ................................ ............... 56
5.1. Screen Failures ................................ ................................ ........................... 56
5.2. Perman ent Discontinuation of Study Treatment(s) ................................ ......[ADDRESS_367690] Accountability ................................ ................................ ................ 62
6.6. Treatment Compliance ................................ ................................ ................ 63
6.7. Treatment of Study Treatment Overdose ................................ .................... 63
7.DOSE MODIFICATIONS, STOPPI[INVESTIGATOR_301051] D MANAGEMENT 
GUIDELINES ................................ ................................ ................................ ......... 63
7.1. Dose Modifications ................................ ................................ ..................... 64
7.1.1. [COMPANY_004]2636771 ................................ ................................ ............... 64
7.1.2. Enzalutamide ................................ ................................ ............... 64
7.2. Stoppi[INVESTIGATOR_2121] ................................ ................................ ......................... 65
7.2.1. QTc Stoppi[INVESTIGATOR_2121] ................................ ................................ ..65
7.2.2. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................ ................ 65
[IP_ADDRESS]. Liver Chemistry Stoppi[INVESTIGATOR_301052] ≤2.5xULN ................................ ................ 65
[IP_ADDRESS]. Liver Ch emistry Stoppi[INVESTIGATOR_301053]/Tumor 
Infiltration at Baseline AND entry criteria 
ALT>2.5xULN but ≤5xULN ................................ ......... 67
[IP_ADDRESS]. Liver Safety Required Actions and Follow-up............. 68
7.2.3. Left Ventricular Ejection Fraction (LVEF) Stoppi[INVESTIGATOR_2121] .......... 70
7.2.4. Valvular Toxicity Stoppi[INVESTIGATOR_2121] ................................ ............... 71
7.3. Management Guidelines for Specific Events Associated with 
[COMPANY_004]2636771 ................................ ................................ .............................. 72
7.3.1. Renal Insufficiency or Other Renal Events ................................ ...72
[IP_ADDRESS]. Parathyroid Hormone (PTH) ................................ .......75
7.3.2. Cardiac -related Toxicities ................................ ............................ 75
[IP_ADDRESS]. Hypertension ................................ .............................. 75
2013N172718_04 CONFIDENTIA L
200331
97.3.3. Rash ................................ ................................ ............................ 76
7.3.4. Diarrhea ................................ ................................ ....................... 77
7.3.5. Vomiting ................................ ................................ ...................... 83
8.STUDY ASSESSMENTS AND PROCE DURES ................................ ..................... 83
8.1. Time and Events Tables ................................ ................................ ............. 84
8.2. Consent ................................ ................................ ................................ ......97
8.2.1. Consent for Pre -Screening ................................ .......................... 97
8.2.2. Consent for Screening ................................ ................................ .97
8.3. Pre-Screening and Screening ................................ ................................ .....97
8.3.1. Pre-Screening:  Determination of PTEN Deficiency Status .......... 97
8.3.2. Screening ................................ ................................ .................... 98
8.4. Demographics and Medi cal History ................................ ............................. 98
8.5. Critical Baseline Assessment ................................ ................................ ......98
8.6. Safety ................................ ................................ ................................ ......... 98
8.6.1. Physical Examination ................................ ................................ ...98
8.6.2. Vital Signs ................................ ................................ .................... 99
8.6.3. ECOG Performance Status ................................ .......................... 99
8.6.4. Electrocardiogram ................................ ................................ ........ 99
8.6.5. Echocardiogram and/or Multi -gated Acquisition (MUGA) 
Scans ................................ ................................ .......................... 99
8.6.6. Laboratory Ass essments ................................ ........................... 100
8.7. Pharmacokinetic Assessments ................................ ................................ .101
8.7.1. PK Assessments: Dose Escalation Phase ................................ .101
8.7.2. PK Assessments:  Dose Expansion Phase ................................ 102
8.7.3. PK Blood Sample Collection ................................ ...................... 102
[IP_ADDRESS]. Additional PK Blood Sample Collection .................... 103
8.7.4. Pharmacokinetic Sample Analysis ................................ ............. 104
8.7.5. Meals, Alcohol, Tobacco and Activity Restrictions ..................... 104
8.8. Clinical Activity ................................ ................................ .......................... 104
8.8.1. Clinical Activity Endpoints ................................ .......................... 105
8.8.2. Disease Assessment ................................ ................................ .105
[IP_ADDRESS]. PSA Response per PC WG2 Criteria ......................... 105
[IP_ADDRESS]. Radiographic Response per PC WG2 Criteria ........... 105
[IP_ADDRESS]. Disease Progression Endpoint ................................ .106
8.9. Translational Researc h................................ ................................ ............. 106
8.9.1. Predictive Biomarkers ................................ ................................ 106
8.9.2. Tumor Biopsies for PD and Disease Progression ...................... 107
8.9.3. Circulating Tumor Cells ................................ .............................. 107
8.9.3 .1. CTC Conversion Rate ................................ .............. 107
8.9.4. Circulating Cell Free DNA, RNA and Soluble Markers ............... 107
8.10. Genetic Research ................................ ................................ ..................... 108
8.11. Exploratory Pharmacokinetic and Pharmacodyn amic Analysis ................. 108
9.ADVERSE EVENTS AND S ERIOUS ADVERSE EVENT S................................ ...108
9.1. Definition of an AE ................................ ................................ .................... 108
9.2. Definition of an SAE ................................ ................................ .................. 109
9.2.1. Sentinel Events ................................ ................................ .......... 110
9.3. Laboratory and Other Safety Assessment Abnormalities Reported 
as AEs and SAEs ................................ ................................ ..................... 111
9.3.1. Cardiovascular Events ................................ ............................... 111
9.3.2. Death Events ................................ ................................ ............. 112
2013N172718_04 CONFIDENTIA L
200331
109.4. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualifying as SAEs ................................ ................................ ................... [ADDRESS_367691] ing AEs and SAEs ................................ ........... 113
9.5.2. Prompt Reporting of SAEs and Other Events to [COMPANY_004] ................ 113
9.5.3. Regulatory Reporting Requirements for SAEs ........................... 115
9.6. Reporting of Pregnancy ................................ ................................ ............ 115
10.CONCOMITANT MEDICATI ONS AND NON -DRUG THERAPI[INVESTIGATOR_5165] ....................... 115
10.1. Permitted Medications ................................ ................................ .............. 116
10.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ................................ ......116
10.2.1. Potential Drug Interactions with [COMPANY_004]2636771 ........................... 117
[IP_ADDRESS]. [COMPANY_004]2636771 as Perpetrator of Drug -Drug 
Interactions ................................ ............................... 117
[IP_ADDRESS]. [COMPANY_004]2636771 as Victim of Drug -Drug 
Interactions ................................ ............................... 118
10.2.2. Potential Drug Interactions with Enzalutamide ........................... 118
11.LIFESTYLE RESTRICTIO NS................................ ................................ ............... 120
11.1. Contraception Requirements ................................ ................................ ....120
11.2. Other:  L ight Sensitivity and Allergens ................................ ...................... 120
11.3. Other: Hydration ................................ ................................ ....................... 121
12.DATA MANAGEMENT ................................ ................................ ......................... 121
13.DATA ANALYSIS AND STATISTICAL CONSIDERATIONS ................................ .121
13.1. Hypotheses ................................ ................................ ............................... 121
13.1.1. Dose Escalation Phase ................................ .............................. 121
13.1.2. Dose Expansion Phase ................................ .............................. 121
13.2. Sample Size Determination ................................ ................................ ......122
13.2.1. Dose Escalation Phase ................................ .............................. 122
13.2.2. Dose Expansion Phase ................................ .............................. 122
13.3. Data Analysis Considerations ................................ ................................ ...123
13.3.1. Analysis Populations ................................ ................................ ..123
13.3.2 .Analysis Data Sets ................................ ................................ .....123
13.3.3. Interim Analysis ................................ ................................ ......... 123
[IP_ADDRESS]. Dose Escalation Phase ................................ ............ 123
[IP_ADDRESS]. Dose Expansion Phase ................................ ............ 123
13.3.4. KeyElements of Analysis Plan ................................ .................. 124
[IP_ADDRESS]. Efficacy Analyses ................................ ..................... 124
[IP_ADDRESS]. Safety Analyses ................................ ........................ 126
[IP_ADDRESS].1. Extent of Exposure ............................... 126
[IP_ADDRESS] .2.Adverse Events ................................ ....126
[IP_ADDRESS].3. Clinical Laboratory Evaluations ............. 126
[IP_ADDRESS].4. Other Safety Measures ......................... 127
[IP_ADDRESS]. Pharmacokinetic Analyses ................................ ........ 127
[IP_ADDRESS]. Pharmacokinetic/Pharmacodynamic Analyses ......... 127
[IP_ADDRESS]. Translational Research Analyses ............................. [ADDRESS_367692] CONSIDERATIONS ................................ ............................. 128
14.1. Posting of Information on Publicly Available Clinical Trial Registers .......... 128
2013N172718_04 CONFIDENTIA L
[PHONE_6251].2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ................................ ................................ ...................... 129
14.3. Urgent Safety Measures ................................ ................................ ........... 129
14.4. Quality Control (Study Monitoring) ................................ ............................ 129
14.5. Quality Assurance ................................ ................................ ..................... 130
14.6. Study and Site Closure ................................ ................................ ............. 130
14.7. Records Retention ................................ ................................ .................... 131
14.8. Provision of Study Results to Investigators, Posting of Information 
on Publicly Available Clinical Trials Registers and Publication .................. 131
15.REFERENCES ................................ ................................ ................................ .....132
16.APPENDICES ................................ ................................ ................................ ......135
16.1. Appendix 1:  ECOG Performance Status ................................ .................. 135
16.2. Appendix 2:  NYHA Functional Classification System ............................... 136
16.3. Appendix 3:  CKD -EPI [INVESTIGATOR_10908] ................................ ................................ 137
16.4. Appendix 4:  Disease Assessment per RECIST 1.1 ................................ ..138
16.5. Appendix 5:  Urine Protein Creatinine (UPC) Ratio ................................ ...146
16.6. Appendix 6:  Liver Safety Drug Restart/Rechallenge Guideline s............... 147
16.7. Appendix 7:  Genetic Research ................................ ................................ 150
16.8. Appendix 8:  Country Specific Requirements ................................ ............ 153
16.9. Appendix 9:  Protocol Amendment Changes ................................ ............. 154
16.9.1. Protocol Changes for Amendment 1 (08 -Sep-2014) from 
Original Protocol (22 -May-2014) ................................ ................ 154
16.9.2. Protocol Changes for Amendment 2 (26 -Feb-2015) from 
Protocol Amendment 1 (08 -Sep-2014) ................................ ....... 154
16.9.3. Protocol changes for Amendment 3 (24 -Jun-2016) from 
Protocol Amendment 2 (26 -Feb-2015) ................................ ....... 208
16.9.4. Protocol changes for Amendment 4 (27 -Jan-2017) from 
Protocol Amendment 3 (24 -Jun-2016) ................................ ....... [ADDRESS_367693] OF A BBREVIATIONS
C Degrees Celsius
F Degrees Fahrenheit
ADP Adenosine diphosphate
AE Adverse Event
ALT Alanine aminotransferase
ANC Absolute neutrophil count
AR Androgen receptor
ASCO American Societ y of Clinical Oncology
AST Aspartate aminotransferase
ATP Adenosine triphosphate
AUC Area under the concentration -time curve
AUC(0 -t) Area under the concentration -time curve from zero over the dosing 
interval
AUC(0 -τ) Area under the concentration -time curve from zero to the las t quantifiable 
blood or plasma concentration
AUC(0 -24) Area under the concentration -time curve from zero (pre -dose) to [ADDRESS_367694] cancer resistant protein
BP Blood pressure
BUN Blood urea nitrogen
C24 Trough concentrat ion
CBC Complete blood count
cfDNA Circulating -free tumor DNA
CI Confidence Interval
CL/F Oral clearance
Cmax Maximum observed concentration
CO [ADDRESS_367695] time in human
g Gram
GCP Good Clinical Practice
GI Gastrointestinal
GnRH Gonadotropin releasing hormone
[COMPANY_004] GlaxoSmithKline
h/hr Hour(s)
HBsAg Hepatitis B surface antigen
HIV Human immunodeficiency virus
HLA Human leukocy te antigen
HPL C High performance liquid chromatograph y
IB Investigator’s Brochure
IBW Ideal bod y weight
ICF Informed consent form
ICH International Conference on Harmonization 
IDSL International Data Standards L ibrary
IEC Independent Ethics Committee
IgG or M Immunoglobulin G or M
IHC Immunohistochemistry
IMP Investigational medicinal product
IND Investigational New Drug
INPP4B Inositol poly phosphate -4-phosphatase t ype II
INR International Normalized Ratio
IP Investigational product
IR Immediate release
IRB Institutional Review Board
IV Intravenous
ka Absorption rate constant
kg Kilogram
L Liter
LCH Langerhans cell histiocy tosis
LDH Lactate dehy drogenase
LHRH Luteinizing hormone releasing hormone
LLN Lower limit of normal
LOH Loss of heteroz ygosity
LVEF Left ventricular ejection fraction
M Mandatory
MCH Mean corpuscular hemoglobin
mCRPC Metastatic castration -resistant prostate cancer
2013N172718_04 CONFIDENTIA L
[ADDRESS_367696]
ORR Objective Response Rate
OTC Over -the-counter
P-gp P-glycoprotein
pAKT Phosphory lated AKT
PCR Polymerase chain reaction
PCWG2 Prostate Cancer Working Group 2
PCWG 3 Prostate Cancer Working Group 3
PD Pharmacod ynamic or progressive disease
PET Positron emission tomograph y or probability of early termination
Pgp P-glycoprotein
PHL PP PH and leukine -rich repeat protein phosphatase (a negative regulator of 
AKT)
PI3K Phosphoinositide 3 -kinase
PI3KCA Phosphatidy linositol -4,5-bisphosphate 3 -kinase, cataly tic subunit alpha
PI3KR1 Phosphoinositide -3-kinase, regulatory  subunit 1 (alpha)
PI3KR3 Phosphoinositide -3-kinase, regulatory  subunit 3 (gamma)
PI3Kβ Phosphoinositide 3 -kinase beta
PK Pharmacokinetic
PR Partial response
PRP Platelet rich plasma
PSA Prostate -specific antigen
PSA50 Prostate -specific antigen decrease from baseline ≥50%
2013N172718_04 CONFIDENTIA L
200331
15PT Prothrombin time
PTEN Phosphatase and tensin homolog
PTH Parathy roid hormone
PTS-DMPK Platform Technology  and Science –Drug Metabolism and 
Pharmacokinetics
PTT Partial thromboplastin time
QTc Corrected QT interval 
QTcB QT interval corrected b y Bazett’s formula
QTcF QT interval corrected b y Fridericia’s formula
RAP Reporting and Anal ysis Plan
RBC Red blood cell
RECI ST Response Evaluation Criteria In Solid Tumors
RNA Ribonucleic acid
RP2D Recommended Phase II dose
rPFS Radiological progression free survival
RR Response rate
SAE Serious adverse eve nt(s)
SBP Systolic blood pressure
SD Stable disease or standard deviation
SRM Study  Reference Manual
t1/[ADDRESS_367697] Upper limit of normal
UPC Urine protein to creatinine 
US [LOCATION_002]
V/F Oral volume of distribution
WBC White blood cells
Wk(s) Week(s)
WNL Within normal limits
Yr Year
Trademark Information
Trademarks of the GlaxoSmithKline 
group of compani esTrademarks not owned by [CONTACT_301146]
2013N172718_04 CONFIDENTIA L
200331
16PROTOCOL SYNOPSIS
TITLE A Phase I, Open -Label, Dose -Finding Study of [COMPANY_004]2636771 Administered in 
Combination with Enzalutamide (Xtandi) in Male Subjects w ith Metastatic 
Castration -Resistant Prostate Cancer (mCRPC)
PROTOCOL 
NUMBER200331
CLINICAL PHASE I
COMPOUND [COMPANY_004]2636771
STUDY 
RATIONALEDespi[INVESTIGATOR_301054], 
relapses are inevitable and metastatic castrat ion-resistant prostate cancer 
(mCRPC) carries considerable morbidity along with shortened survival.  
Previous studies have indicated the importance of the phosphoinositide 
3-kinase (PI3K) pathway in prostate cancer.  A common event in prostate 
cancer progr ession is the loss of tumor suppressor phosphatase and tensin 
homolog (PTEN) in 40 -50% of mCRPC patients that results in the activation of 
the PI3K pathway.  The choice of subject populations represented in this 
study is based on the hypothesis that activa tion of the PI3K pathway in 
mCRPC will result in increased sensitivity to the combination and thus 
subjects will be selected on the basis of PTEN deficiency.
Therapeutic approaches that simultaneously inhibit both the androgen 
receptor (AR) pathway and the PI3K pathway may be more effective than 
inhibition of either pathway alone in mCRPC.  Enzalutamide is an AR inhibitor 
indicated for the treatment of patients with mCRPC.  The proposed Phase I 
study will evaluate the safety and tolerability, pharmacokineti cs (PK), and 
clinical activity to determine the recommended Phase II dose (RP2D) and 
regimen of [COMPANY_004]2636771 in combination with enzalutamide given orally in 
adult male subjects with mCRPC.
STUDY 
OBJECTIVES, 
ENDPOINTS 
AND 
HYPOTHESESPrimary Hypothesis:  The addition of a targeted PI3K pathway inhibitor 
([COMPANY_004]2636771) to enzalutamide treatment can be safely administered with 
ongoing enzalutamide treatment.
Secondary Hypothesis:  The addition of a targeted PI3K pathway inhibitor 
([COMPANY_004]2636771) to enzalutamide can limit mCPRC progression in a clinically 
meaningful way for at least 12 weeks.  The null hypothesis is that the 12 -week 
non-progressive disease (PD) rate is not attractive ( ≤5%).  The alternative 
hypothesis is that the rate is clinically meaningful and, th erefore, the 
compound warrants further development ( ≥30%).  This hypothesis will be 
tested for Part 2 of the study , combining eligible subjects from Part 1. 
2013N172718_04 CONFIDENTIA L
200331
17STUDY 
OBJECTIVES, 
ENDPOINTS 
AND 
HYPOTHESES 
continuedObjectives Endpoints
Primary
To assess the safety and 
tolerability of [COMPANY_004]2636771 + 
enzalutamide administered 
orally once daily continuously 
in subjects with mCRPC.Adverse Events(AE), 
Serious Adverse Events
(SAE) , Dose Limiting 
Toxicitie s(DLTs) , and 
changes in laboratory values, 
Electrocardiograms (E CGs), 
and vital signs (B lood 
Pressue [BP] , temperature 
and heart rate)
To determine the RP2D of 
orally administered 
[COMPANY_004]2636771 + enzalutamide 
in subj ects with mCRPC.Safety and tolerability as 
assessed by [CONTACT_2695], SAEs, 
DLTs, and changes in 
laboratory values, ECGs, and 
vital signs (BP, temperature 
and heart rate)
To evaluate lack of 
progression in the dose 
expansion subjects with  
mCPRC by [CONTACT_301147] 
12weeksNon-PD rate for 12 weeks 
according to PCWG2 criteria 
(either by R esponse 
Evaluation Criteria In Solid 
Tumors [RECIST] 1.1, or 
progression in bone or 
Prostate Specific Antigen 
[PSA] progression with 
accompanying progressi on 
by [CONTACT_393] 1.1 or bone scan
when baseline radiological or 
bone disease present or PSA 
progression if no other 
baseline disease ).
Secondary
To evaluate the clinical 
activity of oral [COMPANY_004]2636771 
+ enzalutamide in the 
treatment of mCRPC (PTEN 
deficient)PSA50 response rate defined 
as the percent of subjects 
achieving PSA50 at 12 
weeks or thereafter (PSA50
is ≥50% decrease in PSA 
from baseline)
Objective Response Rate 
(ORR) defined as complete 
response (CR) rate plus 
partial response (PR) rate 
per RECIST 1.1 
Time to PSA progression 
according to PCWG2 criteria
2013N172718_04 CONFIDENTIA L
200331
18STUDY 
OBJECTIVES, 
ENDPOINTS 
AND 
HYPOTHESES 
continuedTime to radiological 
progression according to 
PCWG2 criteria (either by 
[CONTACT_393] 1.1, and/or 
progression in bone)
Radiological progression free 
survival (rPFS) per 
RECIST1.1 and/or bone 
scans
To determine the effect of 
[COMPANY_004]2636771 on 
enzalutamide PK following 
repeat -dose oral 
administration.Plasma co ncentrations of 
enzalutamide and 
N-desmethyl enzalutamide.
To determine the PK of 
[COMPANY_004]2636771 in the presence 
of enzalutamide.Blood [COMPANY_004]2636771 
concentrations.
Exploratory
To determine the frequency 
of PTEN deficiency in 
subjects with mCRPCFrequency of PTEN -deficient 
mCRPC reported in subjects 
based on pre -screened 
tumors
To determine the mechanism 
of PTEN deficiencyPTEN deletion, mutation or 
promoter methylation
To identify additional 
biomarkers (DNA, RNA or 
protein based) in tumor or in 
circul ation that may predict 
response to oral 
[COMPANY_004]2636771 + enzalutamide Response prediction 
biomarkers based on 
analysis of DNA, RNA, and 
proteins from surrogate 
tissues (e.g., cfDNA) and/or 
tumor tissue
To determine the effect of 
enzalutamide with 
[COMPANY_004]2636771 on the kinetics 
of tumor growthLongitudinal tumor size 
measurements; serum PSA 
levels, change from baseline 
in CTCs
Evaluation of biomarkers in 
CTCs that may predict 
response to combinationAR expression, PTEN FISH 
and other genomic 
evaluations in CTCs
Evaluation of tumor tissue to 
explore explanation for the 
mechanism of resistance to 
combination therapyBased on analysis of DNA, 
RNA and proteins from tumor 
tissue obtained at time of 
progression after initially 
responding to combination 
therapy
To determine 
pharmacodynamic effects of 
drug treatmentRNA/protein analysis of 
pre/post treatment tumor 
biopsies 
2013N172718_04 CONFIDENTIA L
200331
19Abbreviations: AEs, adverse events; AR, androgen receptor; BP, blood pressure; cfDNA, 
circulating -free deoxyribonucleic acid; CTC, circulating tumor cells; DLTs, dose limiting 
toxicities; DNA, deoxyribonucleic acid; ECG, electrocardiogram; FISH, fluorescent in situ 
hybridization; mCRPC, metastatic castration -resistant prostate cancer; PCWG2, Prostate 
Cancer Working Group 2; PD, progressive disea se; PK, pharmacokinetics; PSA, prostate -
specific antigen; PTEN, phosphatase and tensin homolog; RECIST, Response Evaluation in 
Solid Tumors; RNA, ribonucleic acid; RP2D, recommended Phase II dose; SAE, serious 
adverse event(s)
STUDY DESIGN This is a Phase I, open -label, non -controlled, non -randomized, dose -finding, 
multicenter study to determine the RP2D of the oral PI3K beta (PI3K ) 
inhibitor, [COMPANY_004]2636771 in combination with enzalutamide in subjects with 
mCRPC.
Pre-Screening and Screening:   Subjects will b e required to undergo pre -
screening to determine the PTEN status of their tumor.  Details regarding the 
PTEN requirements are provided in the Study Reference Manual.  Subjects 
will sign a separate Informed Consent Form (ICF) to allow for pre -screening of 
archived tumor tissue or tumor tissue from a fresh tumor biopsy.
Subjects will be required to sign another ICF for the main study at Screening 
prior to initiation of any screening procedures or assessments. Screening 
assessments will be conducted to determi ne subject eligibility for enrollment 
into the study.
Dose Escalation Phase
Enzalutamide Run -In Period (Days 1 -14):  Approximately 24 subjects will be 
enrolled in the 14 -day run -in period and receive enzaluta mide monotherapy at 
the approved dose of 160 mg once daily.
Combination Treatment Period (Weeks 1 -4):  Subjects who complete the 
Enzalutamide Run -In Period will begin oral [COMPANY_004]2636771 treatment on 
Week 1, Day 1 of the Combination Treatment Period while cont inuing to 
receive enzalutamide to evaluate safety of the combination therapy.
The combination dose will be studied following a 3+3 dose modification 
procedure.  Additional doses may be explored based upon ongoing 
assessment of safety and PK.  Dose escalati on decisions will be made 
utilizing all available data at the end of the Dose Limiting Toxicity (DLT) 
reporting period (the first 28 days of combination treatment).
The starting dose of [COMPANY_004]2636771 is 300 mg once daily.  The enzalutamide 
dose will remain fi xed at 160 mg once daily.  Additional dose levels of each 
study treatment may be explored based upon ongoing assessment of safety 
and PK.  Dose modification decisions will be made utilizing all available safety 
and PK data at the end of the DLT reporting p eriod (the first 28 days of 
combination treatment).
A minimum of 3 subjects may be enrolled in each subsequent cohort until the 
maximum tolerated dose (MTD) is defined.  Evaluation of at least [ADDRESS_367698] completed 28 days of combination treatment is required prior to 
dose escalation to the next cohort.  Dose escalation will proceed with the 
increment of the [COMPANY_004]2636771 dose increase determined by [CONTACT_301148].
3+3 Dose Escalation Guidelines Based on Toxicity
Number of 
Subjects with a 
DLT Action
0 out of 3 subjects Escalate to next dose level.
1 out of 3 subjects Accrue 3 additional subjects at current dose 
level for a total of 6 subjects
1 out of 6 subjects Escalate to the next dose level. 
2 or more subjects in 
a dosing cohort (up 
to 6subjec ts)Dose escalation will be stopped.  At this 
dose level, the MTD has been exceeded 
(highest dose administered).  Either evaluate 
at a lower intermediate dose (3+3 dosing) or 
expand a prior cohort up to approximately 
20subjects per treatment arm.
Abbrevi ations: DLT, dose limiting toxicity; MTD, maximum tolerated dose
If the combination doses in Cohort 1 are not tolerable, lower doses as defined 
in the de -escalation cohort (Cohort -1) will be evaluated.   If the de -escalation 
cohort (Cohort -1) is not tolerable, further dose escalation using a continuous 
daily dosing schedule for both compounds simultaneously will be terminated.
Dose escalation will proceed until the MTD of the combination regimen is 
identified.  If the dose(s) administered to a given cohort exceeds the MTD, 
intermediate doses may be explored.  Dose escalation decisions will take into 
account all available data, including the safety profile and PK data of prior 
cohorts throughout the time subjects are on study, which will be reviewed by 
[CONTACT_093](s), GlaxoSmithKline ([COMPANY_004]) Medical Monitor, 
pharmacokineticist and statistician.  In the absence of DLTs, the dose of 
[COMPANY_004]2636771 may be escalated to the MTD of [ADDRESS_367699]-time-in-human study (P3K115717).
If diarrhea (in the absence of aggressive diarrhea management), fatigue or 
rash defines the MTD, the cohort in which the toxicity is observed may be 
expanded by [CONTACT_2669] 3 subjects and the efficacy of supportive care eva luated 
prior to further dose escalation.  If supportive care measures ameliorate the 
toxicity without recurrence of the toxicity, further dose escalation may be 
conducted in the presence of appropriate supportive care.
Treatment Continuation Period (Week 5 and thereafter):  Subjects will 
continue to receive the combination treatment of [COMPANY_004]2636771 + 
enzalutamide until criteria are met for discontinuation of study treatment.
2013N172718_04 CONFIDENTIA L
200331
21STUDY DESIGN
continued
Dose Escalation Cohorts
Cohort N [COMPANY_004]2636771 Enzalutamide
-1 3 -6 200 mg once dail y 160 mg once daily
1 3 -6 300 mg once daily 160 mg once daily
2 3 -6 400 mg once daily 160 mg once daily
Cohort Expansion:  Selected dose levels may enroll up to 12 additional 
subjects to ensure a sufficient number of subjects enrolled to assess PK 
and/or safety.  The MTD may be the recommended dose combination for 
future Phase II studies unless there is a lower dose of [COMPANY_004]2636771 that 
provides adequate PK exposure and biologic activity with superior tolerability.
The final decision will be based on the totality of data. 
Alternate dose levels and schedules may also be explored based on 
emerging safety, PK or PD data.
Definition of DLT:   An event will be considered a DLT if the event is 
attributed ( definitely, probably or possibly) to study treatment, occurs within 
the first 28 days of combination treatment (DLT reporting period), and meets 
one of the following criteria:
Grade 3 or greater non -hematologic toxicity that cannot be controlled 
with rout inesupportive measures (e.g., anti -emetics, anti -diarrheals)
Grade 4 neutropenia lasting >5 days
Febrile neutropenia, of any grade or duration as defined by [CONTACT_301149] 4.0 (CTCAE v4.0)
Grade 4 thrombocytopenia
Alanine aminotransferase (ALT) ≥3 times upper limit of normal (ULN) 
(or ALT ≥[ADDRESS_367700] and ≥1.5 times baseline ALT value, if enrolled 
with liver metastases/tumor infiltration at baseline) and bilirubin 
≥2times ULN
Any Grade 2 or greater toxicity per CTCAE v4.0 that that occurs beyon d the 
28-day DLT reporting period which in the judgment of the investigator and 
[COMPANY_004] Medical Monitor would be considered dose limiting
NOTE: Subjects who fail to receive at least 75% of protocol -specified study 
treatment during the DLT reporting period (the first 28 days of combination 
treatment), for reasons OTHER than toxicity, will be replaced if data from the 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367701] the dose selection criteria. 
Subjects who experience an intolerable toxicity causing a dose interruption or 
dose reduction during the Enzalutamide Run -In Period (before the start of 
[COMPANY_004]2636771 combination treatment) will require approval from the [COMPANY_004] 
Medical Monitor in order to continue in the study.  Those subjects not eligible 
for treatment in the Combination Treat ment Period will not be considered in 
the evaluation of DLTs and may be replaced.
Dose Expansion Phase
This phase of the study will evaluate the long term safety of the combination 
treatment as well as the 12 -week non -progressive disease (PD) rate of the 
combination treatment in subjects with mCPRC.  To confirm dose(s) identified 
during dose escalation, multiple dose levels of [COMPANY_004]2636771 in combination 
with enzalutamide may be examined during dose expansion, with each dose 
level cohort enrolling up to 20 su bjects. Using the totality of safety, PK and 
clinical activity data, the RP2D will be confirmed from the dose level(s) which 
are examined in the dose expansion phase. 
Enzalutamide Run -In Period (Days 1 -14):  Following pre -screening and 
screening, approx imately 20 subjects will be enrolled and receive 
enzalutamide monotherapy at the approved dose of 160 mg once daily for 
14days.
Combination Treatment Period (Weeks 1 -4):  Subjects who complete the 
Enzalutamide Run -In Period will begin oral [COMPANY_004]2636771 trea tment on 
Week 1, Day 1 of the Combination Treatment Period at the RP2D dose 
established in the Dose Escalation Phase of the study while continuing to 
receive enzalutamide to evaluate safety of the combination therapy.
Treatment Continuation Period (Week 5 and thereafter):  Subjects will 
continue to receive the combination treatment of [COMPANY_004]2636771 + 
enzalutamide until criteria are met for discontinuation of study treatment.
PK:  Blood and plasma samples for PK analysis of [COMPANY_004]2636771 and 
enzalutamide (includin g its active metabolite, N -desmethyl enzalutamide) will 
be collected on specified PK days in the Dose Escalation and Dose 
Expansion Phase.
Genetic Research : A single blood sample will be collected after Screening, 
preferably on Week 1, Day [ADDRESS_367702] 
completed 12 weeks of treatment. This analy sis may occur using the 
combination of the dose escalation and dose expansion population. If multiple 
dose levels of [COMPANY_004]2636771 are examined during dose expansion to 
establish the RP2D , each dose level cohort will enrol approximately 20 
subjects, increasin g the overall number of subjects targeted for enrolment in 
thisstudy. The sample size planned for the Dose Expansion Phase is not 
driven by [CONTACT_301150].  
INCLUSION/
EXCLUSION
CRITERIAKey Inclusion Criteria 
1. Signed written informed consent provided
NOTE: Separate ICFs must be s igned prior to the pre -screening and 
screening procedures.
2. Males 18 years of age (at the time written consent is obtained for pre -
screening)
3. Histologically or cytologically confirmed diagnosis of prostate 
adenocarcinoma, surgically castrated or continuous medical castration 
(for 8 weeks prior to Screening)
4. Serum testosterone <50 ng/dL (1.7 nM/L)
5. PTEN -deficient tumor as documented from archived or fresh (from pre -
treatment biopsy) tumor tissue analyzed by a [COMPANY_004] selected laboratory
6. Eastern Cooperative Oncol ogy Group (ECOG) performance status of [ADDRESS_367703] 12 weeks of prior continuous therapy with 
enzalutamide
8. Has not been without enzalutamide treatment for >30 days prior to 
enrollment
9. Has documented disease progression following treatment with 
enzalutamide at time of Screening
NOTE: Disease progression is defined by [CONTACT_301151]:
PSA progression defined by [CONTACT_43877]2 criteria (see Section 
[IP_ADDRESS] ), or
Soft tissue disease progr ession defined by [CONTACT_393] 1.1 (see 
Appendix 4 ), or
Bone disease progression defined by [CONTACT_43877]2 criteria (see 
2013N172718_04 CONFIDENTIA L
200331
24INCLUSION/
EXCLUSION 
CRITERIA 
continuedSection [IP_ADDRESS] )
10. Able to swallow and retain orally administered med ication.
11. Adequate baseline organ function at time of Screening defined as:
Hematologic
ANC 1.5 x 10 9/L
Hemoglobin 9 g/dL 
Platelets 100 x 10 9/L
PT/INR and PTT 1.[ADDRESS_367704]
Hepatic
Albumin 2.5 g/dL
Total bilirubin 11.[ADDRESS_367705]
ALT12.5 x UL N
2.[ADDRESS_367706] or >2.[ADDRESS_367707] but 5xULN with 
documented liver 
metastases or tumor 
infiltration
Renal
Urine Protein (via dipstick) 20/+1
UPC3,4<0.2
Serum Creatinine
OR
Estimated Serum Creatinine Clearance 5
OR
24-hr Urine Creatinine ClearanceULN
60 mL/min
60 mL/min
Cardiac
LVEF 50% by [CONTACT_301152] 6(corrected)
Ionized Calcium 6
Vitamin D 6: 25-OH D and 1,25 -OH2 DWNL
WNL
WNL
Abbreviations: ANC, absolute neutrophils count; ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for 
Adverse Events; ECHO, echocardiogram; INR, international normalization ratio; LLN, 
lower limit of normal; LVEF, left ventricular ejection fraction; MUGA, multigated 
acquisition scan; P T, prothrombin time; PTT, partial thromboplastin time; ULN, upper 
limit of normal; UPC, urine protein to creatinine ratio; WNL, within normal limits
1.If ALT or bilirubin values are outside range listed due to Gilbert’s syndrome or 
asymptomatic gallstones, s ubject remains eligible.
2.If subject’s urine protein is >1+ (via dipstick), then UPC ratio will be calculated.  
Subject will be considered eligible for study if UPC ratio is <0.2.
3.UPC ratio is only to be calculated if subject’s urine protein is >1+ via dips tick.
4.The UPC value will not be used to determine eligibility for subjects who are 
unable to obtain uncontaminated urine samples due to their disease.
5.Estimated by [CONTACT_91019] -EPI [INVESTIGATOR_10908] (see Appendix 3 ) 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367708] ementation may be added to achieve values WNL. Calcium 
supplements should be added for subjects with calcium values near the lower 
normal limit. 
NOTE:   Laboratory results obtained during Screening should be used 
to determine eligibility criteria.  In situ ations where laboratory results are 
outside the permitted range, the investigator may opt to retest the 
subject and the subsequent within range screening result may be used 
to confirm eligibility .  
12. Male subject with a female partner of childbearing potent ial or 
pregnant must agree to use two acceptable methods of contraception 
from time of Screening until [ADDRESS_367709] dose of study 
treatments (see Section 11.1).
INCLUSION/ 
EXCLUSION
CRITERIA 
continue dKey Exclusion Criteria
1. Prior treatment with:
Anti-cancer therapy (e.g., chemotherapy with delayed toxicity, 
immunotherapy, biologic therapy or chemoradiation) within 21 days 
(or withi n 42 days if prior nitrosourea or mitomycin C containing 
therapy) prior to enrollment and/or daily or weekly chemotherapy 
without the potential for delayed toxicity within 14 days prior to 
enrollment
Exception: Subjects may remain on luteinizing hormone re leasing 
hormone (LHRH) agonists (i.e., leuprolide, goserelin, triptorelin or 
histrelin) and AR antagonists (e.g., bicalutamide, flutamide, 
nilutamide; but not abiraterone).
Exception: Subjects must have received prior treatment with 
enzalutamide.
Any PI3K, AKT or mammalian target of rapamycin (mTOR) inhibitors
Investigational drug(s) (other than enzalutamide) within 30days or 
5half-lives, whichever is longer, prior to enrollment
2. Prior malignancy other than CRPC.
Exception:   Subjects who have been disease -free for 5 years, or 
subjects with a history of completely resected non -melanoma skin 
cancer or successfully treated in situ carcinoma are eligible.
3. Current use of or anticipated requirement during the study of any 
prohibited medication(s) (see Section 10.2)
4. Any unresolved Grade 2 toxicity (per CTCAE 4.0) from previous anti -
cancer therapy at time of enrollment , except alopecia or Grade 2 anemia 
(if hemoglobin is >9.0 g/dL)
5. Presence of any clinically significant GIabnormality or other condition(s) 
that may alter absorption such as malabsorption syndrome or major 
resection of the stomach or substantial portion of the small intestine
NOTE:  If clarification is needed as to whether a GI abnormality, 
2013N172718_04 CONFIDENTIA L
200331
26INCLUSION/ 
EXCLUSION
CRITERIA 
continuedcondition or res ection will significantly affect the absorption of study 
treatment, contact [CONTACT_301153].
6. Active peptic ulcer disease or history of abdominal fistula, GI perforation, 
or intra -abdominal abscess within 28 days prior to enrollment
7. Previous major surgery within 28 days prior to enrollment
8. Known active infection requiring intravenous (IV) or oral anti -infective 
treatment
9. Presence of hepatitis B surface antigen (HBsAg), p ositive hepatitis C 
antibody test result at time of S creening or within 3 months prior to 
enrollment
10. A positive pre -study drug/alcohol screening (testing at time of Screening 
is not required).
11. A positive test for human immunodeficiency virus (HIV) antibody (testing 
at time of Screening is not required) .
12. Evidence of severe or uncontrolled systemic diseases (e.g., unstable or 
uncompensated respi[INVESTIGATOR_696], hepatic, renal or cardiac disease)
13. History of seizure or any condition that may predispose subject to 
seizur e (e.g., prior cortical stroke or significant brain trauma).  
14. History of loss of consciousness or transient ischemic attack within 12 
months prior to enrollment
15. Has a QTc >450 msec or QTc >480 msec for subjects with bundle 
branch block (BBB)
NOTES: The QT c is the QT interval corrected for heart rate by[CONTACT_35019]’s 
formula (QTcB), Fridericia’s formula (QTcF), and/or another method, 
machine -read or manually over -read.
The specific formula that will be used to determine eligibility and 
discontinuation for an ind ividual subject should be determined prior to 
initiation of the study. In other words, several different formulae cannot 
be used to calculate the QTc for an individual subject and then the 
lowest QTc value used to include or discontinue the subject from th e 
trial.
For purposes of data analysis, QTcB, QTcF, another QT correction 
formula, or a composite of available values of QTc will be used as 
specified in the Reporting and Analysis Plan (RAP).
16. History or evidence of cardiovascular risk including any of the following:
Clinically significant ECG abnormalities including second degree 
(Type II) or third degree atrioventricular block
History of myocardial infarction, acute coronary syndromes (including 
unstable angina), coronary angioplasty, stenting, or by[CONTACT_301154] 6 months prior to enrollment
2013N172718_04 CONFIDENTIA L
200331
27INCLUSION/ 
EXCLUSION
CRITERIA 
continuedClass III or IV heart failure as defined by [CONTACT_301155] ( Appendix 2 )
Left ventricular ejection fraction (LVEF) below 50% 
Known cardia c metastases
17. Poorly controlled hypertension (defined as systolic blood pressure [SBP] 
of ≥150 mmHg or diastolic blood pressure [DBP] of >100 mmHg based 
on a mean of three measurements at approximately 2 -minute intervals)
NOTE:   Initiation or adjustment of antihypertensive medication(s) is 
permitted if done [ADDRESS_367710] (e.g., Bernard -Soulier 
syndrome, Chediak -Higashi syndrome, Glanzmann thrombasthenia, 
storage pool defect)
19. Have a know n immediate or delayed hypersensitivity reaction or 
idiosyncrasy to drugs chemically related to [COMPANY_004]2636771or 
enzalutamide or excipi[INVESTIGATOR_840].
20. Any serious and/or unstable pre -existing medical, psychiatric disorder or 
other conditions that could interfere with su bject’s safety, obtaining 
informed consent or compliance to the study procedures.
21.Exposure to more than 4 investigational medicinal products (IMPs)
within 12 months prior to enrollment
STUDY 
TREATMENT 
DOSE/ROUTE/
REGIMENThe planned starting dose of study treatment will be [COMPANY_004]2636771 300 mg 
orally once daily in combination with enzalutamide 160 mg orally once daily.
Additional doses of each study treatment regimen may be explored based 
upon ongoing assessment of safety, PK or PD.
SAFETY 
ASSESSMENTSSafety assessments will include physical examination, vital signs, ECOG 
performance status, 12 -lead ECGs, echocardiogram/multigated acquisition 
scan and monitoring for AEs.
The following clinical laboratory tests wil l be conducted:
Hematology:   platelet count, red blood cell (RBC) count with RBC indices, 
white blood cell (WBC) count with automated WBC differential, hemoglobin, 
hematocrit and reticulocyte count.
Clinical chemistry: blood urea nitrogen, creatinine, gluc ose (fasting), sodium, 
potassium, chloride, carbon dioxide, calcium (serum and ionized) , vitamin D, 
aspartate aminotransferase (AST), ALT, alkaline phosphatase, total protein, 
albumin, uric acid and total/direct bilirubin, phosphorus, and magnesium.
Urinal ysis: specific gravity, pH, glucose, protein, blood and ketones by 
[CONTACT_5230], and microscopic examination (if blood or protein is abnormal).  
Urine -protein -creatinine (UPC) will also be included if urine protein is >1+ by 
2013N172718_04 CONFIDENTIA L
200331
28SAFETY 
ASSESSMENTS
continueddipstick.
Other tests :  PSA, serum testosterone, parathyroid hormone, and coagulation 
tests (prothrombin time, partial thromboplastin time and international 
normalization ratio).
PK/PD
ASSESSMENTSPK:  In the Dose Escalation and the Dose Expansion Phase, blood and 
plasma samples for PK ana lysis of [COMPANY_004]2636771 and enzalutamide 
(including its active metabolite, N -desmethyl enzalutamide) will be collected.  
Each PK sample should be collected as close as possible to the planned 
time relative to the dose (i.e., time zero) administered to the subj ect on 
specified PK days.
PK Analysis:  Concentrations of [COMPANY_004]2636771 and enzalutamide (including 
its active metabolite, N -desmethyl enzalutamide) will be determined from 
blood and plasma samples obtained during PK sampling using currently 
approved bioanaly tical methodology.  Once the blood and plasma have been 
analyzed for [COMPANY_004]2636771 and enzalutamide any remaining blood and 
plasma may be analyzed for other compound -related metabolites and the 
results reported under a separate [COMPANY_004] PTS -DMPK protocol.
Tumor si ze assessments, expressed as linear tumor dimensions, will be 
described as a function of time.
CLINICAL 
ACTIVITY 
ASSESSMENTDisease assessment will be performed every 8 weeks in all subjects.  
Response will be determined according to the PCWG2 criteria ( either by 
[CONTACT_393] 1.1, PSA progression, and/or progression in bone) .  Subjects whose 
disease responds should have a confirmatory disease assessment(s) 
performed at least [ADDRESS_367711] 1.1 for soft tissue lesions, or progression in PSA or bone lesions 
per PCWG2 criteria.
TRANSLATIONAL 
RESEARCHTumor tissue:  Archived tumor tissue or remaining tumor tis sue from the 
sample submitted for PTEN testing will be utilized to identify potential 
predictive biomarkers (protein, DNA and RNA based markers).  If additional 
tumor tissue is not available, no new biopsy procedure is required for 
predictive biomarker ana lysis.  
Optional progression biopsies for subjects who have initially responded to 
the combination therapi[INVESTIGATOR_301055].  
Genetic and protein based biomarkers will be evaluated to understand the 
mechanism of resistance/prog ression.
2013N172718_04 CONFIDENTIA L
200331
29TRANSLATIONAL 
RESEARCH 
continuedCirculating Tumor Cells (CTC):  Blood will be collected to enumerate CTCs 
in circulation.  The isolated CTCs may also be evaluated for alterations in 
AR, PTEN or other genes.  Additional blood samples will be coll ected to 
isolate CTCs using an EPIC Sciences platform and analyzed for RNA 
expression (e.g. AR variants), protein markers and/or potential genomic 
alterations (PTEN loss, PIK3CB mutations, AR amplifications, etc.).
Plasma Collection for Circulating -free DN A (cfDNA) and soluble marker 
analysis:   Plasma will be collected and analyzed for circulating DNA or RNA 
markers related to disease or the PI3K/Ras/Raf/AR pathway.  The samples 
may also be used to analyze soluble markers of immune response or other 
markers that may predict response.  Other biomarkers identified via 
emerging science relevant to disease or study treatments related pathways 
will also be evaluated.
STATISTICAL
METHODSHypothesis:  
Dose Escalation Phase: The total number of subjects to be enro lled in the 
Dose Escalation Phase is not driven by [CONTACT_301156]. The sample 
size of 24 subjects for the Dose Escalation Phase will provide the following 
95% Clopper -Pearson confidence interval (CI) for safety events.
Safety Events Frequency of Safety Events (95% CI)
1 4.2% (0.1% –21.1%)
2 8.3% (1.0% -27.0%)
3 12.5% (2.7% -32.4%)
4 16.7% (4.7% -37.4%)
8 33.3% (15.6% -55.3%)
12 50.0% (29.1% -70.9%)
16 66.7% (44.7% -84.4%)
20 83.3% (62.6% –95.3%)
21 87.5% (67.6% -97.3%)
22 91.7% (73.0% -99.0%)
23 95.8% (78.9% -99.9%)
Abbreviation: CI, confidence interval
For the Dose Expansion Phase, clinical activity will be evaluated per dose 
level if more than one dose is examined (combing data from Dose Escalation 
Phase) . A targeted PI3K pa thway inhibitor ([COMPANY_004]2636771) added to 
enzalutamide will be tested to see if mCPRC progression can be limited in a 
clinically meaningful way for at least 12 weeks.  The null hypothesis is that 
the 12 -week non -PD rate is not attractive ( ≤5%).  The alternativ e hypothesis 
is that the rate is clinically meaningful and therefore, the compound warrants 
further development ( ≥30%). A maximum of 20 subjects per dose level may 
be enrolled, with a minimum enrollment of 10 subjects. With an actual type I 
error rate (α) of 0.065 and 94.2% power, the design has stoppi[INVESTIGATOR_301056] .  
2013N172718_04 CONFIDENTIA L
200331
30STATISTICAL
METHODS 
continuedThe trial is designed to stop early for futility if the predictive probability of 
success is less than 6%.  The type I error rate, power, and predictive 
probability of success to stop early for futility were derived from explicitly 
stating the minimum and maximum sample size, futility stoppi[INVESTIGATOR_301057], and 
selecti on of the optimizing criterion as the maximization of power under the 
alternative hypothesis.  The Bayesian prior probability used in determining 
the design was Beta (0.10, 0.90), a distribution with a mean response rate 
(defined as lack of disease progres sion at 12 weeks according to PCWG2 
criteria [either by [CONTACT_393] 1.1, PSA progression, and/or progression in bone] ) 
of 10%. Under the null hypothesis, if the true response rate is 5%, the 
expected sample size of the design is 13.1 subjects and probability of early 
termination (PET) is 83.0%. Under the alternative hypothesis, if the true 
response rate is 30%, the expected sample size of the design is 
19.7 subjects and PET is 4.3%.
Number of Subjects 
EnrolledThis Number of  
Responses1to Stop Early 
for Futi lity
10 0
11 0
12 0
13 0
14 0
15 0
16 1
17 1
18 1
19 1
20 2
Abbreviation: PCWG2, Prostate Cancer Working Group [ADDRESS_367712] or bone progression in addition 
to PSA progression to be determined a disease progressor . 
Study Populations:
The All Treated Safety Population is defined as all subjects who r eceive at 
least one dose of [COMPANY_004]2636771 or Enzalutamide .  Safety will be evaluated 
based on this analysis population. 
The All Treated Clinical Activity Population is defined as all subjects who 
received at least one dose of [COMPANY_004]2636771. Clinical activity a nd evaluation of 
non-PD rate will be based on this analysis population. This will include 
subjects from both dose escalation and dose expansion . 
The All Evaluable Population is defined as all subjects from All Treated 
Clinical Activity Population who ha ve at least one post -dose disease 
assessment and have been exposed to study drug for at least [ADDRESS_367713] one PK sample is obtained and analyzed.
Efficacy Analyses:  The All Treated Clinical Activity Population will be used 
for the analysis of efficacy data, and will be summarized separately per dose 
level. Response data per PCWG2 and RECIST 1.1 guidelines will be 
reported.  Further details about efficacy analyses will be outlined in detail in 
the RAP.
Safety Analyses:  TheAll Treated Safety Population will be us ed for the 
analysis of safety data. All serially collected safety endpoints (e.g., laboratory 
tests, vital signs, ECGs) will be summarized according to the scheduled, 
nominal visit at which they were collected and across all on -treatment time 
points using a “worst -case” analysis.
Additional details of the statistical analysis plan will be provided in the RAP .
2013N172718_04 CONFIDENTIA L
[ADDRESS_367714] frequentl y diagnosed cancer among men and the second -
leadin g cause of cancer -related death in men [ American Cancer Society , 2013].  Over the 
past decades the primary  target of treatment has been focused on depleting or blocking 
androgen activity  as the growth of prostate cancer is dependent on androgens.  Hormonal 
therap y has included the use of gonadotropin -releasing hormone (GnRH) analogues, 
androgen receptor (AR) antagonists, ketoconazole and estrogenic compounds.  Despi[INVESTIGATOR_301058], these tumors often eventuall y progress as castration -resistant prostate 
cancer (CRPC).  Once metastatic CPRC (mCPRC) develops, the mean survival time in 
these patients is approximately  16 to 18 mont hs [Karantanos , 2013].
The AR signaling axis frequently  remains active despi[INVESTIGATOR_301059], as is 
clinically  evident by  [CONTACT_301157] -specific antigen (PSA) and h ypersensitivity  to 
even low l evels of residual androgens, suggesting that continued treatment directed at the 
AR signaling axis may  provide benefit.  Overexpression of AR is seen in over 50% of 
CRPC and is thought to be a significant contributor to progression.  Despi[INVESTIGATOR_301060] s in the development of therapeutic options (e.g., abiraterone acetate, 
enzalutamide, etc.), disease progression is inevitable and is seen in the form of resistant 
tumors with PSA expression that suggests an active AR axis.
The phosphoinositide 3 -kinase (P I3K) -AKT pathway  is among the most commonly  
activated pathway s in human cancer and is active in the majority  of metastatic prostate 
cancer [Taylor, 2010; Bitting , 2013] .Activa tion of the PI 3K-AKT pathway can occur 
due to several different aberrations: decreased expression of the inhibitory  phosphatase 
and tensin homolog (PTEN), inositol poly phosphate -4-phosphatase t ype II (INPP4B), 
and pH and leukine -rich repeat protein phospha tase (PHL PP; a negative regulatory  of 
AKT); activating mutations in the PI 3K catal ytic gene phosphatidy linositol -4,5-
bisphosphate 3 -kinase cataly tic subunit alpha (PIK3CA); and decreased expression of the 
PI3K regulatory  genes phosphoinositide -3-kinase reg ulatory  subunit 1 (PI3KR1) and 
phosphoinositide -3-kinase regulatory  subunit 3 (PI3KR3) [ Taylor, 2010]. Loss of PTEN 
protein is observed in 40 to 50% of mCRPC tumors.  Both PTEN loss per se and AKT 
activation regardle ss of mechanism have been associated with poor clinical outcome 
[Yoshimoto , 2008] and recurrence following radical prostatectomy [ Ayala, 2004; 
Bedolla , 2007].
Cross -talk between AR and PI 3K-AKT pathway s has been observed in models of CRPC 
as evidenced b y activation of AKT signalling with AR inhibition [ Carver , 2011].  
Conversel y, AR transcriptional ac tivity  is decreased in PTEN -deficient tumor cells and 
increased b y pharmacological inhibition of PI 3K-AKT pathway  [Carver , 2011; Martin , 
2010].
The concurrent interruption of the AR and PI3K pathway s by [CONTACT_301158]2636771 may  provide additive benefit by  [CONTACT_301159].
2013N172718_04 CONFIDENTIA L
200331
331.2. [COMPANY_004]2636771
[COMPANY_004]2636771 is a potent, orally  bioavailable , adenosine triphosphate (ATP) competitive 
inhibitor of the PI 3Kisoforms. I t inhibits anchorage -independent growth of the majority  
of PTEN -deficient, but not PTEN wild -type tumor cell lines.  In a PTEN -negative human 
prostate cancer xenograft mouse model , treatment results in dose -dependent inhibition of 
AKT phosphory lation and stable disease or tumor growth delay s.
A detailed summary  of in vitro and in vivo non-clinical pharmacology  studies is provided 
in the [COMPANY_004]2636771 I nvestigator Brochure (IB) [GlaxoS mithKline Document Number 
2011N117133_01 ].
1.2.1. Clinical Safety , Pharmacokinetic Data, and Clinical A ctivity  of 
[COMPANY_004]2636771
To date, the administration of [COMPANY_004]2636771 has been limited to subjects with PTEN 
deficient tumor as determined by  [CONTACT_9064]  (IHC) analy sis who were 
enrolled in the first -time-in-human (FT IH) stud y P3B115717.  Doses of [COMPANY_004]2636771 
evaluated have ranged from 25 mg to 500 mg once daily .  The maximum tolerated dose 
(MTD) has been defined as 400 mg orally  once daily .  Dose -limiting toxicities (DLTs) 
observed were h ypophosphatemia and h ypocalcemia. This study  is completed and 
enrolled 65 subjects.
Dose -limiting toxicity  (DLT) of hy pophosphatemia was identified at 500 mg dail y dose 
level, occ urring in 3 of 4 subjects, and resulting in dose reductions and or 
discontinuations.  The hypophosphatemia improved upon discontinuation of 
[COMPANY_004]2636771.  The mechanism(s) of h ypophosphatemia is under investigation.
Safety.  The most frequent adverse events (AEs) with [COMPANY_004]2636771 were Grade 1 or 
Grade 2 gastrointestinal (GI) toxicities, with the most frequentl y reported AEs being 
diarrhea (42%), nausea (40%), fatigue (30%), vomiting (30%), abdominal pain (26%), 
decreased appetite (23%), anemia (21%), constipat ion (17%), headache (17%), 
hypokalemia (15%), cough (13%), dy spnea (13%), edema peripheral (13%), and urinary  
tract infection (11%).
Pharmacokinetics.  Preliminary pharmacokinetic (PK) results from stud y P3B115717 
indicate that [COMPANY_004]2636771 is absorbed orall y with a median time to achieve the peak 
blood concentration (Tmax) of 4 to 5 hrs after single doses of 25 to 500 mg.  The median 
half-life (t1/2) of [COMPANY_004]2636771 ranged from 17.1 to 38.6 hrs across the dose range of 
25mg to 500 mg once daily .  Mean maximum observed concentration (Cmax) and area 
under the concentration -time curve from zero (pre -dose) to 24 hrs [AUC(0 -24)] values on 
Day [ADDRESS_367715] with mCRPC who received 
200 mg [COMPANY_004]2636771 once dail y had a partial response (PR) per Response Eva luation 
Criteria in Solid Tumors (RECI ST) 1.1.  There were 20 (N=65) subjects who had stable 
disease, [ADDRESS_367716] 6 months. Refer to the [COMPANY_004]2636771 IB 
2013N172718_04 CONFIDENTIA L
200331
34[GlaxoSmithKline Document Number 2011N117133_01 ] for additional details on 
available safet y, PK and clinical activity data.
1.3. Enzalutamide (Xtandi)
Testosterone and its active metabolite dihy drotestosterone (DHT) are normally  ligands 
for AR.  Binding to AR causes changes in the composition and conformation, leading to 
nuclear translocation from the cy toplasmic compartment.  Once in the nucleus, the AR 
binds to androgen response elements on target genes (e.g., PSA) and leads to 
transcription of messenger ribonucleic acid (mRNA).  Traditional androgen deprivation 
therap y reduces intracellular concentrations of DHT and results in tumor regression in 
prostate cancer.  However, androgen deprivation therap y does not completely inhibit 
intratumoral androgens or the expression of AR target genes.
The AR is central to the biology  of mCRPC.  The mechanisms that explain resistance to 
traditional androgen deprivation therap y include, but are not limited to, AR amplification 
or point mutations, ligand -independent activation of the AR, and alternative sign alling 
pathway s that no longer involve the AR.
Enzalutamide (Xtandi) is an orall y bioavailable, AR signalling inhibitor approved in the 
[LOCATION_002] (US) and the European Union for the treatment of patients with mCRPC 
[Xtandi , 201 6].  Enzalutamide acts on several steps in the AR signaling pathway , 
including competitive inhibition of androgen binding to ARs and inhibition of AR 
nuclear translocation and its interaction with deoxyribonucleic acid (DNA).  A major 
metabol ite, N -desmeth yl enzalutamide, exhibited similar in vitro activity  to enzalutamide.
Refer to to the approved US Food and Drug Administration (FDA) prescribing 
information [ Xtandi , 201 6] or the Xtandi Prescribing Infor mation for the area where it is 
approved for further details. ].
1.3.1. Clinical Safety , Pharmacokinetic Data, and Clinical A ctivity  of 
Enzalutamide
Safety.  Generall y, treatment with enzalutamide has been well tolerated in subjects with 
CRPC.  Based upon the comp arison of safety  data from the randomized Phase III study  of 
CRPC subjects treated with enzalutamide [ADDRESS_367717] 
common AEs were reported in >5% of subjects:  asthenia/fatigue, back pain, diarrhea, 
arthralgia, hot flush, peripher al edema, musculoskeletal pain, headache, upper respi[INVESTIGATOR_28945], muscular weakness, dizziness, insomnia, lower respi[INVESTIGATOR_23739], spi[INVESTIGATOR_301061] s yndrome, hematuria, paresthesia, anxiety, and 
hypertension.  Grade 3 or hi gher AEs were reported in 47% of subjects receiving 
enzalutamide compared to 53% in placebo -treated subjects.  The most common AE 
leading to discontinuation of treatment was seizure.
Seizure is a risk associated with enzalutamide treatment.  I n a randomize d Phase III study  
of subjects with CRPC, seizures occurred in 7 of 800 (0.9%) enzalutamide subjects 
(160 mg once dail y) compared to no seizures experienced b y subjects receiving placebo.  
The onset of seizures was seen [ADDRESS_367718] -dose.  It is 97 to 98% bound to plasma proteins, 
primarily  albumin.  N -desmethy l enzalutamide is 95 to 97% bound to plasma proteins.  
Enzalutamide is metabolized by  [CONTACT_097]3A 4 and CYP2C8 to an active metabolite 
N-desmeth yl enzalutamide and primaril y eliminated by [CONTACT_171339] (CYP3A4 
and CYP2C8).  The mean t1/2 is 5.8 day s in patients.  With daily  administration, steady  
state is reached after approximately  30 day s. In or der to achieve near -steady  state 
enzalutamide exposure, a 14 -day run-in period has been included in the study  design 
(Section 1.5.3 and Section 3).  Enzalutamide accu mulates approximately  8.3-fold relative 
to a single dose with a mean peak -to-trough ratio of 1.25. A high -fat meal did not alter 
the area under the concentration -time curve (AUC) of enzalutamide or its active 
metabolite, N -desmeth yl enzalutamide.
Clinical Response.  In a randomized, double -blinded, Phase III clinical trial comparing 
enzalutamide with placebo in subjects with mCRPC who had progressed following 
docetaxel -based chemotherap y, enzalutamide prolonged overall survival b y 5 months 
(median survival of 18.4 months with enzalutamide [n=800] compared to 13.6 months 
with placebo [N=399])  which is statistically  and clinically  significant [ Xtandi , 201 6].  
Enzalutamide is approved in the US, Canada, the European Unio n and others (refer to 
Xtandi Prescribing Information in the relevant jurisdiction).  Recently , enzalutamide has 
also been shown to improve survival (32.4 months vs. 30.2 months) in chemotherap y-
naïve subjects with advanced prostate cancer in a separate Ph ase III, randomized, 
placebo -controlled study  [Beer, 2014].
Refer to the approved US FDA prescribing information [ Xtandi , 201 6] or the Xtandi 
Prescribing Information for the area w here it is approved for further details.
1.4. Summary  of Risk Management
The risk of administration of [COMPANY_004]2636771 with enzalutamide has not been assessed in 
clinical trials or in non -clinical toxicology  studies.  In the placebo -controlled Phase III 
clinical tri al (AFFIRM) of subjects with mCRPC who had received docetaxel therapy , 
enzalutamide was administered at a dose of 160 mg dail y (N = 800) versus placebo 
(N=399). The median duration of treatment with enzalutamide was 8.[ADDRESS_367719] medical practice and/or as 
specified in the protocol, includ ing dose modification if specified.
Refer to the [COMPANY_004]2636771 IB [GlaxoSmithKline Document Number 2011N117133_01 ] 
for detailed information concerning the biology , pharmacology , PK and safety .  Refer to 
2013N172718_04 CONFIDENTIA L
200331
36approved US FDA prescribing information [ Xtandi , 201 6] or the Xtandi Prescribing 
Information for the area where it is approved for additional information.
1.4.1. Risk A ssessment
The assessment of the risk of [COMPANY_004]2636771 combination t herap y, and suggestions for 
management of risk, is based on non -clinical data and clinical data from [COMPANY_004]2636771 
monotherap y studies in adults.  I n the event that any  AEs are reported or observed, 
supportive treatment will be provided according to standard medical practice.  Subjects 
will be withdrawn from the study  if a clinicall y significant toxicity  is reported or 
observed.
[IP_ADDRESS]. [COMPANY_004]2636771
Renal and electrolytes : Degenerative changes were observed in the kidneys of rats and 
dogs at 100 mg/kg/day  or 1000 mg/kg/ day, including cellular and tubular changes, with 
chemistry  and urinal ysis findings.  There have been serious, treatment -related reports of 
acute kidney  injury , hypophosphatemia and hy pocalcaemia in [COMPANY_004]2636771 clinical 
trials.  Renal events should be close ly monitored.  It is recommended that patients be 
well-hydrated and avoid the use of NSAIDs.  Calcium and Vitamin D levels will be 
monitored.  Consider supplements in those with calcium levels at or near the lower 
normal limit and those with low Vitamin D levels.  Medical history  will be collected and, 
physical examination and clinical laboratory  tests will be measured frequently  during 
therap y to monitor for potential toxicity .  Guidelines will be implemented including dose 
modification and discontinuation (Section 7.3.1 ) for the management of renal 
insufficiency , renal -related events or electrol yte abnormalities considered to be related to 
study  treatment.  
Gastrointestinal (GI) toxicity : Data from rats receivi ng [COMPANY_004]2636771 showed 
microscopic focal erosions or ulcerations in the stomach at 1000 mg/kg/day .  Grade [ADDRESS_367720] been observed in 
the FTIH stud y (P3B115717).  Eligibility  criteria will exclude an y subject with active 
peptic ulcer disease (see Section 4.1.3 ).  Medical history , phy sical examination and 
clinical laboratory  assessments will be used to identify  and assess toxicity  in the GI tract.  
Supportiv e therap y will be provided according to standard medical practice.  Treatment 
with [COMPANY_004]2636771 will be withheld for an y clinically  significant GI toxicity.
Liver toxicity : In dogs, liver changes including minimal to mild single cell, perivascular 
hepatocell ular necrosis, perivascular mixed inflammatory  cell infiltrate, pi[INVESTIGATOR_301062].  Individual animals with 
liver changes had associated increased in serum alanine aminotransferase (AL T) and 
aspartate a minotransferase (AST).  In the FTIH study  (P3B115717), no serious ( Grade 
3) treatment -related elevations in liver function tests (e.g., AST, total bilirubin) have been 
observed.  Eligibility  criteria (see Section 4.1) will prevent an y subject with significant 
liver dy sfunction from enrolling on the study .  Liver function laboratory  tests will be 
measured frequently  during therapy  to monitor for potential toxicity  and stoppi[INVESTIGATOR_301063], includ ing dose reduction or discontinuation for clinically  significant 
toxicity .
2013N172718_04 CONFIDENTIA L
200331
37Rash:  Events of Grade 1 or 2 rash (no grade ≥3) have been observed in 15% of subjects 
during the dose escalation phase in the FTIH study (P3B115717).  Grade 3 rash was 
observed in 2 subjects in the ongoing expansion cohort of this study .  Both improved with 
supportive car e and interruption of study  treatment.  Both subjects restarted [COMPANY_004]2636771 
at a lower dose.  Medical history  will be collected and phy sical exam will be conducted 
frequentl y during therap y to monitor for potential toxicity .Guidelines including dose 
modif ication and discontinuation (see Section 7.3.3 ) for the management of rash events 
are included in the protocol.
Cardiac effects:  Increased heart weight and marked hypertroph y of the intramural 
coronary  arteries characterized by  [CONTACT_301160].  No microscopic evidence of m yocardial damage was 
observed in this dog.  However, reversible increases in mean arterial pressure, decreases 
in heart rate, and cardiac contractility  that appeared to be secondary  to elevation in blood 
pressure (BP) were observed in a single -dose safety  pharmacology  study  in dogs 300 
mg/kg.  In the FTIH study (P3B115717), no serious ( Grade 3) cardiac events have been 
observed.  Subjects with a history  of uncontrolled hy pertension, heart failure, or known 
significant coronary  artery  disease will be excluded from studies of [COMPANY_004]2636771.  
Cardiac monitoring, including assessment of BP and heart rate, along with 12 -lead 
electrocardiograms (ECG s) will be performed. Specific corrected QT interval (QTc) (see 
Section 7.2.1 ) and/or withdrawal criteria as well as guidance for the management of 
hypertension (see Section [IP_ADDRESS] ) are included in the protocol.
Hematopoietic effects :  In dogs given 1000 mg/kg/day , lymphoid necrosis was observed 
in the spleen, ly mph nodes, and gut associated l ymphoid tissues with no associated 
changes in peripheral white blood cell (W BC) counts.  Decreased th ymus weights were 
observed in rats given 1000 mg/kg/day , with mildly  increased mean total WBC, 
neutrophil, monocy te, and ly mphocy te counts in female rats, likel y due to GI and kidney 
inflammation.  I n the FTIH study  (P3B115717), no Grade [ADDRESS_367721] been observed.  Eligibility  criteria (see Section 4.1) will 
exclude a subject with clinically  significant, abnormal hematology  laboratory  parameters.  
Comple te blood counts with differential will be monitored frequentl y to identify  and 
assess hematologic toxicity .  Supportive therapy  will be provided according to local 
standard medical practice.  Treatment with [COMPANY_004]2636771 will be withheld for a clinicall y 
significant toxicity .
Because of published non -clinical data indicating that p110β play s an important role in 
adenosine diphosphate (ADP) -induced platelet aggregation [ Martin , 2010; Nylander , 
2012], subjects with a history  of congenital platelet function defects will not be eligible.  
In addition, concomitant usage of anti -platelet agents that act at platelet purinergic 
receptors is prohibited.  Caution is recommended when [COMPANY_004]263677 1 and aspi[INVESTIGATOR_301064] .
Reproductive effects : To reduce the risk of reproductive effects from [COMPANY_004]2636771 
based upon a bursal hemorrhage noted in the ovary of 3 rats (two after 4 weeks dosing 
and one following a 2 -week recovery  period) given 1 000 mg/kg/day , specific guidelines 
and precautions for male subjects (and their female partners of childbearing potential) are 
provided in the protocol (see Section 11.1).
2013N172718_04 CONFIDENTIA L
200331
[IP_ADDRESS]. Enzalutamide
Seizure.  In the placebo -controlled Phase III clinical trial (AFFI RM) of subjects with 
mCRPC who had received docetaxel therap y, enzalutamide was administered at a dose of 
160 mg dail y (N = 800) versus placebo (N = 399).  Seizure occurred in 0.9% of subjects 
receiving enzalutamide.
Caution should be used in administering enzalutamide to subjects with a history  of 
seizures or other predisposing factors including, but not limited to, underly ing brain 
injury , stroke, primary  brain tumors or brain metastases, or alcoholism. In addition , the 
risk of seizure may  be increased in subjects receiving concomitant medicinal products 
that lower the seizure threshold and therefore, subjects requiring such products should be 
excluded (Section 10.2).  Enzalutamide should be discontinued if a seizure occurs while 
on treatment.
Cardiovascular effect.  The AFFIRM stud y excluded subjects with recent myocardial 
infarction (within 6 months of study  enrollment) or unstable angina (within 3 months of 
study  enroll ment), [LOCATION_001] Heart Association (NYHA) Class III or IV heart failure 
(Appendix 2 ) except if left ventricular ejection fractio n (LVEF) ≥45%, long QT, QT 
interval corrected b y Fridericia’s formula (QTcF) >[ADDRESS_367722] with significant 
cardiovascular disease from enrolling on the study.
[IP_ADDRESS]. Potential O verlappi[INVESTIGATOR_301065]:  According to the prescribing information for enzalutamide, Grade 1 to 4 
diarrhea was reported in 22% of subjects (N=800) with Grade 3 or 4 diarrhea reported 
among 1% of these subjects (versus 0.3% of placebo treated subject s).  Diarrhea is an 
observed AE with [COMPANY_004]2636771 monotherap y (reported in 42% of subjects overall, 
regardless of causality ; Grade 2 events in 6% of subjects and Grade 1 in all others; no 
Grade 3 or 4 events), diarrhea would be considered a potential overlap pi[INVESTIGATOR_301066]2636771 in combination with enzalutamide.
Fatigue: Based upon data reported for the integrated safet y population for enzalutamide, 
fatigue was reported in 40.5% (422/1043) of subjects, resulting in 0.8% (8/1043) subjects 
from discontinuin g treatment with enzalutamide.  Fatigue may  also be seen as an 
expected adverse effect due to androgen deficiency in this subject population.  With 
[COMPANY_004]2636771 monotherapy , fatigue has been reported in 30% of subjects (N=53), mostly  
Grade 1 or 2 with 4% of subjects reporting Grade 3 or higher events.  Given the potential 
of occurrence of fatigue from any  of the study  treatments, it is considered a potential 
overlappi[INVESTIGATOR_301067]2636771 with enzalutamide.
[IP_ADDRESS]. Risk of Drug -Drug Int eraction
The risk for [COMPANY_004]2636771 to affect enzalutamide via enzy mes of CYP3A4 and CYP2C8 
is low but not fully  discharged.  It is unknown if enzalutamide could potentially  affect the 
exposure of [COMPANY_004]2636771 via UDP -glucuronos yltransferase (UGT) inhibition or
induction, while the drug -drug interaction (DDI) risk on [COMPANY_004]2636771 via organic 
2013N172718_04 CONFIDENTIA L
200331
39anionic transferase protein (OATP) transporter inhibition by  [CONTACT_301161]2636771.
1.4.2. Benefit A ssessment
This is the initial clin ical experience with [COMPANY_004]2636771 in combination with 
enzalutamide, therefore, the benefit:risk has yet to be established.  The benefit:risk should 
be favorable if the anticipated level of efficacy  is demonstrated.
There is a risk of lack of efficacy  with th e combination as subjects entering the study  will 
have progressed after receiving enzalutamide.  Such a risk may  be acceptable given the 
following:
Further treatment with enzalutamide may  continue to provide benefit as seen from 
the limited data suggesting some evidence of response in patients receiving 
abiraterone following abiraterone, enzalutamide following abiraterone, and from 
abiraterone following enzalutamide.  Rate of growth may  still be lower with 
enzalutamide than without enzalutamide (precedent f rom trastuzumab beyond 
progression).  A 14 -day run-in period of treatment with enzalutamide 
monotherap y will be continuous with prior enzalutamide therap y, with the 
exception of an allowed 30 day drug holiday  from enzalutamide treatment, in 
order to achiev e near -steady  state enzalutamide exposure.
Mechanisms of resistance to enzalutamide may  provide less growth activity  
relative to unrestrained AR stimulation upon withdrawal of enzalutamide
Mechanism of response may  rely upon activation of the PI 3K pathway  and 
inhibition of the PI 3K pathway  while maintaining AR inhibition may  be 
efficacious.
Additional considerations for subjects who participate in this study  may  include:
Potential benefit of receiving [COMPANY_004]2636771 in combination with enzalutamide 
treatment du ring study  duration that may  have clinical utility
Contribution to the process of developi[INVESTIGATOR_007] a new treatment in mCRPC
Medical evaluations/assessments associated with study  procedures (e.g., phy sical 
examinations, ECGs, clinical laboratory  tests, etc.)
1.4.3. Over all Benefit:Risk Conclusion
Taking into account the measures to be taken to minimize the risk to subjects 
participating in this study, the potential risks identified in association with [COMPANY_004]2636771 
in combination with enzalutamide are justified b y the antic ipated benefits that may  be 
afforded to subjects with mCRPC.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367723]  inhibitor can be co -administered safel y with 
enzalutamide, thus allowing further investigation of their ability  to rever se resistance to 
this AR inhibitor.  Future studies may  also assess whether the combination can delay  the 
onset of resistance in enzalutamide -naïve CRPC or increase the response rate to 
enzalutamide.
1.5.2. Rationale for Study  Population
A common event in prostat e cancer progression is the loss of tumor suppressor PTEN in 
40 to 50% of mCRPC patients that results in the activation of the PI 3K pathway .  
Subjects with PTEN -deficient tumors are selected for this study  as these tumors are more 
likely  to have activation of the PI 3K pathway  and to potentially  benefit from specific 
inhibition of this pathway .  Tumors of subjects who have progressive disease following 
prior AR pathway  inhibition with enzalutamide are likely  to be reliant on resistance 
pathway s, such as the PI3K pathway .  In addition, these two pathway s (PI3K and AR) are 
believed to modulate each other.  Continued suppression of the AR pathway is a hallmark 
of treatment in mCRPC, and thus, this treatment approach is included in this study .
1.5.3. Dose Rationale
This study  will be the first clinical experience with the combination of [COMPANY_004]2636771 + 
enzalutamide.  Therefore this study  will evaluate the safet y of the combination regimen in 
order to determine its future development.  Based on current clinical experience, 
overlappi[INVESTIGATOR_50685], other than diarrhea and fatigue, are not anticipated with the 
combination.  Subjects will be enrolled only  if they  are currentl y tolerating a full dose of 
enzalutamide.  Enzalutamide will be administered at the approved dose of 160 mg once 
daily  and should remain fixed during treatment.
Results from a study  of inhibition of PI 3Kin PC -[ADDRESS_367724] be 
above a target level to maintain inhibi tion of the target enz yme.  After treatment with 
[COMPANY_004]2636771, inhibition of phosphory lated AKT (pAKT) occurred rapi[INVESTIGATOR_2478] y (within 1 hr) 
with the maximum inhibition (80%) occurring 2 hrs after administration of 10 mg/kg in 
the mice.  Doses of [ADDRESS_367725] been investigated in Study  
P3B115717. The range of blood [COMPANY_004]2636771 trough concentrations (C24) at stead y-
state in the 200 mg once daily  cohort of Study  P3B115717 (2.62 –13.4 g/mL ) exceeded 
the largest Cmax observed in mice after administr ation of 10 mg/kg/day  (1.093 g/mL).  
Therefore, preliminary  PK results from Study  P3B115717 demonstrate that doses of 
2013N172718_04 CONFIDENTIA L
200331
41200mg or greater once daily  achieved s ystemic exposure to [COMPANY_004]2636771 that resulted in 
pharmacologic effects consistent with inhibition o f PI3Kin preclinical models.
Changes in phosphory lated and total protein levels of AKT, [COMPANY_004]3β and p70S6K in the 
platelet rich plasma (PRP) collected at various time points on Day  [ADDRESS_367726] -dose 
on Day  1 revealed that 19 subjects had a >50% decrease in phospho (Ser473)/total AKT 
at 2 hrs.  Thirteen of the 20 subjects treated with 100 to 500 mg [COMPANY_004]2636771 had >80% 
decrease in phospho (Ser473)/total AKT between pre -treatment and [ADDRESS_367727] -dose 
on Day  1.  A similar decrease in phospho -[COMPANY_004]3 β (Ser9), an AKT substrate, was also 
observed.  These data suggest that treatment with [COMPANY_004]2636771 at the explored doses 
results in pathway  inhibition (a surrogate to target engagement) in PRP.
A dose of 400 mg of [COMPANY_004]2636771 once dail y was determined to be the MTD and was 
selected as the recommended Phase II dose (RP2D) for [COMPANY_004]2636771 monotherap y 
treatment based on safet y, PK, and pharmacod ynamic (PD) data from Study P3B115717.  
The proposed starting dose of [COMPANY_004]2636771 in the present study  will be 300 mg onc e 
daily  which is 75% of the RP2D as a single agent determined in Study  P3B115717.  The 
starting dose for the present study  is lower than the monotherap y RP2D to decrease the 
probability  of overlappi[INVESTIGATOR_301068]2636771 and enzalutamide.  Prelimina ry 
results from Study  P3B115717 indicate that [ADDRESS_367728]  inhibition.
For enzalutamide, the approved dose of 160 mg once dail y was selected.  Given the lo ng 
t1/[ADDRESS_367729] clinical experience for the combination.  The dose -finding cohorts are 
large enough that less common but important safety  risks may  be identif ied.  Any  clinical 
efficacy  seen will also be described as the population under study  has great unmet need 
for active therapi[INVESTIGATOR_014], and will be assessed through the use of response criteria defined in 
the Prostate Cancer Working Group 2 (PCWG2) guidelines.
Inthe dose expansion phase, the cohorts are large enough to anal yze the 12 -week non -
progressive disease (PD) rate.
2. OBJECTIVES A ND ENDPO INTS
2.1. Hypothesis
Primary Hypothesis:  The addition of a targeted PI 3K pathway  inhibitor ([COMPANY_004]2636771) 
to enzalutamide can be safel y administered with ongoing enzalutamide treatment.
2013N172718_04 CONFIDENTIA L
200331
42Secondary Hypothesis:  The addition of a targeted PI 3K pathway  inhibitor 
([COMPANY_004]2636771) to enzalutamide can limit mCPRC progression in a clinically meaningful 
way for at least 12 weeks.  The null hy pothesis is that the 12 -week non -PD rate is not 
attractive ( ≤5%).  The alternative hy pothesis is that the rate is clinicall y meaningful and, 
therefore, the compound warrants further development ( ≥30%).  This h ypothesis will be 
tested using a combination of d ata provided in both the dose escalation and dose 
expansion phases.
2.2. Objectives and Endpoints
Objectives Endpoints
Primary
To assess the safety and 
tolerability of [COMPANY_004]2636771 + 
enzalutamide administered orally 
once daily continuously in subjects 
with mCRP C.AEs, SAEs, DLTs, and changes in laboratory 
values, ECGs, and vital signs (BP, 
temperature and heart rate)
To determine the RP2D of orally 
administered [COMPANY_004]2636771 + 
enzalutamide in subjects with 
mCRPC.Safety and tolerability as assessed by [CONTACT_2695], 
SAEs, D LTs, and changes in laboratory 
values, ECGs, and vital signs (BP, 
temperature and heart rate)
To evaluate lack of progression in 
the dose expansion subjects with  
mCPRC by [CONTACT_301162] 12 weeksNon-PD rate for 12 weeks accordin g to 
PCWG2 criteria (either by [CONTACT_393] 1.1, or 
progression in bone or PSA progression with 
accompanying progression by [CONTACT_393] 1.1 
or bone scan when baseline radiological or 
bone disease present or PSA progression if 
no other baseline disease ).
Secondary
To evaluate the clinical activity of 
oral [COMPANY_004]2636771 + enzalutamide 
in the treatment of mCRPC (PTEN 
deficient)PSA50 response rate defined as the percent 
of subjects achieving PSA50 at 12 weeks or 
thereafter (PSA50 is ≥50% decrease in PSA 
from baseline)
Objective Response Rate (ORR) defined as 
complete response (CR) rate plus partial 
response (PR) rate per RECIST 1.1 
Time to PSA progression acco rding to 
PCWG2 criteria
Time to radiological progression according to 
PCWG2 criteria (either by [CONTACT_393] 1.1, PSA 
progression and/o r progression in bone)
Radiological progression free survival (rPFS) 
per RECIST1.1 and/or bone scans
2013N172718_04 CONFIDENTIA L
200331
43Objectives Endpoints
To determine the effect of 
[COMPANY_004]2636771 on enzalutamide PK 
following repeat -dose oral 
administration.Plasma concentrations of enzalutamide and 
N-desmethyl enzalutamide.
To determine the PK of 
[COMPANY_004]2636771 in the presence of 
enzalutamide.Blood [COMPANY_004]2636771 concentrations.
Exploratory
To determine the frequency of 
PTEN deficiency in subjects with 
mCRPCFrequency of PTEN -deficient mCRPC 
reported in subjects based on pre -screened 
tumors
To determine the mechanism of 
PTEN deficiencyPTEN deletion, mutation or promoter 
methylation
To identify additional biomarkers 
(DNA, RNA or protein based) in 
tumor or in circulation that may 
predict response to oral 
[COMPANY_004]2636771 + enzalutamide Response prediction biomarkers based on 
analysis of DNA, RNA, and proteins from 
surrogate tissues (e.g., cfDNA) and/or tumor 
tissue
To determine the effect of 
enzalutamide with [COMPANY_004]2636771 
on the kinetics of tumor growthLongitudinal tumor size measurements; 
serum PSA levels, change from baseline in 
CTCs
Evaluation of biomarkers in CTCs 
that may predict response to 
combinationAR expression, PTEN FISH and other 
genomic evaluations in CTCs
Evaluation of tumor tissue to 
explo re explanation for the 
mechanism of resistance to 
combination therapyBased on analysis of DNA, RNA and 
proteins from tumor tissue obtained at time 
of progression after initially responding to 
combination therapy
To determine pharmacodynamic 
effects of dr ug treatmentRNA/protein analysis of pre/post treatment 
tumor biopsies 
Abbreviations: AEs, adverse events; AR, androgen receptor; BP, blood pressure; cfDNA, circulating -free 
deoxyribonucleic acid; CTC, circulating tumor cells; DLTs, dose limiting toxicit ies; DNA, deoxyribonucleic acid; ECG, 
electrocardiogram; FISH, fluorescent in situ hybridization; mCRPC, metastatic castration -resistant prostate cancer; 
PCWG2, Prostate Cancer Working Group 2; PD, progressive disease; PK, pharmacokinetics; PSA, prostate -specific 
antigen; PTEN, phosphatase and tensin homolog; RECIST, Response Evaluation in Solid Tumors; RNA, ribonucleic 
acid; RP2D, recommended Phase II dose; SAE, serious adverse event(s)
3. INVESTIGA TIONAL PLA N
This is a Phase I, open -label, non -controlled, n on-randomized dose finding, dose 
escalation, multicenter study  to determine the RP2D of the oral PI3K inhibitor, 
[COMPANY_004]2636771 in combination with enzalutamide in subjects with mCRPC.  The study  
will be conducted in two phases: the Dose Escalation Phase and the Dose Expansion 
Phase.  Each phase of the study  will consist of a pre -screening period, a screening period, 
2013N172718_04 CONFIDENTIA L
200331
44three treatment periods (Enzalutamide Run -In Period, Combination Treatment Period and 
Treatment Continuation Period), and a post -treatment follow -up visit.
Subjects with PTEN deficient mCRPC (determined during pre -screening), who have 
documented progression per Prostate Cancer Working Group 2 (PCWG2) criteria (either 
by [CONTACT_16622] [RECI ST] 1.1, prostate -specific an tigen 
[PSA] progression, and/or progression in bone), will be enrolled in the Dose Escalation 
Phase and Dose Expansion Phase of the stud y.  
In the Dose Escalation Phase, subjects will be enrolled into dose -finding cohorts to 
evaluate the safet y and PK to guide the selection of the MTD of [COMPANY_004]2636771.  Dosing 
decisions will be based on all available data at the end of each DLT reporting period (the 
first 28 day s of combination treatment).  Decisions for dose determination for subsequent 
cohorts will be docum ented and maintained b y each site and in the [COMPANY_004] Trial Master 
Files (TMF).
In the Dose Expansion Phase, subjects will be assigned to receive [COMPANY_004]2636771 at doses 
identified at or below the MTD in the Dose Escalation Phase while continuing treatment 
with enz alutamide to evaluate the long -term safety  of the combination as well as the 12 -
week non -PD rate. This may  include multiple dose levels in order to establish the RP2D 
of the combination treatment at the conclusion of combination treatment in any  dose 
level . 
Safety Assessments: Throughout the stud y, safety will be assessed through standard 
measures, including ph ysical examinations, vital signs, clinical laboratory  tests, 12 -lead 
ECGs and monitoring of AEs.  Efficacy  will be assessed by  [CONTACT_5292],
computed tomograph y (CT) scan or magnetic resonance imaging (MRI), radionuclide 
bone scans, circulating tumor cells (CTC) enumeration, and PSA.  Pharmacokinetic (PK) 
blood samples will be collected from all subjects to evaluate if there is an effect of 
[COMPANY_004]2636771 on the PK of enzalutamide and to quantify  the s ystemic exposure to 
[COMPANY_004]2636771.
Clinical Response Assessments: The determination of clinical response, including 
disease progression, will be assessed b ythe PCWG2 criteria (see Section 8.8.2 ).  The 
assess ment of the 12 week non -PD-ratewill also be determined b y PCWG2 criteria 
(either b y RECI ST1.1, PSA progression, and/or progression in bone).
Biomarker Assessments:  Planned biomarker assessments include: 1) Identify  potential 
predictive biomarkers (protein, DNA, ribonucleic acid [RNA] based) in archived tumor 
tissue/pre -treatment biopsies; 2) enumeration of CTCs in circulation and evaluation of 
genetic alterations or expression of AR, PTEN or other genes in isolated CTCs; 3) 
Assessment of circulating DNA/RNA and other soluble markers in plasma to better 
understand clonal evolution and other predictive circulating biomarkers; and 4) 
understand the mechanism of resistance in tumor tissues biopsies (optional ) at time of 
progression 5) assess pharmacod ynamic effects b y collecting pre/post treatment tumor 
biopsies
Protocol waivers or exemptions are not allowed.  Therefore, adherence to the study  
design requirements, including those specified in the Time and Eve nts Tables 
(Section 8.1) are essential.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367730] information not mandated to be present in this protocol is 
provided in the accompany ing Study  Reference Manual (SRM).  The SRM will provide 
thesite personnel with administrative and detailed technical information that does not 
impact subject safet y.
3.1. Pre-Screening and Screening
All subjects will be required to undergo pre -screening to determine the PTEN deficiency  
status of their tumor at the [COMPANY_004] selected laboratory.
Pre-screening may  be performed prior to confirmation of progression on 
enzalutamide 
Subjects will be required to sign a separate Pre -Screening Informed Consent 
Form (ICF) to allow for pre -screening of archived or fresh tumor biops y 
samples
Details of the PTEN requirements are provided in SRM.
Only  subjects who have completed pre -screening and who have been confirmed to have 
PTEN -deficient tumor will be eligible to enter into screening.  Subjects will be required 
to sign another Inform ed Consent Form (ICF) for the main study  at Screening prior to 
initiation of any  screening procedures or assessments.
Screening assessments will be conducted to determine subject eligibility for enrollment 
into the study .  Enrollment is defined as the fir st dose of enzalutamide monotherapy  on 
Day [ADDRESS_367731] dose of 
enzalutamide.
2013N172718_04 CONFIDENTIA L
200331
463.2.2. Combination Treatment Period
Subjects who complete the Enzalutamide Run -In Period will begin oral G SK2636771 
treatment on Week 1, Day  1 of the Combination Treatment Period while continuing to 
receive enzalutamide to evaluate safet y of the combination therap y.
3.2.3. Treatment Continuation Period
Subjects will continue to receive the combination treatment of GS K2636771 + 
enzalutamide from Week 5 and thereafter will be seen in the clinic every  4 weeks.  
Subjects will continue study  treatment until clinical benefit is no longer apparent (see 
Section 5.2), in the opi[INVESTIGATOR_3078] n of the treating ph ysician, or until unacceptable AE, 
withdrawal of consent, permanent discontinuation of treatment or death.
The study  will be considered completed approximately  [ADDRESS_367732] dose of 
study  treatment(s) for all subject who permanently discontinue study  treatments, during 
the Enzalutamide Run -In Period (and/or do not enter the Combination Treatment Period), 
or for those who permanently  discontinue study  treatments during the Combination 
Treatment or Treatment Continuation Period due to disease prog ression.  
Subjects who withdraw from the study  during the Combination Treatment or Treatment 
Continuation Period without disease progression should complete the Extended 
Follow -up Visits where they  will be contact[CONTACT_457]  3months ( 14 day s) until disease
progression, death, withdrawal of consent, or subject is lost to follow -up.  Contact [CONTACT_301163] a clinic visit, a telephone contact ,or an e-mail.  The initiation of any new anti -
cancer treatments and date of last contact [CONTACT_28801] .  Subjects who 
discontinue the Extended Follow -Up Visits for reasons other than death, loss to follow -
up, or withdrawal of consent s hould have a Post -Extended Follow -Up/EOS Visit 
performed.
3.3. Discussion of Study  Design
This is the first clinical experience with the com bination of [COMPANY_004]2636771 with 
enzalutamide.  The study is designed to provide a robust evaluation of the safet y for the 
combination treatment.  Additional doses and/or dosing schedules of [COMPANY_004]2636771 with 
enzalutamide may  be explored in each of the cohorts, i f necessary .
The dosing of enzalutamide will be administered at the US FDA approved dose (refer to 
the Prescribing Information for enzalutamide [ Xtandi , 201 6].  Study  treatment will 
continue until there is no longer c linical benefit (see Section 5.2), in the opi[INVESTIGATOR_1070], or until an unacceptable AE (including stoppi[INVESTIGATOR_873] 
7.2), withdrawal o f consent, permanent discontinuation of study  treatment, or death 
2013N172718_04 CONFIDENTIA L
200331
47occurs.  Investigators will use the PCWG2 criteria to determine clinical response to each 
treatment.
3.4. Dose Escalation Phase
In the Dose Escalation Phase, the dose of [COMPANY_004]2636771 will follow a modified 3+3 dose 
escalation procedure to evaluate the safet y and PK for each combination dose level and to 
guide selection of the combination dose for dose expansion .  
A minimum of 3 subjects may  be enrolled in each subsequent cohort until the MTD (see 
Section 3.4.4 ) is defined.  Evaluation of at least [ADDRESS_367733] completed 28 days 
of treatment with the combination is required prior to dose escalation to the next cohort.  
Dose escalation decisions will be by  [CONTACT_093](s), [COMPANY_004] Medical Monitor, 
pharmacokineticist, and statistician following review of all available data.  Dose 
escalation will proceed with the increment of dose increase or decrease as determined b y 
toxicity  rules outlined in Table 1.
Table 1 3+3 Dose Escalation Guidelines Based on Toxicity
Number of Subjects with a DLT Action
0 out of 3 subjects Escalate to next dose level.
1 out of 3 subjects Accrue 3 additional subj ects at current dose level for a total 
of 6 subjects
1 out of 6 subjects Escalate to the next dose level. 
2 or more subjects in a dosing cohort (up to 
6 subjects)Dose -escalation will be stopped.  At this dose level, the 
MTD has been exceeded (highest d ose administered).  
Either evaluate at a lower intermediate dose (3+3 dosing) or 
expand a prior cohort up to approximately 20 subjects per 
treatment arm.
Abbreviations: DLT, dose limiting toxicity; MTD, maximum tolerated dose
If the combination doses in Cohort 1 are not tolerable, lower doses will be evaluated.  If 
the de -escalation cohort (Cohort -1) is not tolerable, additional dose levels of 
[COMPANY_004]2636771 or alternative dosing schedules may  be explored based upon ongoing 
assessment of safet y, PD and PK.  Dose modification decisions will be made utilizing all 
available data at the end of each DLT reporting period (the first 28 days of combination 
treatment).
Dose escalation will proceed until the MTD of the combination regimen is identified.  If 
the dose(s) administered to a given cohort exceeds the MTD as defined in Section 3.4.4 , 
intermediate doses may  be explored.  Dose escalation decisions will take into account all 
available data, including the safet y profile and PK data of prior cohorts throughout the 
time subjects are on study , which will be reviewed by  [CONTACT_093](s), [COMPANY_004] Medical 
Monitor, pharmacokineticist and statistician.  The dose escalation decision for the 
subsequent cohort and rationale will be documented in writing with copi[INVESTIGATOR_301069]’s study  files and the TMF at [COMPANY_004].  In the absence of DLTs, the dose of 
[COMPANY_004]2636771 may  be escalated to the MTD of 400 mg as determined in the FTIH study  
(P3K115717).
2013N172718_04 CONFIDENTIA L
200331
48If diarrhea (in the absence of agg ressive diarrhea management), fatigue, or rash defines 
the MTD, the cohort in which the toxicity  is observed may  be expanded b y at least 
3subjects and the efficacy  of supportive care evaluated prior to further dose escalation.  
If supportive care measures ameliorate the toxicity without recurrence of the toxicity , 
further dose escalation may  be conducted in the presence of appropriate supportive care.
Table [ADDRESS_367734] adequate data on safety , 
PD or PK.  Subjects may be en rolled at previously completed dose levels for the purpose 
of obtaining additional PK and/or PD data.
3.4.2. Alternative Dosing Schedules
Alternative schedules may  be evaluated if emerging data suggest that continuous daily  
dosing will result in excessive toxicit y.  Onl y those alternative schedules exploring 
dosing less frequent than current dosing schedule will be evaluated.  If alternative dosing 
schedules are explored, PK sampling times will be modified to reflect the new dosing 
schedule.
3.4.3. Definition of Dose Lim iting Toxicity
The DLT criteria appl y only  during the Dose Escalation Phase, and impacts the decisions 
around whether the MTD has been determined, and/or decisions around whether to 
escalate or de -escalate the next dose level, but do not apply  to the manda ted management 
of an individual subject as with the liver stoppi[INVESTIGATOR_3418].
Subjects who fail to receive at least 75% of the protocol -specified stud y treatment during 
the DLT reporting period (the first 28 day s of combination treatment) for reasons 
OTHER than toxicity  will be replaced if data from the replacement subject could impact 
the dose selection criteria.  
An event will be considered a DLT if the event is attributed (definitel y, probably or 
possibly ) to study  treatment, occurs within the first 28 d ays of combination treatment 
(DLT reporting period), and meets one of the following criteria:
Grade 3 or greater non -hematologic toxicity  that cannot be controlled with routine
supportive measures (e.g., antiemetics, antidiarrheals)
Grade 4 neutropenia las ting >5 day s
2013N172718_04 CONFIDENTIA L
200331
49Febrile neutropenia, of any  grade or duration as defined by  [CONTACT_301164] 4.0 (CTCAE v4.0)
Grade 4 thrombocy topenia
Alanine aminotransferase (ALT) >3 times upper limit of normal (ULN) with
bilirubin >2 times UL N or ALT ≥[ADDRESS_367735] and ≥1.5 times baseline ALT 
value, if enrolled with liver metastases/tumor infiltration at baseline), together 
with bilirubin ≥[ADDRESS_367736])
Any Grade 2 or greater toxicity  (per CTCAE v4.0) that occurs bey ond the 28 -day DLT 
reporting period which in the judgment of the investigator and [COMPANY_004] Medical Monitor 
would be considered dose limiting will also be considered a DLT.
Subjects who experience an intolerable toxicity  causing a dose interruption or dose 
reduction during the Enzalu tamide Run -In Period (before the start of [COMPANY_004]2636771 
combination treatment) will require approval from the [COMPANY_004] Medical Monitor in order to 
continue in the study .  Those subjects not eligible for the combination phase will not be 
considered in the evaluatio n of DLTs and may  be replaced.
3.4.4. Maximum Tolerated Dose
The MTD is defined as the highest dose at which no more than one of [ADDRESS_367737] 28 day s of combination therapy .  The MTD will be 
exceeded if 2 or more subjects in a coho rt of up to 6 subjects experience a DL T.
3.5. Dose Expansion Phase
Enrollment in the Dose Expansion Phase of the study  may  begin once a suspected MTD 
hasbeen determined in the Dose Escalation Phase. Up to 20 additional subjects per dose 
level may be enrolled t o better characterize the safety  profile, PK, and clinical activity  of 
the recommended doses of the combination of [COMPANY_004]2636771 + enzalutamide for future 
studies. One or more combination doses may  be explored in the Dose Expansion Phase 
based on the MTD iden tified in the Dose Escalation Phase of the study .To fully  evaluate 
additional combination dose s, up to [ADDRESS_367738] 
not completed the treatment phase of the stud y (see Section 5.2) at the time of the final 
analysis may  be transferred to a con tinued access study , if available.
3.6. Recommended Phase II Dose
The RP2D will be considered the lowest dose of [COMPANY_004]2636771 explored (at or below 
MTD) that provides adequate PK exposure and biologic activity  with a superior 
tolerability  profile. If multiple dos e levels are explored in dose expansion, the RP2D will 
be based on the totalit y of data. 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367739] Dose Escalation
Subjects enrolled in a lower combination cohort may  be subsequentl y escalated to a 
higher dose combination once safet y has been establis hed and after consultation with the 
[COMPANY_004] Medical Monitor.
3.7.1. Evaluation of Futility
Futility  will be evaluated when there is adequate enrollment. The methodology  for 
evaluation of futility  is based on the predictive probability  of success if enrollment 
continu es to 20 subjects per dose level [Lee, 2008] . The predictive probability  design is 
similar to a Green -Dahlberg design in that it allows for early  stoppi[INVESTIGATOR_16589] . The 
differences are that the predictive probability design allows for evaluation of stoppi[INVESTIGATOR_301070], rather than at onl y two stages, once a minimum number of 
subjects are evaluable. In this particular study , we will stop only  for futility . While the 
two designs have similar ty pe I and t ype II error rates, the probability  of early  termination 
is greater with the predictive probability  design.
After [ADDRESS_367740] not progressed in 12 weeks will guide further enrollment 
according to the rules summarized in Table 3.  The decision to terminate the Dose 
Expansion Phase will not depend solel y on the results of the statistical methodology, but 
will take all factors i nto account. These factors include the representation of predictive 
biomarkers, such as Androgen receptors, in the subjects treated at the time of interim 
analysis; and the totality  of the safet y, tolerability , PK, and PD data. Additional subjects 
target ing a specific biomarker profile may  be enrolled in the cohort at the discretion of 
the study  team, even if the predictive probability  suggests a low likelihood of clinical 
activity  in this cohort.
Table [ADDRESS_367741] ive Probability  Design
Number of Subjects 
EnrolledThis Number of  
Responses 1to Stop Early 
for Futility
10 0
11 0
12 0
13 0
14 0
15 0
16 1
17 1
18 1
19 1
20 2
Abbreviations: PCWG2, Prostate Cancer Working Group 2; PSA, prostate -
specific anti gen; RECIST, Response Evaluation Criteria in Solid Tumors
1. Response for the purpose of futility is defined as lack of disease 
progression at [ADDRESS_367742] may  continue study  treatment until the treatment discontinuation criteria are 
met (see Section 5.2).  Additional guidelines regarding dose modifications are provided 
in Section 7.1.  
3.9. Treatment A ssignment
Each subject will be assigned a unique subject number that will remain consistent fo r the 
duration of the study .  This number will be assigned sequentially  from a range of subject 
numbers provided for each site in the SRM.  Upon completion of all required pre -
screening and screening procedures and assessments, eligible subjects must be ap proved 
for enrollment b y a member of the [COMPANY_004] central study team according to the procedures 
detailed in the SRM.
3.10. Blinding
This is an open -labeled study .
4. STUDY POPULA TION
4.1. Subject Selection Criteria
4.1.1. Number of Subjects
A total of between approximately  44and 64subjects will be enrolled in this study .  
Dose Escalation Phase:  The number of dose levels and the level at which the MTD is 
reached cannot be determined in advance.  An adequate number of subjects will be 
enrolled to establish the recommended dose fo r further stud y.  It is estimated that 
approximately  24 subjects will be enrolled in the Dose Escalation Phase.
Dose Expansion Phase:  In the Dose Expansion Phase, it is estimated that approximately  
[ADDRESS_367743] 
completed 12 weeks of treatment (see Section 3.7.1 ). This anal ysis may  occur using the 
combination of the dose escalation and dose expansion population. I f multiple dose levels
of [COMPANY_004]2636771 are examined during dose expansion to establish the RP2D, each dose 
level cohort will enrol approximately  [ADDRESS_367744] 
eligibility  is provided in the IB for [COMPANY_004]2636771 [GlaxoSmithKline Document Number 
2011N117133_01 ] and the Prescribing Information for enzalutamide [ Xtandi , 201 6].
2013N172718_04 CONFIDENTIA L
[ADDRESS_367745] meet ALL of the following criteria:
1.Signed written informed consent provided
NOTE: Separate ICFs must be signed prior to the pre -screening and screening 
procedures.
2.Males 18 years of age (at the time written consent is obtained for pre -screening)
3.Histologicall y or c ytologically  confirmed diagnosis of prostate adenocarcinoma, 
surgi cally  castrated or continuous medical castration (for 8 weeks prior to 
Screening)
4.Serum testosterone <50 ng/dL (1.7 nM/L)
5.PTEN -deficient tumor as documented from archived or fresh (from pre -treatment 
biopsy ) tumor tissue analy zed by  a [COMPANY_004] selected laborat ory
6.Eastern Cooperative Oncology  Group (ECOG) performance status of [ADDRESS_367746] 12 weeks of prior continuous therapy  with enzalutamide
8.Has not been without enzalutamide treatment for >30 day s prior to enrollment
9.Has documented disease pro gression following treatment with enzalutamide at time 
of Screening
NOTE: Disease progression is defined by  [CONTACT_167664]:
PSA progression defined by  [CONTACT_43877]2 criteria (see Section [IP_ADDRESS] ),or
Soft tissue disease progression defined b y RECI ST 1.1 (see Appendix 4 ), or
Bone disease progression defined b y PCWG2 criteria (see Section [IP_ADDRESS] )
10.Able to swallow and r etain orally  administered medication.
11.Adequate baseline organ function at time of Screening defined as:
Hematologic
ANC 1.5 x 10 9/L
Hemoglobin 9 g/dL 
Platelets 100 x 10 9/L
PT/INR and PTT 1.[ADDRESS_367747]
Hepatic
Albumin 2.5 g/dL
Total bilirubin 11.5x ULN
AST
ALT12.[ADDRESS_367748]
2.[ADDRESS_367749] or >2.[ADDRESS_367750] but 
5xULN with documented liver 
metastases or tumor infiltration
2013N172718_04 CONFIDENTIA L
200331
53Renal
Urine Protein (via dipstick)20/+1
UPC3,4<0.2
Serum Creatinine
OR
Estimated Serum Creatinine Clearance 5
OR
24-hr Urine Creat inine ClearanceULN
60 mL/min
60 mL/min
Cardiac
LVEF 50% by [CONTACT_301165] 6(corrected)
Ionized Calcium 6
Vitamin D 6: 25-OH D and 1,25 -OH2 DWNL
WNL
WNL
Abbreviations: ANC, absolute neutrophils count; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; ECHO, echocardiogram; INR, 
international normalization ratio; LLN, lower limit of normal; LVEF, left ventricular ejection fraction; MUGA, 
multigated acquisition scan; PT, prothrombin time; PTT, partial thromboplastin time; ULN, upper limit of 
normal; UPC, urine protein to creatinine ratio; WNL, within normal limits
1.If ALT or bilirubin values are outside range listed due to Gilbert’s syndrome or asymptomatic gallstones, 
subject remains eligible.
2. If subject’s urine protein is >1+ (via dipstick), then UPC ratio will be calculated.  Subject will be 
considered eligible for study if UPC ratio is <0.2.
3. UPC ratio is only to be calculated if subject’s uri ne protein is >1+ via dipstick.
4. The UPC value will not be used to determine eligibility for subjects who are unable to obtain 
uncontaminated urine samples due to their disease.
5. Estimated by [CONTACT_91019] -EPI [INVESTIGATOR_10908] (see Appendix 3 ).
6. Vitamin D supplementation may be added to achieve values WNL.   Calcium supplements should be 
added for subjects with calcium values near the lower normal limit.
NOTE:   Laboratory results obtained during Screening should be used to determine 
eligibility  criteria.  In situations where laboratory  results are outside the permitted 
range, the investigator may  opt to retest the subject and the subsequent within range 
screening result may  be used to confirm eligibility .  
12.Male subject with a female part ner of childbearing potential or pregnant must agree 
to use two acceptable methods of contraception from time of Screening until 
3months after the last dose of study  treatments (see Section 11.1).
4.1.3. Exclusion Cri teria
Deviations from exclusion criteria are not allowed because they  can potentially  
jeopardize the scientific integrit y of the study, regulatory acceptability or subject safet y.  
Therefore, adherence to the criteria as specified in the protocol is essent ial.
Subjects meeting ANY of the following criteria must not be enrolled in the study :
1.Prior treatment with:
2013N172718_04 CONFIDENTIA L
200331
54Anti-cancer therap y (e.g., chemotherap y with delay ed toxicity , immunotherapy , 
biologic therap y or chemoradiation) within 21 days (or within 42 day sif prior 
nitrosourea or mitomy cin C containing therapy ) prior to enrollment and/or daily  
or weekl y chemotherap y with the potential for delay ed toxicity  within 14 day s 
prior to enrollment
Exception: Subjects may remain on luteinizing hormone releasing horm one 
(LHRH) agonists (i.e., leuprolide, goserelin, triptorelin or histrelin) and AR 
antagonists (e.g., bicalutamide, flutamide, nilutamide), except abiraterone.
Exception: Subjects must have received prior treatment with enzalutamide.
Any PI3K, AKT or mamma lian target of rapam ycin (mTOR) inhibitors
Investigational drug(s) (other than enzalutamide) within 30days or 5 half-lives, 
whichever is longer, prior to enrollment
2.Prior malignancy  other than CRPC.
Exception:   Subjects who have been disease -free for 5 y ears, or subjects with a 
history  of completely  resected non -melanoma skin cancer or successfull y treated in 
situcarcinoma are eligible.
3.Current use of or anticipated requirement during the study  of any  prohibited 
medication(s) (see Section 10.2)
4.Any unresolved Grade 2 toxicity  (per CTCAE 4.0) from previous anti -cancer 
therap y at time of enrollment , except alopecia or Grade 2 anemia (if hemoglobin is 
>9.0 g/dL)
5.Presence of an y clinically significant G Iabnormalit y or other condition(s) that may  
alter absorption such as malabsorption sy ndrome or major resection of the stomach 
or substantial portion of the small intestine
NOTE:  If clarification is needed as to whether a GI abnormalit y, condition or 
resection will s ignificantly affect the absorption of study  treatment, contact [CONTACT_301166].
6.Active peptic ulcer disease or history  of abdominal fistula, GI  perforation, or intra -
abdominal abscess within 28 day s prior to enrollment
7.Previous major surgery  withi n 28 day s prior to enrollment
8.Known active infection requiring intravenous (IV) or oral anti -infective treatment
9.Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody  test 
result at time of S creening or within 3 months prior to enrollment
10.A positive pre -study  drug/alcohol screening (testing at time of Screening is not 
required).
11.A positive test for human immunodeficiency  virus (HIV) antibody  (testing at time of 
Screening is not required) .
12.Evidence of severe or uncontrolled sy stemic diseases (e.g., unstable or 
uncompensated respi[INVESTIGATOR_696] , hepatic, renal or cardiac disease)
2013N172718_04 CONFIDENTIA L
[PHONE_6252].History  of seizure or an y condition that may  predispose subject to seizure (e.g., prior 
cortical stroke or significant brain trauma).  
14.History  of loss of consciousne ss or transient ischemic attack within 12 months prior 
to enrollment
15.Has a QTc >450 msec or QTc >480 msec for subjects with bundle branch block 
(BBB)
NOTES: The QTc is the QT interval corrected for heart rate by[CONTACT_35019]’s formula 
(QTcB), Fridericia’s formul a (QTcF), and/or another method, machine -read or 
manually  over -read.
The specific formula that will be used to determine eligibility  and discontinuation for 
an individual subject should be determined prior to initiation of the study . In other 
words, severa l different formulae cannot be used to calculate the QTc for an 
individual subject and then the lowest QTc value used to include or discontinue the 
subject from the trial.
For purposes of data analy sis, QTcB, QTcF, another QT correction formula, or a 
compo site of available values of QTc will be used as specified in the Reporting and 
Analy sis Plan (RAP).
16.History  or evidence of cardiovascular risk including any  of the following:
Clinically  significant ECG abnormalities including second degree (Ty peII) or 
third degree atrioventricular block
History  of m yocardial infarction, acute coronary  syndromes (including unstable 
angina), coronary  angioplasty , stenting, or by [CONTACT_90607] 
6months prior to enrollment
Class III or IV heart failure as define d by [CONTACT_301167] ( Appendix 2 )
Left ventricular ejection fraction (LVEF) below 50% 
Known cardiac metastases
17.Poorly  controlled h ypertension (defined as s ystolic blood pressure [SBP] of 
≥150 mmHg or diastolic blood pressure [DBP] of >100 mmHg based on a mean of 
three measurements at approximately  2-minute intervals)
NOTE:   Initiation or adjustment of antihy pertensive medication(s) is permitted if 
done [ADDRESS_367751] (e.g., Bernard -Soulier s yndrome, 
Chediak -Higashi s yndrome, Glanzmann thrombasthenia, storage pool defect)
19.Have a known immediate or delay ed hy persensitivity  reaction or idiosy ncrasy  to 
drugs chemicall y rela ted to [COMPANY_004]2636771or enzalutamide or excipi[INVESTIGATOR_840].
20.Any serious and/or unstable pre -existing medical, psy chiatric disorder or other 
conditions that could interfere with subject’s safety , obtaining informed consent or 
compliance to the stud y procedures.
2013N172718_04 CONFIDENTIA L
[PHONE_6253].Exposur e to more than 4 investigational medicinal products (IMPs) within [ADDRESS_367752] will be considered a screen failure if:
subject signs the pre -screening ICF but does not complete pre-screening, or
subject completes the pre -screening, signs the screening ICF but does not 
complete screening or does not meet the eligibility criteria for enrollment, or
subject is withdrawn from the study  before receiving an y stud y treatment
Minimal co re data for screen failures will be collected from source documentation at the 
site, entered into the electronic case report forms (eCRFs), and transmitted to [COMPANY_004].  The 
minimal core data includes the following:
Reason(s) for screen failure
Demograph y
Eligi bility
SAE (if applicable)
5.2. Permanent Discontinuation of Study  Treatment(s)
Study  treatment(s) will be permanently  discontinued for any  of the following reasons:
Disease progression defined with regards to termination of study  treatment 
as: Radiographic pro gression in soft tissue or bone by  [CONTACT_393] 1.1 for 
subjects with measurable disease, OR
Bone progression on bone scan according to the PCWG2 criteria (Section 
[IP_ADDRESS] ), OR
When it is determined in the opi[INVESTIGATOR_301071] (NLCB) 
from treatment.
NOTE: Subjects who are tolerating therap y and meet criteria for disease 
progression solel y on the basis of rising PSA or fo r the worsening of an isolated 
disease site that is not clinically  significant will NOT be required to discontinue 
treatment and can continue treatment until they  are NL CB from treatment 
[Scher , 2016].
NOTE:  Subjects must meet the PCWG2 guidelines for disease progression 
to avoid premature discontinuation of study treatment(s).
Unacceptable toxicity  (including meeting liver chemistry  stoppi[INVESTIGATOR_301072] 7.2)
2013N172718_04 CONFIDENTIA L
200331
57NOTE: If the subject voluntarily  discontinues from treatment due to toxicity , 
‘adverse event’ will be recorded as the primary  reason for permanently  
discontinuation on the eCRF.
Substantial protocol deviation(s)
Death 
Investigator’s discretion
Lost to follow -up
Intercurrent illness that prevents further administration of study  treatment(s)
Withdrawal of consent by  [CONTACT_301168]/or data 
collection
If subject withdraws consent for further treatment, the subject should return 
for Post -Treatment Follow -up Visit as indicated in the Time and Events 
Tables (Section 8.1).
If subject withdraws consent for further treatment and data collection, then no 
additional study  visits, including a p ost-treatment follow -up visit, or data 
collection should occur.  All samples collected for the biomarker anal ysis at 
the time of withdrawal will proceed for anal ysis to meet the intended 
objectives defined in this protocol, unless consent for further anal yses is 
withdrawn b y the subject.
Study  closure or termination
If study  treatment(s) is/are permanently  discontinued, the subject will not be allowed to 
be retreated.  The primary reason for permanently discontinuing study  treatment(s) must 
be documented in the subject’s medical records and eCRF.
All subjects who have study  treatment(s) permanently  discontinued will have safet y 
assessments at the time of discontinuation and during post -study  treatment follow -up as 
specified in Time and Events Tables (Section 8.1).
Treatment Discontinuation without Disease Progression: All subjects who permanentl y 
discontinue study  treatment(s) without disease progression should be followed for 
progression according to the protocol schedule until:
A new anti -cancer therapy  is initiated, or
Disease progression occurs, or
Death
5.3. Subject Completion
A subject will be considered to have completed the study  if the subject dies or otherwise 
progresses during the study  treatment or post -treatment follow -up period. All other 
subjects will be considered to have withdrawn from the study .
2013N172718_04 CONFIDENTIA L
[ADDRESS_367753]’s last 
visit.
5.5. Treatment after the End of the Study
The investigator is responsible for ensuring that consideration has been given for the 
post-study  care of the subject’s medical condition whether or not [COMPANY_004] is providing 
specific post -study  treatment.  For this study , post -study  treatment will not be provi ded.
Upon discontinuation from the assigned stud y treatment, subject should complete the 
required withdrawal and follow -up evaluations prior to transitioning to a rollover study  if 
one is available, initiating further anti -cancer therapy  or treatment with any 
investigational agent.
Refer to the Time and Events Tables (Section 8.1) for follow -up assessments and 
procedures.
6. INVESTIGA TIONAL PRODUCT
The term ‘stud y treatment’ is used throughout the protocol to descri be any  combination 
of investigational products (I P) received by  [CONTACT_278813].  Study  
treatment may  therefore refer to the individual study  treatments or the combination of 
those study  treatments.
A description of each IP is provid ed in the following sections.
6.1. [COMPANY_004]2636771 [COMPANY_004] Investigational Product
[COMPANY_004]2636771 will be provided to sites by  [CONTACT_23983].  
The contents of the label will be in accordance with all applicable regulatory  and/or legal 
requirements.
Product name: [CONTACT_23983]2636771
Formulat ion description: Each 100 mg capsule contains [COMPANY_004]2636771B (tromethamine, tris salt) 
equivalent to 100 mg of [COMPANY_004]2636771A 
Shell composition: gelatin, red iron oxide (E172) and titanium dioxide 
(E171)
Dosage form: Capsule (gelatin)
Unit dose strength(s): 100 mg
Physical description: 100 mg: Pi[INVESTIGATOR_8745], size [ADDRESS_367754] gelatin capsule
Route/Frequency/Duration: Oral/once daily/continuous until treatment withdrawal
Dosing Instructions: See Section 6.3.[ADDRESS_367755]
Initiall y, in countries where it is approved (i.e., US), sites will need to obtain 
enzalutamide (Xtandi) from local commercial stock in order to provide enrolled subjects 
with an adequate supply  of enzalutamide while on study . 
In countries where regulatory  authorities mandate that the Sponsor must supply  all study  
treatment(s) required for study  participation, [COMPANY_004] will provide an adequate supply  of 
enzalutamide (from commercial stock) directl y to the site for enrolled su bjects.  
Enzalutamide will be provided to subjects at no cost to begin taking enzalutamide on the 
first day  (Day  1) of the Enzalutamide Run -In Period and throughout their participation in 
the study .  If a subject does not qualify  for entry  into the study  based on the tests or 
assessments performed during pre -screening and screening, then enzalutamide will not be 
provided to them.
The sourcing of enzalutamide from commercial stock will continue until which time 
(estimate within the first quarter of 2015) GS K will begin supply ing all sites with an 
adequate inventory  of commercial US sourced enzalutamide; an appropriate amendment 
will be made to the Quality  section of the Investigational New Drug (IND) and Clinical 
Trials Application (CTA).
The contents of the label will be in accordance with all applicable regulatory  
requirements.
Product name: [CONTACT_301227] (Xtandi)
Formulation description: Each capsule contains fill solution: enzalutamide, caprylocaproyl 
macrogolglycerides, butylhydroxyanisole, and butylhydr oxytoluene
Dosage form: Capsule (soft gelatin)
Unit dose strength(s): 40 mg 
Physical description: White to off -white oblong liquid filled soft gelatin capsule imprinted in 
black ink with ENZ
Route/Administration/
Duration:Oral/once daily, within 5 mi nutes of [COMPANY_004]2636771 administration/ 
continuous until treatment withdrawal
Dosing Instructions: See Section 6.3.2 for dosing instructions.
6.3. Administration of Study  Treatments
Dosing Time: Subjects will be instr ucted to take their doses of stud y treatment 
([COMPANY_004]2636771 and enzalutamide) at the same time each day  if possible (24 hr intervals).  
Morning dosing is required until the last serial PK blood and plasma sample are obtained 
on Day  29 of Week 5 (Treatment Con tinuation Period).  Once the last serial PK sample is 
obtained, dosing of stud y treatments can occur an ytime during the day.  For subjects who 
wish to switch to evening dosing, the subject is to delay  their next doses of study  
treatments b y 12 hrs.  
2013N172718_04 CONFIDENTIA L
200331
60Dosin g at Home: On days when subjects do not have a scheduled stud y visit in the clinic 
subjects will be instructed to self -administer their doses of study  treatments at home 
under fasted conditions, at least 1 hr before or 2 hrs after a meal.
Dosing during the Enzalutamide Run -In Period (Days 1 -14): Enzalutamide is the only  
study  treatment taken during the Run -In Period. The intent of this Enzalutamide Run -In 
Period is to achieve near -steady  state plasma concentrations of enzalutamide prior to 
initiating combin ation therap y with [COMPANY_004]2636771.  Subjects should be instructed to take 
their once dail y dose of enzalutamide every  morning at the same time each day  if 
possible (24 -hr intervals) during the Enzalutamide Run -In Period. Specific instructions 
for the administr ation of enzalutamide on Day  14 of the Enzalutamide Run -In Period are 
provided in the Dosing on PK Sampling Days during the Dose Escalation Phase section 
below.
Dosing on Scheduled Study Visit Days: Most of the scheduled study  visit day s during 
the first 5 weeks of combination treatment will require a pre -dose blood, plasma, and/or 
urine sample for anal ysis of PK, CTC, and/or urine electrol ytes. On Day 1 of Weeks 8 
and 12 during the Treatment Continuation Period, pre -dose blood and plasma samples for 
analysis of PK are required. On Day  1 of Week 8 and every  8 weeks thereafter during the 
Treatment Continuation Period, pre -dose blood and urine samples for analy sis of CTC 
(through Week 32 only ) and urine electrol ytes are also required. Subjects should be 
instru cted to withhold their doses of stud y treatments on mornings of these scheduled 
study  visits as follows:
Dosing on PK Sampling Days during the Dose Escalation Phase: 
Day 14 (Enzalutamide Run -In Period); the day prior to administration of the 
first dose of [COMPANY_004]2636771) :  Subjects will fast overnight (at least 8 hrs) and 
remain fasting the morning of this stud y visit.  Subjects will be instructed to 
withhold their dose of enzalutamide on the morning of this study  visit.  After the 
pre-dose PK plasma sample is drawn, subjects will be administered their doses of 
enzalutamide in the clinic and will tocontinue fasting for an additional 2 hrs.  
Day 29, Week 5 (Treatment Continuation Period): Subjects will fast overnight 
(at least 8 hrs) and remain fasting the mor ning of this study  visit.  Subjects will be 
instructed to withhold their doses of stud y treatment on the morning of this study  
visit.  After the pre -dose PK blood and plasma samples are drawn, subjects will be 
administered their doses of study  treatments i n the clinic and will continue fasting 
for an additional 2 hrs. 
Weeks 8 and 12 (Treatment Continuation Period): Subjects will be instructed 
to withhold their doses of study  treatment prior to these study  visits. After the pre -
dose PK blood and plasma sa mples are drawn, subjects will be administered their 
doses of study  treatments in the clinic under fasted conditions, at least 1 hr before 
or 2hrs after a meal (an overnight fast is not required) .
Dosing on PK Sampling Days during the Dose Expansion Phas e:  
Day 29, Week 5 (Treatment Continuation Period) :  
2013N172718_04 CONFIDENTIA L
[ADDRESS_367756] 1 hr before or 2 hrs after a meal (an overnight fast is not required). 
oSubjects scheduled for an afternoon clinic visit will be instructed to take 
their doses of stud y treatments at the usual time on the morning of this 
study  visit, at least 1 hr before or 2 hrs after a meal (an overnight fast is 
not required) .  
Weeks 8 and 12 (Treatment Continuation Period): Subjects will be instructed 
to withhold the doses of study  treatment prior to the study  visit during Weeks [ADDRESS_367757] 1 hr before or 2 hrs aft er a meal.
Dosing on CTC and Ur ine Electrolyte Sampling Days:  Subjects will be instructed to 
withhold the ir doses of study  treatments on the morning of study  visits when a blood or 
urine sample is to be obtained for anal ysis of CTCs and/or urine electrol ytes, 
respectivel y.  After the pre -dose blood sample is drawn and/or the pre -dose urine sample 
is collected, subjects will have their doses of study treatments administered in th eclinic, 
at least 1 hr before or 2 hrs after a meal (an overnight fast is not required) .
Vomiting: If a subject vomits after taking stud y treatment(s), the subject should be 
instructed NOT to retake the dose and should take the next scheduled dose of study  
treatment(s).  If vomiting persists , the subject should contact [CONTACT_31691].
Missed Doses: If subject misses a dose of study  treatment(s), the subject should be 
instructed to take the missed dose as soon as they  realize it was missed, but not take the 
missed dose if there are less than [ADDRESS_367758] diary  for either [COMPANY_004]2636771 or enzalutamide and in the eCRF.
Capsules: [COMPANY_004]2636771 and enzalutamide capsules should be swallowed whole and not 
chewed, opened, or dissolved.
6.3.1. [COMPANY_004]2636771
For this study , the starting dose of [COMPANY_004]2636771 is 300 mg taken orall y once dail y.  
[COMPANY_004]2636771 is to be administered within 5 minutes prior to enzalutamide and under 
fasted conditions, either 1 hr before or 2 hrs after a meal and with approximately  200 mL 
of water (unless otherwise instru cted in Section 6.3.1 for study  visit day s when PK, CTC, 
or urine electrol yte sampling is required). 
Subjects shall abstain from ingestion of an y food or drink containing grapefruit and 
grapefruit juice, Sevill e oranges or pomelos within [ADDRESS_367759] dose of 
[COMPANY_004]2636771 (Week 1, Day  1 of Combination Treatment Period) until the last dose of 
study  treatment.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367760] prescribing information for enzalutamide [ Xtandi , 201 6], the 
recommended dose of enzalutamide 160 mg (four 40 mg capsules) taken orally  once 
daily  will be administered during this study .  
Enzalutamide may  be taken with or without food on each day  of the Enzalutamide Run -In 
Period ( Days1-13).  Specific instructions for the administration of enzalutamide on 
Day 14 of Enzalutamide Run -In Period may  be found in Section 6.3.2 .  Once 
combination therap y (GS K2636771 + enzalutamide) begins on We ek 1, Day  1 of the 
Combination Treatment Period of both the Dose Escalation Phase and the Dose 
Expansion Phase, enzalutamide is to be administered within 5 minutes after the 
administration of [COMPANY_004]2636771 and under fasted conditions, either 1 hr before or 2 hrs 
after a meal (unless otherwise instructed in Section 6.3.2 for study  visit day s when PK, 
CTC, or urine electrol yte sampling is required). 
6.4. Handling and Storage of Study  Treatments
Handling: Under normal cond itions of handling and administration, the study  treatments 
are not expected to pose significant safet y risks to site staff.  Material Safety Data Sheets 
(MSDS) for [COMPANY_004]2636771 and enzalutamide describing the occupational hazards and 
recommended handling pr ecautions will be provided to site staff within the SRM.
Adequate precautions must be taken to avoid direct contact [CONTACT_23970].  In the case of unintentional occupational exposure notify  the study  monitor, the 
[COMPANY_004] Medical Monitor and/ or the study  manager.
Storage: All study  treatments ([COMPANY_004]2636771 and enzalutamide) must be stored in a 
secure area under the following conditions for each product:  
[COMPANY_004]2636771:  Store under appropriate ph ysical conditions for the product as 
stated on the l abel.  Refer to the SRM regarding temperature excursions.
Enzalutamide (Xtandi):  Store under appropriate phy sical conditions for the 
product as stated on the label. Refer to the SRM regarding temperature 
excursions.
Access to and administration of study  treatments will be limited to the investigator and 
authorized site staff.  Study  treatments must be dispensed or administered only  to subjects 
who qualify  for entry  in this study  and in accordance with the protocol.  Subjects should 
be reminded that all stu dy treatments should be stored at home out of the reach of 
children.
6.5. Product A ccountability
In accordance with local regulatory  requirements, the investigator, designated site staff, 
or head of the medical institution (where applicable) must document the a mount of 
investigational product dispensed and/or administered to study  subjects, the amount 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367761] be maintained and reconciled with study treatment and 
compliance records.  Treatment start and stop dates including dates for tr eatment delay s 
and/or dose reductions will also be recorded in the eCRF.
6.7. Treatment of Study  Treatment Overdose
In the event of a [COMPANY_004]2636771 or enzalutamide overdose (defined as administration of 
more than the protocol -specified dose), the investigator shou ld contact [CONTACT_301169]/SAEs and laboratory  
abnormalities.
Subjects suspected of overdose should be monitored at least until through five t1/[ADDRESS_367762] 
dose of stud y treatment (or suspected overdose).
Information regarding the suspected overdose administered should be documented in the 
eCRF.
7. DOSE MODIFICA TIONS, STOPPI[INVESTIGATOR_301073] S
The following dose modifications, stoppi[INVESTIGATOR_3418], and manage ment guidelines for 
specific events associated with [COMPANY_004]2636771 are provided as guidance and should not act 
as a replacement for sound clinical judgment.  The investigator should use clinical 
judgment to determine which study  treatment may be contributing t o the toxicity  
necessitating dose adjustment, and make the appropriate change for that agent.  The 
severit y of AEs will be graded utilizing the CTCAE v4.0.  
If a given toxicity  is considered to be related to one specific study  treatment by  [CONTACT_192682] r but not both, then dose modification should only  occur with the study  
treatment associated with the specific toxicity  or event of clinical concern.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367763] be discussed and agreed with the [COMPANY_004] Medical 
Monitor.
Table 4 Dose Modification for [COMPANY_004]2636771
Toxicity Grade Dose Modification of [COMPANY_004]2636771
Grade 1 Cont inue at current dose level.  Consider supportive care.
Grade 2Consider withholding dose until toxicity resolves to Grade 1 or baseline.  Upon 
resolution, then restart at current dose level.  Consider supportive care.
Grade 3Withhold dose until toxicity resolves to Grade 1 or baseline.  Upon resolution, 
then consider dose reducing by [CONTACT_301170]. Consider supportive 
care. 
Grade 4 Permanently discontinue study treatment.
[COMPANY_004]2636771:   The dose of [COMPANY_004]2636771 should be adjusted in increments of 100 mg.  
Table 5below illustrates an example using the starting dose of 300 mg once daily .
Table 5 Dose Levels for [COMPANY_004]2636771
Dose Level [COMPANY_004]2636771 Dose (mg)
Starting dose [ADDRESS_367764], 
treatment with enzalutamide should be held for 7 day s or until the event resolves to 
Grade 2 or less.  Then, treatment with enza lutamide may  be resumed at the same dose 
level (160 mg [4 capsules]) or at a reduced dose of 120 mg (3 capsules) or 80 mg 
(2capsules) or per local prescribing information, if warranted.
2013N172718_04 CONFIDENTIA L
200331
657.2. Stoppi[INVESTIGATOR_2121]
7.2.1. QTc Stoppi[INVESTIGATOR_2121]
QTc >500 msec 
OR
Change from baseline of QTc >60 msec
For subjects with underlying BBB, follow the discontinuation criteria listed below:
Baseline QTc with B BB Discontinuation QTc with B BB
<450 msec >500 msec
450 –480 msec ≥[ADDRESS_367765] safet y and evaluate liver event etiology (in alignment with the US FDA 
premarketing clinical liver safety  guidance) .  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
[IP_ADDRESS]. Liver Chemistry  Stoppi[INVESTIGATOR_301074] A lgorithm for 
Subjects WITH entry criteria A LT ≤2.5xULN

2013N172718_04 CONFIDENTIA L
[ADDRESS_367766] ry Stoppi[INVESTIGATOR_2121] –Liver Stoppi[INVESTIGATOR_301075] A LT ≤2.5xULN
ALT absolute ALT 5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin1, 2ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT 3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN andcannot be monitored weekly for 4 weeks
Symptomatic3ALT 3xULN associated with symptoms (new or worsening) believed to be related 
to liver injury or hypersensitivity
Abbreviations: ALT, alanine amino transferase; INR, international normalization ratio; SAE, serious adverse event; 
ULN, upper limit of normal
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinu e study treatment for that subject if ALT 3xULN and bilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary bilirubin on 
dipstick, indicating direct bilirubin elevations and suggesting liver injury.
2. All events of ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairmen t or cirrhosis); INR measurement is not required and the threshold value stated will 
not apply to subjects receiving anticoagulants .
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant p ain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia) .
2013N172718_04 CONFIDENTIA L
200331
[IP_ADDRESS]. Liver Chemistry  Stoppi[INVESTIGATOR_301074] A lgorithm 
including Subjects WITH Documented Liver Metastases/Tumor 
Infiltration at Basel ine A ND entry  criteria A LT>2.5xULN but ≤5xULN

2013N172718_04 CONFIDENTIA L
200331
68Table 7 Liver Chemistry  Stoppi[INVESTIGATOR_2121] –Liver Stoppi[INVESTIGATOR_301076]/Tumor Infiltration at 
Baseline A ND Entry  Criteria A LT>2.5xULN but ≤5xULN
ALT absolute Both ALT 5xULN and2x baseline value
ALT Increase Both ALT 3xULN and≥1.5x baseline value that persists for 4 weeks
Bilirubin1, 2ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT 3xULN andINR>1.5, if INR measured
Cannot Monitor Both ALT 3xULN and≥1.5x baseline value that cannot be monitored for 4 weeks
Symptomatic3Both ALT3xULN and≥1.5x baseline value associated with symptoms (new or 
worsening) believed to be related to liver injury or hypersensitivity
Abbrev iations: ALT, alanine aminotransferase; INR, international normalization ratio; SAE, serious adverse event; 
ULN, upper limit of normal
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immedi ately available, discontinue study treatment for that subject if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick, indicating direct bilirubi n elevations and suggesting liver injury.
2. All events of ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants .
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomit ing, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia) .
[IP_ADDRESS]. Liver Safety  Required Actions and Follo w-up
Table 8 Required A ctions and Follo w-Up Assessments Following A NY Liver 
Stoppi[INVESTIGATOR_159833] -Up Assessments
Immediately discontinue study treatment
Report the event to [COMPANY_004] within 24 hrs
Complete the liver event eCRF and complete 
an SAE data collection tool if the event also 
meets the criter ia for an SAE2
Perform liver event follow -up assessments 
Monitor the subject until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge subject with 
study treatment unless allowed per protoc ol Viral hepatitis serology1
Only in those with underlying chronic hepatitis B at 
study entry (identified by [CONTACT_301171] B 
surface antigen) quantitative hepatitis B DNA and 
hepatitis delta antibody3
Blood sample for PK analysis, obtained 24-[ADDRESS_367767] dose4
Serum creatine phosphokinase and lactate 
dehydrogenase.
Fractionate bilirubin, if total bilirubin 2xULN
2013N172718_04 CONFIDENTIA L
200331
69Actions Follow -Up Assessments
and [COMPANY_004] Medical Governance approval is 
granted (refer to Appendix 6 )
If restart/rechallenge not allowed per 
protocol or not granted , permanently 
discontinue study treatment and may 
continue subject in the study for any protocol 
specified follow -up assessments
MONITORING:
For bilirubin or INR criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase and bilirubin ) and 
perform liver event follow -up assessments 
within 24hrs
Monitor subjects twice week ly until liver 
chemistries resolve, stabilize or return to 
within baseline
A specialist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow -up assessments within 
24-72 hrs 
Monitor subjects weekly until liver chemistries 
resolve, stabilize or return to within baselineObtain complete blood count with differential to 
assess eosinophilia
Record the appearance or worsening of clinical 
symptoms of liver injury, or hypersensitivity, on the 
AE eCRF
Record use of concomitant medications on the 
concomitant medications eCRF includ ing 
acetaminophen, herbal remedies, other OTC 
medications
Record alcohol use on the liver event alcohol 
intake eCRF
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney microsomal 
antibodies, and quant itative total IgG or gamma 
globulins.
Serum acetaminophen adduct HPLC assay 
(quantifies potential acetaminophen contribution to 
liver injury in subjects with definite or likely 
acetaminophen use in the preceding week 
[James ,2009]).
Liver imaging (ultrasound, MRI or CT ) and /or liver 
biopsy to evaluate liver disease ; complete Liver 
Imaging and/or Liver Biopsy eCRFs
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CT, co mputed 
tomography; DNA, deoxyribonucleic acid; eCRF, electronic case report form; [COMPANY_004], GlaxoSmithKline; HPLC, high 
performance liquid chromatography; hrs, hours; IgG/IgM, immunoglobulin G or M; INR, international normalization 
ratio; MRI, magnetic resonanc e imaging; OTC, over -the-counter; PCR, polymerase chain reaction; PK, 
pharmacokinetic; RNA, ribonucleic acid; SAE, serious adverse event; SRM, Study Reference Manual; ULN, upper 
limit of normal
1.Includes: Hepatitis A IgM antibody; Hepatitis B surface antige n and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing); Hepatitis E IgM antibody
2.All events of ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not req uired and the threshold value stated 
will not apply to subjects receiving anticoagulants
3.If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus 
(where needed) [ Le Gal , 2005].
4.Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the eCRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the dat e/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_301077] S RM.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367768] with entry criteria ALT ≤2.5xULN
ALT 3xULN but <5xULN
andbilirubin <2xULN, without symptoms 
believed to be related to liver injury or 
hypersensitivity andwho can be monitored 
weekly for [ADDRESS_367769] with documented liver 
metastases/tumor infiltration at baseline 
AND entry criteria ALT>2.5xULN but ≤5xULN
ALT ≥3xULN and 1.5x baseline value butALT 
<5xULN and 2x baseline value andbilirubin 
<2xULN , without symptoms believed to be 
related to liver injury, or hypersensitivity and
who can be monitored weekly fo r 4 weeksNotify the [COMPANY_004] Medical Monitor within [ADDRESS_367770] 
safety. 
Subject can continue study treatment
Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabili ze or return to 
within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
For subjects with entry criteria ALT ≤2.5xULN
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to within 
baseline.
For subjects with documented liver 
metastases/tumo r infiltration at baseline AND entry 
criteria ALT>2.5xULN but ≤5xULN
If, after 4 weeks of monitoring, ALT <3xULN and 
<1.5x baseline value, and bilirubin <2xULN, monitor 
subjects twice monthly until liver chemistries 
normalize or return to within baseline
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; [COMPANY_004], GlaxoSmithKline; hrs, hours; 
ULN, upper limit of normal
Refer to Appendix 6 for liver safet y drug restart or rechallenge guidelines.
7.2.3. Left Ventricular Ejection Fraction (LVEF) Stoppi[INVESTIGATOR_301078] y (or multigated acquisition [MUGA] scan) must be performed at 
Screening and as clinically  indicated as outlined in the Time and Events Tables 
(Section 8.1).  Subjects who have an absolute decrease of >10% in LVEF compared with 
baseline andthe ejection fraction is below the institution’s lower limit of normal (LLN) 
should temporarily  discontinue treatment with [COMPANY_004]2636771 and have a repeat evaluation 
of LVEF within 1 week.  Echocardiogram (ECHO) or MUGA should be repeated every  
1to 2weeks for [ADDRESS_367771] and within 
10% of baseline.
If the LVEF recovers (defined as LLN and absolute decrease 10% compared 
with baseline) at an y time during the next [ADDRESS_367772] may  be restarted on 
[COMPANY_004]2636771 at a reduced dose.  For such subjects, monitoring of LVEF will be 
2013N172718_04 CONFIDENTIA L
200331
71performed 2 and 4 weeks after re -challenge, and every  4 weeks thereafter for a 
total of 16 weeks and then per protocol.
If repeat LVEF does not recover within 4 weeks, treatment with [COMPANY_004]2636771 
should be permanentl y discontinued.  Ejection fraction should be monitored 
every  4weeks for a total of 16 weeks or until resolution.
Subjects with Grade 3 or 4 (sy mptomatic) left ventricular s ystolic dy sfunction must 
discontinue treatment with [COMPANY_004]2636771.  Ejection fraction should be monitored every 
4weeks for a total of 16 weeks or unti l resolution.  If recovery  occurs (LVEF 
>institutional LLN and sy mptom resolution) within 4 weeks, treatment with 
[COMPANY_004]2636771 may  be restarted at a reduce dose in consultation with the [COMPANY_004] Medical 
Monitor.
Copi[INVESTIGATOR_301079] (or MUGA scans) and cardiology  consultations performed on 
subjects who experience a >10% decrease in LVEF from baseline and whose cardiac 
ejection fraction is <institution’s LLN will be required by  [CONTACT_301172].  I nstructions 
for submitting qualify ing ECHOs (or MUGA scans) are provide d in the SRM.
7.2.4. Valvular Toxicity  Stoppi[INVESTIGATOR_301080] a new asy mptomatic, moderate regurgitation or stenosis by  [CONTACT_301173] (Grade 2 mitral/tricuspid/aortic valvular toxicity  per CTCAE v4.[ADDRESS_367773] a repeat evaluation by  
[CONTACT_301174] 1 week.  An ECHO (or MUGA scan) should be repeated every 1 to 
2weeks for 4 weeks or until valve recovery  to baseline.
If the valve recovers to baseline an y time during the next [ADDRESS_367774] may  be 
restarted on [COMPANY_004]2636771 at a reduced dose(s).  For such subjects, monitoring of 
the valve via ECHO (or MUGA scan) will then be performed 2 and 4 weeks 
after re -challenge, and every  4 weeks the reafter for 8 weeks and then per 
protocol.
If repeat ECHO (or MUGA scan) does not reveal valve recovery  to baseline 
within [ADDRESS_367775] should permanently  discontinue [COMPANY_004]2636771.  
The valve should continue to be monitored via ECHO (or MUGA sca n) every  
4weeks for 8 weeks or until resolution.
Subjects with a Grade 3 or 4 (s ymptomatic, severe regurgitation/stenosis by  [CONTACT_301175]) valvular toxicity  must discontinue 
[COMPANY_004]2636771.  Valvular toxicity  should continue to be monitored every  4weeks for 
8weeks or until resolution.  If recovery  occurs (return to baseline via imaging AND 
symptom resolution) within [ADDRESS_367776] may  restart [COMPANY_004]2636771 at a reduced 
dose after consultation and approval of the [COMPANY_004] Medical Monitor .
Copi[INVESTIGATOR_301081](s) (or MUGA scan) and cardiology  consultations performed on 
subjects who experience valvular toxicity  will be required b y [COMPANY_004] for review.  
Instructions for submitting qualify ing ECHOs (or MUGA scans) are provided in the 
SRM.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367777] to continue in the study  (refer to the SRM).  
7.3.1. Renal Insufficiency  or Other Renal Events
Prior to start of study  treatment, concomitant medications should be reviewed for the 
potential risk of inducing nephrotoxicity  and concomitant medications should be 
modified if clinically  possible.
Close monitoring of serum creatinine, calcium and phosphate and treatment interruption 
for increased ser um creatinine >2 mg/dL (or >0.5 mg/dL above baseline), hy pocalcemia, 
and hy pophosphatemia, respectivel y, should occur.  Nephrology  consultation should also 
be considered.
Calcium should be carefully  managed in all subjects and especially  in subjects with b one 
lesions /metastases and in those on treatment s that are associated with hy pocalcemia, 
including but not limited to, bisphosphanates (e.g., zoledronic acid) or denosumab 
(RANK -L inhibitor). Subjects with baseline calcium levels at or near the lower norma l 
limit and those with Vitamin D below the normal limit should be treated with 
supplements.  Subjects who develop h ypocalcemia should be closely monitored and 
managed per Table 10. 
Guidelines regarding the managem ent of renal insufficiency  or renal -related events 
considered to be related to study  treatment are provided in Table 10.
Table 10 Management and Dose Modifications for Renal Events
Assessmen t Action and Dose Modification
Urine dipstick 
protein 2+Monitor for concomitant medications (e.g., NSAIDs) or medical conditions 
(e.g., urinary tract infection) associated with positive urinary protein dipstick 
test (see SRM for further details)
Assess BP and ensure it is well -controlled (<140/90 mmHg)
Obtain a random UPC ratio (see Appendix 5 )
UPC ratio 3 Repeat UPC within 24 hrs of previous result
If repeat UPC confirms UPC ratio 3, permanently discontinue treat ment 
with [COMPANY_004]2636771
Consult with [COMPANY_004] Medical Monitor
UPC ratio >0.5 
but<3Repeat UPC within 24 hrs of previous result
If repeat UPC confirms UPC >0.5 but <3, interrupt treatment with 
[COMPANY_004]2636771
Evaluate urine sediment (rule out RBC casts)
Consider consu lt with nephrologist regarding further management
Reassess UPC ratio at least weekly or more frequently if clinically indicated
If UPC ratio improves to 0.5 within 14 days :
2013N172718_04 CONFIDENTIA L
200331
73Assessmen t Action and Dose Modification
Restart treatment with [COMPANY_004]2636771 with dose reduced one dose level
Continue monito ring UPC ratio weekly for 4 weeks
Resume urinalysis testing at frequency indicated in Time and Events 
Tables (Section 8.1)
If UPC ratio fails to improve to 0.5 within 14 days :
Discontinue treatment with [COMPANY_004]2636 771
Consult with a nephrologist regarding further management
Consult with [COMPANY_004] Medical Monitor
If UPC ratio elevation recurs after one dose level reduction:
Discontinue treatment with [COMPANY_004]2636771; withdraw subject from study 
unless there is agreement between investigator and [COMPANY_004] Medical 
Monitor that subject will benefit from continued treatment following 
recovery of UPC ratio to 0.5
UPC 0.5 Continue treatment with [COMPANY_004]2636771 at same dose level without 
interruption
Serum creatinine 
0.3mg/dL 
(26.5 µmol/L ) 
increase from 
baselineRepeat serum creatinine level within 24 hrs of previous result
If repeat value confirms serum creatinine 0.3 mg/dL ( 26.5 µmol/L ) 
increase from baseline:
Immediately interrupt treatment with [COMPANY_004]2636771
Evaluate and treat possible causes for elevated serum creatinine (e.g., 
renal outflow obstruction, sepsis, dehydration, hypotension, GI bleed, 
medications [e.g., trimethoprim, ketoconazole or cimetidine] that 
increase serum creatinine level)
Obtain blood sample for PK analysis , if within [ADDRESS_367778] 
dose ( refer to Section [IP_ADDRESS] for details on PK sample collection)
Obtain serum chemistries for calcium, phophorus and magnesium
Obtain UA, UPC and urine electrolytes
Consider o ral or IV hydration, if clinically indicated; and 24 -hour Urine 
Creatinine Clearance assessment, where feasible
Repeat serum creatinine level every 7 days or more frequently if 
clinically indicated
If serum creatinine fails to improve ( 0.3 mg/dL [ 26.5 µmol/L] increase 
persists) within 14 days following dose interruption:
Permanently discontinue treatment with [COMPANY_004]2636771
Consult with [COMPANY_004] Medical Monitor
If serum creatinine improves (<0.3 mg/dL [ <26.5 µmol/L ] increase from 
baseline) within 14 days following dose interruption:
Restart treatment with [COMPANY_004]2636771 with dose reduced by [CONTACT_37387]
Repeat serum creatinine level every 4 weeks or more frequently if 
clinically indicated
If elevated serum creatinine recurs after one dose reduction ( 0.3mg/dL 
[26.5 µmol/L ] increase from baseline):
Repeat serum creatinine within 24 hrs to confirm result
If repeat serum creatinine confirms increase, w ithdraw subject 
from treatment/study unless there is agreement between 
investigator and [COMPANY_004] Medical Monitor that subjec t will benefit from 
continued treatment following recovery of serum creatinine 
(0.3mg/dL [<26.5 µmol/L ] increase from baseline)
2013N172718_04 CONFIDENTIA L
200331
74Assessmen t Action and Dose Modification
If repeat serum creatinine fails to confirm increase, c ontinue 
treatment with [COMPANY_004]2636771 at same dose level without 
interrupti on and o btain blood sample for PK analysis , within [ADDRESS_367779] dose ( refer to Section [IP_ADDRESS] for details on PK 
sample collection)
Hypocalcemia
(serum calcium 
Grade 1)
or
Hypophosphatemia
(seru m phosphate 
Grade 3 or 
symptomatic 
Grade 2)Administration of oral calcium supplements to subjects with calcium levels at or 
near the lower limit of normal should be considered
For subjects with Grade1 hypocalcemia, administer oral calcium supplements 
andevaluate the need for Vitamin D supplementation.
For hypocalcemia > Grade 1, r epeat serum calcium and Vitamin D, and 
phosphate level within 24 hrs of previous result
If repeat value confirms > Grade 1serum calcium, or symptomatic 
Grade 2 serum phosphate.
Immediately interrupt t reatment with [COMPANY_004]2636771
Treat as clinically indicated by [CONTACT_301176] i.v. calcium gluconate (1 g/10 ml) and evaluate the need for 
Vitamin D supplement ation .
Obtain serum PTH level
Obtain blood sample for PK analysis, if requested (see SRM), within 
24-[ADDRESS_367780] dose (refer to Section [IP_ADDRESS] for details on PK 
sample collection)
Obtain urine samples for urine creatinine, calcium, phosphate, and 
protein at treatment interruption; repeat every 7 days
Repeat serum calcium or phosphate level every 7 days or more 
frequently if clinically indicated
If serum calcium fails to improve to WNL or if serum phosphate fails to 
improve to asymptomatic Grade 2 wit hin 14 days following dose 
interruption:
Permanently discontinue treatment with [COMPANY_004]2636771
Consult with [COMPANY_004] Medical Monitor
If serum calcium improves to WNL or serum phosphate improves to 
asymptomatic Grade 2 within 14 days following dose interruption:
Restart treatment with [COMPANY_004]2636771 with dose reduced by [CONTACT_37387]
Repeat serum calcium or phosphate level per Time and Events Tables 
(Section 8.1) or more frequently if clinically indicated
If decreased serum c alcium or phosphate levels reoccurs after one dose 
reduction :
Repeat serum calcium or phosphate levels within 24 hrs to confirm 
result
If repeat serum calcium or phosphate levels confirm decrease, 
withdraw subject from treatment/study unless there is agre ement 
between investigator and [COMPANY_004] Medical Monitor that subject will 
benefit from continued treatment following recovery of serum 
calcium or phosphate to baseline with dose of [COMPANY_004]2636771 
further reduced one dose level.
If repeat serum calcium or phosphate fails to confirm a decrease, c ontinue 
treatment with [COMPANY_004]2636771 at same dose level without interruption
2013N172718_04 CONFIDENTIA L
200331
75Abbreviations:  BP, blood pressure; GI, gastrointestinal; [COMPANY_004], GlaxoSmithKline; IV, intravenous; mmHg, millimeters of 
mercury; NSAIDs, non -steroidal a nti-inflammatory drugs; PK, pharmacokinetics; PTH, parathyroid hormone; RBC, red 
blood cell; SRM, Study Reference Manual; UPC, urine/protein/creatinine ratio
Details regarding collection and testing of urine specimens are provided in the SRM.
[IP_ADDRESS]. Parathy roid Hormone (PTH)
Serum parath yroid hormone (PTH) level will be assessed on the first day of combination 
treatment (Week 1, Day  1 of Combination Treatment Period).  Subsequently  a serum 
PTH level should be obtained for an y subject who experiences Grade 2 or gr eater 
hypocalcemia or hy pophosphatemia while on study  (refer to Table 10).
7.3.2. Cardiac -related Toxicities
Reversible increases in mean arterial pressure and decreases in heart rate and cardiac 
contractility  that were c onsidered secondary  to an elevation in blood pressure were 
observed in a single dose safet y pharmacology study  in dogs administered 300 mg/kg of 
[COMPANY_004]2636771.  I n the ongoing FTIH study , no Grade [ADDRESS_367781] 
been observed.  Subjects with a history  of uncontrolled hy pertension, heart failure, or 
known significant coronary  artery  disease are excluded from this study .  Cardiac 
monitoring, including assessment of BP and heart rate, along with 12 -lead ECGs, will be 
performed.
[IP_ADDRESS]. Hypertension
Hypertension is defined as a pathological increase in BP; a repeatedl y elevated BP 
exceeding 140/90 mmHg.  Hy pertension has been reported with [COMPANY_004]2636771; however, 
the mechanism b y which it may cause h ypertension has not been established.  I t should 
be noted th at hypertension may resolve as the study treatment is cleared and that there 
may be a risk for rebound hy potension.  An y time antihy pertensive medication(s) is/are 
adjusted, ambulatory  BP monitoring should be considered.
2013N172718_04 CONFIDENTIA L
200331
76Table 11 Management and Dose Modification for Hypertension
Grade1 Action and Dose Modification
Grade 1:
SBP 120 -139 mmHg or DBP 80 -89 mmHg1) No interruption in treatment with [COMPANY_004]2636771; 
maintain current dose. 
2) Careful monitoring of BP. Ambulatory BP monitor ing 
should be considered.
Grade 2:
SBP 140 -159 mmHg or DBP 90 -99 mmHg, 
medical intervention may be indicated1) No interruption in treatment with [COMPANY_004]2636771; 
maintain current dose.
2) Begin antihypertensive medication(s), adjust dose of 
current antihyp ertensive medication(s), or begin an 
additional antihypertensive medication(s). 
3) Titrate antihypertensive medication(s) during next 
2weeks until hypertension Grade 1.
4) If hypertension is not Grade 1 within 2 weeks, follow 
steps outlined for Grade 3 .
Grade 3:
SBP 160 mmHg or DBP 100 mmHg, 
medical intervention indicated1) Interrupt treatment with [COMPANY_004]2636771.
2) Begin antihypertensive medication, or adjust dose of 
current antihypertensive medication(s), or begin an 
additional antihypertensive medic ation(s).
3) Titrate antihypertensive medication(s) during next 
2weeks as indicated until hypertension Grade 1. Restart 
study treatment at a previously evaluated dose with at 
least a with a 25% dose reduction.
5) If hypertension is not Grade 1 within 2 weeks, 
permanently discontinue treatment with [COMPANY_004]2636771 and 
follow -up per protocol.
Grade 4:
Life-threatening, malignant hypertension, 
urgent intervention indicatedPermanently discontinue treatment with [COMPANY_004]2636771 and 
follow -up per protocol.
Abbreviati ons:  BP, blood pressure; CTCAE, Common Terminology Criteria for Adverse Events; DBP, diastolic blood 
pressure; mmHg, millimeters of mercury; SBP, systolic blood pressure
1.Grading is based on CTCAE v4.0.
7.3.3. Rash
Subjects should be informed to protect themselv es against direct sun exposure and to 
avoid exposure to known allergens.  Subjects should contact [CONTACT_301177] a rash.  Full supportive care should be provided to subjects who experience 
a rash while on stud y.  Information con tained in this section is a guideline. The 
investigator’s best medical judgment should determine medical intervention for rash .
2013N172718_04 CONFIDENTIA L
200331
77Table 12 Management and Dose Modification for Rash
1stOccurrence 2ndOccurrence 3rdOccurrence
Grade 13 Symptomatic care 1
Consider oral steroids if multiple occurrences 2
Grade 23 Consider oral 
steroids 2 Consider oral 
steroids 2
Hold study treatment 
until <Grade 1, then 
resume at full dose Administer oral 
steroids 2
Hold study treatment 
until Grade 1 then 
restart treatment with 
[COMPANY_004]2636771 with 
dose reduced one
dose level.
Grade 3 3, 
4 Consider oral 
steroids 2
Hold study 
treatment until 
Grade 1, then 
resume at full 
dose Administer oral 
steroids 2
Hold study treatment 
until Grade 1 then 
restart treatment with
[COMPANY_004]2636771 with 
dose reduced one
dose level. Administer oral 
steroids 2
Hold study treatment 
until Grade 1 then 
restart treatment with 
[COMPANY_004]2636771 with 
dose reduced 2dose 
levels.
Grade 4 3, 
4 Administer oral 
steroids 2
Hold study 
treatment until 
Grade 1 t hen 
restart 
treatment with 
[COMPANY_004]2636771 
with dose 
reduced one
dose level. Administer oral 
steroids 2
Hold study treatment 
until Grade 1 then 
restart treatment with 
[COMPANY_004]2636771 with 
dose reduced 2dose 
levels. Discontinue treatment 
with [COMPANY_004]2636771.
1.Recommende d symptomatic measures (for all grades) includes topi[INVESTIGATOR_8826] (e.g., hydrocortisone 1% or 2.5% 
cream), antihistamines, hypoallergenic moisturizers and emollients for dry skin (e.g., 5 -10% urea in cetomacrogel 
cream or soft paraffin).
2.Oral steroid ther apy should follow institutional standard of care (e.g., short course of tapering dose of 
methylprednisolone or prednisone).
3.Dermatology consult should be considered for Grade 3 rash or multiple occurrences of Grade 2.
4.Obtain blood sample for PK analysis, if within [ADDRESS_367782] dose (see Section [IP_ADDRESS] ). 
7.3.4. Diarrhea
Epi[INVESTIGATOR_301082]2636771 monotherap y. 
Other frequent causes for diarrhea, including concomi tant medications (e.g., stool 
softeners, laxatives, antacids, etc.), infections by  C. difficile or other pathogens, partial 
bowel obstruction, should be clinically  excluded.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367783] been developed b y an American Society  of 
Clinical Oncology  (ASCO) panel for treating chemotherapy -induced diarrhea [ Benson , 
2004].  Presented in the sections below are the recommended guidelines for the 
management of diarrhea in subjects receiving [COMPANY_004]26367 71.  These guidelines were 
derived from the recommendations published by  [CONTACT_114477] [ Benson , 2004].
Early identification and intervention is critical for the optimal management of diarrhea.  
A subject’s baseline b owel patterns should be established so that changes in patterns can 
be identified while subject is on treatment.
An assessment of frequency , consistency  and duration as well as knowledge of other 
symptoms such as fever, crampi[INVESTIGATOR_007], pain, nausea, vomiting, di zziness and thirst should be 
taken at baseline.  Consequently  subjects at high risk of diarrhea can be identified.  
Subjects should be educated on signs and s ymptoms of diarrhea with instructions to 
report an y changes in bowel patterns to the ph ysician.
Itis recommended that subjects keep a diary  and record the number of diarrhea epi[INVESTIGATOR_301083].  They  should also include information on any  dietary  changes or 
other observations that may  be useful in the evaluation of their diarrhea history .
If subjects present with diarrhea of an y grade, check they  are receiving the study  
treatment correctl y (i.e., single dose, rather than splitting it through the day).  Obtain 
information on food (solid and liquid) and over -the-counter (OTC) medication(s),
including herbal supplements, taken during the treatment period.
Guidelines regarding management and dose reduction for diarrhea considered to be 
related to stud y treatments by [CONTACT_301178] 13.  Also, see 
guidance on h ydration in Section 11.3.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367784] epi[INVESTIGATOR_76337] (i.e., unformed stool) 
and contact [CONTACT_093].
Administer loperamide: Initial dose: 4 mg. 
Subsequent doses: 2 mg after each unformed 
stool
1.Re-evalu ate after 24 hrs:
2.If diarrhea is resolving: continue 
loperamide treatment at 2 mg dose after each 
unformed stool until diarrhea -free (i.e., bowel 
patterns return to baseline) for 12 hrs.  If 
diarrhea recurs, re -initiate loperamide as 
need edto maintain nor mal bowel pattern.
3.If diarrhea is NOT resolving: continue 
loperamide 2 mg every 4 hrs for the next 
24hrs; re -evaluate after 24 hrs.  If not 
resolving, administer loperamide 2 mg after 
each unformed stool until diarrhea free 
(i.e., bowel patterns return to baseline) for 
12hrs.  If diarrhea is not resolving, continue 
loperamide 2 mg every 4 hrs and re -evaluate 
every 24 hrs.
2.Dietary modifications:
4.Stop all lactose containing products and eat 
small meals
5.Avoid spi[INVESTIGATOR_70329], fried and fatty foods, raw 
vegetables and other foods high in fiber
6.Avoid caffeine and alcohol (can irritate bowel 
and increase motility)
7.Hydration:  Drink 8 to 10 large glasses of clear 
liquids (e.g., water, electrolyte drink) daily.  
Avoid acidic drinks such as tomato juice and 
fizzy soft drinks
8.Supplement diet to include food rich in 
potassium (e.g., bananas, potatoes, apricots; 
evaluate their impact on diarrhea due to fiber 
content (e.g., apricots)Continue study 
treatments at current 
dose.
Continue supportive care 
until diarrhea resolves 
(diarrhea free for 12 hrs 
and bowel pattern 
returns to baseline)
If diarrhea recurs after 
stoppi[INVESTIGATOR_301084], resume 
loperamide treatment, 
re-introduce diet 
modifications, and 
continue study 
treatments at current 
dose.
2013N172718_04 CONFIDENTIA L
200331
80Grade Management Action and D ose 
Modification
Uncomplicated 
Diarrhea -
Grade 1
continued3.If Grade 1 diarrhea persists for >1 week with
loperamide treatment, consider treatment with 
second -line agents (i.e., octreotide, budesonide or 
tincture of opi[INVESTIGATOR_1890]).
4.If Grade 1 diarrhea persists fo r≥2 weeks, refer to 
Persistent Grade 2 diarrhea management 
guidelines.
Uncomplicated 
Diarrhea –
Grade 21.Instruct subject to start supportive care immediately 
at the first epi[INVESTIGATOR_76337] (i.e., unformed stool) 
and contact [CONTACT_093].
9.Administer loperamide: Initial dose: 4 mg.  
Subsequent doses: 2 mg every 4 hrs or after 
each unformed stool
10.Re-evaluate after 24 hrs:
11. If diarrhea is resolving: continue 
loperamide treatment at 2 mg dose after each 
unformed stool until diarrhea free (i.e., bowel 
patterns return to baseline) for 12 hrs.  If 
diarrhea recurs, re -initiate loperamide as 
need edto maintain normal bowel pattern.
12. If diarrhea is NOT resolving: consider 
loperamide 2 mg every 2 hrs for the next 
24hrs.  If Grade 2 diarrhea persists after 48 
hrs of loperamide treatment, start treatment 
with second -line agents (i.e., octreotide, 
budesonide or tincture of opi[INVESTIGATOR_1890]).  Consider 
performing stool work -up, CBC, electrolytes 
and other tests as appropriate.
2.Dietary modifications:
13.Stop all lactose containing p roducts and eat 
small meals
14.Avoid spi[INVESTIGATOR_70329], fried and fatty foods, bran, raw 
vegetables and other foods high in fiber.  Eat 
foods low in fiber (i.e., lean meat, rice, skinless 
chicken or turkey, fish, eggs, canned or cooked 
skinless fruits, cooked/pureed vege tables)
15.Avoid caffeine and alcohol (can irritate bowel 
and increase motility)
16.Hydration:  Drink 8 to 10 large glasses of clear 
liquids (e.g., water, electrolyte drink) daily.  
Avoid acidic drinks such as tomato juice and 
fizzy soft drinksContinue study 
treatments at current 
dose.
Continue supportive care 
until diarrhea resolves 
(diarrhea free for 12 hrs / 
bowel pattern returns to 
baseline)
Once diarrhea has 
resolved, subject may 
gradually re -introduce 
foods from their normal 
diet.
If diarrhea recurs after 
stoppi[INVESTIGATOR_301084], resume 
loperamide treatment, re -
introduce diet 
modifications, and 
continue study 
treatments at current 
dose.
2013N172718_04 CONFIDENTIA L
200331
81Grade Management Action and Dose 
Modification
Uncomplicated 
Diarrhea –
Grade 2
continued17.Supplement diet to inclu de food rich in 
potassium (e.g., bananas, potatoes, apricots ); 
evaluate their impact on diarrhea due to fiber 
content (e.g., apricots) 
18.If diarrhea recurs, refer to Recurrent Diarrhea 
management guidelines.
Persistent  
(≥3days/ 
72hrs) 
Diarrhea –
Grade 21.If Grade 2 diarrhea persists for ≥[ADDRESS_367785].Hold treatment with 
[COMPANY_004]2636771 and 
enzalutamide until 
symptoms have resolved 
to Grade 1 or baseline 
bowel pattern.
Once diarrhea has 
resolved, continue 
treatment with 
[COMPANY_004]2636771 and 
enzalutamide at reduced 
dose.
Recurrent 
Diarrhea (>1 
occurrence) -
(Grade 2)If second occurrence of Grade 2 diarrhea recurs, 
resume loperamide treatment and re -introduce diet 
modifications.Once diarrhea resolves 
to Grade 1 or baseline, 
consider re -starting study 
treatments 
([COMPANY_004]2636771 +  
enzalutamide) at a 
reduced dose
Complicated 
Diarrhea2–
Grade [ADDRESS_367786] call investigator 
immediately for any complicated severe 
diarrhea event.
2.If loperamide has not been initiated, initiate 
loperamide immediately.  Initial dose: 4 mg.  
Subsequent doses: 2 mg every 2 hrs or after 
each unformed stool .
3.Refer to the dietary modif ications for Grade 1 
and 2 uncomplicated diarrhea (above).
4.For dehydration use IV fluids as appropriate.  If 
subject presents with severe dehydration, 
administer octreotide.
5.Perform stool work -up, complete blood count, 
electrolytes and other tests as appro priate
6.Administer antibiotics (i.e., fluoroquinolones) as 
needed, especially if diarrhea is persistent 
beyond 24 hrs or if fever or Grade 3 or 4 
neutropenia is presentHold treatment with 
[COMPANY_004]2636771 and 
enzalutamide until 
symptoms have resolved 
to Grade 1 or baseline 
bowel pattern and 
without complicating 
factors present.
Once diarrhea resolves 
to Grade 1 or baseline, 
consider re -starting study 
treatments 
([COMPANY_004]2636771 
+enzalutamide) at a 
reduced dose 
Continue supportive care 
until diarrhea resolves 
(diarrhe a free for 24 hrs 
and bowel pattern 
returns to baseline)
2013N172718_04 CONFIDENTIA L
200331
82Grade Management Action and Dose 
Modification
Complicated 
Diarrhea2–
Grade [ADDRESS_367787] call investigator 
immediately for any complicated severe 
diarrhea event.
8.If loperamide has not been initiated, initiate 
loperamide immediately.  Initial dose: 4 mg.  
Subsequent doses: 2 mg every 2 hrs or after 
each unformed stool .
9.Refer to the dietary modifications for Grade 1 
and 2 uncom plicated diarrhea (above).
10.For dehydration use IV fluids as appropriate.  If 
subject presents with severe dehydration, 
administer octreotide.
11.Perform stool work -up, complete blood count, 
electrolytes and other tests as appropriate
12.Administer antibiotics (i .e.,fluoroquinolones) as 
needed, especially if diarrhea is persistent 
beyond [ADDRESS_367788] at risk for life threatening 
complications.
Complicated 
Diarrhea –
Grade 41.Instruct subject that they must call investigator 
immediately for any complicated Grade 4 
diarrhea event.
2.If loperamide has not been initiated, initiate 
loperamide immediately.  Initial dose: 4 mg.  
Subsequent doses: [ADDRESS_367789].
6.Administer antibiotics (i.e., fluoroquinolones) as 
needed, especially if diarrhea is persistent 
beyond [ADDRESS_367790] at risk for life threatening 
complicati ons.Hold treatment with 
[COMPANY_004]2636771 and 
enzalutamide
Consult with [COMPANY_004] 
Medical Monitor to 
discuss subject’s event 
history, re -initiation of 
study treatments, and 
dose modifications, once 
symptoms have resolved 
to Grade 1 or baseline 
bowel pattern
Continue s upportive care 
until diarrhea resolves 
(diarrhea free for 24 hrs 
and bowel pattern 
returns to baseline)
Abbreviations: CBC, complete blood count; GI, gastrointestinal; hrs, hours; IV, intravenous; mg, milligram(s)
2013N172718_04 CONFIDENTIA L
200331
837.3.5. Vomiting
Table 14 Management and Dose Modification for Events of Vomiting
Grade Action and Dose Modification
≤Grade 1 Continue study treatments at current dose.
Grade 2 Hold until ≤Grade 1.  Resume study treatments at same dose level.
Grade 3Hold1until <Grade 2.  Resu me study treatments at one dose level lower, if 
indicated. 2
Grade 4 Withdraw study treatments.
1.Subjects requiring a delay of >14 days should be withdrawn from treatment and/or study.
2. Subjects requiring >2 dose reductions should be withdrawn from treatmen t and/or study.
It is recommended that any  event of vomiting should be managed with the use of 
antiemetics.  Also, see guidance on h ydration in Section 11.3.
8. STUDY A SSESSMENTS A ND PROCEDURES
This section lists the parameters of each planned study  assessment.  The timing of each 
assessment for the Dose Escalation Phase is listed in the Time and Events Table 
(Section 8.1).  Further details for study  procedures and asse ssments can be found in the 
SRM.
The timing and number of planned study  assessments, including safet y, PK, and 
biomarker assessments, may  be altered during the course of the study  based on newly  
available data (e.g., to obtain data closer to the time of pe ak blood concentrations) to 
ensure appropriate monitoring.  An y addition or deletion of a stud y assessment, including 
any significant change in the timing or frequency  of an assessment, must be approved and 
documented b y [COMPANY_004], and will require a protocol am endment, except in a situation where 
additional assessments are required to immediately address an y safety concerns.  The 
institutional review board (I RB)/independent ethics committee (IEC) will be informed of 
any safet y issues that require alteration of t he safety  monitoring scheme.  No more than 
500 mL  of blood will be collected over a period of 30 day s, including any  extra 
assessments that may  be required.
Whenever vital signs, 12 -lead ECGs and blood draws are scheduled for the same nominal 
time, the ass essments should occur in the following order: 12 -lead ECG, vital signs, and 
then blood draws (see SRM for additional details).
Procedures conducted as part of the subject’s routine clinical management (e.g., blood 
count, imaging stud y) and obtained prior t o signing of informed consent may  be utilized 
for screening or baseline purposes provided the procedure meets the protocol -defined 
criteria and has been performed in the timeframe of the study .
2013N172718_04 CONFIDENTIA L
200331
848.1. Time and Events Tables
This section consists of the Time and E vents Tables and supplemental footnotes to 
describe the assessment windows and sequencing of study -specific assessments and 
procedures.
Additional unplanned blood, plasma and/or optional tumor samples may be requested 
with patient consent and investigator agreement as needed to better characterize safet y 
and response(s) in subjects.
2013N172718_04 CONFIDENTIA L
200331
85Table 15 Time and Events Table for Dose Escalation Phase
Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28
Extended
Follow -Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day    
-14 to
Day -1Day 1
to
Day 13Day 
14Wk 1, 
Day 1Wk 2, 
Day 8Wk 3, 
Day 
15Wk 4, 
Day 
22Wk 5, 
Day 
29Week 8 and every 4 
weeks thereafterEvery 3 
months
Visit Window +1 day 1 
day1
day1
day1
day+5 days Week 12 only; 
3 days for all other visits+1
day-2/+7 
days14 
days3 
days
Clinical Assessments
Informed Consent X3 X4
Demographics X
Medical History X
Determination of 
PTEN Deficiency 
StatusM5
Safety Assessments
ECOG PS X X X X X Week 8 and then Q 8wks X X X
Physical Exam X X Week 8 and then Q8wks X X
Height8 X
Weight X X Week 8 and then Q8wks X X
Vital Signs9 X X X X X X X X X
12-Lead ECG10 X6 X Week 8 and then Q8wks X X
ECHO/MUGA X6,7 As clini cally indicated
AE Monitoring Continuous X11 X11
Concomitant 
MedicationsX Continuous X
2013N172718_04 CONFIDENTIA L
200331
86Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28
Extended
Follow -Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day    
-14 to
Day -1Day 1
to
Day 13Day 
14Wk 1, 
Day 1Wk 2, 
Day 8Wk 3, 
Day 
15Wk 4, 
Day 
22Wk 5, 
Day 
29Week 8 and every 4 
weeks thereafterEvery 3 
months
Visit Window +1 day 1 
day1
day1
day1
day+5 days Week 12 only; 
3 days for all other visits+1
day-2/+7 
days14 
days3 
days
Laboratory Assessments12    
Hematology/
Clinical ChemistryX6 X33 X X X X X X X
Ionized Calcium X6 X X X X X X X X
Vitamin D34 X6 X X X
Coagulation: 
PT, PTT, INRX6 X X
Liver Function Tests X6 X X X X X X X X
Urinalysis13
Urine Microscopy13
UPC14X6 X X X X X
Urine Electrolytes15 X6 X33 X X X Week [ADDRESS_367791] Scan o r MRI19 X6,7 Week 8 and then Q8wks 
to Week 48; then 
Q12wksX X
2013N172718_04 CONFIDENTIA L
200331
87Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28
Extended
Follow -Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day    
-14 to
Day -1Day 1
to
Day 13Day 
14Wk 1, 
Day 1Wk 2, 
Day 8Wk 3, 
Day 
15Wk 4, 
Day 
22Wk 5, 
Day 
29Week 8 and every 4 
weeks thereafterEvery 3 
months
Visit Window +1 day 1 
day1
day1
day1
day+5 days Week 12 only; 
3 days for all other visits+1
day-2/+7 
days14 
days[ADDRESS_367792] ScanX6,7
Bone Scan20 X6,7 Week 12 and then 
Q12wksX X
Biomarker Assessments
CTC –-Janssen21 X X X Weeks 8, 16, 24, and 32 X
CTC –EPIC22 X Week 8 only X
Predictive 
Biomarker: Tumor 
Tissue23X
Progression Tumor 
Biopsy24X
Tumor Biopsies for 
Pharmaco -
dynamics24X X24
cfDNA/RNA/Soluble 
Mark ers25X X X Weeks 8, 16, 24, and 32 X
Blood Sample for 
Genetic Research26X
Study Treatments27
Enzalutamide Continuous Continuous
[COMPANY_004]2636771 Continuous
2013N172718_04 CONFIDENTIA L
200331
88Abbreviations: AE, adverse event; cfDNA, circulating -free tumo r DNA; CT, computed tomography; CTC, circulating tumor cells; ECG, electrocardiogram; ECHO, echocardiogram; 
ECOG, Eastern Cooperative Oncology Group; EOS, End of Study; HbA1C, hemoglobin A1C; INR, international normalization ratio; M, mandatory; MRI, magne tic resonance imaging; 
MUGA, multigated acquisition scan; O, optional; PD, pharmacodynamics; PK, pharmacokinetics; PS, performance status; PSA, pros tate-specific antigen; PT, prothrombin time; PTEN, 
phosphatase and tensin homolog; PTH, parathyroid hormone; PTT, partial thromboplastin time ; Q4wks, every 4 weeks; Q8wks, every 8 weeks; Q12wks, every 12 weeks; UPC, 
urine:protein:creatinine; Wk(s), week(s)
1. Study Assessments: All assessments may be performed more frequently if clinically appropriate. Assessments scheduled on days of dosing should be completed prior to the 
administration of study treatments, unless otherwise specified
2. Study Assessments: Assessments throughout the study are calendar based starting from Week 1, Day 1 of the Combination Treatment Per iod (the first dose of combination 
treatment).  Dose interruptions should not alter the assessment schedule for any subsequent treatment period.
3. Pre-Screen ing Informed Consent :Separate pre -screening informed consent must be obtained prior to initiation of any pre -screening procedures or assessments.
4. Screening Informed Consent : Informed consent must be obtained prior to initiation of any screening procedures or assessments ..
5. PTEN Deficiency Status (Mandatory): Tumor tissue samples (archived or fresh tumor t issue obtained by [CONTACT_094] -treatment biopsy) will be collected to determine PTEN deficiency 
status of the tumor by [CONTACT_119094].  Refer to the SRM for details about the number of slides to be subm itted, preparation, handling and shippi[INVESTIGATOR_007].  Results of 
the PTEN deficiency testing from the central laboratoryonly will be used to determine if the subject is eligible to continue Screening.  Only subjects with PTEN deficient tumor 
based on central laboratorytesting results will be screened.  Any re maining tumor tissue may be used for other predictive biomarker analyses if consent has been obtained.
6. Screening: When possible, screening assessments that require imaging, ECG, ECHO/MUGA, or laboratory studies should be performed AFTER PT EN status has bee n 
determined.
7. Screening: All screening assessments must be completed and all entry criteria must be met prior to assessments on Day 1 of Enzalutamide Run -In Period .  EXCEPTION:  
ECHO /MUGA must be completed within 28 days of enrollment (Day 1 of Enzalutamid e Run -In Period), and disease assessment must be completed within 28 days (35 days if MRI 
is used) prior to enrollment (Day 1 of the Enzalutamide Run -In Period) .
8. Height is only measured at Screening .
9. Vital Signs:  Blood pressure, temperature and heart ratewill be measured.  Vital signs may be measured more frequently if clinical lywarranted.
10. ECG: A single 12 -lead ECG is to be performed before vital signs are measured and any blood draws, if assessments are planned at the same nominal time point.
11. AE Monitor ing: Continued monitoring of AEs applies only to ongoing events at time of treatment discontinuation.
12. Laboratory Assessments: Refer to Section 8.6.6 (Table 17) for list of specific laboratory tests to be performed.  Assessments may be performed within 24 hrs prior to scheduled 
visit (liver function tests and urine tests for UPC may be performed up to 72 hrs prior to a scheduled visit) to ensure avail ability of results.
13. Urinalysis and Urine Microscopy:  Urinalysis and urine microscopy will be performed at the time points indicated .Assessments may be performed within 24 hrs prior to a 
scheduled visit to ensure availability of results.
14. UPC:   Urine sample for UPC is to be col lected at the time points indicated. Perform UPC with the first morning urine specimen (if possible) when urine dipstick protein 2+.  Urine 
samples for UPC may be collected up to [ADDRESS_367793] will remain eligible for the study.
15. Urine Electrolytes:   Urine samples will be obtained at Screening, pre -dose on Day 1 (Week 1), Day 3 OR Day 4, Day 15 (Week 3), Day 22 (Week 4) of the Combination 
Treatment Period, Week 8 and then every 8 weeks ( 3 days) thereafter during the Treatment Continuation Period, and at the post -treatment follow -up visit to determine urine 
electrolytes (magnesium, phosphorus and calcium) and urine creatinine.
16. Parathyroid Hormone (PTH): Assessment of PTH will be performed if a Grade 2 or higher hypocalcemia or hypophosphatemia is reported.
2013N172718_04 CONFIDENTIA L
[PHONE_6254]. PK Blood Sampling:  Day 14 (Enzalutamide Run -In Period): Plasma samples for analysis of enzalutamide and N -desmethyl enzalutamide will be collected at pre-dose and 0.5, 
1, 2, 3, 4, and [ADDRESS_367794] dose of combination study treatment ([COMPANY_004]2636771 and 
enzalutamide) . Week 5, Day 29 (Treatment Continuation Period): Blood and plasma samples for analysis of [COMPANY_004]2636771, enzalutamide and N -desmethyl enzalutamide will be 
collected at pre -dose and 0.5, 1, 2, 3, 4, and [ADDRESS_367795]-dose .  Week 8 and Week 12 (Treatment Continuation Period): Blood and plasma samples for analysis of [COMPANY_004]2636771, enzalutamide and N -
desmethyl enzalutamide will be collected pre -dose only.
18. Diseas e Assessments: Disease assessments at Screening must be performed within 28 days prior to enrollment (Day 1 of the Enzalutamide Run -In Period), or within 35 days 
prior to enrollment (Day [ADDRESS_367796] scan or MRI:   Scans should be performed at Screening, Week 8 and then every 8 weeks ( 7 days) during the first 48 weeks of the Treatment Continuation Period and then 
every 12 weeks ( 7 days) thereafte r in the Treatment Continuation Period, and at the time of disease progression.  All confirmatory scans are to be performed w ithin 4 weeks 
(3days) of a CR or PR.  If a subject discontinues treatment for reasons other than disease progression, disease ass essments should continue every [ADDRESS_367797] withdrawal of consent, or death.
20. Bone Scan:   A bone scan is required for all subjects at Screening.  For subjects without bone disease at ba seline, subsequent bone scans should be performed as clinically 
indicated.  Subjects with bone metastases at baseline should have a bone scan performed at Week 12 and then every 12 weeks ( 7days) thereafter in the Treatment 
Continuation Period, or as clin ically indicated, and at the time of disease progression .  If a subject discontinues treatment for reasons other than disease progression, bone scans 
should continue every [ADDRESS_367798] withdrawal of consent, or death.
21. CTC-Janssen:   Whole blood samples will be obtained at Screening; pre -dose on Day 1 (Week 1) and Day 22 (Week 4) of the Combination Treatment Period; pre -dose on Day 1 
of Weeks 8, 16, 24 and 32 of the Treatment Continuation Period; and at time of disease progression.
22. CTC-EPIC:  Whole blood samples will be obtained at Screening, pre -dose on Day 1 of Week 8 of the Treatment Continuation Period, and at the time of disease progression for 
protein and genomic analysis.
23. Predictive Biomarkers Tumor Tissue:  For subjects enrolled into the study, additional slides of tumor tissue samples will be collected and submitted to the design ated laboratory 
for analysis once a subject has received their first dose of [COMPANY_004]2636771 on Week 1, Day 1 of the Combination Treatment Period.  Tumor tissue may be obtained from archived 
tissue samples or fresh tumor tissue submitted for the PTEN testing.  If additional tumor tissue is not available, no new bio psy procedure is required for predictive biomarke r 
analysis.  Refer to the SRM for details about the number of slides to be submitted, preparation, handling and shippi[INVESTIGATOR_007].
24. Tumor Biopsies for PD and progression : These biopsies are optional and may be undertaken in select cases upon agreement with the inves tigator and when consent is 
provided by [CONTACT_423]. For pharmacodynamic biomarker analyses, fresh tissue biopsies would be collected between Day 12 of the Enzalutamide Run -in Period and Week 
1/Day 1, prior to any treatment with [COMPANY_004]2636771, and [ADDRESS_367799] dose between Days 8 and 15 of the Combination Treatment Period (post -treatment).   For subjects who 
consent to the optional progression biopsy, a fresh tumor biopsy should be completed if the subject initially responded to co mbination treatment and then progressed.
25. cfDNA/RNA/Soluble Markers:   Plasma samples will be obtained from collected blood samples at Screening, pre -dose on Weeks 1, 4, 8, 16, 24, and 32 of the Combination 
Treatment Period, and at the time of treatment discontinuation due to disease p rogression.  Plasma will be analyzed for genomic changes in the circulating tumor DNA, RNA, and 
soluble markers.
26. Genetic Research: A 6-mL blood sample should be collected after Screening, preferably on Week 1, Day 1 of the Combination Treatment Period, if informed consent has been 
obtained for genetic research.
27. Study Treatment: Enzalutamide monotherapy should be taken once daily during the Enzalutamide Run -In Period.  Enzalutimide will be self adiministered in the clinic on Day 14 
of the Enzalutamide Run -InPeriod.  [COMPANY_004]2636771 and enzalutamide will be administered in the clinic on Week 1, Day 1 of the Combination Treatment Period and on days when 
blood, plasma, and/or urine samples are collected for analysis of PK, CTC, and/or urine electrolytes.
2013N172718_04 CONFIDENTIA L
[PHONE_6255]. Post -Treatm ent Follow -UpVisit : ONLY subjects who withdraw during the Enzalutamide Run -In Period or withdraw from study treatment due to   disease progression (see 
Section 5.2)should have a post -treatment follow -up visit conducted within approximately 30 days ( -2/+7 days) of last dose of study treatment(s).  If a subject is unable 
to return to the clinic due to hospi[INVESTIGATOR_059], site staff is encouraged to call subject for assessment of AEs.   
29. Extended Follow -UpVisits :  Subjects who withdraw from study treatment without disease progression should be contact[CONTACT_457] 3 months ( 14 days) until disease 
progression, death, withdrawal of consent, or subject is lost to follow -up.  Contact [CONTACT_301179] a clinic visit, a telephone co ntact ,or an e-mail.  The initiation of any new anti -cancer 
treatments and date of last contact [CONTACT_28801].
30. Post -Extended Follow -Up/EOS Visit:   ONLY subjects who discontinue the Extended Follow -Up Visits should have a Post -Extended Follow -Up/EOS Visit performed.
31. Subjects are not required to discontinue treatment on the basis of PSA progression alone or for the worsening of an isolated disease site that is not clinically significant (see 
Section 5.2).
32. When collected as part of the routine standard of care for a subject, LDH will be reported.
33. Complete clinical chemistries laboratory assessments at Week1/Day 1 and again on either Day 3 or Day 4 .  The Day 3 or Day 4 assessments can be completed at a local 
laboratory and does notrequire a clinic visit.   The hematology panel does NOT need to be collected on Day 3/ Day.4. Review of these labs must occur before Week 2, Day 1 visit. 
34. Includes assessments for 25-OH D and 1,25 -OH2 D .
35. Includes urine and blood and/o r serum samples.  Must be collected at the same time of day ( 1 hour) to eliminate diurnal effects, and after fasting.  See SRM for additional details 
on the specific assessments and sample collection.  
2013N172718_04 CONFIDENTIA L
200331
91Table 16 Time and Events Tab le for Dose Expansion Phase
Study Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment Follow-Up 
Visit28
Extended
Follow -Up  
Visits29Post -
Extende
d Follow -
Up
/EOS 
Visit30
Day -14 
to
Day -1Day 1 to Day 
14Wk 1, 
Day 1Wk 2, 
Day 8Wk 3, 
Day 
15Wk 4, 
Day 
22Week 
5, Day 
29Week 8 and every 4 
weeks thereafterEvery 3 
months
Visit W indow +1 
day1 
day1
day1
day1
day+5days Week 12 only; 
3 days for all other 
visits+1
day-2/+7 
days14 
days3 
days
Clinical Assessments
Informed Consent X3 X4
Demographics X
Medical History X
Determin ation of PTEN 
Deficiency StatusM5
Safety Assessments
ECOG PS X X X X X Week 8 and then 
Q8wksX X X
Physical Exam X X Week 8 and then 
Q8wksX X
Height8 X
Weight X X Week 8 and then 
Q8wksX X
Vital Signs9 X X X X X X X X X
12-Lead ECG10 X6 X Week 8 and then 
Q8wksX X
ECHO/MUGA X6,7 As clinically indicated
AE Monitoring Continuous X11 X11
2013N172718_04 CONFIDENTIA L
200331
92Study Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment Follow-Up 
Visit28
Extended
Follow -Up  
Visits29Post -
Extende
d Follow -
Up
/EOS 
Visit30
Day -14 
to
Day -1Day 1 to Day 
14Wk 1, 
Day 1Wk 2, 
Day 8Wk 3, 
Day 
15Wk 4, 
Day 
22Week 
5, Day 
29Week 8 and every 4 
weeks thereafterEvery 3 
months
Visit W indow +1 
day1 
day1
day1
day1
day+5days Week 12 only; 
3 days for all other 
visits+1
day-2/+7 
days14 
days3 
days
Concomitant Medications X Continuous X
Laboratory Assessments12
Hematology/
Clinical Chemis tryX6 X X X X X X X X
Ionized Calcium X6 X33 X X X X X X X
Vitamin D34 X6 X X X
Coagulation: 
PT, PTT, INRX6 X X
Liver function Tests X6 X X X X X X X X
Urinalysis13
Urine Microscopy13
UPC14X6 X X X X X
Urine Electrolytes15 X6 X33 X X Week 8 and then 
Q8wksX
Parathyroid Hormone X As clinically indicated16
Bone Markers35 X X Weeks  12 and  24 X X
PSA and LDH32 X6 X X X X X
Serum Testosterone X6 X X
PK Assessments
PK Blood Sampling17 X Weeks 8 and 12
2013N172718_04 CONFIDENTIA L
200331
93Study Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment Follow-Up 
Visit28
Extended
Follow -Up  
Visits29Post -
Extende
d Follow -
Up
/EOS 
Visit30
Day -14 
to
Day -1Day 1 to Day 
14Wk 1, 
Day 1Wk 2, 
Day 8Wk 3, 
Day 
15Wk 4, 
Day 
22Week 
5, Day 
29Week 8 and every 4 
weeks thereafterEvery 3 
months
Visit W indow +1 
day1 
day1
day1
day1
day+5days Week 12 only; 
3 days for all other 
visits+1
day-2/+7 
days14 
days[ADDRESS_367800] scan or MRI19 X6,7 Week 8 and then 
Q8wks to Week 48; 
then Q12wksX X
Chest X -ray or Chest CT 
scanX6,7
Bone Scan20 X6,7 Week 12 and then 
Q12wksX X
Biomarker Assessments
CTC –Janssen21 X X X Weeks 8, 16, 24, and 
32X
CTC –EPIC22 X Week 8 only X
Predictive Biomarker: 
Tumor Tissue23X
Progression Tumor 
Biopsy24X
Tumor Biopsies for 
Pharmacodynamics24X (Day 14) X24
cfDNA/RNA/Soluble 
Markers25X X X Weeks 8, 16, 24, and 
32X
2013N172718_04 CONFIDENTIA L
200331
94Study Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment Follow-Up 
Visit28
Extended
Follow -Up  
Visits29Post -
Extende
d Follow -
Up
/EOS 
Visit30
Day -14 
to
Day -1Day 1 to Day 
14Wk 1, 
Day 1Wk 2, 
Day 8Wk 3, 
Day 
15Wk 4, 
Day 
22Week 
5, Day 
29Week 8 and every 4 
weeks thereafterEvery 3 
months
Visit W indow +1 
day1 
day1
day1
day1
day+5days Week 12 only; 
3 days for all other 
visits+1
day-2/+7 
days14 
days3 
days
Biomarker Assessments continued
Blood Sample for 
Genetic Research26X
Study Treatments27
Enzalutamide Continuous Continuous
[COMPANY_004]2636771 Continuous
Abbreviations: AE, adverse event; cfDNA, circulating -free tumor DNA; CT, computed tomography; CTC, circulating tumor cells; ECG, electrocardiogram; ECHO, echocardiogram; 
ECOG, Eastern Cooperative Oncology Group; EOS, End of Study; HbA1C, hemoglobin A1C; INR, international normalization ratio; M, mandatory; MRI, magnetic resonance imaging; 
MUGA, multigated acquisition scan; O, optional; PD, pharmacodynamics; PK, pharmacokinetics; PS, performance status; PSA, pros tate-specific antigen; PT, p rothrombin time; PTEN, 
phosphatase and tensin homolog; PTH, parathyroid hormone; PTT, partial thromboplastin time ; Q4wks, every 4 weeks; Q8wks, every 8 weeks; Q12wks, every 12 weeks; UPC, 
urine:protein:creatinine; Wk(s), week(s)
1. Study Assessments: All assessments may be performed more frequently if clinically appropriate. Assessments scheduled on days of dosing should be comple ted prior to the 
administration of study treatments, unless otherwise specified
2. Study Assessments: Assessments throughout the study are calendar based starting from Week 1, Day 1 of the Combination Treatment Period (the first dose of combination 
treatment).  Dose interruptions should not alter the assessment schedule for any subsequent treatment period.
3. Pre-Screen ing Informed Consent :Separate pre -screening informed consent must be obtained prior to initiation of any pre -screening procedures or assessments.
4. Screening Informed Consent : Informed consent must be obtained prior to initiation of any screening procedures or assessments ..
5. PTEN Deficiency Status (Mandatory): Tumor tissue samples (archived or fresh tumor tissue obtained by [CONTACT_094] -treatment biopsy) will be collected to determine PTEN deficiency 
status of the tumor by [CONTACT_119094].  Refer to the SRM for details a bout the number of slides to be submitted, preparation, handling and shippi[INVESTIGATOR_007].  Results of 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367801] is eligible to continue Screening.  Only subjects with PTEN defi cient tumor 
based on central laboratorytesting results will be screened.  Any remaining tumor tissue may be used for other predictive biomarker analyses if consent has been obtained.
6. Screening: When possible, screening assessments that require imaging, ECG , ECHO/MUGA, or laboratory studies should be performed AFTER PTEN status has been 
determined.
7. Screening: All screening assessments must be completed and all entry criteria must be met prior to assessments on Day 1 of Enzalutamide Run -In Period .  EXCEPTION:   
ECHO /MUGA must be completed within 28 days of enrollment (Day 1 of Enzalutamide Run -In Period), and disease assessment must be completed within 28 days (35 days if MRI 
is used) prior to enrollment (Day 1 of the Enzalutamide Run -In Period) .
8. Height is only measured at Screening .
9. Vital Signs:  Blood pressure, temperature and heart rate will be measured.  Vital signs may be measured more frequently if clinical lywarranted.
10. ECG: A single 12 -lead ECG is to be performed before vital signs are measured and any bl ood draws, if assessments are planned at the same nominal time point.
11. AE Monitoring: Continued monitoring of AEs applies only to ongoing events at time of treatment discontinuation.
12. Laboratory Assessments: Refer to Section 8.6.6 (Table 17)for list of specific laboratory tests to be performed.  Assessments may be performed within 24 hrs prior to scheduled 
visit (liver function tests and urine tests for UPC may be performe d up to 72 hrs prior to a scheduled visit) to ensure availability of results.
13. Urinalysis and Urine Microscopy:  Urinalysis and urine microscopy will be performed at the time points indicated .Assessments may be performed within 24 hrs prior to a 
scheduled visit to ensure availability of results.
14. UPC:   Urine sample for UPC is to be collected at the time points indicated. Perform UPC with the first morning urine specimen (if possible) when urine dipstick protein 2+.  Urine 
samples for UPC may be collected up to [ADDRESS_367802] will remain eligible for the study.
15. Urine Electrolytes:   Urine samples will be obtained at Screening, pre -dose on Day 1 (Week 1), Day 3 OR Day 4, Day 15 (Week 3), Day 22 (Week 4) of the Combination 
Treatment Period, Week 8 and then every 8 weeks ( 3 days) thereafter during the Treatment Conti nuation Period, and at the post -treatment follow -up visit to determine urine 
electrolytes (magnesium, phosphorus and calcium) and urine creatinine.
16. Parathyroid Hormone (PTH): Assessment of PTH will be performed if a Grade 2 or higher hypocalcemia or hypoph osphatemia is reported.
17. PK Blood Sampling:  Week 5, Day 29 (Treatment Continuation Period): Blood and plasma samples for analysis of [COMPANY_004]2636771, enzalutamide and N -desmethyl enzalutamide 
will be collected at pre -dose and 1, 2,and3 hrs post -dose if a morn ing clinic visit is scheduled, or at approximately [ADDRESS_367803]-dose .  Week 8 
andWeek 12 (Treatment Continuation Period): Blood and plasma samples for analysis of [COMPANY_004]2636771, enzalutamide and N -desmethyl enzalutamide will be collected pre -
dose only.
18. Disease Assessments: Disease assessments at Screening must be performed within 28 days prior to enrollment (Day 1 of the Enzalu tamide Run -In Period), or within 35 days 
prior to enrollment (Day [ADDRESS_367804] scan or MRI:   Scans should be performed at Screening, Week 8 and then every 8 weeks ( 7 days) during the first 48 weeks of the Treatment Continuation Period and then 
every 12 weeks ( 7 days) thereafter in the Treatment Continuation Period, and at the time of disease progression.  All confirmatory scans are to be perform ed within 4 weeks 
(3days) of a CR or PR.  If a subject discontinues treatment for reasons other than disease progression, disease assessments sho uld continue every [ADDRESS_367805] withd rawal of consent, or death.
20. Bone Scan:   A bone scan is required for all subjects at Screening.  For subjects without bone disease at baseline, subsequent bone scans should be performed as clinically 
indicated.  Subjects with bone metastases at baseline sho uld have a bone scan performed at Week 12 and then every 12 weeks ( 7days) thereafter in the Treatment 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367806] withdrawal of consent, or death.
21. CTC-Janssen:   Whole blood samples will be obtained at Screening; pre -dose on Day 1 (Wee k 1) and Day 22 (Week 4) of the Combination Treatment Period; pre -dose on Day 1 
of Weeks 8, 16, 24 and 32 of the Treatment Continuation Period; and at time of disease progression.
22. CTC-EPIC:  Whole blood samples will be obtained at Screening, pre -dose on Da y 1 of Week 8 of the Treatment Continuation Period, and at the time of disease progression for 
protein and genomic analysis.
23. Predictive Biomarkers Tumor Tissue:  For subjects enrolled into the study, additional slides of tumor tissue samples will be collec ted and submitted to the designated laboratory 
for analysis once a subject has received their first dose of [COMPANY_004]2636771 on Week 1, Day 1 of the Combination Treatment Period.   Tumor tissue may be obtained from archived 
tissue samples or fresh tumor tissue su bmitted for the PTEN testing.  If additional tumor tissue is not available, no new biopsy procedure is required for predictiv e biomarker 
analysis.  Refer to the SRM for details about the number of slides to be submitted, preparation, handling and shippi[INVESTIGATOR_007].
24. Tumor Biopsies for PD and progression : These biopsies are optional and may be undertaken in select cases upon agreement with the investigator and when consent is 
provided by [CONTACT_423]. For pharmacodynamic biomarker analyses, fresh tissue biopsies would be collected between Day 12 of the Enzalutamide Run -in Period and Week 
1/Day 1, prior to any treatment with [COMPANY_004]2636771, and [ADDRESS_367807] dose between Days 8 and 15 of the Combination Treatment Period (post -treatment).   For subjects who 
consent to the opt ional progression biopsy, a fresh tumor biopsy should be completed if the subject initially responded to combination treatmen t and then progressed. .
25. cfDNA/RNA/Soluble Markers:   Plasma samples will be obtained from collected blood samples at Screening, pre -dose on Weeks 1, 4, 8, 16, 24, and 32 of the Combination 
Treatment Period, and at the time of discontinuation of treatment due to disease progression.  Plasma will be analyzed for ge nomic changes in the circulating tumor DNA, RNA, 
and soluble markers.
26. Gene tic Research: A 6-mL blood sample should be collected after Screening, preferably on Week 1, Day 1 of the Combination Treatment Period, if informed consent has been 
obtained for genetic research.
27. Study Treatment: Enzalutamide monotherapy should be taken on ce daily during the Enzalutamide Run -In Period.  Enzalutimide will be self adiministered in the clinic on Day 14 
of the Enzalutamide Run -In Period.  [COMPANY_004]2636771 and enzalutamide will be administered in the clinic on Week 1, Day 1 of the Combination Treatmen t Period and on days when 
blood, plasma, and/or urine samples are collected for analysis of PK, CTC, and/or urine electrolytes.
28. Post -Treatment Follow -UpVisit : ONLY subjects who withdraw during the Enzalutamide Run -In Period or withdraw from study treatme nt due to disease progression see 
Section 5.2) should have a post -treatment follow -up visit conducted within approximately 30 days ( -2/+7 days) of last dose of study treatment(s).  If a subject is unable to retu rn to 
the clinic due to hospi[INVESTIGATOR_059], site staff is encouraged to call subject for assessment of AEs.   
29. Extended Follow -UpVisits :  Subjects who withdraw from study treatment without disease progression should be contact[CONTACT_457] 3 months ( 14 days) unti l disease 
progression, death, withdrawal of consent, or subject is lost to follow -up.  Contact [CONTACT_301179] a clinic visit, a telephone contact ,or an e-mail.  The initiation of any new anti -cancer 
treatments and date of last contact [CONTACT_28801].
30. Post-Extended Follow -Up/EOS Visit:   ONLY subjects who discontinue the Extended Follow -Up Visits should have a Post -Extended Follow -Up/EOS Visit performed.
31. These assessments should be completed at the time of disease progression that leads to discontinuation of treatment.  Subjects are not required to discontinue treatment on the 
basis of PSA progression alone or for the worsening of an isolated disease site that is not clinically significant (see Section 5.2).
32. When collected as part of the routine standard of care for a subject, LDH will be reported.
33. Complete clinical chemistries laboratory assessments at Week1/Day 1 and again on either Day 3 or Day 4 .  The Day 3 or Day 4 assessments can be completed at a local 
laboratory and does notrequire a clinic visit.  The hematology panel does NOT need to be collected on Day 3/ Day.4. Review of these labs must occur before Week 2, Day 1 visit.
34. Includes assessments for 25-OH D and 1,25 -OH2 D . 
35. Includes urine and blood and/or serum samples.  Must be collected at the same time of day ( 1 hour) to eliminate diurnal effects, and after fasting.  See SRM for additional details 
on the specific assessments and sample collection
2013N172718_04 CONFIDENTIA L
[ADDRESS_367808] adequate time to provide written informed consent of his or her 
own free will and prior to conducting an y study procedures according to International 
Conference on Harmon ization (I CH) and applicable local regulations and guidelines.  
Each subject will be provided a cop y of their signed I CF prior to the initiation of any  
study  procedures.
8.2.1. Consent for Pre -Screening
The subject will be asked to provide written informed consen t for pre -screening prior to 
any of the pre -screening assessments outlined in the Time and Events Tables 
(Section 8.1) being performed.
8.2.2. Consent for Screening
If, during pre -screening, the subject is determined t o have a PTEN deficient tumor, the 
subject will be asked to provide written informed consent prior to screening for 
enrollment in the study .  The investigator or other designated study  personnel will 
determine if the subject is eligible for enrollment in t he study  by [CONTACT_301180] 8.1.
8.3. Pre-Screening and Screening
8.3.1. Pre-Screening:  Determination of PTEN Deficiency  Status
A pre -screening assessment must be completed to determine the PTEN deficiency  status 
of the subject’s tumor. 
After written informed consent is provided by  [CONTACT_423], archived tissue will be 
submitted to determine the PTEN deficien cy status of the subject’s tumor.  If archival 
tumor tissue is not available, fresh tumor tissue should be obtained by  a pre -treatment 
biopsy  to determine PTEN deficiency .  The PTEN testing will be performed at a [COMPANY_004] 
selected laboratory  or laboratories and the tumor specimen should be provided to that 
laboratory  or laboratories.  The PTEN status will be communicated to sites by  [CONTACT_301181].
If anal ysis of the archival tumor tissue specimen is not PTEN -deficient, fresh tumor 
tissue may  be submit ted to determine PTEN deficiency .
Details regarding pre -screening assessment and procedures with handling, processing and 
shippi[INVESTIGATOR_301085].
2013N172718_04 CONFIDENTIA L
[ADDRESS_367809] provide written info rmed consent for 
screening will be eligible to undergo specific screening assessments to determine 
eligibility  for the study .
Screening assessments and procedures will be performed as indicated in the Time and 
Events Tables (Section 8.1).  Screening assessments may  be carried out over one or more 
days but should be completed within [ADDRESS_367810] planned dose of 
enzalutamide monotherapy  (Day  1 of Enzalutamide Run -In Period), unless otherwise 
indicated .
Details regarding screening assessments and procedures are provided in the SRM.
8.4. Demographics and Medical History
Demographic data will include gender, year of birth, height, weight, ethnicity and 
geographic ancestry .
Medical, surgical, and treatment hist ory including date of first diagnosis, histology , 
current sites of disease as well as cardiovascular risk factors, alcohol and tobacco history , 
plus family  history  will be taken as part of the medical history  and disease status.
8.5. Critical Baseline A ssessmen t
Cardiovascular medical history /risk factors will be assessed at baseline.
8.6. Safet y
Measurements used to evaluate safet y will include physical examinations, vital sign (BP, 
temperature and heart rate) measurements, ECOG performance status, 12 -lead ECGs, 
ECH O/MUGA, clinical laboratory  tests and monitoring for AEs.  Planned time points for 
all safet y assessments are listed in the applicable Time and Events Tables (Section 8.1).
Additional time points for safet y test s (such as vital signs, ph ysical examinations or 
laboratory  tests) may  be added during the course of the study  based on newly  available 
data to ensure appropriate safet y monitoring.
8.6.1. Physical Examination
A complete ph ysical examination will be performed by  a qualified ph ysician according to 
local practices.  At minimum, the examination should include assessments of the head 
and neck, ey es, ears, nose, throat, skin, thy roid, neurological, lungs, cardiovascular, 
abdomen (liver and spleen), ly mph nodes and extr emities.  Complete phy sical 
examinations will be performed as indicated in the Time and Events Tables (Section 8.1) 
and as medicall y indicated throughout the stud y.
Height and weight will be measured and recorde d as indicated in the Time and Event 
Tables (Section 8.1).
2013N172718_04 CONFIDENTIA L
200331
998.6.2. Vital Signs
Vital sign measurements will include BP, temperature, and heart rate.  Vital signs may  be 
measured as indicated in the Time and Event Tables (Section 8.1) or more frequentl y if 
warranted b y clinical condition of the subject.  Refer to the SRM for details regarding 
measurement of vital signs.
8.6.3. ECOG Performance Status
A subject’s performance status wil l be assessed using the ECOG performance status scale 
(Appendix 1 ) as indicated in the Time and Events Tables (Section 8.1).
8.6.4. Electrocardiogram
Electrocardiograms (12 -Lead EC Gs) will be performed as indicated in the Time and 
Events Tables (Section 8.1) and obtained using an ECG machine that automatically  
calculates the heart rate and measures PR, QRS, QT, and QTc intervals.
At each assessment, a [ADDRESS_367811] 5 minutes in a semi -recumbent or supi[INVESTIGATOR_12251].
If there are an y clinicall y significant abnormalities including, but not limited to, 
QTcF >[ADDRESS_367812] 5 minutes apart.
Refer to Section 7.2.1 for QTc stoppi[INVESTIGATOR_301086] .
Results of the ECG will be transmi tted to a central storage facility .  An y duplicate 
ECGs performed will be collected and evaluated, transmitted and stored in the same 
manner.
Electrocardiograms (ECGs) may  be centrall y reviewed during the stud y on a post -
hoc basis in response to any  potent ial ECG safet y concerns or at the end of the study .  
Any findings will be summarized and shared with study  investigators but are not 
intended for individual subject safet y management.
Refer to the SRM for further details on submission of ECGs.
8.6.5. Echocardiogr am and/or Multi -gated A cquisition (MUG A) Scans
Echocardiograms (ECHOs) or MUGA scans will be performed at baseline to assess 
cardiac ejection fraction and cardiac valve morphology  for the purpose of study  
eligibility , as specified in the Time and Events Ta bles (Section 8.1).  Additional ECHO 
assessments may  be performed if clinicall y warranted.  The evaluation of the 
echocardiographer should include an evaluation for LVEF and both right and left -sided 
valvular le sions.
Copi[INVESTIGATOR_301087] >10% in LVEF compared to baseline concurrent with LVEF < institutional LLN 
may be required by  [CONTACT_301172].
2013N172718_04 CONFIDENTIA L
[ADDRESS_367813] with a laboratory  value outside 
the reference range(s) may  be included onl y if the investigator and [COMPANY_004] Medical Monitor 
agree that it is unlikely  to introduce additional risk factors and will not interfere with 
study  procedures.
All laboratory  tests with values that are significantly  abnormal during participation in the 
study  or within [ADDRESS_367814] dose of stud y treatments should be repeated until the 
values return to normal or baseline.  If such values do not return to normal within a 
period judged reasonable by  [CONTACT_093], the etiology  should be identified and the 
sponsor notified.
If additional non -protocol -specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (i.e., AE, SAE or dose modification) 
the results must be recorded in the subject’s eCRF.
All laboratory  samples must be appropriatel y labelled and submitt ed with the applicable 
laboratory  requisition form(s) according to central or local laboratory  guidelines.  
Reference ranges will be provided to the site for each laboratory  used b y the site during 
the course of the study .
Refer to the SRM for details on t he appropriate processing, handling and shippi[INVESTIGATOR_301088]/or additional blood draws.
2013N172718_04 CONFIDENTIA L
200331
101Table 17 Clinical Laboratory  Assessments
Hematology
Platelet Count RBC Indices : Automated WBC Differential :
WBC Count ( absolute) MCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Clinical Chemistry
BUN Potassium AST Total and direct bilirubin 1
Creatinine Chloride2ALT Uric Acid2
Glucose Total CO 2 Alkaline phosphatase Albumin
Sodium Calcium Lactate dehydrogenase4Total Protein
Magnesium Phosphate
Urine Testing
Urinalysis Specific gravity
pH, glucose, protein, blood and ketones by [CONTACT_301182] (if clinically warranted or protein >1)
UPC3
Urine electrolytes Urinary calcium, magnesium and phosphorus; urine creatinine from same urine 
specimen
Other tests
PSA 
Serum Testosterone
Coagulation Tests: PT/PTT/INR
Serum Parathyroid Hormone (PTH)
Ionized Calcium
25-OH D and 1,25 -OH2 D
Bone Markers 5
Abbreviations: ALT , alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; INR, 
international normalization ratio; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume; PSA, prostate -
specific antigen; PT, prothrombin time; PTH, parath yroid hormone; PTT, partial thromboplastin time; RBC, red blood 
cell; ULN, upper limit of normal; UPC, urine/protein/creatinine ratio; WBC, white blood cell
1. Direct bilirubin is required only if the total bilirubin is elevated ( [ADDRESS_367815])
2. Chemistry evalu ation of chloride or uric acid is not required where there are logistical constraints.
3. See Appendix [ADDRESS_367816] this information.
5. Refer to SRM
8.7. Pharmacokinetic Assessments
8.7.1. PK A ssessments: Dose E scalation Phase
Plasma samples for PK analy sis of enzalutamide and N -desmeth yl enzalutamide will be 
collected from all subjects on Day  [ADDRESS_367817] of [COMPANY_004]2636771 on the PK of enzalutamide and to quan tify 
the sy stemic exposure to [COMPANY_004]2636771, enzalutamide and N -desmethy l enzalutamide.
2013N172718_04 CONFIDENTIA L
[PHONE_6256].7.2. PK A ssessments:  Dose Expansion Phase
A reduced PK sampling strategy  will be used for subjects in the Dose Expansion Phase 
(on Day  29 of Week 5).  Pre -dose blood and plasm a samples will also be collected on 
Day 1 of Weeks 8 and 12 of the Treatment Continuation Period) to quantify the s ystemic 
exposure to [COMPANY_004]2636771, enzalutamide and N -desmethy l enzalutamide.
8.7.3. PK Blood Sample Collection
Blood and/or plasma samples for PK anal ysis of [COMPANY_004]2636771 and/or enzalutamide and 
N-desmeth yl enzalutamide will be collected at the time points indicated in the Time and 
Events Tables (see Section 8.1).  Whenever possible, blood for PK samples should be 
drawn from the peripheral arm vein or from a central IV port.  Each PK sample should be 
collected as close as possible to the planned time relative to the dose (i.e., time zero) 
administered to the subject on serial PK day s.  Once preliminary  PK data h ave been 
reviewed, the planned sample collection times or study  day may  be revised based on 
newly  available data (i.e., to obtain data closer to the time of peak plasma concentration) 
to ensure appropriate monitoring.  These changes must be approved and do cumented b y 
[COMPANY_004], but will not constitute a protocol amendment.  
For Dose Escalation Phase:  Blood and/or plasma samples for anal ysis of [COMPANY_004]2636771, 
enzalutamide and N -desmethy l enzalutamide will be collected according to a serial 
sampling scheme in the Do se Escalation Phase.  
Day 14 (Enzalutamide Run -In Period); the day prior to administration of the 
first dose of [COMPANY_004]2636771):  Subjects will be instructed to fast overnight (at least 
8 hrs) and withhold their dose of enzalutamide prior to the study  visit o n Day 14.  
Study  treatments will be administered in the clinic after the pre -dose blood draw 
is completed.  Subjects will continue to fast for [ADDRESS_367818] -dose of enzalutamide (total of 
7samples).
Day 29, Week 5 (Treatment Continuation Period): Subjects will be instructed 
to fast overnight (at least 8 hrs) and withhold the doses of study  treatment prior to 
the stu dy visit. Study  treatments will be administered in the clinic after the pre -
dose blood draws are completed.  Subjects will continue to fast for [ADDRESS_367819] -dose (total of 14 samples).
Weeks 8 and 12 (Treatment Continuation Period):  Subjects will be instructed 
to withhold the doses of study  treatment prior to the study  visit (no overnight fast 
is necessary ). Study  treatments will be administered in the clinic after the pre -
dose blood draws are completed, either 1 hr before or 2 hrs after a meal. Blood 
and plasma samples for the anal ysis of [COMPANY_004]2636771, enzalutamide and N -
desmethy l enzalutami de will be collected pre -dose only  (total of 2 samples per 
visit).
2013N172718_04 CONFIDENTIA L
200331
103For Dose Expansion Phase:  Blood and plasma samples for analy sis of [COMPANY_004]2636771, 
enzalutamide and N -desmethy l enzalutamide will be collected according to a sparse 
sampling scheme in the Dose Expansion Phase.  Overnight fast is not necessary  for any  
of these PK day s. Study  treatments should be administered either 1 hr before or 2 hrs 
after a meal.
Day 29, Week 5 (Treatment Continuation Period):  
oSubjects scheduled for a morning clinic visit w ill be instructed to withhold 
the doses of study  treatments prior to the study  visit.  Study  treatments will 
be administered in the clinic after the pre -dose blood draws are completed 
(either 1 hr before or 2 hrs after a meal). Blood and plasma samples for
analysis of [COMPANY_004]2636771, enzalutamide and N -desmethy l enzalutamide 
will be collected at pre -dose and 1, 2, and [ADDRESS_367820] -dose (total of 
8samples).
oSubjects scheduled for an afternoon clinic visit will take their doses of 
study  treatments at the usual tim e in the morning (either 1 hr before or 
2hrs after a meal).  Blood and plasma samples for anal ysis of 
[COMPANY_004]2636771, enzalutamide and N -desmethy l enzalutamide will be 
collected approximately  [ADDRESS_367821] -dose (total of 
6samples).
Week s 8 and 12 (Treatment Continuation Period) :  Subjects will be instructed 
to withhold the doses of study  treatment prior to the study  visit. Study  treatments 
will be administered in the clinic after the pre -dose blood draw is completed 
(either 1 hr before o r 2 hrs after a meal). Blood and plasma samples for the 
analysis of [COMPANY_004]2636771, enzalutamide and N -desmethy l enzalutamide will be 
collected pre -dose onl y (total of 2 samples per visit). 
Details of PK blood and plasma sample collection (including volume to be collected), 
processing, storage and shippi[INVESTIGATOR_42232] .
[IP_ADDRESS]. Additional PK Blood Sample Collection
Blood and plasma samples for PK analy sis will also be collected within [ADDRESS_367822] dose of study  treatment(s) at the tim e of a treatment -emergent AE of special 
interest unless the event occurs on the same day  that the Day  14 (Enzalutamide Run -In 
Period) and/or Week 5, Day  29 (Treatment Continuation Period) PK samples are 
obtained.
The date/time of the PK blood and plasma sa mple draw and the date/time of the last dose 
of study  treatments prior to the PK blood and plasma sample draws will be recorded on 
the eCRF.  If the date or time of the last dose of study  treatment is unclear, provide the 
subject’s best approximation.  I f the date/time of the last dose of study  treatment cannot 
be approximated OR PK blood or plasma samples cannot be collected in the time period 
indicated above, do not obtain a PK samples.  Refer to the SRM for instructions on 
sample handling and shippi[INVESTIGATOR_301089].
2013N172718_04 CONFIDENTIA L
[PHONE_6257].7.4. Pharmacokinetic Sample A nalysis
Blood and plasma anal ysis will be performed under the control of [COMPANY_004] Platform 
Technology  and Science -Drug Metabolism and Pharmacokinetics (PTS -DMPK)/Scinovo, 
the details of which will be included in the SRM. Concentrations of [COMPANY_004]2636771, 
enzalutamide and N -desmethy l enzalutamide will be determined in blood and plasma 
samples using the currently  approved bioanal ytical methodology .Raw data will be 
archived at the bioanal ytical site (detailed in the SRM).
Once the blood and plasma has been anal yzed for [COMPANY_004]2636771, enzalutamide and N -
desmethy l enzalutamide any  remaining blood or plasma may be analy zed for other 
compound -related metabolites and the results reported under a separate [COMPANY_004] PTS -DMPK 
protocol.
8.7.5. Meals, Alcohol, Tobacco and A ctivity Restrictions
Meals
Subjects will be instructed to take study  treatments at least 1 hr before or 2 hrs after a 
meal unless otherwise instructed due to PK, CTC and/or urine electrol yte sampling (see 
Section 6.3for details).
Alcohol
During each dosing session in which serial PK samples are collected, subjects will 
abstain from ingesting alcohol for 24 hrs prior to dosing until collection of the final PK 
sample.
Tobacco
Smoking while in the clinical unit will not be permitted. Subjects who use tobacco 
products may  use nicotine patches while they  are in the clinical unit.
Activity
All subjects will abstain from strenuous exercise for 48 hrs prior to each blood collection 
for PK and/or cli nical laboratory  tests.  Subjects may  participate in light recreational 
activities during studies (e.g., watch television, reading).
8.8. Clinical Activity
Refer to the Time and Events Tables (Section 8.1) for the sc hedule of disease 
assessments to be performed to assess the clinical activity  of the combination therap y.  
Assessments must be performed on a calendar schedule and should not be affected b y 
dose interruptions or delays.  For post -baseline assessments, a wi ndow of [ADDRESS_367823] scans, MRIs and bone scans.
2013N172718_04 CONFIDENTIA L
[PHONE_6258].8.1. Clinical A ctivity Endpoints
The secondary  endpoint to evaluate the clinical activity  of oral [COMPANY_004]2636771 + 
enzalutamide will be assessed using the disease progression endpoint (see Section 
[IP_ADDRESS] ) which differs from the disease progression criteria that lead to discontinuation of 
treatment (see Section 5.2).  CTC response will also be determined and reported as an 
exploratory  endpoint.
8.8.2. Disease A ssessment
The primary  endpoint is to evaluate the 12 week non -PD rate of oral [COMPANY_004]2636771 + 
enzalutamide according to PCWG2 guidelines (either b y RECI ST 1.1, PSA progression, 
and/or progression in bone). These assessments at Week [ADDRESS_367824] 12 
weeks (+ 5day  window) after start of combination treatment.
For th is study , the disease assessment will include the assessment of multiple parameters: 
RECI ST 1.1 (see Appendix 4 ), PSA values per PCWG2 criteria (see Section [IP_ADDRESS] ), and 
radiographic response per PCGW2 criteria (see Section [IP_ADDRESS] ).
[IP_ADDRESS]. PSA Response per PCWG2 Criteria
Only  subjects who have a baseline PSA value and at least one post -baseline assessment 
will be included in the analy sis of PSA response.
PSA Response Rate is defined as proportion of subjects with a decrease of ≥50% in the 
PSA concentration from the baseline PSA value determined at least 12 weeks after start 
of treatment and confirmed after ≥4weeks b y an additional PSA evaluation.
PSA progression [Scher , 2008] is defined as:
If there has been a decline from baseline : time from start of therap y to first PSA 
increase that is 25% and 2 ng/mL in absolute value from the nadir, and which is 
confirmed b y a second value 3 or more weeks later (i.e., a confirmed rising trend) at 
least 12 weeks after the start of combination treatment
If there has NOT been a decline from baseline : time from start of therap y to first 
PSA increase that is 25% and 2 ng/mL  in absolute value from the baseline value, 
determined at least 12 weeks after star t of combination treatment
[IP_ADDRESS]. Radiographic Response per PCWG2 Criteria
Bone progression [Scher , 2008] is defined as the appearance of ≥[ADDRESS_367825] -treatment bone 
scan (Week 12) will be used as the baseline scan with which all future bone scans are 
compared. The date of progression is the date of the firs t scan that shows a minimum of 2 
additional new lesions.  Subjects should not be discontinued from study  treatment(s) due 
to the occurrence of bone scan changes in the first 12 weeks of combination treatment 
that do not meet PCWG2 guidelines for progressio n.
2013N172718_04 CONFIDENTIA L
[PHONE_6259].8.2.3. Disease Progression Endpoint
The disease progression endpoint is defined by  1 or more of the following criteria:
PSA progression according to the PCWG2 criteria (Section [IP_ADDRESS] )with 
accompan ying progression by [CONTACT_23603] 1.1 or bone scan for subjects with 
measeurable baseline disease OR PSA progression if no measurable baseline 
disease
Radiographic progression in soft tissue or bone by [CONTACT_23603] 1.1 for subjects with 
measurable disease
Bone progression on bone scan according to the PCWG2 criteria 
(Section 8.8.2 .2).
Subjects are not required to discontinue treatment on the basis of meeting PSA 
progression alone or for the worsening of an isolated disease site that is not c linically  
significant (see Section 5.2) 
8.9. Translational Research
The anal ysis of biomarkers may  depend on emerging pre -clinical and clinical biomarker 
data.  All collected samples will be retained for a maximum o f 15years after the last 
subject completes the study . If subject withdraws consent for further treatment and data 
collection, all samples collected for the biomarker anal ysis at the time of withdrawal will 
still proceed for anal ysis to meet the intended o bjectives defined in this protocol. Details 
on sample collection, processing, storage and shippi[INVESTIGATOR_301090].
8.9.1. Predictive Biomarkers
For subjects enrolled into the study , additional slides of tumor tissue samp les will be 
collected and submitted to the designated central laboratory  foranaly sis once a subject 
has received their first dose of [COMPANY_004]2636771 on Week 1, Day  1 of the Combination 
Treatment Period.  The remaining tumor tissue submitted for the PTEN testin g may  be 
utilized for predictive biomarker anal ysis.  If additional tumor tissue is not available, no 
newy  biopsy  procedure is required in order to obtain tumor tissue for predictive 
biomarker anal ysis.  
Genetic changes known to alter or regulate PTEN fun ction including mutation, loss of 
heterozy gosit y (LOH), silencing due to promoter methylation may  be assessed.  
Additional proteins, DNA, RNA, or microRNA, related to activity of [COMPANY_004]2636771and 
enzalutamide or prostate cancer may  also be anal yzed.  Any rema ining tumor tissue may  
also be utilized to further develop a diagnostic assay.
Details on sample collection, processing, storage and shippi[INVESTIGATOR_249208].
2013N172718_04 CONFIDENTIA L
[PHONE_6260].9.2. Tumor Biopsies for PD and Disease Progression
If consent is provided b y the su bject, optional fresh tumor biopsies may  be collected prior 
to combination treatment and [ADDRESS_367826] -treatment effects. 
For subjects who initially responded to combination therap y and then progress, an 
optional progression tumor biopsy  is requested in order to better understand the 
mechanism of resistance. It is preferable to obtain this biopsy  from a new lesion or a 
lesion which had previously  responded and then progressed.  Biops y samples from other 
lesions will be accepted as well.  Both soft tissue and bone biopsies will be accepted.
Details on sample c ollection, processing, storage and shippi[INVESTIGATOR_301091].
8.9.3. Circulating Tumor Cells
Blood samples will be collected and analy zed to enumerate CTCs in circulation at the 
time points indicated in the Time and Events Tables (Section 8.1).  The enumerated 
CTCs may  also be utilized for additional anal ysis like alterations in AR or PTEN genes 
and may  include additional genes implicated in the prostate cancer or related to AR/PI 3K 
signalling pathway .  If baselines CTCs are not observed in a subject, [COMPANY_004] may  ask to 
terminate the further sampling for CTC enumeration in those subjects.
Additional blood samples will be collected at the time points indicated in the Time and 
Events Tables (S ection 8.1) to isolate CTCs using an EPI C Sciences platform.  The 
isolated CTCs will be analy zed for AR variants or other protein markers and potential 
genomic alterations (e.g., PTEN allele loss, AR amplificati ons, etc.).
If subject withdraws consent for further treatment and data collection, all samples 
collected for the biomarker anal ysis at the time of withdrawal will still proceed for 
analysis to meet the intended objectives defined in this protocol.
Details on sample collection, processing, storage and shippi[INVESTIGATOR_301092].
[IP_ADDRESS]. CTC Conversion Rate
CTC enumeration will be performed at a central laboratory  using the anal ytically  valid 
CellSearch s ystem (Verid ex LL C).  For subjects with baseline CTC counts of 5 cells per 
7.5 mL  of blood, a conversion is defined as a decline in the CTC count to <[ADDRESS_367827] been found to correlate 
with increasing tumor burden and decline following therapy .  Furthermore, cfDNA in 
cancer subjects can harbor many  genetic alterations (m utations, copy  number changes, 
aberrant meth ylation), which are generally  consistent with the tumor of origin. Thus, 
tumor -specific circulating cfDNA has the potential to be a useful biomarker of 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367828] perpendicular diameters, described as a function of time using 
a 2-parameter model may  be explored.  Model parameters wil l be determined after 
administration of enzalutamide + [COMPANY_004]2636771.
The effect of [COMPANY_004]2636771 and enzalutamide on PSA levels also may  be explored.  
Models including a linear model and a maximum effect model (Emax) may  be fit to the 
change in PSA levels versu s blood or plasma concentrations of [COMPANY_004]2636771, 
enzalutamide, and/or N -desmethy l enzalutamide.
This study  will also include biopsies in subjects who consent to these optional 
procedures.  Evaluation of pre and post treatment tumor tissue will be explored t o 
determine pharmacod ynamic effects.  The mechanism of resistance to combination 
therap y will be explored in subjects who have progressed after initially responding to the 
combination therap y.  
9. ADVERSE EVENTS A ND S ERIOUS ADVERSE EVENT S
The investigator or site staff will be responsible for detecting, documenting and reporting 
events that meet the definition of an AE or SAE as outlined in Section 9.1and 
Section 9.2, respectivel y.
9.1. Definition of an A E
An AE is an y untoward medical occurrence in a subject or clinical investigation subject, 
temporally  associated with the use of a medicinal product, whether or not considered 
related to the medicinal product.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
2013N172718_04 CONFIDENTIA L
[ADDRESS_367829].  For marketed medicinal products, this 
also includes failure t o produce expected benefits, abuse, or misuse.
Examples of events meeting the definition of an AE include:
Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or grade of the condition
New conditio ns detected or diagnosed after study  treatment administration even 
though it may  have been present prior to the start of the study
Signs, sy mptoms, or the clinical sequelae of a suspected interaction
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/SAE) .
“Lack of efficacy ” or “failure of expected pharmacological action” per se is not to be 
reported as an AE or SAE.  However, an y signs and s ymptoms and/or clinical sequelae 
resulting from “lack of efficacy ” will be reported as an AE or SAE, if they  fulfill the 
definition of an AE or SAE. 
Events that do not meet the definition of an AE include:
Medical or surgical procedure (e.g., endoscop y, appendectom y); the condition that 
leads to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition (s) present 
or detected at the start of the study  that do not worsen.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition. 
9.2. Defin ition of an SAE
A serious adverse event (SAE) is any  untoward medical occurrence that, at any  dose:
a.Results in death
b.Is life -threatening
NOTE:   The term 'life -threatening' in the definition of 'serious' refers to an event in 
which the subject was at risk o f death at the time of the event.  It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires hospi[INVESTIGATOR_23916]:   In general, hospi[INVESTIGATOR_301093] t he subject has been detained 
(usually  involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur du ring hospi[INVESTIGATOR_1084]. 
2013N172718_04 CONFIDENTIA L
200331
110If a complication prolongs hospi[INVESTIGATOR_23919], the 
event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_122669] a pre -existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability /incapacity , or
NOTE:   The term disability  means a substantial disruption of a person’s ability  to 
conduct normal life functions.  This definition is not intended to include experiences 
of relativel y minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (e.g. sprained ankle) which may  
interfere or prevent ev eryday life functions but do not constitute a substantial 
disruption.
e.Is a congenital anomal y/birth defect. 
f.Medical or scientific judgment should be exercised in deciding whether reporting is 
appropriate in other situations, such as important medical even ts that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_23951]. These should also be c onsidered 
serious. Examples of such events are invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug depen dency  or drug abuse.
g.Protocol -Specific SAES:
All events of possible study  treatment -induced liver injury  with 
hyperbilirubinemia defined as ALT [ADDRESS_367830], and
Bilirubin 2 times UL N (>35% direct) (or ALT ≥3times UL N and INR >1.5 if 
INR is measured) or termed ‘Hy ’s Law’ events (INR measurement is not 
required and the threshold value stated will not apply  to patients receiving 
anticoagulants).
NOTE:  Bilirubin fractionation should be performed if testing is available.  If 
testing is not available, record presence of detectable urinary  bilirubin on 
dipstick indicating direct bilirubin elevations and suggesting liver injury .  If 
testing is unavailable and a subject meets the c riterion of total bilirubin ≥[ADDRESS_367831], then the event is still reported as a SAE.  If INR is obtained, include 
values on the SAE form.  INR elevations >1.[ADDRESS_367832] severe liver injury .
Any new primary  cancer(s)
9.2.1. Sentinel Events
A Sentinel Event is a [COMPANY_004] -defined S AE that is not necessaril y drug -related but has been 
associated historicall y with adverse reactions for other drugs and is therefore worth y of 
heightened pharmacovigilance.  The [COMPANY_004] Medical Monitor is accountable for reviewing 
all SAEs for possible Sentine l Events which is mandated at [COMPANY_004].  The [COMPANY_004] Medical 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367833] additional clinical information on an urgent basis if a possible 
Sentinel Event is identified on SAE review.  The current [COMPANY_004] -defined Sentinel Events 
are listed below:
Acquired Long QT Syndrome
Agranulocy tosis/Severe Neutropenia 
Anaph ylaxis & Anaph ylactoid Reactions 
Hepatotoxicity
Acute Renal Failure
Seizure
Stevens -Johnson Sy ndrome/Toxic Epi[INVESTIGATOR_262679]
9.3. Laboratory  and Other Safety  Assessment A bnormalities 
Reported as A Es and SA Es
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis), or 
other safet y assessments (e.g., ECGs, radiological scans, vital signs measurements) 
including those that worsen from baseline, and event felt to be clinicall y signific ant in the 
medical and scientific judgment of the investigator are to be recorded as an AE or SAE, 
in accordance with the definitions provided.
In addition, an associated AE or SAE is to be recorded for an y laboratory  test result or 
other safet y assessment that led to an intervention, including permanent discontinuation 
of study  treatment, dose reduction, and/or dose interruption/delay .
Any new primary  cancer must be reported as an SAE.
Any clinically  significant safet y assessments that are associated with the underly ing 
disease, unless judged b y the investigator to be more severe than expected for the 
subject's condition, are not to be reported as AEs or SAEs.
9.3.1. Cardiovascular Events
Investigators will be required to fill out event specific data collection to ols for the 
following AEs and SAEs:  
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
2013N172718_04 CONFIDENTIA L
200331
112Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
This information should be recorded in the specific cardiovascular eCRF within 1 week 
of when the AE/SAE(s) are first reported.
9.3.2. Death Events
In addition, all deaths, whether or not they  are considered SAEs, will require a specific 
death data collection tool to be completed.  The death data collection tool includes 
questions regarding cardiovascular (including sudden cardiac death) and non -
cardiovascular death.
This information should be recorded in the specif ic death eCRF within [ADDRESS_367834] reported.
9.4. Disease -Related Events and/or Disease -Related Outcomes 
Not Qualify ing as SAEs
An event which is part of the natural course of the disease under stud y (i.e., disease 
progression or hospi[INVESTIGATOR_301094]) does not need to be reported as 
an SAE.
Death due to disease under study  is to be recorded on the Death eCRF form.
However, if the underly ing disease (i.e., progression) is greater than that which would 
normally  be expected for the subject, or if the investigator considers that there was a 
causal relationship between treatment with stud y treatment(s) or protocol 
design/procedures and the disease progression, then this must be reported as an SAE.
9.5. Time Period and Frequency  of Detecting A Es and SA Es
The investigator or site staff is responsible for detecting, documenting and reporting 
events that meet the definition of an AE or SAE.
AEs will be collected from the time the first dose of enzalutamide is administered on 
Day 1 of th e Enzalutamide Run -In Period until 30 days following discontinuation of 
study  treatments regardless of initiation of a new cancer therap y or transfer to hospi[INVESTIGATOR_6125].
SAEs will be collected over the same time period as stated above for AEs.  In addition, 
any SAE assessed as related to study  participation (e.g., protocol -mandated procedures, 
invasive tests, or change in existing therap y), study  treatment or [COMPANY_004] concomitant 
medication must be recorded from the time a subject consents to participate in the study  
2013N172718_04 CONFIDENTIA L
[ADDRESS_367835]. All SAEs will be reported to [COMPANY_004] within 
24hrs, as indicated in Section 9.5.2 .
After discontinuation of study  treatment, the investigator will monitor all AEs/SAEs that 
are ongoing until resolution or stabilization of the event or until the subject is lost to 
follow -up.  At an y time after [ADDRESS_367836] be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended 
and non -leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence.  Examples of appropriate questions include:
“How are you feeling?”
“Have you had an y (other) medical problems since y our last visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , since your 
last visit/contact?”
9.5.2. Prompt Reporting of SA Es and Other Events to [COMPANY_004]
SAEs, pregnancies (in femal e partner of male subject), and liver function abnormalities 
meeting pre -defined criteria will be reported promptly  by [CONTACT_301183].
2013N172718_04 CONFIDENTIA L
200331
114Initial Reports Follow -up Information on a Previous 
Report
Type of Event Time Frame Documents Time Frame Documents
All SAEs 24 hrs SAE data collection 
tool24 hrs Updated SAE data 
collection tool 
“Cardiovascular (CV) 
events” and/or 
“death”Initial and 
follow -up 
reports to be 
completed 
within 1 week 
of when the 
CV event or 
death is 
reported“CV events” 
and/or “death” 
data collection 
tool(s) if 
applicableInitial and 
follow -up reports 
to be completed 
within 1 week of 
when the CV 
event or dea th is 
reportedUpdated “CV 
events” and/or 
“death” data 
collection tool(s) if 
applicable
Pregnancy 2 Weeks Pregnancy 
Notification Form2 Weeks Pregnancy 
Follow -up Form
Liver chemistry abnormalities:
ALT [ADDRESS_367837] and 
bilirubin [ADDRESS_367838] 
(>35% dire ct) (or ALT 
[ADDRESS_367839] and INR 
>1.5, if INR is 
measured)324 hrs1 SAE data collection 
tool;
Liver Event eCRF 
and liver imaging 
and/or biopsy 
eCRFs if 
applicable224 hrs Updated SAE data 
collection tool. 
Updated Liver Event 
eCRF2
ALT [ADDRESS_367840]; ALT 
3times ULN with 
hepatitis or rash or 
3times ULN 4weeks24 hrs1 Liver Event eCRF2 24 hrs Updated Liver Event 
eCRF2
ALT [ADDRESS_367841] and 
<[ADDRESS_367842] and 
bilirubin <[ADDRESS_367843] cannot be 
monitored weekly 
for 4 weeks2
Abbreviations: ALT, alanine aminotransferase; eCRF, electronic case report form; [COMPANY_004], GlaxoSmithKline; hrs, hours; 
INR, international normalization ratio; SAE, serious adverse event; ULN , upper limit of normal
1. [COMPANY_004] to be notified at onset of liver chemistry elevations to discuss subject safety.
2. Liver Event Documents (i.e., “Liver Event eCRF” and “Liver Imaging eCRF” and/or “Liver Biopsy eCRF”, as 
applicable) should be completed as soon as possible
3. INR measurement is not required; if measured, the threshold value stated will not apply to subjects receiving 
anticoagulants.
Methods for detecting, recording, evaluating, and following up on AEs and SAEs are 
provided in the SRM.
2013N172718_04 CONFIDENTIA L
[PHONE_6261].5.3. Regulatory  Report ing Requirements for SA Es
Prompt notification of SAEs by  [CONTACT_23997] y of subjects are met.
[COMPANY_004] has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  [COMPANY_004] will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authorit y, IRB/I EC and investigators.
Investig ator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and [COMPANY_004] policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety report descri bing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from [COMPANY_004] will file it with 
the IB and will notify  the I RB/IEC, if appropriate according to local requirements.
9.6. Reporting of Pregnancy
The investigator must attempt to col lect pregnancy  information on any  female partners of 
male study  subjects who become pregnant while the subject is enrolled in the study .  
Pregnancy  information must be reported to [COMPANY_004] as described below.
Any pregnancy  that occurs during stud y participation must be reported using a clinical 
trial pregnancy  form.  To ensure subject safet y, each pregnancy  must be reported to [COMPANY_004] 
within [ADDRESS_367844] be followed up to 
determine outcome (including premature terminatio n) and status of mother and child.  
Pregnancy  complications and elective terminations for medical reasons must be reported 
as an AE or SAE.  Spontaneous abortions must be reported as an SAE.
Any SAE occurring in association with a pregnancy  brought to the investigator’s 
attention after the subject has completed the stud y and considered b y the investigator as 
possibly  related to the study  treatment, must be promptly  reported to [COMPANY_004].
10. CONCOM ITANT MEDICA TIONS A ND NON -DRUG 
THERA PI[INVESTIGATOR_301095] a complete list of prescription and OTC medications 
that have been taken within 4 weeks prior to Screening.  Subjects will be instructed to 
inform the investigator prior to starting any  new medication(s), including herbal and OTC 
products, taken from the time of the first dose of enzalutamide monotherapy on Day  1 of 
the Enzalutamide Run -In Period until the end of the study  (i.e., through the post -
treatment follow -up visit).  Any  concomitant medication(s), including OTC and herbal 
product(s), taken duri ng the study  will be recorded in the eCRF. At a minimum, the drug 
name, dose and the dates of administration are to be recorded.  Additionall y, a complete 
list of all prior cancer therapi[INVESTIGATOR_42214].
2013N172718_04 CONFIDENTIA L
[ADDRESS_367845] of permitted or prohibited medications are made as a result of 
emerging data, formal documentation will be provided to the investigative site by  [CONTACT_23983].
Any such changes will be communicated to the investigative sites in the form of a letter, 
which should be stored in the study  file.
Recommended guidelines for the use of concomitant medication(s) with the combination 
of [COMPANY_004]2636771 with enzalutamide are provi ded in the following sections.
10.1. Permitted Medications
Supportive Care:  Subjects should receive full supportive care during the study , 
including transfusions of blood and blood products, and treatment with antibiotics, 
antiemetics, antidiarrheals, calcium s upplements, Vitamin D supplements, and analgesics, 
and other care as deemed appropriate, and in accordance with local institutional 
guidelines.
Growth Factors and Bisphosphonates:  The use of growth factors and bisphosphonates 
(if on a stable dose for at l east 4 weeks) is permitted while participating in this study .  
However, the initiation of growth factors and bisphosphonates is not allowed during the 
first 4 weeks of stud y treatment.
Steroids:  Use of steroids is discouraged while subject is undergoing t reatment on this 
study.  However, steroids (up to a maximum of 10 mg of prednisone or equivalent) are 
permitted provided that the subject has been on a stable dose for at least 4 weeks prior to 
enrollment.
Anticoagulants:  Prophy lactic doses of anticoagula nts (i.e., heparin, warfarin) are 
permitted provided that the subject meets the prothrombin time (PTT)/I nternational 
Normalization Ratio (I NR) entry  criteria (see Section 4.1.2 ) and INR is monitored in 
accordanc e with local institutional practice.  Therapeutic doses of warfarin (defined as a 
dose resulting in INR >1.5) are prohibited within [ADDRESS_367846]-treatmen t follow -up visit.  Caution should be exercised if aspi[INVESTIGATOR_301096]2636771.
NSAIDs: Use of NSAIDs should be avoided during the study .
10.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_301097] [ADDRESS_367847] dose of 
enzalutamide monotherapy  (Day  1 of the Enzalutamide Run -In Period); unless otherwise 
stated) and while on treatment in this study :
Any investigational drug(s)
2013N172718_04 CONFIDENTIA L
200331
117Other anti -cancer therapy (chemotherapy , radiation therap y, immunoth erapy, 
biologic therap y, or hormone therap y other than for replacement).
NOTE:  If administration of medicall y indicated anti -cancer therap y is required 
while on study , prior approval from a [COMPANY_004] Medical Monitor must be obtained.  
Study  treatment must be he ld while the anti -cancer therap y is administered.  Re -
starting of stud y treatment following the completion of anti -cancer therap y also 
requires prior approval of the [COMPANY_004] Medical Monitor.
5-alpha reductase inhibitors (e.g., finasteride, dutasteride)
Androge ns (e.g., testosterone, dihy droepi[INVESTIGATOR_2119])
Herbal medication(s) that may  affect PSA levels (e.g., saw palmetto)
Other herbal medications including, but not limited to: St. John’s wort, kava, 
ephedra (ma huang), gingko biloba, yohimbe and ginseng.
10.2.1. Pote ntial Drug Interactions with [COMPANY_004]2636771
[IP_ADDRESS]. [COMPANY_004]2636771 as Perpetrator of Drug -Drug Interactions
A preliminary  study  suggested the potential of CYP3A4 inhibition by  [CONTACT_23983]2636771; 
however, subsequent studies using human recombinant CYP3A4 and pooled human liver 
microsomes did not confirm this at concentrations tested (up to 100 M). The 
preliminary  study  indicated [COMPANY_004]2636771 did not inhibit CYP1A2, 2C8, 2C9, 2C19 and 
2D6 at up to 25 µM (10.8 g/mL), the risk is low but was not fully  discharged at higher 
concentrati ons.  Medications that have a narrow therapeutic index and are substrates of 
CYP3A4 should be used with caution within 7 days or 5 half-lives (whichever is longer) 
prior to the first dose of [COMPANY_004]2636771 (Week 1, Day  1 of the Combination Treatment 
Period) an d for the duration of study  treatment through the post -treatment follow -up visit 
(Table 18).  Medications that have a narrow therapeutic index and are substrates of 
CYP1A2, CYP2C8, 2C9 and 2C19, CYP2D6 and CYP2B6 s hould be used with caution.  
[COMPANY_004]2636771 did not inhibit transporters OATP1B1, OATP1B3, breast cancer resistance 
protein (BCRP) and p -glycoprotein (P -gp) up to 23 -30 µM in vitro. Due to high 
[COMPANY_004]2636771 concentrations (up to 100 M) observed in the FTIH stud y (P3B115717), 
there is a risk for renal transporter inhibition; however, in vitro data to discharge this risk 
is pending.  Therefore, medications that are sensitive substrates of renal transporters OAT 
and OCT2 should be used with caution when administere d with [COMPANY_004]2636771 (example 
drugs are listed in Table 18). 
2013N172718_04 CONFIDENTIA L
200331
118Table 18 Drugs Potentially  Affected by  [CONTACT_23983]2636771: Use with Caution
Drugs/Agents Therapeutic Area
CYP3A4 Substrates
dihydroergot amine, ergonovine, ergotamine, methylergonovine Ergot derivatives
Pi[INVESTIGATOR_301098], flecainide, lidocaine, mexilitine, amiodarone, quinidine, 
propafenoneAntiarrhythmics
tacrolimus, sirolimus Immune modulators
quetiapi[INVESTIGATOR_050], risperidone, clo zapi[INVESTIGATOR_050], atomoxetine Miscellaneous
Antiplatelet agents
ticlopi[INVESTIGATOR_5325], prasugrel or ticagrelor Antiplatelet
Renal Transporter (OAT, OCT2) Substrates 
Methotrexate Antineoplastic
dofetilde, pi[INVESTIGATOR_14959], procainamide Antiarrhythmic
Metformin Antidiabeti c
[IP_ADDRESS]. [COMPANY_004]2636771 as Victim of Drug -Drug Interactions
Pre-clinical and in vitro data suggested [COMPANY_004]2636771 is a substrate for UDP -
glucuronosy ltransferase (UGT) enz ymes, while CYP enzy mes do not appear to mediate 
the major metabolism pathway s of [COMPANY_004]2636771. Ther efore, drugs that are inhibitors and 
inducers of UGT enzy mes should be used with caution ( Table 19).
Effect on [COMPANY_004]2636771 exposure due to inhibition of transporters OATP1B1 and 
OATP1B3 is low due to the high permea bility of [COMPANY_004]2636771. 
Table [ADDRESS_367848] [COMPANY_004]2636771: Use with Caution
Generic Drug Name [CONTACT_301228] (e.g., rifampin, rifabutin, rifapentine) Antibiotics
carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin, s -mephenytoin Antiepi[INVESTIGATOR_301099], probenecid, ranitidine, cyclosporine, diflunisal, sertraline, valproic 
acid, atavaquone, methadone, methsuximide, o lanzapi[INVESTIGATOR_050], retigabineMiscellaneous
Caution is also recommended when [COMPANY_004]2636771 and aspi[INVESTIGATOR_301100] .
10.2.2. Potential Drug Interactions with Enzalutamide
The following information is provided as an initial reference, however, please refer to the 
approved US FDA prescribing information [ Xtandi , 2016 ] or the Xtandi Prescribing 
Information for the area where it is approved for the most current DDI information and 
contraindicated medications .
Drugs that Inhibit or Induce CYP3A4:  Co-administration of enzalutamide with the 
strong CYP3A4 inhibitor itraconazole caused a slight increase (1.3 -fold) in the composite 
AUC for enzalutamide plus N -desmeth yl enzalutamide.  Strong CYP3A4 inducers (e.g., 
2013N172718_04 CONFIDENTIA L
200331
119carbamazepi[INVESTIGATOR_050], phenobar bital, pheny toin, rifabutin, rifampin, or rifapentine) are likel y to 
reduce the plasma exposure of enzalutamide.  Moderate CYP3A4 inducers (e.g., 
bosentan, efavirenz, etravirine, modafinil, nafcillin) and St. John’s Wort may  also reduce 
the plasma exposure of enzalutamide.  I nvestigators should use clinical judgment as to 
whether or not to co -administer these agents.
Drugs that Inhibit or Induce CYP2C8:  Co-administration of enzalutamide with a strong 
CYP2C8 inhibitor (e.g., gemfibrozil) increased the AUC o f enzalutamide plus N -
desmethy l enzalutamide by  2.2-fold in health y volunteers.  Due to the potential for the 
change in enzalutamide exposure, co -administration with a strong CYP2C8 inhibitor is 
not recommended.  If co-administration of enzalutamide cannot be avoided, reduce the 
dose of enzalutamide to 80 mg (2 capsules) once daily .  If the administration of a strong 
CYP2C8 inhibitor is discontinued, the dose of enzalutamide should be increased to the 
previous dose level.
The effects of CYP2C8 inducers on t he PK of enzalutamide have not been evaluated; 
therefore, co -administration of a strong or moderate CYP2C8 inducer (e.g., rifampin) 
should be avoided.  Use of concomitant medication(s) with no or minimal CYP2C8 
induction potential is recommended.
Effect of Enzalutamide on Drug Metabolizing Enzymes:  Enzalutamide is a strong 
CYP3A4 inducer and a moderate inducer of CYP2C9 and CYP2C19 in humans and may  
lead to loss of efficacy  of many  commonly  used medicinal products.  Therefore, 
co-administration of enzaluta mide with products with a narrow therapeutic range that are 
metabolized by  [CONTACT_097]3A4 (e.g., alfentanil, cy closporine, dihy droergotamine, pi[INVESTIGATOR_3924], 
quinidine, sirolimus or tacrolimus), CYP2C9 (e.g., pheny toin, warfarin), and CYP2C19 
(e.g., S -mephen ytoin) shoul d be avoided as enzalutamide may  decrease the plasma 
exposure of these drugs.  If enzalutamide is co -administered with an anticoagulant 
metabolized by  [CONTACT_097]2C9 (such as warfarin or acenocoumarol) additional INR monitoring 
should be conducted.
Transporters :  Concomitant use of enzalutamide with medicinal products that are 
sensitive substrates or transporters should generally be avoided if their therapeutic effect 
is of large importance to the subject, and if dose adjustments cannot easily  be performed 
based on monitoring of efficacy  or plasma concentrations. 
Enzalutamide and N -desmethy l enzalutamide are potential inhibitors, but not substrates, 
of the efflux transporter P -gp.  Enzalutamide may also be an inhibitor of BCRP, MRP2 
and OAT3.  Medicinal products wi th a narrow therapeutic range that are substrates for 
P-gp (e.g., colchicine, dabigatran etexilate, digoxin), BCRP, MRP2 or OAT3 
(e.g., methotrexate) should be used with caution when administered concomitantly  with 
enzalutamide and may  require dose adjustm ent to maintain optimal plasma 
concentrations.  Enzalutamide and its major metabolites are unlikel y to inhibit the in vivo 
transport of OATP1B1, OATP1B3, OCT1, OCT2 or OAT1 substrates at clinically  
relevant concentrations.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367849] dose of study  treatment.  The two acceptable methods o f contraception are:
1.Condom (as barrier method) is required, and 
2.One of the following methods is also required:
Established use of oral, injected or implanted hormonal method by  [CONTACT_262096]
Use of intrauterine device or intrauterine s ystem by  [CONTACT_301184], or
Tubal ligation performed on female partner at least [ADDRESS_367850]
Use of additional barrier method including contraceptive sponge or 
occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent
(foam/gel/film/cream/suppository )
Vasectom y or other surgical castration of male subject at least [ADDRESS_367851]
Abstinence:  Male subjects may  also elect abstinence, defined as sexual inactivity  
consistent with th e preferred and usual lifest yle of the subject.  Periodic abstinence 
(e.g., calendar, ovulation, sy mptothermal, post -ovulation methods) and withdrawal are 
notacceptable methods of contraception.  Complete abstinence from sexual intercourse 
must occur for [ADDRESS_367852] dose of study  treatments.
Sperm Donation:  Subjects must not donate sperm from the day  of the first dose of 
enzalutamide monotherapy  on Day  [ADDRESS_367853] dose of study  treatments.
11.2. Other:  Light Sensitiv ity and A llergens
During this stud y, subjects should be instructed to protect themselves ag ainst direct sun 
exposure and to avoid exposure to known allergens.  Upon onset of an y rash(es) during 
the study , subjects should be instructed to contact [CONTACT_301185] 7.3.3 should be followed b y investigators/sites.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].3. Other: Hy dration
Subjects are to be instructed to avoid deh ydration while participating in the study .  
Subjects who have inadequate oral intake or who have difficult y maintaining h ydration
should discontinue treatment with [COMPANY_004]2636771 until adequate oral intake can be 
maintained.  If the subject must discontinue treatment for more than [ADDRESS_367854] should be withdrawn from the study .
12. DATA MANAGEMENT
For this study , data will be collected using a [COMPANY_004] defined eCRF, transmitted 
electronically  to [COMPANY_004] and combined with data provided from other sources in a validated 
data sy stem.
Management of clinical data will be performed in accordance with applicable [COMPANY_004] 
standards and data cleaning procedures to ensure the integrity of the data, e.g., removing 
errors and inconsistencies in the data.  Adverse events and concomitant medications 
terms will be coded using the Medical Dictionary for Regulatory  Activities (MedDRA)
and an internal validated medication dictionary , [COMPANY_004] Drug.  Electronic CRF (including 
queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_301101] y.
When laboratory  samples (i.e., hemat ology  and clinical chemistry ) are analy zed by  a 
central laboratory  the results will be stored in a database maintained b y the central 
laboratory  and transferred to [COMPANY_004] at agreed times.
In all cases, subject initials will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] 
policy .
13. DATA ANALYSIS AND STA TISTICAL CONSIDERA TIONS
13.1. Hypotheses
13.1.1. Dose Escalation Phase
No formal statistical h ypotheses will be tested.  All analy ses will be descriptive and 
exploratory .
13.1.2. Dose Expansion Phase
The hy pothesized non -PD rate is provided in Section 13.2.[ADDRESS_367855] that non -
PD rate is less than or equal to the null hy pothesis rate versus the non -PD rate is greater 
than or equal to the alternative rate is being performed using the stoppi[INVESTIGATOR_301102] 13.2.2 .  Descriptive statistics will be used to describe the response data at the 
dose(s)used in the expanded cohort (s).
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].2. Sample Size Determination
13.2.1. Dose Escalation P hase
The total number of subjects to be enrolled in the Dose Escalation Phase is not driven by  
[CONTACT_42371], and will depend on the number of dose levels, number of 
subjects enrolled in each dose level, and the number of subjects enrolled at the 
recommended dose to evaluate long term safet y.  It is estimated that 24 subjects will be 
enrolled for the Dose Escalation Phase.  The sample size of 24 subjects for the Dose 
Escalation Phase will provide the following 95% Clopper -Pearson confidence int ervals 
(CI) for safet y events as well as response data.
Safety Events Frequency of Safety Events (95% CI)
1 4.2% (0.1% –21.1%)
2 8.3% (1.0% -27.0%)
3 12.5% (2.7% -32.4%)
4 16.7% (4.7% -37.4%)
8 33.3% (15.6% -55.3%)
12 50.0% (29.1% -70.9%)
16 66.7% (44.7% -84.4%)
20 83.3% (62.6% –95.3%)
21 87.5% (67.6% -97.3%)
22 91.7% (73.0% -99.0%)
23 95.8% (78.9% -99.9%)
Abbreviation: CI, confidence interval
13.2.2. Dose Expansion Phase
An initial dose finding will be used to establish the MTD for the comb ination arm.  Once 
the final dose is confirmed, at least 10 subjects will be enrolled at the appropriate dose 
level , using decision rules defined in Table 3.  The sample size and stoppi[INVESTIGATOR_301103] [ Lee, 2008].
Utilizing a null and alternative hy pothesis of 5% and 30% respectivel y, a maximum of 
20subjects will be enrolled, with a minimum enrollment of 10 subjects. With an actual 
type I error rate ( α) of 0.065 and 94.2% power, the design has stoppi[INVESTIGATOR_301104] .  The trial is designed to stop earl y for futility  if the predictive probability  of 
success is less than 6%.  The ty pe I error rate, power, and predictive probability  of 
success to stop early  for futility  were derived from explicitly  stating the minimum and 
maximum sample size, futility  stoppi[INVESTIGATOR_301057], and selection of the optimizing criterion as 
the maximization of power under the alternative hy pothesis.  The Bay esian prior 
probability  used in determining the design was Beta (0.10, 0.90), a distribution with a 
mean response rate (defined as lack of disease progression at 12 weeks according to 
PCWG2 criteria) of 10%. Under the null h ypothesis, if the true response rate is 5%, t he 
expected sample size of the design is 13.1 subjects and probability  of early  termination 
(PET) is 83.0%. Under the alternative h ypothesis, if the true response rate is 30%, the 
expected sample size of the design is 19.7 subjects and PET is 4.3%.
2013N172718_04 CONFIDENTIA L
200331
123However , the decision to terminate the Dose Expansion Phase will not depend solely  on 
the results of the statistical methodology , but will take all factors into account. Additional 
subjects in a cohort may  be enrolled even if the predictive probability  suggests a low 
likelihood of activity  in the Expansion Cohort (see Section 3.7.1 ).
13.3. Data Analysis Considerations
13.3.1. Analysis Populations
The All Treated Saf ety Population is defined as all subjects who receive at least one do se 
of [COMPANY_004]2636771 or Enzalutamide.  Safet y will be evaluated based on this analysis 
population. 
The All Treated Clinical Activity Population is defined as all subjects who received at 
least one dose of [COMPANY_004]2636771. Clinical activity  and evaluation of non -PD rate will be 
based on this anal ysis population.  This will include subjects from both dose escalation 
and dose expansion .
The All Evaluable Population is defined as all subjects from All Treated Clinical
Activity  Population who have at least one post -dose disease assessment and have been 
exposed to study  drug for at least [ADDRESS_367856] 
withdrawn from the study for an y reason. Dose Expansion futility  anal yses will be based 
on this population.
Pharmacokinetic (PK) Popula tion:  The PK Population will consist of all subjects from 
the All Treated Population for whom a PK sample is obtained and anal yzed.
Additional analy sis populations may  be defined in the RAP.
13.3.2. Analysis Data Sets
The construction of analy sis data sets will b e performed in accordance with all applicable 
[COMPANY_004] standards and procedures.
13.3.3. Interim A nalysis
[IP_ADDRESS]. Dose Escalation Phase
In the Dose Escalation Phase, available safety  data will be reviewed and summarized on 
an ongoing basis.  Review of preliminary  safet y data f rom all available dose cohorts will 
be performed in each study  treatment combination before starting a new dose cohort and 
before selecting a dose level for expansion. Safet y will be reviewed on an ongoing basis 
by [CONTACT_301186] y Monitoring Team, composed of study investigators and key  [COMPANY_004] personnel 
including the medical monitor, study manager, and study  statistician. 
[IP_ADDRESS]. Dose Expansion Phase
After the initial 10 subjects become evaluable at a dose level using a combination of dose 
escalation and dose expansion su bjects , 12-week non -PD rate will be reviewed on an 
2013N172718_04 CONFIDENTIA L
200331
124ongoing basis and the number of responses observed will be compared with the stoppi[INVESTIGATOR_301105] 13.2.2 .
13.3.4. Key Elements of A nalysis Plan
Data will be listed and summarized according to the [COMPANY_004] reporting standards, where 
applicable. Complete details will be documented in the RAP. Any  deviations from, or 
additions to, the original anal ysis plan described in this protocol will be documented in 
the RAP a nd final study  report.
As it is anticipated that accrual will be spread thinly  across centers and summaries of data 
by [CONTACT_301187], data from all participating 
centers will be pooled prior to anal ysis.
All data up to the time of study  completion/withdrawal from study  will be included in the 
analysis, regardless of duration of treatment.
As the duration of treatment for a given subject will depend on efficacy  and tolerability , 
the duration of follow -up will vary  between subjects. Consequently  there will be no 
imputation for missing data.
Demographic and baseline characteristics will be summarized.
Summaries will generally  be provided by  [CONTACT_9084].
Details on the determination of tumor response are given in Appendix 4 .  Additional 
details on efficacy  and safety  anal yses are provided in Section [IP_ADDRESS] and 
Section [IP_ADDRESS] , respectively .
[IP_ADDRESS]. Effica cy Analyses
TheAll Treated Clinical Activity  Population will be used for the anal ysis of efficacy  
data, and will be summarized separatel y for each dose level combining data from both 
dose escalation and does expan sion.  Efficacy  analy ses will be provided separatel y for 
each dose level .
Primary Analyses
The primary  anal ysis is to determine whether the 12 -week non PD rate is greater than or 
equal to 5%.  The [ADDRESS_367857] 1.1 or bone scan when 
baseline disease present or PSA progression solely if no other baseline disease. Subjects 
with unknown or missing response will not be treated as not having PD (i.e., subjects 
with NE will be included in the denominator when calculating the percentage of non -PD). 
Non-PD rate will be provided along with corresponding exact 95% CIs.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367858] 1.1 response data will be reported.  Subjects with unknown or missing 
response data, including those who withdraw from the study  without an assessment, will 
be treated as non -responders (i.e., they  will be included in the denominator when 
calculating the percentage). No imputation will be performed for missing lesion 
assessment or tumor response data.  An exact 95% CI  will be computed for the PSA [ADDRESS_367859] 1.1 confirmed response rate.
Further details about the efficacy  anal yses will be outlined in the RAP.
PSA Response Rate
PSA Resp onse rate (RR) is defined as proportion of subjects with a decrease of 50% in 
the PSA concentration from the baseline PSA value determined at least 12 weeks after 
start of treatment and confirmed after ≥4weeks by [CONTACT_301188] 95% confidence interval. Waterfall plots 
will be presented that show the maximum percentage of change in PSA reduction from 
baseline.
Objective Resp onse Rate
The objective response ( ORR) rate is defined as the percentage of subjects with a 
confirmed complete response (CR) or a partial response (PR) at an y time as per PCWG3 -
modified RECI ST 1.1 ( Appendix 5 ). Subjects with unknown or missing response will be 
treated as non -responders, i.e. these subjects will be included in the denominator when 
calculating the percentage. The number and t ypes of responses, as outlined in PCWG3 -
modified RECI ST 1.1, will be listed and summarized separatel y, as appropria te. The 
observed ORR, observed confirmed and unconfirmed ORR will be reported at the interim 
and final anal ysis for each cohort specified in treated dose, if data warrant. The estimates 
along with 95% exact confidence interval (CI) will be provided.
Radiog raphic Progression -free survival (rPFS) will be defined as the time from 
combination study  treatment start until the first date of either disease progression or death 
due to an y cause. The date of disease progression will be defined as the earliest date of
disease progression as assessed b y the investigator using RECI ST version 1.[ADDRESS_367860] adequate 
disease assessment (e.g. assessment where visit level response is CR, PR, or stable 
disease [SD]) prior to the extended loss to follow -up or start of new anti -cancer therap y, 
respectivel y. Further details on rules for censoring will be provided in the RAP. rPFS will 
be summarized by  [CONTACT_301189] -Meier quantile 
estimates along with 2 -sided 95% CIs 
Time to PSA progression
If there has been a decline from baseline : time from start of combination treatment to 
first PSA increase that is 25% and 2  ng/mL  in absolute value from the nadir, and
which is confirmed b y a second value 3 or more weeks later (i.e., a confirmed rising 
trend) at least 12 weeks after the start of treatment.
2013N172718_04 CONFIDENTIA L
200331
126If there has NOT been a decline from baseline : time from start of therap y to first
PSA increase that is 25% and 2  ng/mL  in absolute value from the baseline value, 
determined at least [ADDRESS_367861] 1.1 and/ or confirmed 
bone progression as defined in Section [IP_ADDRESS] . Time to radiological progression will be 
summarised us ing Kaplan -Meier methods b y dose level.
[IP_ADDRESS]. Safety  Analyses
TheAll Treated Safet y Population will be used for the anal ysis of safet y data. All serially 
collected safet y endpoints (e.g., laboratory  tests, vital signs, ECGs) will be summarized 
according to the scheduled, nominal visit at which they  were collected and across all on -
treatment time points using a “worst -case” analy sis.Complete details of the safet y 
analyses will be provided in the RAP.
[IP_ADDRESS].1. Extent of Exposure
The number of subjects administered study  treatment will be summarized according to 
the duration of therap y. Details pertaining to dose interruptions or dose modification will 
also be listed.
[IP_ADDRESS].2. Adverse Events
Adverse events (AEs) will be coded using Medical Dictionary  for Regulatory  Activities 
(MedDR A) and grouped by  [CONTACT_9313].  AEs will be graded b y the investigator 
according to the CTCAE v4.0 .
Events will be summarized by  [CONTACT_301190], by  [CONTACT_53428].  Separate summaries will be given for all AEs, treatment -
related AEs, SAEs and AEs leading to discontinuation of study  treatment.  Adverse 
events (AEs), if listed in the CTCAE v4.0, will be summarized by  [CONTACT_91016].  
Otherwise, the AEs will be summarized by  [CONTACT_301191] -limiting toxicities (DL Ts) will be listed for each subject and summarized by  [CONTACT_301192]  (IDSL) standards.
The incidence of deaths and the primary  cause of death will be summarized.
[IP_ADDRESS].3. Clinical Laboratory Evalua tions
Hematology  and clinical chemistry  data will be summarized at each scheduled 
assessment according to CTCAE v4.0 grade .  Laboratory  data will also be summarized 
according to the subjects’ baseline grade and maximum grade post -dose.   The proportion 
of values l ying outside the reference range will also be presented for laboratory  tests that 
are not graded because there are no associated CTCAE 4.0 criteria.  Summaries will 
include data from scheduled assessments only , and all data will be reported accordin g to 
the nominal visit date for which it was recorded (i.e., no visit windows will be applied).  
2013N172718_04 CONFIDENTIA L
200331
127Unscheduled data will be included in “overall” and “an y post -screening” summaries 
which will capture a worst -case across all scheduled and unscheduled visits p ost first 
dose of study  treatment.  Further details are provided in the RAP.
[IP_ADDRESS].4. Other Safety Measures
The results of scheduled assessments of vital signs, 12 -lead ECG and ECOG performance 
status will be summarized.  Summaries will include data from scheduled assessments 
only.  All data will be reported according to the nominal visit date for which it was 
recorded (i.e., no visit windows will be applied).  All data will be listed.  Further details 
are provided in the RAP.
[IP_ADDRESS]. Pharmacokinetic A nalyses
Pharmacokineti c anal ysis will be the responsibility of the Clinical Pharmacology  
Modeling and Simulation Department, [COMPANY_004].  Statistical anal yses of the PK parameter 
data will be the responsibility  of [COMPANY_004] Discovery  Biometrics and Clinical Statistics.
Concentration -time da ta for [COMPANY_004]2636771, enzalutamide and N -desmethy l enzalutamide 
from the Dose Escalation Phase will be anal yzed via standard non -compartmental 
methods.  Parameters calculated include the area under the concentration -time curve from 
[ADDRESS_367862] quantifiable blood or plasma concentration [AUC(0 -t)] and/or over the 
dosing interval [AUC(0 -τ)], Cmax, and Tmax, if data permit.  Population PK parameters 
for [COMPANY_004]2636771 including oral clearance (CL/F), oral volume of distribution (V/F), and 
absorption rate constant (ka) will be estimated b y pooling all data from this study  with 
historical data, if data permit.  Dependent on the final structural PK model, additional PK 
parameters may  also be estimated. Sources of variability  in PK parameters will be 
investigated during population modeling.  Demographic pa rameters including, but not 
limited to age, sex, race, body  weight, relevant laboratory  parameters, will be evaluated 
as potential predictors of inter -and intra -subject variability  for PK parameters.  
Population PK modeling will be performed using the non -linear mixed effects software 
NONMEM (Globomax LLC; Hanover, MD, US).  Population PK of the active 
metabolite(s) may  be characterized as appropriate.
Further details of the PK anal yses will be described in the RAP.
[IP_ADDRESS]. Pharmacokinetic/Pharmacody namic A nalyses
Exploratory  anal yses will be performed to examine the relationship(s) between exposure 
(e.g., dose, plasma concentrations of [COMPANY_004]2636771 , enzalutamide and N -desmethy l 
enzalutamide or other measure of exposure), and PD endpoints such as tumor size. 
Paramete rs describing the kinetics of tumor growth will be determined after 
administration of [COMPANY_004]2636771 + enzalutamide.  Model parameters generated with data 
will be compared to investigate differences in the effect on tumor growth kinetics after 
administration o f [COMPANY_004]2636771 + enzalutamide.
Pharmacokinetic/PD models also may  be applied to describe the relationship between PK 
parameters and endpoints of clinical efficacy  and safet y (PSA and RECI ST response rate, 
change from baseline in PSA, change from baseline in CTCs), as determined appropriate. 
Graphical anal ysis will be used initially  to determine if there are any  apparent 
2013N172718_04 CONFIDENTIA L
200331
128relationships between PK parameters and clinical endpoint.  A simple linear model and 
Emax may  be used to describe any  apparent relationship( s). More complex models will 
be considered if appropriate.
Further details of PK/PD anal yses will be described under a separate RAP.  Results of the 
PK/PD analy ses may  be included in a report separate from the clinical study  report 
(CSR).
[IP_ADDRESS]. Translational Res earch A nalyses
All biomarker analy ses will be conducted on the All Treated Population unless otherwise 
stated.  Translational research anal yses may  include evaluation of PD indicators to 
explore the kinetics of tumor growth and molecular markers that may  be predictive of 
clinical benefit.
Circulating tumor cells (CTC) may  be evaluated for AR expression and other genomic 
markers that may  be predictive of clinical benefit, as well as decreases in CTC from 
baseline.
Plasma collection at baseline, post -treatmen t and at time of disease progression will be 
used to anal yze cfDNA, RNA and other soluble markers to understand clonal evolution, 
monitor response and explore predictive biomarkers .  Archival or fresh biopy  tissue may  
be utilized to identify  potential pred ictive biomarkers (protein, DNA and RNA based 
markers).  Optional PD and progression biopsies for subjects who have progressed from 
initially  responding to the combination therapy  may  also be requested to understand 
pharmacod ynamic effects and mechanism(s) of resistance.
Select biomarker data may be reported for all subjects consenting to pre -screening, based 
on the All Screened Population. Frequency  of PTEN negative mCRPC subjects during 
pre-screening, as well as evidence of PTEN deletion, mutation, and pr omoter 
methy lation, may  be examined to further understand the mechanism of PTEN deficiency .
The results of these biomarker investigations may  be reported separatel y from the main 
CSR.  Analy tic strategies for the final anal ysis of all biomarker data will b e influenced b y 
the data available (e.g., available material).  Generally , all endpoints will be descriptivel y 
and/or graphically  summarized but may  be further determined at the completion of data 
collection.
14. STUDY CONDUCT CONSIDERA TIONS
14.1. Posting of Informa tion on Publicly  Available Clinical Trial 
Registers
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrollment of subjects begins.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].2. Regulatory  and Ethical Considerations, Including the 
Informed Conse nt Process
Prior to initiation of a study  site, [COMPANY_004] will obtain favorable opi[INVESTIGATOR_1649]/approval from the 
appropriate regulatory  agency  to conduct the stud y in accordance with I CH Good Clinical 
Practice (GCP) and applicable country -specific regulatory  requiremen ts.
The study  will be conducted in accordance with all applicable regulatory  requirements .
The study  will be conducted in accordance with ICH GCP, all applicable subject privacy  
requirements, and the ethical principles that are outlined in the Declaration of 
Helsinki 2008, including, but not limited to:
IRB/IEC review and favorable opi[INVESTIGATOR_1649]/approval of study  protocol and any 
subsequent amendments.
Subject informed consent.
Investi gator reporting requirements .
[COMPANY_004] will provide full details of the above proced ures, either verball y, in writing, or both .
Written informed consent must be obtained from each subject prior to participation in the 
study .
In approving the clinical protocol the IEC/I RB and, where required, the applicable 
regulatory  agency  are also appro ving the optional assessments, e.g. genetic research 
described in Appendix [ADDRESS_367863].
The Sponsor will work with the investigator to ensure the IRB/IE C is notified.
14.4. Qualit y Control (Study  Monitoring)
In accordance with applicable regulations, Good Clinical Practice (GCP), and [COMPANY_004] 
procedures, the site will be contact[CONTACT_301193], stud y requ irements, and their responsibilities to satisfy  regulatory , 
ethical, and [COMPANY_004] requirements.  When reviewing data collection procedures, the 
2013N172718_04 CONFIDENTIA L
200331
130discussion will include identification, agreement and documentation of data items for 
which the eCRF will serve as th e source document.
The investigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents and to allocate their time and 
the time to their staff to monitor to discuss findings and an yissues.
Monitoring visits will be conducted in a manner to ensure that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  other 
study  agreements, ICH GCP, and all applicable regulatory  requirements.
14.5. Qualit y Assurance
To ensure compliance with I CH GCP and all applicable regulatory  requirements, [COMPANY_004] 
may conduct qualit y assurance audits of the site. Regulatory agencies may conduct a 
regulatory  inspection at any  time during or after completion of the study . In the event of 
an audit or inspection, the investigator (and institution) must agree to grant the auditor(s) 
and inspector(s) direct access to all relevant documents and to allocate their time and the 
time of their staff to discuss any  findings/relevant issues.
14.6. Stud y and Site Closure
The end of the stud y is defined as the date of the last visit of the last subject enrolled.
Upon completion or termination of the study , the monitor wil l conduct site closure 
activities with the investigator or site staff (as appropriate), in accordance with applicable 
regulations, I CH GCP, and [COMPANY_004] Standard Operating Procedures.
[COMPANY_004] reserves the right to temporaril y suspend or terminate the stud y at an y time for 
reasons including (but not limited to) safety  issues, ethical issues, or severe 
noncompliance.  If [COMPANY_004] determines that such action is required, [COMPANY_004] will discuss the 
reasons for taking such action with the investigator or head of the medical institu tion 
(where applicable).  When feasible, [COMPANY_004] will provide advance notice to the investigator 
or head of the medical institution of the impending action.
If a stud y is suspended or terminated for safet y reasons, [COMPANY_004] will promptly  inform all 
investigators, h eads of the medical institutions (where applicable),and/or institutions 
conducting the study .  [COMPANY_004] will also promptly  inform the relevant regulatory  authorities 
of the suspension/termination along with the reasons for such action.  Where required b y 
applic able regulations, the investigator or head of the medical institution must inform the 
IRB/IEC promptly  and provide the reason(s) for the suspension/termination.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].7. Records Retention
Following closure of the study , the investigator or head of the medical insti tution (where 
applicable) must maintain all site study  records (except for those required by  [CONTACT_24000]) in a safe and secure location.  The records must 
be easil y accessible when needed (e.g., for a [COMPANY_004] audit or regulator y inspection) and 
must be available for review in conjunction with assessment of the facility , supporting 
systems, and relevant site staff.
Where permitted b y local laws/regulations or institutional policy, some or all of the 
records may  be maintained in a format other than hard cop y (e.g., microfiche, scanned, 
electronic); however, caution must be exercised before such action is taken.  The 
investigator must ensure that all reproductions are legible and are a true and accurate 
copy  of the original.  In add ition, they  must meet accessibility  and retrieval standards, 
including regeneration of a hard cop y, if required.  The investigator must also ensure that 
an acceptable back -up of the reproductions exists and that there is an acceptable quality  
control proce dure in place for creating the reproductions.
[COMPANY_004] will inform the investigator of the time period for retaining the site records in order 
to comply  with all applicable regulatory  requirements.  The minimum retention time will 
meet the strictest standard ap plicable to a particular site, as dictated b y local 
laws/regulations, [COMPANY_004] standard operating procedures, and/or institutional requirements.
The investigator must notify  [COMPANY_004] of any  changes in the archival arrangements, including, 
but not limited to archival of records at an off -site facility  or transfer of ownership of the 
records in the event that the investigator is no longer associated with the site.
14.8. Provision of Study  Results to Investigators, Posting of 
Information on Publicly  Available Clinical Trials Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity  to review the complete study  results at a [COMPANY_004] site or other mutually -
agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encouraged to share the summary  results with the study  subjects, as 
appropriate.
The results summary  will be posted to the Clinical Study  Register no later than [ADDRESS_367864]’s last visit.  When manuscript 
publication in a peer reviewed journal is not feasible, a statement will be added to the 
register to explain the reason for not publishing
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE]. REFERENCES
American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer 
Society , 2013.
Andrade RJ, R obles M, Lucena MI.  Rechallenge in drug -induced liver injury : the 
attractive hazard.  Expert Opin Drug Saf . 2009;8:709 -714.
Ayala G, Thompson T, Yang G, Frolov A, L i R, Scardino P, Ohori M, Wheeler T & 
Harper W. High levels of phosphory lated form of Akt -1in prostate cancer and non -
neoplastic prostate tissues are strong predictors of biochemical recurrence. Clinical 
Cancer Research . 2004;10:6572 -6578.
Bedolla R, Prihoda TJ, Kreisberg J I, Malik SN, Krishnegowda NK, Troy er DA & Ghosh 
PM. Determining risk of biochemical recurrence in prostate cancer b y 
immunohistochemical detection of PTEN expression and Akt activation. Clinical Cancer 
Research. 2007;13:3860 -3867.
Beer TM, Armstrong AJ, Sternberg, CN, et al: Enzalutamide in men with chemotherap y-
naive metastat ic prostate cancer (mCRPC): Results of phase III PREVAIL study . 
Genitourinary  Cancers Sy mposium. Abstract LBA1. Presented January  30, 2014.
Benson AB, Ajani JA, Catalano RB, et al. Recommended Guidelines for the Treatment of 
Cancer Treatment -Induced Diarrh ea. J Clin Oncol. 2004;22(14):2918 -2926.
Bitting RL, Armstrong AJ. Targeting the PI3K/AKT/mTOR pathway  in castration -
resistant prostate cancer. Endocrine -Related Cancer . 2013;20:R83 –R99.
Carver BS, Chapi[INVESTIGATOR_61222] C, Wongvipat J, Hierony mus H, Chen Y, Chandarlap aty S, Arora 
VK, Le C, Koutcher J, Scher H et al. Reciprocal feedback regulation of PI3K and 
androgen receptor signaling in PTEN -deficient prostate cancer. Cancer Cell . 
2011;19:575 –586.
Devine, BJ.  Case Number 25 Gentamicin Therapy:  Clinical Pharmacology Case 
Studies.  Drug Intelligence and Clinical Pharmacy . 1974;8:[ADDRESS_367865] R, Dancey  J, 
Arbuck S, Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, 
Lacombe D, Verweij J.  New re sponse evaluation criteria in solid tumours:  Revised 
RECI ST guidelines (version 1.1).  European Journal of Cancer . 2009;45:228 -247.
GlaxoSmithKline Document Number 2011N117133_01 . Investigator’s Brochure for 
[COMPANY_004]2636771. 04 -Mar-2014.
Hunt, CM.  Mitochondri al and immunoallergic injury  increase risk of positive drug 
rechallenge after drug -induced liver injury : A s ystematic review.  Hepatol . 
2010;52:2216 -2222.
2013N172718_04 CONFIDENTIA L
200331
133James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinet ics of Acetaminophen -Protein Adducts in Adults with 
Acetaminophen Overdose and Acute L iver Failure. Drug Metab Dispos.
2009;37(8):1779 -1784.
Karantanos T, Corn PG, Thompson TC.  Prostate cancer progression after androgen 
deprivation therap y: mechanisms of castrate resistance and novel therapeutic approaches. 
Oncogene. 2013;32:5501 -5511.
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény  P, Gault E.  Quantification 
of Hepatitis Delta Virus RNA in Serum by  [CONTACT_31861] -Time PCR I ndicates 
Different P atterns of Virological Response to Interferon Therap y in Chronically  Infected 
Patients.  J Clin Microbiol . 2005;43(5):2363 –2369.
Lee JJ, L iu DD. A predictive probability  design for Phase II cancer clinical trials.  Clin 
Trials . 2008;5(2); 93 -106.
Martin V, Guillermet -Guibert J, Chicanne G, Cabou C, Jandrot -Perrus M, Plantavid M, 
Vanhaesebroeck B, Pay rastre B, Gratacap MP. Deletion of the p110beta isoform of 
phosphoinositide 3 -kinase in platelets reveals its central role in Akt activation and 
thrombus format ion in vitro and in vivo. Blood . 2010;115:2008 -2013.
NCI-CTCAE (NCI Common Terminology  Criteria for Adverse Events), Version 4, 
DCTD, NCI , NIH, DHHS, May  28, 2009.
Nylander S, Kull B, Bjorkman JA, Ulvinge JC, Oakes N, Emanuelsson BM, Andersson 
M, Skarby  T,Inghardt T, Fjellstrom O, Gustafsson D. Human target validation of 
phosphoinositide 3 -kinase (PI3K)β: effects on platelets and insulin sensitivity , using 
AZD6482 a novel PI3Kβ inhibitor . J Thromb Haemost . 2012;10:2127 -2136.
Oken MM, Creech RH, Tormey  DC, et al. Toxicity  and response criteria of the Eastern 
Cooperative Oncology  Group. Am J Clin Oncol . 1982;5:649 -655.
Papay  JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, Hunt CM.  Drug -induced liver 
injury  following positive drug rechallenge.  Regul Tox Ph arm. 2009;54:84 -90. 
Scher HI, Halabi S, Tannock I, et al. Design and End Points of Clinical Trials for Patients 
With Progressive Prostate Cancer and Castrate Levels of Testosterone: 
Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 
2008;26:1148 -1159.
Scher HI, Morris MJ, Stadler WM, et al.  Trial Design and Objectives for Castration -
Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical 
Trials Working Group 3. J Clin Oncol . 2016;34:1402 -1418.
Taylor BS, Schultz N, Hierony mus H, Gopalan A, Xiao Y, Carver BS, Arora VK, 
Kaushik P, Cerami E, Reva B et al. Integrative genomic profiling of human prostate 
cancer. Cancer Cell. 2010;18:11 –22.
2013N172718_04 CONFIDENTIA L
200331
134The Criteria Committee of the [LOCATION_001] Heart Association (NYH A). Nomenclature and 
Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. [LOCATION_011], Mass: 
Little, Brown & Co. 1994:253 –256.
Xtandi (enzalutamide) Product Package Insert.  Astellas Pharma US, Inc, Northbrook, IL 
and Medivation Inc., San Francisco, CA. October 2016.
Yoshimoto M, Joshua AM, Cunha I W, Coudry  RA, Fonseca FP, L udkovski O, Zielenska 
M, Soares FA, Squire JA. Absence of TMPRSS2:ERG fusions and PTEN losses in 
prostate cancer is associated with a favorable outcome. Modern Pathol . 2008;21:1451 -
1460.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE]. APPENDICES
16.1. Appendix 1:  ECOG Performance Status
Assessment of Eastern Cooperative Oncology  Group (ECOG) performance status to 
evaluate daily  living abilities is required at Screening as well as routinel y throughout the 
treatment and at tr eatment discontinuation [ Oken , 1982]: 
Reference:
Oken MM, Creech RH, Tormey  DC, et al. Toxicity  and response criteria of the Eastern 
Cooperative Oncology  Group. Am J Clin On col. 1982;5:[ADDRESS_367866] been excluded.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].2. Appendix 2:  NYHA  Functional Classification Sy stem
The [LOCATION_001] Heart Association (NYHA) Functional Classification: Class I, II, III 
or IV Heart Failure [ NYHA , 1994 ] provides a simple way  of classi fying the extent of 
heart failure.  It places subjects in one of 4 categories based on the level of limitation 
experienced during ph ysical activity :
Class Symptoms
Class I
(Mild)No limitation of physical activity.  Ordinary physical activity does not cau se 
undue fatigue, palpi[INVESTIGATOR_42243] (shortness of breath).
Class II
(Mild)Slight limitation of physical activity.  Comfortable at rest, but ordinary 
physical activity results in fatigue, palpi[INVESTIGATOR_42243].
Class III
(Moderate)Marked limitatio n of physical activity.  Comfortable at rest, but less than 
ordinary physical activity results in fatigue, palpi[INVESTIGATOR_42243].
Class IV
(Severe)Unable to carry out any physical activity without discomfort.  Symptoms of 
cardiac insufficiency at rest. If any physical activity is undertaken, discomfort 
is increased.
Reference:
The Criteria Committee of the [LOCATION_001] Heart Association (NYHA). Nomenclature and 
Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. [LOCATION_011], Mass: 
Little, Brown & Co. 1994:253 –256.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].3. Appendix 3:  CKD -EPI [INVESTIGATOR_301106]://www.qxmd.com/calculate/egfr -using -ckd-epi.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].4. Appendix 4:  Disease A ssessment per RECIST 1.1
Disease progression and response evaluations will be determined according to the 
definitions es tablished in the Response Evaluation Criteria in Solid Tumors 
(RECI ST)1.1 [Eisenhauer , 2009].
Assessment Guidelines
The same diagnostic method, including use of contrast when applicable, must be 
used throughout the s tudy to evaluate a lesion.   Contrast agents must be used in 
accordance with the Image Acquisition Guidelines.
All measurements should be taken and recorded in millimeters (mm), using a ruler or 
calipers.
Ultrasound is not a suitable modality  of disease as sessment.  If new lesions are 
identified by  [CONTACT_2207], confirmation by  [CONTACT_301194] y (CT) or magnetic 
resonance imaging (MRI) is required.
CT and MRI:   Contrast enhanced CT with [ADDRESS_367867] b y use of the same imaging examinations.  Whenever possible the same 
scanner should be used.
NOTE: If CT contrast is contraindicated, acquire and submit a contrast -enhanced 
MRI of the abdomen/pelvis and an unenhanced CT of the chest in place of the 
enhanced CT for complete lesion assessment.
X-ray:  In general, X -rayshould not be used for target lesion measurements owing to 
poor lesion definition.  Lesions on chest X -ray may  be considered measurable if they  are 
clearl y defined and surrounded by [CONTACT_6776]; however, chest CT is preferred over 
chest X -ray.
Brain Scan:   If brain scans are required, then contrast enhanced MRI is preferable to 
contrast enhanced CT.
Bone Scan (typi [INVESTIGATOR_301107]) :  Refer to Prostate Cancer Working Group 2 
(PCWG2) guidelines.
Baseline Assessments
The following baseline disease (lesion) assessments must be performed within 28 day s 
(or within 35 day s if disease assessment is assessed by  [CONTACT_9268]) p rior to first dose of 
enzalutamide (Day  1 of Enzalutamide Run -In Period) to identify  target and non -target 
lesions:
2013N172718_04 CONFIDENTIA L
200331
139CT/MRI:  A CT scan with contrast of the chest, abdomen, and/or pelvis, or other 
areas as indicated b y the subject’s underl ying disease, is r equired for assessment 
of baseline disease burden.
NOTE: Although CT scan is preferred, MRI may be used as an alternative 
method of baseline disease assessment for abdomen/pelvis, especiall y for those 
subjects where a CT scan is contraindicated due to alle rgy to contrast, provided 
that the method used to document baseline status is used consistently  throughout 
study  treatment to facilitate direct comparison.  An unenhanced CT of the chest 
can replace the enhanced CT of the chest, but MRI of the chest is not
recommended.
Bone Scan:  A baseline bone scan is required for all subjects.  For subjects 
without bone disease at baseline, subsequent bone scans should only  be performed 
as clinically  indicated (e.g., presentation of bone pain).  For subjects with bone 
disease at baseline, a bone scan is required every  12 weeks or as clinicall y 
indicated.  In addition, in order to confirm a complete response (CR) in a subject 
with bone disease at baseline, a bone scan must be performed [ADDRESS_367868] set of ima ges showing CR to 4 weeks after the next protocol specified 
assessment.
For subjects with palpable/superficial lesions, clinical disease assessments by  [CONTACT_301195] y treatment as clinically 
indica ted.
Confirmation of CR and partial response (PR) are required per protocol.  Confirmation 
assessments must be performed no less than 4 weeks (±3 day s) after the criteria for 
response have initially  been met and may  be performed at the next protocol schedu led 
assessment.  If a confirmation assessment is performed prior to the next protocol schedule 
assessment, the next protocol scheduled evaluation is still required (e.g., evaluations must 
occur at each protocol scheduled time point regardless of unschedule d assessments).
Baseline documentation of target and non -target lesions 
All baseline lesion assessments must be performed within 28 day s (or within 35 day s 
if disease assessment is assessed by  [CONTACT_9268]) prior to the first dose of enzalutamide 
(Day 1 of the Enz alutamide Run -In Period).
Lym ph nodes that have a short axis of <10 mm are considered non -pathological and 
should not be recorded or followed.
Pathological l ymph nodes with <15 mm and but 10 mm short axis are considered 
non-measurable.
Pathological l ymph nodes with 15 mm short axis are considered measurable and 
can be selected as target lesions; however, l ymph nodes should not be selected as 
target lesions when other suitable target lesions are available.
Measurable lesions up to a maximum of 2 lesions pe r organ and 5 lesions in total, 
representative of all involved organs, should be identified as target lesions, and 
2013N172718_04 CONFIDENTIA L
200331
140recorded and measured at baseline.  These lesions should be selected on the basis of 
their size (lesions with the longest diameter) and their suitability  for accurate 
repeated measurements (either b y imaging techniques or clinicall y).
Note: Cystic lesions thought to represent cy stic metastases should not be selected as 
target lesions when other suitable target lesions are available.
Note : Measu rable lesions that have been previously  irradiated and have not been 
shown to be progressing following irradiation should not be considered as target 
lesions. 
Lytic bone lesions or mixed ly tic-blastic lesions, with identifiable soft tissue 
components, tha t can be evaluated b y CT or MRI can be considered measurable.   
Bone scans, fluorodeox yglucose -positron emission tomograph y (FDG -PET) scans or 
X-rays are not considered adequate imaging techniques to measure bone lesions.
All other lesions (or sites of dis ease) should be identified as non -target and should 
also be recorded at baseline. Non -target lesions will be group b y organ. 
Measurements of these lesions are not required, but the presence or absence of each 
should be noted throughout follow -up. 
Post-Baseline Assessments
For all subjects, post -baseline assessment should evaluate disease sites identified by  
[CONTACT_301196].  Post -baseline disease assessment (CT scan or MRI) is required every  
8weeks (7 day s) during the first 48 weeks of treatment and then every  12 weeks 
(7days) thereafter or as clinically  indicated.
For subjects with no bone disease at baseline , subsequent bone scans should only  be 
performed as clinicall y indicated (e.g., presentation of bone pain).
For subjects with bone disease at basel ine, a bone scan is required every  12weeks 
(7days) or as clinicall y indicated.
Follow -up Assessments for Subjects Permanently Discontinued from Study 
Treatment
Refer to Section 5.2(Permanent Discontinuation from Study  Treatment) and the Time 
and Events Tables (see Section 8.1) for follow -up assessment of subjects who are to be 
followed for disease progression after permanently discontinuing from study treatment.
Assessment of Subject Completion
If the last radiographic assessment was more than 4 weeks prior to withdrawal from study  
and progressive disease has not been documented, a disease assessment should be 
obtained at the time of withdrawal from stud y. 
2013N172718_04 CONFIDENTIA L
200331
141Guidelin es for Evaluation of Disease
Measurable and Non -measurable Definitions
Measurable lesion:
A non -nodal lesion that can be accuratel y measured in at least one dimension (longest 
dimension) of
[ADDRESS_367869] double the slice thickness (e.g., if the slice thickness is [ADDRESS_367870] be 20 mm).
10 mm caliper/ruler measurement b y clinical exam or medical photography . 
[ADDRESS_367871] x -ray.
Additionally  lymph nodes can be considered pathologicall y enlarged and measurable if:
[ADDRESS_367872] or MRI  (slice thickness 
recommended to be no more than 5 mm).  At baseline and follow -up, onl y the short 
axis will be measured.
Non-measurable lesion: 
All other lesions including lesions too small to be considered measurable (longest 
diameter <10 mm or pathological l ymph nodes with ≥10 mm and <15 mm short axis) as 
well as truly  non-measurable lesions, which include: leptomeningeal disease, ascites, 
pleural or pericardial effusions , inflammatory  breast disease, l ymphangitic involvement 
of the skin or lung, abdominal masses/abdominal organomegal y identified by [CONTACT_301197].
Measurable disease : The presence of at least one measurable lesion.  Palpable lesions 
that are not measurable by [CONTACT_159887].
Non-Measurable only disease : The presence of only  non-measurable lesions.
Response Criteria
Evaluation of target lesions
Definitions for assessment of response for target lesion(s) are as follows:
Complete Response (CR):   Disappearance of all targ et lesions.  An y pathological 
lymph nodes must be <10mm in the short axis.
Partial Response (PR):   At least a 30% decrease in the sum of the diameters of 
target lesions, taking as a reference, the baseline sum of the diameters (e.g., percent 
change from ba seline).
2013N172718_04 CONFIDENTIA L
200331
142Stable Disease (SD) :  Neither sufficient shrinkage to qualify  for PR nor sufficient 
increase to qualify  for progressive disease.
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of 
target lesions, taking as a reference , the smallest sum of diameters recorded since the 
treatment started (e.g., percent change from nadir, where nadir is defined as the 
smallest sum of diameters recorded since treatment start). In addition, the sum must 
have an absolute increase from nadir o f 5 mm.
Not Applicable (NA ): No target lesions at baseline.
Not Evaluable (NE): Cannot be classified b y one of the five preceding definitions.
Note:
If lymph nodes are documented as target lesions the short axis is added into the sum 
of the diameters (e.g. , sum of diameters is the sum of the longest diameters for non -
nodal lesions and the short axis for nodal lesions).  When ly mph nodes decrease to 
non-pathological size (short axis <10 mm) they  should still have a measurement 
reported in order not to overst ate progression.
If at a given assessment time point all target lesions identified at baseline are not
assessed, sum of the diameters cannot be calculated for purposes of assessing CR, 
PR, or SD, or for use as the nadir for future assessments.  However, th e sum of the 
diameters of the assessed lesions and the percent change from nadir should be 
calculated to ensure that progression has not been documented.  If an assessment of 
PD cannot be made, the response assessment should be NE.
All lesions (nodal and n on-nodal) should have their measurements recorded even 
when very  small (e.g., 2 mm).  I f lesions are present but too small to measure, 5 mm 
should be recorded and should contribute to the sum of the diameters, unless it is 
likely  that the lesion has disapp eared in which case 0 mm should be reported.
If a lesion disappears and reappears at a subsequent time point it should continue to 
be measured.  The response at the time when the lesion reappears will depend upon 
the status of the other lesions.  For examp le, if the disease had reached a CR status 
then PD would be documented at the time of reappearance.  However, if the response 
status was PR or SD, the diameter of the reappearing lesion should be added to the 
remaining diameters and response determined bas ed on percent change from baseline 
and percent change from nadir.
Evaluation of non -target lesions
Definitions for assessment of response for non -target lesions are as follows:
Complete Response (CR):   The disappearance of all non -target lesions. All ly mph
nodes identified as a site of disease at baseline must be non -pathological 
(e.g., <10mm short axis).
Non-CR/Non -PD:  The persistence of 1 or more non -target lesion(s) or lymph nodes 
identified as a site of disease at baseline ≥10 mm short axis.
Progressi ve Disease (PD) : Unequivocal progression of existing non -target lesions. 
2013N172718_04 CONFIDENTIA L
200331
143Not Applicable (NA): No non -target lesions at baseline.
Not Evaluable (NE): Cannot be classified b y one of the four preceding definitions.
Note:
In the presence of measurable disease , progression on the basis of solely  non-target 
disease requires substantial worsening such that even in the presence of SD or PR in 
target disease, the overall tumor burden has increased sufficientl y to merit 
discontinuation of therapy .
Sites of non -targe t lesions, which are not assessed at a particular time point based on 
the assessment schedule, should be excluded from the response determination (e.g., 
non-target response does not have to be "Not Evaluable").
New Lesions
New malignancies denoting disease progression must be unequivocal.  Lesions identified 
in follow -up in an anatomical location not scanned at baseline are considered new 
lesions.
Any equivocal new lesions should continue to be followed.  Treatment can continue at 
the discretion of the inve stigator until the next scheduled assessment.  If at the next 
assessment the new lesion is considered to be unequivocal, progression should be 
documented.
Evaluation of Overall Response
The table below presents the overall response at an individual time po int for all possible 
combinations of tumor responses in target and non -target lesions with or without the 
appearance of new lesions for subjects with measurable disease at baseline.
Evaluation of Overall Response for Subjects with Measurable Disease at Bas eline
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR or NA No CR
CR Non-CR/Non -PD or NE No PR
PR Non-PD or NA or NE No PR
SD Non-PD or NA or NE No SD
NE Non-PD or NA or NE No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
Abbreviations:  CR, complete response, PR, partial response, SD, stable disease, PD, progressive disease, NA, Not 
applicable; NE, Not Evaluable
Note:
Subjects with a global deterioration of health status requiring discontinuation of 
treatment wit hout objective evidence of disease progression at that time should 
be classified as having "symptomatic deterioration."  Objective response status 
2013N172718_04 CONFIDENTIA L
200331
144is determined b y evaluations of disease burden.  Every effort should be made to 
document the objective progre ssion even after discontinuation of treatment.  
In some circumstances, it may  be difficult to distinguish residual disease from 
normal tissue.  When the evaluation of CR depends on this determination, it is 
recommended that the residual lesion be investig ated (fine needle 
aspi[INVESTIGATOR_337]/biopsy ) to confirm the CR.
Evaluation of best overall response
The best overall response is the best response recorded from the start of the treatment 
until disease progression/recurrence and will be determined programmatically  by [CONTACT_91078].
To be assigned a status of SD, follow -up disease assessment must have met the SD 
criteria at least once after first dose at a minimum interval of 56 day s
If the minimum time for SD is not met, best response will depend on the subsequent 
assessments.  For example if an assessment of PD follows the assessment of SD and 
SD does not meet the minimum time requirement the best response will be PD.  
Alternativel y, subjects lost to follow -up after an SD assessment not meeting the 
minimum time criteria will be considered not evaluable.
Confirmation Criteria:
To be assigned a status of PR or CR, a confirmatory  disease assessment should be 
performed no less than 4 weeks (±3 day s) after the crit eria for response are first met.
Confirmation of Response per RECIST 1.[ADDRESS_367873] 4 weeks (±3 day s) after the criteria for response have initially  been met 
andmay be performed at the next protocol scheduled assessment.  If a confirmation 
assessment is performed prior to the next protocol -specified assessment, the next 
protocol -specified evaluation is still required (e.g., evaluations must occur at each 
protocol scheduled time point regardless of unscheduled assessments).
Bone disease:  To confirm a CR in a subject with bone disease at baseline, a bone scan 
that was obtained before the response assessment indicating a CR must have been 
obtained no earlier than [ADDRESS_367874] be done no 
more than 4 weeks after the next protocol specified assessment in order to confirm a CR.
Brain metastases:  To confirm a CR in a solid tumor subject with brain metastases at 
baseline, brain imaging that is obtained before the response assessment indicating a CR 
must have been obtained no earlier than [ADDRESS_367875] be done no more 
than 4 weeks (±3 day s) after the next protocol specified assessment in order to confirm a 
CR.
2013N172718_04 CONFIDENTIA L
200331
145Reference:
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey  J, 
Arbuck S, Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, 
Lacombe D, Verweij J.  New response evaluation criteria in solid tumours:  Revised 
RECI ST guidelines (ve rsion 1.1).  European Journal of Cancer . 2009;45:228 -247.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].5. Appendix 5:  Urine Protein Creatinine (UPC) Ratio
Clinical meaning of UPC
There is a good correlation between the ratio of protein concentration to creatinine 
concentration in a random urine sample and the amount of protein excreted over 24 hrs.  
Creatinine excretion is fairly  constant throughout the day  regardless of changes in urine 
flow rate.
Normal protein excretion is <150 mg/24 hrs and is similar for men and women.
Men excrete 20 mg to 25 mg o f creatinine/kg of body  weight/day .
Women excrete 15 mg to 20 mg of creatinine/kg of body  weight/day .
Calculating UPC
UPC ratio = Urine protein (mg/dL) / Urine creatinine (mg/dL). 
UPC ratio ≈ equivalent to grams of protein excreted in urine over 24 hrs. 
Example:   Subject has a urine protein = 90 mg/dL and urine creatinine = 30 mg/dL.  
UPC ratio= (90 mg/dL) / (30 mg/dL) =  3  
The calculated UPC ratio is 3, which correlates to roughl y 3 g pr otein excretion in a 
24-hr period.
Units for UPC ratio
Note: To calculate UPC, protein and creatinine concentrations must be expressed in the 
same units (mg/dL, g/L, or μmol/L). If, for example, protein concentration is expressed 
in mg/dL  and creatinine concentration is expressed in µmol/L , conversion of one of the 
concentration values is required.  Conversion factors are: 
From To Conversion Factor 
Conventional Units: mg/dL SI Units: µmol/L Multiply by 88.4
SI Units: µmol/L Conventional Units: mg/dL Divide 88.4 
References:
NKF: NKF KDOQI Guidelines [I nternet].  National Kidney  Foundation; nd.  KDOQI 
Clinical Practice Guidelines for Chronic Kidney  Disease: Evaluation, Classification, and 
Stratification.  Available from 
http://www.kidney .org/profess ionals/KDOQI/guidelines_ckd/p5_lab_g5.htm
Xin G, Wang M, Jian L , Xu F, Wang H.  Protein -to-creatinine ratio in spot urine samples 
as a predictor of quantitation of proteinuria 2004. Clinica Chimica Acta 350:35 -39.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].6. Appendix 6:  Liver Safety  Drug Restart/Rec hallenge 
Guidelines
If subject meets liver chemistry  stoppi[INVESTIGATOR_90549]/rechallenge subject with 
study  treatment unless:
GlaxoSmithKline ([COMPANY_004]) Medical Governance approval is granted (as described 
below),
Independent ethics committee (IEC) and /or institutional review board (IRB) 
approval is obtained, if required, and
Separate consent for treatment restart/rechallenge is signed b y the subject
If [COMPANY_004] Medical Governance approval to restart/rechallenge subject with study  treatment 
is not granted , then subject must permanentl y discontinue study  treatment and may  
continue in the study  for protocol -specified follow -up assessments.
1.Rechallenge Following Liver Stoppi[INVESTIGATOR_90568] -induced liver injur y (DILI), drug rechallenge is associated with a 13% 
mortality across all drugs in prospective studies [Andrade , 2009]. Clinical outcomes 
vary by [CONTACT_9934], with nearl y 50% fatalit y with halothane re -administered within 1 mon th of 
initial injury . However, some drugs seldom result in recurrent liver injury  or fatalit y.  
Risk factors for a fatal drug rechallenge outcome include:
Hypersensitivity [Andrade , 2009] with initial liver injury  (e.g., fever, rash, 
eosinophilia) 
jaundice or bilirubin >2 x upper limit of normal (ULN) with initial liver injury  
(direct bilirubin >35% of total)
subject currently  exhibits severe liver injury  defined by : [CONTACT_301198] (ALT) ≥3 x UL N, bilirubin ≥[ADDRESS_367876] (direct bilirubin >35% 
of total), or international normalization ratio (INR)>1.5
serious adverse event or fatality  has previously  been observed with rechallenge 
of the drug [ Papay , 2009; Hunt , 2010]
evidence of treatment -related preclinical liability  (e.g., reactive metabolites; 
mitochondrial impairment) [ Hunt , 2010]
Rechallenge refers to resuming study  treatment following DILI. Because of the risks
associated with rechallenge after DILI this should only  be considered for a subject for 
whom there is compelling evidence of benefit from a critical or life -saving medicine, 
there is no alternative approved medicine available, and a benefit:risk assessmen t of 
rechallenge is considered to be favorable.
2013N172718_04 CONFIDENTIA L
200331
148Approval b y [COMPANY_004] for rechallenge with study treatment can be considered where:
Investigator requests consideration of rechallenge with study  treatment for a subject 
who is receiving compelling benefit with stu dy treatment that exceeds risk, and no 
effective alternative therapy  is available.
IEC or IRB approval for rechallenge with study  treatment must be obtained, as 
required.
If the rechallenge is approved by  [CONTACT_90652], the subject 
must be provided with a clear description of the possible benefits and risks of study  
treatment administration, including the possibility  of recurrent, more severe liver 
injury  or death.  
The subject must also provide signed informed consent specificall y for the 
rechallenge with study  treatment.  Documentation of informed consent must be 
recorded in the study  chart.  
Study  treatment must be administered at the dose specified by  [CONTACT_23983].
Subjects approved b y GS K Medical Governance for rechallenge with stud y 
treatm ent must return to the clinic twice a week for liver chemistry  tests until stable 
liver chemistries have been demonstrated and then standard laboratory  monitoring 
may resume as per protocol.
If after study  treatment rechallenge, subject meets protocol -defined liver chemistry  
stoppi[INVESTIGATOR_3418], study  treatment should be permanently  discontinued. 
[COMPANY_004] Medical Monitor, and the IEC or IRB as required, must be informed of the 
subject’s outcome following stud y treatment rechallenge. 
[COMPANY_004] to be notified of any adverse events , as per Section 9.
2.Restart Following Transient Resolving Liver Stoppi[INVESTIGATOR_301108] y treatment following liver stoppi[INVESTIGATOR_301109] a clear underl ying cause (other than DILI) of the liver event (e.g., biliary  obstruction, 
pancreatic events, hy potension, acute viral hepatitis). Furthermore, there should be no 
evidence of alcoholic hepatitis or hy persensitivity, and the study  treatme nt should not be 
associated with human leukocy te antigen (HLA) markers of liver injury .
Approval b y [COMPANY_004] for study treatment restart can be considered where:
Investigator requests consideration for stud y treatment restart if liver chemistries 
have a clear u nderl ying cause (e.g., biliary  obstruction, hy potension and liver 
chemistries have improved to normal or are within 1.5 x baseline and 
ALT<3xUL N).
Restart risk factors (e.g. ,fever, rash, eosinophilia, or hy persensitivity , alcoholic 
hepatitis ), possible s tudy treatment -induced liver injury  or study  treatment has an 
2013N172718_04 CONFIDENTIA L
200331
149HLA genetic marker associated with liver injury  (e.g. lapatinib, abacavir, 
amoxicillin/clavulanate) are reviewed and excluded
IEC or IRB approval of study  treatment restart must be obtained, as required.
If restart of stud y treatment is approved b y [COMPANY_004] Medical Governance in writing, the 
subject must be provided with a clear description of the possible benefits and risks of 
study  treatment administration, including the possibility  of recurrent, mo re severe 
liver injury  or death.
The subject must also provide signed informed consent specificall y for the study  
treatment restart.  Documentation of informed consent must be recorded in the study  
chart.  
Study  treatment must be administered at the dose specified b y [COMPANY_004].
Subjects approved b y GS K Medical Governance for restarting stud y treatment must 
return to the clinic once a week for liver chemistry tests until stable liver chemistries 
have been demonstrated and then laboratory  monitoring may  resume as per protocol.
If after study  treatment re -start, subject meets protocol -defined liver chemistry  
stoppi[INVESTIGATOR_3418], follow usual stoppi[INVESTIGATOR_53058].
[COMPANY_004] Medical Monitor, and the IEC or IRB as required, must be informed of the 
subject’s outcome f ollowing study  treatment restart.
[COMPANY_004] to be notified of any adverse events, as per Section 9of the protocol.
REFERENCES:
Andrade RJ, Robles M, Lucena MI.  Rechallenge in drug -induced liver injury : the 
attractiv e hazard.  Expert Opin Drug Saf . 2009;8:709 -714.
Hunt, CM.  Mitochondrial and immunoallergic injury  increase risk of positive drug 
rechallenge after drug -induced liver injury : A s ystematic review.  Hepatol . 
2010;52:2216 -2222.
Papay  JI, Clines D, Rafi R, Yu en N, Britt SD, Walsh JS, Hunt CM.  Drug -induced liver 
injury  following positive drug rechallenge.  Regul Tox Pharm . 2009;54:84 -90.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].7. Appendix 7:  Genetic Research
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investi gate the relationship between genetic 
variants and: 
Response to medicine, including an y treatment regimens under investigation in this 
study  or an y concomitant medicines;
Cancer susceptibility , severity , and progression and related conditions
Genetic dat a may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from multiple clinical studies to investigate these research objectives.
Appropriate desc riptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Reporting and Analy sis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations w ill be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Population
Any subject who is enrolled in the study  can participate in genetic research.  Any  subject 
who has received an allogeneic bone marrow transplant must be excluded from the 
genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.  
A 6-mLblood sample will be taken for deoxyribonucleic acid (DNA) extraction. A 
blood sample is collected at the baseline visit (Day 1 preferabl y for this study) , after 
the subject has been randomized and provided informed consent for genetic research. 
If a subject initially  declines to participate in genetic research and then changes their 
mind, a sample shou ld be obtained at the earliest opportunity .  Instructions for 
collection and shippi[INVESTIGATOR_278799]. 
The DNA from the blood sample may  undergo quality  control anal yses to confirm 
the integrit y of the sample. I f there are concerns regarding the quality  of the sample, 
then the sample may  be destroy ed. The blood sample is taken on a single occasion 
unless a duplicate sample is required due to an inability  to utilize the original sample.  
2013N172718_04 CONFIDENTIA L
200331
151The genetic sample is lab elled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study .   This number can be traced or linked back to 
the subject by  [CONTACT_132018]. Coded samples do not carry  personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_367877] 
completes the study , or GlaxoSmithKline ([COMPANY_004]) may  destroy  the samples sooner.  [COMPANY_004] 
or those working with [COMPANY_004] (for example, other res earchers) will only  use samples 
collected from the study  for the purpose stated in this protocol and in the informed 
consent form.  Samples may  be used as part of the development of a companion 
diagnostic to support the [COMPANY_004] medicinal product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subjects who do not wish to participate in the genetic research may  still participate in the 
clinical study .  Genetic informed consent must be obtained prior to any  blood being 
taken.
Subje ct Withdrawal from Study
If a subject who has consented to participate in genetic research withdraws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning th e genetic sample, if alread y 
collected:
Continue to participate in the genetic research in which case the genetic DNA sample 
is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a subject withdraws consent fo r genetic research or requests sample destruction for an y 
reason, the investigator must complete the appropriate documentation to request sample 
destruction within the timeframe specified b y [COMPANY_004] and maintain the documentation in 
the site study  records . 
Genotype data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis. 
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time of withdrawn consent will continue 
to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is de termined that the subject 
does not meet the entry  criteria for participation in the study , then the investigator should 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367878]’s Genetic Data
[COMPANY_004] may  summarize the geneti c research results in the clinical study  report, or 
separately  and may  publish the results in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] do es not inform the subject, 
family  members, insurers, or employ ers of individual genoty pi[INVESTIGATOR_131978]’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the informatio n generated from genetic 
studies is generall y preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusio n in clinical care.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].8. Appendix 8:  Country  Specific Requirements
[LOCATION_008] ([LOCATION_006]): The [LOCATION_006] Specific QTc Stoppi[INVESTIGATOR_301110].
In line with local requirements, a subject enrolled and participating in this study  in 
the [LOCATION_006] that meets the criteria QTc1 below will have study  treatment withheld:
QTcB >[ADDRESS_367879] will benefit from further treatment.
Abbreviations: ECG, electrocardiogram; [COMPANY_004], GlaxoSmithKline; QTc, corrected QT 
interval; QTcB, corrected QT interval b y Bazett’s formula ; [LOCATION_006], [LOCATION_008]
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].9. Appendix 9:  Protocol A mendment Changes
16.9.1. Protocol Changes for A mendment 1 (08 -Sep-2014) from Original 
Protocol (22 -May-2014)
Where the A mendment A pplies
This amendment applies to all sites and countries.
Summary  of Amendment Changes wit h Rationale
Amendment 1 incorporates changes to Section 5.2, Permanent Discontinuation of Study  
Treatment(s) for clarification as requested b y the Medicines and Healthcare products 
Regulatory  Agency  (MHRA) in the [LOCATION_008].
List of Specific Changes
Section 5.2, Permanent Discontinuation of Study Treatment(s)
REVI SED TEXT
Subjects may  receive study  treatment until disease progression, unacceptable toxicity , 
including meeting stoppi[INVESTIGATOR_301111] 7.2.2, or 
death.  S tudy treatment(s) maywillbe permanently discontinued for an y of the following 
reasons:
Disease progression
Death
Unacceptable AE (including meeting liver chemistry  stoppi[INVESTIGATOR_23894] 7.2.2)
Substantial protocol deviation(s)
16.9.2. Protocol Changes for A mendment 2 (26 -Feb-2015) from Protocol 
Amendment 1 (08 -Sep-2014)
Where the A mendment A pplies
This amendment applies to all sites and countries.
Summary  of Amendment Changes with Rationale
Amendment [ADDRESS_367880] of authors and primary  medical monitor 
(contact [CONTACT_3031]) due to changes in personnel assignment within [COMPANY_004]; list of 
abbreviations was revised appropriatel y based upon addition/deletion of abbreviated 
terms used throughout the protocol; Time and Events Tables were re vised for 
clarification of assessments and procedures to be performed and to reflect changes made 
throughout the bod y of the protocol.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367881] Information
Role Name [CONTACT_301229] -
hours 
Phone/ 
Cell/
Pager 
NumberFax 
Number[COMPANY_004] Address
Primary 
Medical 
MonitorMD, PhDGlaxoSmithKline
[ADDRESS_367882] paragraph
REVISED TEXT
This study  is ongoing; and, as of February  2014, [ADDRESS_367883]- dose.  It is 97 to 98% bound to plasma proteins, 
primarily albumin.  N -desmethy l enzalutamide is 95 to 97% bound to plasma proteins.  
Enzalutamide is metabolized by  [CONTACT_097]3A4 and CYP2C8 to an active metabolite 
N-desmeth yl enzalutamide and primaril y eliminated by [CONTACT_171339] (CYP3A4 
and CYP2C8).  The mean t1/2 is 5.8 day s in patients.  With daily  administration, steady  
state is reached a fter approximately  30 day s. In order to achieve near -steady state 
enzalutamide exposure, a 14- day run -in period has been included in the study 
design (Section 1.5.3, and Section 3).   Enzalutamide accumulates approximately  8.3-
fold relative to a single dose with a mean peak -to-trough ratio of 1.25. A high -fat meal 
did not alter the area under the concentration-time curve (AUC) of enzalutamide or its 
active metabolite, N -desmethy l enzalutamide.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2013N172718_04 CONFIDENTIA L
200331
156Section [IP_ADDRESS]  Risk of Drug -Drug Interaction (NEW SECTION)
NEW TEXT
The risk for [COMPANY_004]2636771 to affect enzalutamide via enzymes of CYP3A4 and 
CYP2C8 is low but not fully discharged.  It is unknown if enzalutamide could 
potentially affect the exposure of [COMPANY_004]2636771 via UGT inhibition or induction, 
while the drug -drug interaction (DDI) risk on [COMPANY_004]2636771 via OATP transporter 
inhibition by [CONTACT_301199]2636771.
Section 1.4.2  Benefit Assessment
REVISED TEXT
2ndparagraph, 1stbullet:
Further treatment with enzalutamide may continue to provide benefit as seen from 
the limited data suggesting some evidence of response in patients receiving 
abiraterone following abiraterone, enzalutamide following abiraterone, and from 
abiraterone following enzalutamide.  Rate of growth may  still be lower with 
enzalutamide than without enzalutamide (precedent from trastuzumab beyond 
progression).  A 14 -day run -in period of treatment with enzalutamide 
monotherapy will be continuous with prior enzalutamide therapy, with the 
exception of an allowe d 30 day drug holiday from enzalutamide treatment, in 
order to achieve near -steady state enzalutamide exposure.
Section 1.5.3  Dose Rationale
REVISED TEXT
5thparagraph:   A dose of [ADDRESS_367884] ed as the recommended Phase II dose (RP2D) for [COMPANY_004]2636771 
monotherap y treatment based on safety, PK, and pharmacod ynamic (PD) data from Study  
P3B115717.  The proposed starting dose of [COMPANY_004]2636771 in the present study  will be 300 
mg once dail y which is 75% o f the RP2D as a single agent determined in Study  
P3B115717.  The starting dose for the present study  is lower than the monotherapy  RP2D 
to decrease the probability of overlappi[INVESTIGATOR_301068]2636771 and enzalutamide.  
Preliminary  results from Study  P3B115717 indicate that [ADDRESS_367885]  inhibition.
NEW TEXT
6thparagraph:   For enzalutamide, the approved dose of 160 mg once daily was 
selected.  Given the long half -life of enzalutamide, a run -in period of 14 days is 
included in the study design.  The intent of this run -in period is to achieve near -
steady state plasma concentrations of enzalutamide prior to initiating combination 
therapy with [COMPANY_004]2636771.
2013N172718_04 CONFIDENTIA L
200331
157Section 2.2 Objectives and Endpoints
REVISED TEXT
Objectives Endpoints
Primary
To assess the safety and 
tolerability of [COMPANY_004]2636771 + 
enzalutamide administered orally 
once daily continuously in 
subjects with mCRPC.AEs, SAEs, DLTs, and changes in 
laboratory values, ECGs, and vital signs 
(BP, temperature and pulse heart rate)
To determine the RP2D of orally 
administered [COMPANY_004]2636771 + 
enzalutamide in subjects with 
mCRPC.Safety and tolerability as assessed by 
[CONTACT_2695], SAEs, DLTs, and changes in 
laboratory values, ECGs, and vital signs 
(BP, temperature and heart rate)
Section 3 Investigational Plan
REVISED TEXT
This is a Phase I, open -label, non -controlled, non -randomized dose -escalation, 
multicenter study  to determine the RP2D of the oral PI 3Kinhibitor, [COMPANY_004]2636 771 in 
combination with enzalutamide in subjects with mCRPC.  The study  will be conducted in 
two phases: the Dose Escalation Phase and the Dose Expansion Phase.  Each phase of 
the study will consist of a pre -screening period and three treatment periods: 
Enzalutamide Run -In Period, Combination Treatment Period and Treatment 
Continuation Period. 
Subjects with PTEN deficient mCRPC (determined during pre -screening), who have 
documented progression per Prostate Cancer Working Group 2 (PCWG2) criteria 
(either by [CONTACT_16622] [RECIST] 1.1, prostate -
specific antigen [PSA] progression, and/or progression in bone), will be enrolled in 
the Dose Escalation Phase and Dose Expansion Phase of the study.  
In the Dose -Escalation Phase, subje cts will be enrolled to receive [COMPANY_004]2636771 + 
enzalutamide and will be approved based on review of available screening data by  [CONTACT_301200].  Dosing will be conducted in 28 day  treatment 
periods.  Decisions for dose determinatio n for subsequent cohorts will be documented 
and maintained b y each site and in the [COMPANY_004] Master Study  Files.
In the Dose Escalation Phase, subjects will be enrolled into dose -finding cohorts to 
evaluate the safety and PK to guide the selection of the RP2D of [COMPANY_004]2636771.  
Dosing decisions will be based on all available data at the end of each DLT reporting 
period (the first 28 days of combination treatment).  Decisions for dose 
determination for subsequent cohorts will be documented and maintained by [CONTACT_301201] (TMF).
2013N172718_04 CONFIDENTIA L
200331
158In the Dose Expansion Phase, subjects will be assigned to receive [COMPANY_004]2636771 at the 
MTD or RP2D determined in the Dose Escalation Phase while continuing treatment with 
enzalutamide to evaluate the long -term safety  of the combination as well as the 12 -week 
non-PD rate.
Safety Assessments:  Throughout the stud y, safety will be assessed through standard 
measures, including ph ysical examinations, vital signs, clinical laboratory  tests, 12 -lead 
ECGs and monitoring of AEs .  Efficacy  will be assessed by  [CONTACT_5292], 
computed tomograph y (CT) scan or magnetic resonance imaging (MRI), radionuclide 
bone scans, circulating tumor cells (CTC) enumeration, and PSA.  Pharmacokinetic (PK) 
blood samples will be collected from all subjects to evaluate if there is an effect of 
[COMPANY_004]2636771 on the PK of enzalutamide and to quantify  the s ystemic exposure to 
[COMPANY_004]2636771.
Clinical Response Assessments: The determination of clinical response, including 
disease progression, will be asses sed b y both the PCWG2 criteria (see Section 8.8.2).  
The assessment of the 12 week non -PD-rate in the dose expansion phase will also be 
determined b y PCWG2 criteria (either b y RECI ST 1.1, PSA progression, and/or 
progression in bone).
Biomarker Assessments: Planned biomarker assessments include:  1) Identify  potential 
predictive biomarkers (protein, DNA, RNA based) in archival tumor tissue/pre -dose 
biopsies; 2) enumeration of CTCs in circulation and evaluation of alterations in AR or 
PTEN genes (or other gen omic markers) in isolated CTCs; 3) Assessment of gene 
mutations in cfDNA and other soluble markers in plasma to better understand clonal 
evolution and other predictive circulating biomarkers; and 4) understand the mechanism 
of resistance in tumor tissues b iopsies (optional) at time of progression.
Subjects will continue study  treatment until clinical benefit is no longer apparent, in the 
opi[INVESTIGATOR_301112], or until unacceptable AE, withdrawal of consent, or 
death.  A post -treatment follow -upvisit will be performed within [ADDRESS_367886] dose 
of study  treatment(s).  The study  will be considered completed approximately  [ADDRESS_367887] further efficacy  data if warranted.
Protocol waivers or exemptions are not allowed.  Therefore, adherence to the study  
design requirements, including those specified in the Time and Events Tables 
(Section 8.1) are essential.
Supplementary  study  conduct in formation not mandated to be present in this protocol is 
provided in the accompany ing Study  Procedures Reference Manual ( SRPM).  The SPM 
will provide the site personnel with administrative and detailed technical information that 
does not impact subject saf ety.
2013N172718_04 CONFIDENTIA L
200331
159Section 3.1 Prescreening and Screening (New Section)
NEW TEXT (originally in Section 3.2):
All subjects will be required to undergo pre -screening to determine the PTEN 
deficiency status of their tumor at the [COMPANY_004] selected laboratory.
Pre-screening may be performed prior to confirmation of progression on 
enzalutamide 
Subjects will be required to sign a separate Pre -Screening Informed 
Consent Form (ICF) to allow for pre -screening of archived or fresh 
tumor biopsy samples
Details of the PTEN requirements are provided in SRM.
Subjects with PTEN -deficient tumors may enter into Screening for the study.  
Subjects meeting all screening criteria (Section 4.1.2 and Section 4.1.3) may enroll 
into the Treatment Periods of the study.
Section 3.2 Treatment Periods (N ew Section)
Section 3.2.1  Enzalutamide Run -In Period (New Section)
NEW TEXT
Subjects will be enrolled in the [ADDRESS_367888] dose 
of enzalutamide.
Section 3.2.2  Combination Treatment Period (New Section)
NEW TEXT
Subjects who complete the Enzalutam ide Run -In Period will begin oral 
[COMPANY_004]2636771 treatment on Week 1, Day 1 of the Combination Treatment Period 
while continuing to receive enzalutamide to evaluate safety of the combination 
therapy.
2013N172718_04 CONFIDENTIA L
200331
160Section 3.2.3  Treatment Continuation Period (New Section)
NEW TEXT
Subjects will continue to receive the combination treatment of [COMPANY_004]2636771 + 
enzalutamide from Week [ADDRESS_367889] -Treatment Follow -Up
REVISED TEXT, 2ndparagraph
The dosing of enzalutamide will be administered at the US FDA approved dose (refer to 
the Presc ribing Information for enzalutamide [Xtandi, 2013].  Study  treatment will 
continue until there is no longer clinical benefit, in the opi[INVESTIGATOR_871], or until 
an unacceptable AE (including stoppi[INVESTIGATOR_873] 7.2), withdrawal of 
consent, permanent discontinuation of treatment, or death occurs.  Investigators will 
use the PCWG2 criteria to determine clinical response to each treatment.
NEW TEXT
A post -treatment follow -up visit will be performed within [ADDRESS_367890] dose of
study treatment(s) for all subject who permanently discontinue study treatments, 
during the Enzalutamide Run -In Period (and/or do not enter the Combination 
Treatment Period), or for those who permanently discontinue study treatments 
during the Combination Treatment or Treatment Continuation Period due to 
disease progression.  
Subjects who withdraw from the study during the Combination Treatment or 
Treatment Continuation Period without disease progression should complete the 
Extended Follow -up Visits where they will be contact[CONTACT_457] 3 months ( 14 days) 
until disease progression, death, withdrawal of consent, or subject is lost to follow -
up.  Contact [CONTACT_301179] a clinic visit, a telephone contact ,or an e-mail.  The 
initiation of any new anti -cancer treat ments and date of last contact [CONTACT_301202] .  Subjects who discontinue the Extended Follow -Up Visits prior to 
disease progression, death, or withdrawal of consent s hould have a Post -Extended 
Follow -Up/EOS Visit performed.
Section 3.4  Dose Escalati on Phase
REVISED TEXT
1stparagraph: In the Dose -Escalation Phase, the dose of [COMPANY_004]2636771 will follow a 
modified 3+3 dose -escalation procedure to evaluate the safet y and PK for each 
2013N172718_04 CONFIDENTIA L
200331
161combination dose level and to guide selection of the RP2D of the combinati on.  Subjects 
with PTEN deficient mCRPC who are receiving a stable dose of enzalutamide with 
recent demonstrated progression per PCWG2 criteria (either b y RECIST 1.1, PSA 
progression, and/or progression in bone) will be enrolled.
2ndparagraph, last senten ce:Dose escalation will proceed with the increment of dose 
increase or decrease as determined b y toxicity  rules outlined in Table 1.
Section 3.4.[ADDRESS_367891] the new 
dosing schedule.
Section 3.4.3  Definition of Dose Limiting Toxicity
NEW TEXT
1stparagraph:  The DLT criteria apply only during the dose finding stage, and 
impacts the decisions around whether the MTD has been determined, and/or 
decisio ns around whether to escalate or de -escalate the next dose level, but do not 
apply to the mandated management of an individual subject as with the liver 
stoppi[INVESTIGATOR_3418].
Last paragraph:  Subjects who experience an intolerable toxicity causing a dose 
interruption or dose reduction during the Enzalutamide Run -In Phase (before the 
start of [COMPANY_004]2636771 combination treatment) will require approval from the [COMPANY_004] 
Medical Monitor in order to continue in the study.  Those subjects not eligible for 
the combination ph ase will not be considered in the evaluation of DLTs and may be 
replaced.
REVISED TEXT
Subjects who fail to receive at least 75% of protocol -specified stud y treatment during the 
DLT reporting period (the first 28 day s of combination treatment), for reasons OTHER 
than toxicity , will be replaced if data from the replacement subject could impact the dose 
selection criteria.  
An event will be considered a DLT if the event is attributed (definitel y, probably or 
possibly ) to study  treatment, occurs within the fi rst 28 day s ofcombination treatment
(DLT reporting period), and meets one of the following criteria:
2013N172718_04 CONFIDENTIA L
200331
162Bullets 5 and 6:
Alanine aminotransferase (ALT) >3 times upper limit of normal (ULN) with
bilirubin >2 times UL N (or ALT >[ADDRESS_367892] and 150% of baseline ALT, if 
enrolled with liver metastases/tumor infiltration at baseline) (or ALT ≥[ADDRESS_367893] and ≥1.5 times baseline ALT value, if enrolled with liver 
metastases/tumor infiltration at baseline), together with bilirubin ≥[ADDRESS_367894])
Any Grade [ADDRESS_367895] sentence: Enrollment in the Dose Expan sion Phase of the stud y ma y begin once the 
MTD and RP2D have been determined at the RP2D in the Dose Escalation Phase.  
Section 3.6.1  Evaluation of Futility
REVISED TEXT
Futility will be evaluated in the Dose Expansion Phase of the study.   The 
methodolog y is based on the predictive probability of success if enrollment continues to 
20 subjects [L ee, 2008] . The predictive probability  design is similar to a Green -Dahlberg 
design in that it allows for earl y stoppi[INVESTIGATOR_16589]. The differences are that the 
predictive probability  design allows for evaluation of stoppi[INVESTIGATOR_301113], 
rather than at only  two stages, once a minimum number of subjects are evaluable. In this 
particular stud y, we will stop only  for futility . While the two designs have similar ty pe I 
and ty pe II error rates, the probability  of early  termination is greater with the predictive 
probability  design.
After [ADDRESS_367896] may  continue study  treatment until the treatment discontinuation criteria are 
met (see Section 5.2).  Additional guidelines regarding dose modifications are 
provided in Section 7.1.   Prior to administration of additional study  treatment bey ond 
the first 28 day s (the DLT reporting period), clinically  significant AEs should be resolved 
to baseline or Grade 1.
Section 3.[ADDRESS_367897] number range (range will be provided in the SRM).  
Upon completion of all required pre -screening and screening procedures and 
assessments, eligible subjects will be enrolled b y the study  team.  Subjects will be 
identified by  a unique subject number that will remain consistent for the duration of the 
study .
NEW TEXT
Each subject will be assigned a unique subject number that will remain consistent 
for the duration of the study.  This number will be assigned sequentially from a 
range of subject numbers provided for each site in the SRM.  Upon completion of all 
requ ired pre -screening and screening procedures and assessments, eligible subjects 
must be approved for enrollment by a member of the study team according to the 
procedures detailed in the SRM.
Section 4.1.1  Number of Subjects
REVISED TEXT
A total of approxim ately  44 subjects will be enrolled in this study .  In the Dose 
Escalation Phase, additional subjects/cohorts may  be enrolled to allow for evaluation of 
additional dose levels. The sample size planned for the Dose Expansion Phase is not 
driven by  [CONTACT_301203] l considerations as the cohort is meant to further understand the safet y 
implications of enrolling subjects to combination therap y for an extended period of time.  
See Section 13.2 for sample size assumptions.
Dose Escalation Phase:  The number of dose lev els and the level at which the MTD is 
reached cannot be determined in advance.  An adequate number of subjects will be 
enrolled to establish the recommended dose for further stud y.  It is estimated that 
approximately  24 subjects will be needed for the Dose Escalation Phase.
Dose Expansion Phase:  In the Dose Expansion Phase, it is estimated that approximately  
[ADDRESS_367898] 
completed 12 weeks of treatment (see Section 3.5.1). altho ugh if the first 10 subjects 
progress with mCPRC, the dose expansion will be stopped.
2013N172718_04 CONFIDENTIA L
200331
164The sample size planned for the Dose Expansion Phase is not driven by [CONTACT_301204].  See 
Section 13.2 for sample size assumptions.
Section 4.1.2 Inclusion Criteria #1, #2, #3, #5, #7, #8, #9, #11 and #12
NEW TEXT
New Inclusion Criteria #8 (all subsequent criteria hav e been renumbered):  Has not been 
without enzalutamide treatment for >30 days prior to enrollment
REVISED TEXT
1.  Signed written informed consent
NOTE:  Separate ICFs must be signed prior to the pre -screening and 
screening procedures.
2. Males ≥18 y ears o f age (at the time written consent is obtained for pre -screening )
3. Histologicall y or c ytologically  confirmed diagnosis of prostate adenocarcinoma, 
surgically  castrated or continuous medical castration ( for ≥8 weeks prior to Screening )
5. PTEN -deficient t umor as documented from archived or fresh (from pre-treatment
biopsy ) tumor tissue analy zed by  a [COMPANY_004] selected laboratory
7. Has completed at least 12 weeks of prior continuous therapy  with enzalutamide
NOTE: A 30 day  or less treatment (enzalutamide) holida y will be permitted prior to 
Screening.
8. Most recent enzalutamide dose received is [ADDRESS_367899] 2 weeks prior to enrollment
9. Has documented disease progression progressive disease at time of enrollment 
following treatment with enzalutamide at a time of Screening.
NOTE: Disease progression is defined as one or more of the following criteria:
11.  Adequate baseline organ function at the time of Screening defined as:
Renal
Urine Protein (via dipstick)2 0/+1
UPC3,4 <0.2
Serum Creatinine
OR
Estimated Serum Creatinine Clearance5
OR
24-hr Urine Creatinine ClearanceULN
60 mL/min
60 mL/min
Cardiac
LVEF 50% by [CONTACT_301205]6 ≤Grade 1
Serum Calcium (corrected) WNL
2013N172718_04 CONFIDENTIA L
200331
165Abbreviations: ANC, absolute neutrophils count; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events ; ECHO, echocardiogram; 
INR, international normali zation ratio; LLN, lower limit of normal ; LVEF, left ventricular ejection fraction; 
MUGA, multigated acquisition scan; PT, prothrombin time; PTT, partial thromboplastin time; ULN, upper limit 
of normal; UPC, urine protein to creatinine ratio; WNL, within n ormal limits
1. If ALT or bilirubin values are outside range listed due to Gilbert’s syndrome or asymptomatic gallstones, 
subject remains eligible.
2. If subject’s urine protein is >1+ (via dipstick), then UPC ratio will be calculated.  Subject will be 
considere d eligible for study if UPC ratio is <0.2.
3. UPC ratio is only to be calculated if subject’s urine protein is >1+ via dipstick.
4. The UPC value will not be used to determine eligibility for subjects who are unable to obtain 
uncontaminated urine samples due to their disease.
5. Estimated by [CONTACT_301206] (see Appendix 3).
6. Per CTCAE v4.0, Grade 1 hypophosphatemia is <LLN –2.5 mg/dL (<LLN –0.8 mmol/L)
NOTE:   Laboratory results obtained during Screening should be used to determine 
eligibility  crite ria.  In situations where laboratory  results are outside the permitted 
range, the investigator may  opt to retest the subject and the subsequent within range 
screening result may  be used to confirm eligibility .  
12. Male subject with a female partner of ch ildbearing potential or pregnant must have 
either a prior vasectomy  or agree to use two acceptable methods effective of 
contraception as described in Section 11.[ADDRESS_367900] a QT interval corrected for heart rate according to Fridericia’s formula 
(QTcF) <470 msec or <480 msec with bundle branch block (BBB).
NOTE:   For subject eligibility , withdrawal, and for purposes of data analy sis, 
QTcF will be used.  The QTcF shoul d be based on single or averaged QTc values 
of triplicate ECGs obtained over a brief recording period.
Section 4.1.3 Exclusion Criteria #1, #4, #5, #6, #11, #15, #16, #18 and #22
REVISED TEXT
1. Prior treatment with:
Exception: Subjects may remain on lutei nizing hormone releasing hormone 
(LHRH) agonists (i.e., leuprolide, goserelin, triptorelin or histrelin) and AR 
antagonists (e.g., bicalutamide, flutamide, nilutamide).
Exception: Subjects must have received prior treatment with enzalutamide.
Any PI3K, AKT or mammalian target of rapam ycin (mTOR) inhibitors
Investigational drug(s) (other than enzalutamide) within 30days or 5 half -lives, 
whichever is longer, prior to enrollment
2013N172718_04 CONFIDENTIA L
[PHONE_6262].  A ny unresolved Grade 2 toxicity (per CTCAE v4.0) toxicity from previous anti -
cancer therap y at the time of enrollment , except alopecia or Grade 2 anemia (if 
hemoglobin is >9.0 g/dL)
5. Hypophosphatemia Any Grade 2 h ypophosphatemia (per CTCAE v4.0) at the time of 
enrol lment
6. Serum calcium Grade 1 (per CTCAE v4.0) at time of enr ollmenton Day  -1, unless 
ionized calcium is within normal range
11. Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody  test 
result at time of Screening or within [ADDRESS_367901] to seizure (e.g., prior 
cortical stroke or significant brain trauma).  History  of loss of consciousness or transient 
ischemic attack within 12 months of randomization enrollment
18. Poorly  contro lled hy pertension (defined as s ystolic blood pressure [SBP] of 
≥150 mmHg or diastolic blood pressure [DBP] of >100 mmHg based on a mean of 
three measurements at approximately  2-minute intervals)
NOTE:   Initiation or adjustment of antihy pertensive medication(s) is permitted if 
done within 30 or more days prior to en rollment .
22. Exposure to more than 4 investigational medicinal products (IMPs) within [ADDRESS_367902] dose of study  treatment enrollment
NEW TEXT
16.Has a QTc >450 msec or QTc >480 msec for subjects with bundle branch 
block (BBB)
NOTES: The QTc is the QT interval corrected for heart rate by[CONTACT_35019]’s 
formula (QTcB), Fridericia’s formula (QTcF), and/or another method, 
machine -read or manually over -read.
The specific formula that will be used to determine eligibility and 
discontinuation for an indiv idual subject should be determined prior to 
initiation of the study. In other words, several different formulae cannot be 
used to calculate the QTc for an individual subject and then the lowest QTc 
value used to include or discontinue the subject from the trial.
For purposes of data analysis, QTcB, QTcF, another QT correction formula, 
or a composite of available values of QTc will be used as specified in the 
Reporting and Analysis Plan (RAP).
Section 5.2 Permanent Discontinuation of Study Treatment(s)
REVIS ED TEXT
Subjects may  receive study  treatment until disease progression, unacceptable toxicity , 
including meeting stoppi[INVESTIGATOR_301111] 7.2.2, or 
death.  Study  treatment(s) will be permanently  discontinued for any  of th e following 
reasons:
2013N172718_04 CONFIDENTIA L
200331
167Disease progression
NOTE:  Subjects must meet the PCWG2 guidelines for disease progression 
to avoid premature discontinuation of study treatment(s).
Treatment Discontinuation due to PSA rise:   Following PCWG2 
guidelines, subjects shoul d not be discontinued from study 
treatment(s) solely due to PSA rise during the first 12 weeks of 
treatment (Section [IP_ADDRESS]).
Treatment Discontinuation due to Bone Scan changes:  Subjects should 
not be discontinued from study treatment(s) due to the occur rence of 
bone scan changes in the first 12 weeks that do not meet PCWG2 
guidelines for progression (Section [IP_ADDRESS]).
Unacceptable toxicity  (including meeting liver chemistry  stoppi[INVESTIGATOR_301072] 7.2.2)
NOTE: If the subject voluntarily d iscontinues from treatment due to 
toxicity, ‘adverse event’ will be recorded as the primary reason for 
permanently discontinuation on the eCRF.
Substantial protocol deviation(s)
Death 
Investigator’s discretion
Lost to follow -up
Intercurrent illness that p revents further administration of study  treatment(s)
Withdrawal of consent by  [CONTACT_301168]/or data 
collection
If subject withdraws consent for further treatment, the subject should return 
for Post -Treatment Follow -up Visit as indicated in the Time and Events 
Tables (Section 8.1).
If subject withdraws consent for further treatment and data collection, then no 
additional study  visits, including a post -treatment follow -up visit, or data 
collection should occur.  All samples collec ted for the biomarker anal ysis at 
the time of withdrawal will proceed for anal ysis to meet the intended 
objectives defined in this protocol , unless consent for further analyses is 
withdrawn by [CONTACT_423] .
Study  closure or termination
If study  treatment(s) is/are permanently  discontinued, the subject will not be allowed to 
be retreated.  The primary reason for permanently discontinuing study  treatment(s) must 
be documented in the subject’s medical records and electronic case report form (eCRF).
All subjects who have study treatment(s) permanently discontinued will have safet y 
assessments at the time of discontinuation and during post -study  treatment follow -up as 
specified in Time and Events Tables (Section 8.1).
2013N172718_04 CONFIDENTIA L
200331
168Treatment Discontinuation without Disease Prog ression: All subjects who permanentl y 
discontinue study  treatment(s) without disease progression should be followed for 
progression in the Extended Follow -Up Visits according to the protocol schedule until:
A new anti -cancer therapy  is initiated, or
Diseas e progression occurs, or
Subject withdrawal, or
Death
Treatment Discontinuation due to PSA rise:   Following PCWG2 guidelines, subjects 
should not be discontinued from study  treatment(s) solely  due to PSA rise during the first 
12 weeks of treatment (Section [IP_ADDRESS]).
Treatment Discontinuation due to Bone Scan changes:  Subjects should not be 
discontinued from study  treatment(s) due to the occurrence of bone scan changes in the 
first 12 weeks that do not meet PCWG2 guidelines for progression (Section [IP_ADDRESS]) .
Section 5.[ADDRESS_367903] to follow -up, has withdrawn consent, or at the investigator’s 
discretion is no longer being followed.
Section 6.[ADDRESS_367904]
REVISED TEXT
Dosing Instructions: Dose with approximately 200 mL of water.  [COMPANY_004]2636771 should be taken 
prior to enzalutamide in the morning (once last PK sample is obtained 
morning dosing is not required).  Subjects should fast for at least 1hr 
before and [ADDRESS_367905]
DELETED TEXT
Enzalutamide (Xtandi) will be sourced locall y from commercial stock for sites in 
countries where it is approved (e.g., US).  The conten ts of the label will be in accordance 
with all applicable regulatory  requirements.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367906] supply  all study  treatment(s) required for study  
participation.
NEW TEXT
Initially, in countries where it is approved (i.e., US), sites will need to obtain 
enzalutamide (Xtandi) from local commercial stock in order to prov ide enrolled 
subjects with an adequate supply of enzalutamide while on study. 
In countries where regulatory authorities mandate that the Sponsor must supply all 
study treatment(s) required for study participation, [COMPANY_004] will provide an adequate 
supply of en zalutamide (from commercial stock) directly to the site for enrolled 
subjects.  
Enzalutamide will be provided to subjects at no cost to begin taking enzalutamide 
on the first day (Day 1) of the Enzalutamide Run -In Period and throughout their 
participation in the study.  If a subject does not qualify for entry into the study 
based on the tests or assessments performed during the pre -screening and screening 
periods, then no further supply of enzalutamide will be provided to them.
The sourcing of enzalutamide from commercial stock will continue until which time 
(estimate within first quarter of 2015) [COMPANY_004] will begin supplying all sites with an 
adequate inventory of commercial, US sourced enzalutamide; an appropriate 
amendment will be made to the Quality section of the IND and CTA.
The contents of the label will be in accordance with all applicable regulatory 
requirements.
Route/Administration/
Duration:Oral/once daily, within 5 minutes of [COMPANY_004]2636771 administration/
continuous until treatment withdrawal
Sectio n 6.3 Administration of Study Treatments
REVISED TEXT
Dosing Time: Subjects will be instructed to take their doses of study  treatment 
([COMPANY_004]2636771 and enzalutamide) at the same time each day  if possible (24 hr intervals).  
Morning dosing is required until t he last serial PK blood and plasma sample are 
obtained on Day 29 of Week 5 (Treatment Continuation Period .  Once the last serial 
PK sample is obtained, dosing of study treatments can occur anytime during the 
day.  For s ubjects who wish to switch to evening dosing may do so once the last PK 
blood sample is obtained.  To switch to evening dosing , the subject is to delay  their next 
doses of study treatments by 12hrs.  
Dosing at Home on Non -PK Sampling Days : On days when subjects do not have a 
scheduled study visit in the clinic, s ubjects will be instructed to takeself-administer
2013N172718_04 CONFIDENTIA L
[ADDRESS_367907] 1 hr before or 
2hrs after a meal , on days when no PK blood samples are to be drawn .
Dosing during the Enzalut amide Run -In Period (Days 1 to 14): Enzalutamide is the 
only study treatment taken during the Enzalutamide Run -In Period.  The intent of 
this Enzalutamide Run -In Period is to achieve near -steady state plasma 
concentrations of enzalutamide prior to initiati ng combination therapy with 
[COMPANY_004]2636771.   Subjects should be instructed to take their once daily dose of 
enzalutamide every morning at the same time each day if possible (24 -hr intervals) 
during the Enzalutamide Run -In Period. Specific instructions for the administration 
of enzalutamide on Day 14 of the Enzalutamide Run -In Period are provided in the 
Dosing on PK Sampling Days during the Dose Escalation Phase section below.
Dosing on Scheduled Study Visit Days: Most of the scheduled study visit days during 
the first 5 weeks of combination treatment will require a pre -dose blood, plasma, 
and/or urine sample for analysis of PK, CTC, and/or urine electrolytes. On Day 1 of 
Weeks 8 and 12 during the Treatment Continuation Period, pre -dose blood and 
plasma samples f or analysis of PK are required. On Day 1 of Week 8 and every 8 
weeks thereafter during the Treatment Continuation Period, pre -dose blood and 
urine samples for analysis of CTC (through Week 32 only) and urine electrolytes 
are also required. Subjects should be instructed to withhold their doses of study 
treatments on mornings of these scheduled study visits as follows:
Dosing on PK Sampling Days: For dense serial PK day s, subjects should fast overnight 
(at least 8 hrs) and remain fasting the morning of dosing until study  treatment is 
administered.  After dosing of stud y treatment, subjects will continue to fast for an 
additional [ADDRESS_367908] 1 hr before and 2 hrs after administration of study  treatment.
Dosing on PK Sampling Days during the Dose Escalation Phase: 
Day 14 (Enzalutamide Run -In Period): the day prior to administration of the 
first dose of [COMPANY_004]2636771:  Subjects will fast overnight (at least 8 hrs) and remain 
fasting the morn ing of this study  visit.  Subjects will be instructed to withhold 
their dose of enzalutamide on the morning prior to the of this study  visit. on Day  
-1.  After the pre -dose PK plasma sample is draw nblood draw is completed , 
subjects will be administered the ir doses of enzalutamide in the clinic and will 
asked to continue fasting for an additional 2 hrs. 
Day 29, Week 5 (Treatment Continuation Period): Subjects will fast overnight 
(at least 8 hrs) and remain fasting the morning of this study  visit.  Subjects will be 
instructed to withhold the doses of study  treatment on the morning of this prior
to the study  visit. on Day  29 of Wk 5. After the pre -dose pK blood and plasma 
samples are drawn draw is completed , subjects will be administered their doses 
of study  treatments in the clinic and asked to willcontinue fasting for an 
additional 2 hrs. 
2013N172718_04 CONFIDENTIA L
200331
171Weeks 8 and 12 (Treatment Continuation Period): Subjects will be instructed 
to withhold their doses of study  treatment prior to these study  visits. After the 
pre-dose PK blood and plasma samples are drawn, s ubjects will have be 
administered their doses of study  treatments administered in the clinic after the 
pre-dose blood draw is completed and under fasted conditions, at least 1 hr before 
or 2hrs after a meal (an overni ght fast is not required) .
Dosing on PK Sampling Days during the Dose Expansion Phase:  
Day 29, Week 5 (Treatment Continuation Period) :  
oSubjects scheduled for a morning clinic visit will be instructed to withhold 
the doses of study  treatments prior to this study  visit on Day  [ADDRESS_367909] 1 hr before or 2 hrs after a meal (an overnight fast is 
not required). 
oSubjects scheduled for an afternoon clinic visit will be instructed to take 
their doses of stud y treatments at the usual time on the morning of this 
study visit and under fasted conditions , at least 1 hr before or 2 hrs after a 
meal (an overnight fast is not required) .  
Weeks 8 and 12 (Treatment Continuation Period): Subjects will be instructed 
to withhold the doses of study  treatment prior to the study  visit during Wks [ADDRESS_367910] 1 
hr before or 2 hrs after a meal.
Dosing on CTC and Ur ine Electrolyte Sampling Days:  Subjects will be instructed 
to withhold the ir doses of study treatments on the morning of study visits when a 
blood or urine sample is to be obtained for analysis of CTCs and/or urine 
electrolytes, respectively.  After the pre -dose blood sample is drawn an d/or the 
pre-dose urine sample is collected, subjects will have their doses of study 
treatments administered in th eclinic, at least 1 hr before or 2 hrs after a meal
(an overnight fast is not required).
Vomiting: If a subject vomits after taking stud y treatment(s), the subject should be 
instructed NOT to retake the dose and should take the next scheduled dose of study  
treatment(s).  If vomiting persists, the subject should contact [CONTACT_093].
Missed Doses: If subject misses a dose of study  treatment( s), the subject should be 
instructed to take the missed dose as soon as they  realize it was missed, but not take the 
missed dose if there are less than [ADDRESS_367911] diary for either [COMPANY_004]26367 71 or enzalutamide and in the 
eCRF.
2013N172718_04 CONFIDENTIA L
200331
172Section 6.3.1 [COMPANY_004]2636771
REVISED TEXT
For this study, the starting dose of [COMPANY_004]2636771 is 300 mg taken orally once daily.  
[COMPANY_004]2636771 should is to be administered within 5 minutes prior to enzalutamide and 
under fasted conditions, either 1 hr before or 2 hrs after a meal andwith approximately  
200mL of water (unless otherwise instructed in Section 6.3 for study visit days when 
PK, CTC, or urine electrolyte sampling is required).
Subjects shall abstain from ingestion of any food or drink containing grapefruit and 
grapefruit juice, Seville oranges or pomelos within [ADDRESS_367912] dose of 
[COMPANY_004]2636771 (Week 1, Day 1 of Combination Treatment Period) until the last dose of 
study  treatment.
Section 6.3.[ADDRESS_367913] prescribing information for enzalutamide [ Xtandi , 2013], the 
recommended dose of enzalutamide 160 mg (four 40 mg capsules) taken orally  once 
daily  will be administered during this study .  Enzalutamide may  be taken with or witho ut 
food except on day s of PK sampling when enzalutamide should be administered under 
fasted conditions, either 1 hr before or 2 hrs after a meal.   
Enzalutamide may be taken with or without food on each day of the Enzalutamide 
Run-In Period (Days 1 -13).  S pecific instructions for the administration of 
enzalutamide on Day 14 of the Enzalutamide Run -In Period may be found in 
Section 6.3.  Once combination therapy ([COMPANY_004]2636771 + enzalutamide) begins on 
Week 1, Day 1 of the Combination Treatment Period,  e nzalut amide should is to be 
administered within 5 minutes after ofthe administration of [COMPANY_004]2636771 .  When 
administered with [COMPANY_004]2636771, enzalutamide should be administered and under fasted 
conditions, either 1 hr before or 2 hrs after a meal (unless otherwise i nstructed due to PK 
sampling; see Section 6.3). in Section 6.3 for study visit days when PK, CTC, or urine 
electrolyte sampling is required).
Section 6.4  Handling and Storage of Study Treatments
REVISED TEXT
Handling: Under normal conditions of handling and administration, the study  treatments 
are not expected to pose significant safet y risks to site staff.  Material Safety Data Sheets 
(MSDSs) for [COMPANY_004]2636771 and enzalutamide describing the occupational hazards and 
recommended handling precautions will be provided to site staff if required by  [CONTACT_301207].
Storage: All study  treatments ([COMPANY_004]2636771 and enzalutamide) must be stored in a 
secure area under the appropriate ph ysicalfollowing conditions for each p roduct:  Access 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367914] be dispensed or administered only  to subjects 
enrolled in the study  and in accordance with the protocol.
[COMPANY_004]2636 771:  Store under appropriate ph ysical conditions for the product as 
stated on the label . Refer to the SRM regarding temperature excursions.
Enzalutamide:  Recommended storage is 20 C to 25 C (68 F to 77 F) in a dry  
place.  Excursions permitted from 15 C to 30C (59 F to 86 F).Store under 
appropriate physical conditions for the product as stated on the label .  Refer 
to the SRM regarding temperature excursions.
Access to and administration of study treatments will be limited to the investigator 
and authoriz ed site staff.  Study treatments must be dispensed or administered only 
to subjects who qualify for entry in this study and in accordance with the protocol.  
Subjects should be reminded that all study treatments should be stored at home out 
of the reach of children.
All study  treatments should be stored out of the reach of children.
Section 6.[ADDRESS_367915] 
dose of study  treatment (or suspected overdose).
Section [ADDRESS_367916] as a replacement for sound clinical judgment.  The investigator should use clinical 
judgment to determine which study  treatment may be contributing to the toxicity  
necessitating dose adjustment, and make the appropriate change for that agent.  The 
severit yof AEs will be graded utilizing the CTCAE v4.0.  Guidelines for dose 
modifications and interruptions for management of specific toxicities are provided in this 
section.
If a given toxicity is considered to be related to one specific study treatment by [CONTACT_301208], then dose modification should only occur with the study 
treatment associated with the specific toxicity or event of clinical concern.
2013N172718_04 CONFIDENTIA L
200331
174Section 7.1.1  [COMPANY_004]2636771 (NEW Section Header)
Text moved from Section 7.1 to Section 7.1.1
REVISED TEXT
Dose modification guidelines for [COMPANY_004]2636771 are outlined in Table 4for clinically  
significant toxicities that are deemed related to study  treatment but are not addressed 
specificall y in Section 7.27.3.  If a given toxicity  is considered to be related to one 
specific stud y treatment by [CONTACT_301209], then dose modification should 
only occur with the study treatment associated with the specific toxicity  or event of 
clinical concern.
Section 7.2.1 QTc Stoppi[INVESTIGATOR_301114] T
If QTcF >500 msec (Grade 3 or 4 QTc prolongation) or uncorrected QT >600 msec 
(averaged manual overread of [ADDRESS_367917] 15 minutes), then the following 
guidelines should be followed:
Hold study  treatments
Discuss with [COMPANY_004] Medical Monitor
Correct any electrol yte abnormalities
If QTcF resolves to [ADDRESS_367918] will benefit from further treatment.
If QTcF does N OT resolve to 470 msec, discontinue study  treatments 
permanentl y.
NEW TEXT
QTc >500 msec 
OR
Change from baseline of QTc >60 msec
For subjects with underlying bundle branch block (BBB), follow the 
discontinuation criteria listed below:
Baseline QTc with BBB Discontinuation QTc with B BB
<450 msec >500 msec
450 –480 msec ≥[ADDRESS_367919] safet y 
and to evaluate liver event etiology  during administration of study  treatments and the 
follow -up period. The liver chemistry  stoppi[INVESTIGATOR_301115] 2.[ADDRESS_367920] at study  entry  is provided in Section [IP_ADDRESS] and for subjects with documented liver 
metastases or tumor infiltration at baseline AND entry  criteria ALT>2.[ADDRESS_367921] but ≤[ADDRESS_367922] in Section [IP_ADDRESS].
NEW TEXT
Liver chemistry stoppi[INVESTIGATOR_301116] (in alignment with the US 
FDA premarketing clinical liver safety guidance).  
http:// www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM174090.pdf.
Section [IP_ADDRESS] Liver Chemistry Stoppi[INVESTIGATOR_301117] ≤2.[ADDRESS_367923]
DELETED TEXT
Liver Safet y Required Actions and Follow -up Assessments can be found in Appendix 6.
2013N172718_04 CONFIDENTIA L
200331
176NEW TEXT
Table 6 Liver Chemistry Stoppi[INVESTIGATOR_2121] –Liver Stoppi[INVESTIGATOR_301118] ≤2.5xULN
ALT absolute ALT 5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin1, 2ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) 
INR2ALT 3xULN and INR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT 3xULN associated with symptoms (new or worsening) believed to be 
related to liver injury or hypersensitivity
Abbreviations: ALT, alanine aminotransferase; INR, international normalization ratio; SAE, serious adverse 
event; ULN, upper limit of normal
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is 
not immediately available, discontinue study treatment for that subject if ALT 3xULN and bilirubin 
2xULN. Additionally, if serum bilirubin fracti onation testing is unavailable, record presence of detectable 
urinary bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.
2. All events of ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5 , if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE 
2013N172718_04 CONFIDENTIA L
200331
177(excluding studies of hepatic impairment or cirrhosis); INR measurement is not required and the 
threshold value stated will not apply to subjects rec eiving anticoagulants .
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as 
fever, rash or eosinoph ilia).
Section [IP_ADDRESS] Liver Chemistry Stoppi[INVESTIGATOR_301119]/Tumor Infiltration at 
Baseline AND Entry Criteria ALT>2.5xULN but ≤5xULN
DELETED TEXT
Liver Safet y Required Actions an d Follow -up Assessments can be found in Appendix  7.
2013N172718_04 CONFIDENTIA L
200331
178NEW TEXT
Table 7 Liver Chemistry Stoppi[INVESTIGATOR_2121] –Liver Stoppi[INVESTIGATOR_301120]/Tumor Infiltration at Baseline AND 
Entry Criteria ALT>2.5xULN but ≤5xULN
ALT abso lute Both ALT 5xULN and 2x baseline value
ALT Increase Both ALT 3xULN and ≥1.5x baseline value that persists for 4 weeks
Bilirubin1, 2ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) 
INR2ALT 3xULN and INR>1.5, if INR measured
Cannot Mon itor Both ALT 3xULN and ≥1.5x baseline value that cannot be monitored for 4 
weeks
Symptomatic3Both ALT 3xULN and ≥1.5x baseline value associated with symptoms (new 
or worsening) believed to be related to liver injury or hypersensitivity
Abbreviations: ALT, alanine aminotransferase; INR, international normalization ratio; SAE, serious adverse 
event; ULN, upper limit of normal
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is 
not immediately av ailable, discontinue study treatment for that subject if ALT 3xULN and bilirubin 
2xULN. Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable 
urinary bilirubin on dipstick, indicating direct bilirubin elevat ions and suggesting liver injury.
2013N172718_04 CONFIDENTIA L
[PHONE_6263]. All events of ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE 
(excluding studies o f hepatic impairment or cirrhosis); INR measurement is not required and the 
threshold value stated will not apply to subjects receiving anticoagulants .
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, rig ht 
upper quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as 
fever, rash or eosinophilia) .
Section [IP_ADDRESS] Liver Safety Required Actions and Follow -up (NEW SECTION)
NEW TEXT
Table 8 Required Actions and Follow -Up Assessments Following ANY Liver 
Stoppi[INVESTIGATOR_159833] -Up Assessments
Immediately discontinue study treatment
Report the event to [COMPANY_004] within 24 hrs
Complete the liver event eCRF and 
complete an SAE data collection tool if 
the event also meets th e criteria for an 
SAE2
Perform liver event follow -up 
assessments 
Monitor the subject until liver chemistries
resolve, stabilize, or return to within 
baseline (see MONITORING below)
Do not restart/rechallenge subject with 
study treatment unless allowed pe r 
protocol and [COMPANY_004] Medical Governance 
approval is granted (refer to Appendix 6)
If restart/rechallenge not allowed per 
protocol or not granted, permanently 
discontinue study treatment and may 
continue subject in the study for any 
protocol specified follow -up assessments
MONITORING:
For bilirubin or INR criteria: 
Repeat liver chemistries (include ALT, 
AST, alkaline phosphatase and bilirubin ) 
and perform liver event follow -up 
assessments within 24 hrs
Monitor subjects twice weekly until liver 
chemistries res olve, stabilize or return to 
within baselineViral hepatitis serology1
Only in those with underlying chronic hepatitis 
B at study entry (identified by [CONTACT_23977] 
B surface antigen) quanti tative hepatitis B DNA 
and hepatitis delta antibody3
Blood sample for PK analysis, obtained 24-[ADDRESS_367924] dose4
Serum creatine phosphokinase and lactate 
dehydrogenase.
Fractionate bilirubin, if total bilirubin 2xULN
Obtain complete blood count with differential 
to assess eosinophilia
Record the appearance or worsening of clinical 
symptoms of liver injury, or hypersensitivity, 
on the AE eCRF
Record use of concomitant medications on the 
concomitant medications eCRF including 
acetaminophen, herbal reme dies, other OTC 
medications
Record alcohol use on the liver event alcohol 
intake eCRF
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney microsomal 
antibodies, and quantitative total IgG or 
gamma glo bulins.
Serum acetaminophen adduct HPLC assay 
(quantifies potential acetaminophen 
2013N172718_04 CONFIDENTIA L
200331
180Actions Follow -Up Assessments
A specialist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (include ALT, 
AST, alkaline phosphatase, bilirubin) and 
perform liver event follow -up 
assessments within 2 4-72 hrs 
Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within baselinecontribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week [ James, 2009]).
Liver imaging (ultrasound, MRI or CT ) and /or 
liver b iopsy to evaluate liver disease; complete 
Liver Imaging and/or Liver Biopsy eCRFs
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CT, 
computed tomography; DNA, deoxyribonucleic acid; eCRF, electronic case report form; [COMPANY_004], 
GlaxoSmithKline; HPLC, high performance liquid chromatography; hrs, hours; IgG/IgM, immunoglobulin 
G or M; INR, international normalization ratio; MRI, magnetic resonance imaging; OTC, over -the-counter; 
PCR, polymerase chain reaction; PK, pharmacokinetic; RNA, ribonucleic acid; SAE, serious adverse 
event; SRM, Study Reference Manual; ULN, upper limit of normal
1. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); 
Hepatitis C RNA; Cytomegalovir us IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if 
unavailable, obtain heterophile antibody or monospot testing); Hepatitis E IgM antibody
2. All events of ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE 
(excluding studies of hepatic impairment or cirrhosis); INR measurement is not required and the 
threshold value stated will not apply to subjects recei ving anticoagulants
3. If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA 
virus (where needed) [ Le Gal , 2005].
4. PK sample may not be required for subjects known to be receiving placebo or non -[COMPANY_004] comparator 
treatments .  Record the date/time of the PK blood sample draw and the date/time of the last dose of study 
treatment prior to blood sample draw on the eCRF. If the date or time of the last dose is unclear, provide 
the subject’s best approximation. If the da te/time of the last dose cannot be approximated OR a PK 
sample cannot be collected in the time period indicated above, do not obtain a PK sample. Instructions 
for sample handling and shippi[INVESTIGATOR_301121] S PM.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367925] with entry criteria ALT ≤2.5xULN
ALT 3xULN but <5xULN and bilirubin 
<2xULN, without symptoms believed to be 
related to liver injury or hypersensitivity and 
who can be monitored weekly for [ADDRESS_367926] with documented liver 
metastases/tumor infiltration at baseline 
AND entry criteria ALT>2.5xULN but ≤5xULN
ALT ≥3xULN and 1.5x baseline value but
ALT <5xULN and 2x baseline value and 
bilirubin <2xULN, without symptoms 
believed to be related to liver injury, or 
hypersensitivity and who can be monitored 
weekly for 4 weeksNotify the [COMPANY_004] Medical Monitor within [ADDRESS_367927] 
safety. 
Subject can continue study treatment
Subject must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) un til they resolve, stabili ze or return to 
within baseline 
If at any time subject meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
For subjects with entry criteria ALT ≤2.5xULN
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice 
monthly until liver chemistries normalize or 
return to within baseline.
For subjects with documented liver 
metastases/tumo r infiltration at baseline AND entry 
criteria ALT>2.5xULN but ≤5xULN
If, after 4 weeks of monitoring, ALT <3xULN and 
<1.5x baseline value, and bilirubin <2xULN, 
monitor subjects twice monthly until liver 
chemistries normalize or return to within 
baseline
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; [COMPANY_004], GlaxoSmithKline; hrs, 
hours; ULN, upper limit of normal
Refer to Appendix 6 for liver safety drug restart or rechallenge guidelines.
Section 7.2.3 Events Associated with G SK2636771 –renamed Left Ventricular 
Ejection Fraction (LVEF) Stoppi[INVESTIGATOR_301122] (or multigated acquisition [MUGA] scan) must be performed at 
Screening and as clinically indicated as outlined in the Time and Events Tables 
(Section 8.1).  Subjects who have an absolute decrease of >10% in LVEF compared 
with baseline and the ejection fraction is below the institution’s lower limit of 
normal (LLN) should temporarily discontinue treatment with [COMPANY_004]2636771 and 
have a repeat evaluation of L VEF within [ADDRESS_367928] and within 10% of baseline.
2013N172718_04 CONFIDENTIA L
200331
182If the LVEF recovers (defined as LLN and absolute decrease 10% 
compared with baseli ne) at any time during the next [ADDRESS_367929] may be 
restarted on [COMPANY_004]2636771 at a reduced dose.  For such subjects, monitoring 
of LVEF will be performed 2 and 4 weeks after re -challenge, an d every 4 
weeks thereafter for a total of 16 weeks and then per protocol.
If repeat LVEF does not recover within 4 weeks, treatment with 
[COMPANY_004]2636771 should be permanently discontinued.  Ejection fraction should 
be monitored every 4 weeks for a total of 16 w eeks or until resolution.
Subjects with Grade 3 or 4 (symptomatic) left ventricular systolic dysfunction must 
discontinue treatment with [COMPANY_004]2636771.  Ejection fraction should be monitored 
every 4 weeks for a total of 16 weeks or until resolution.  If recov ery occurs (LVEF 
>institutional LLN and symptom resolution) within 4 weeks, treatment with 
[COMPANY_004]2636771 may be restarted at a reduce dose in consultation with the [COMPANY_004] 
Medical Monitor.
Copi[INVESTIGATOR_301079] (or MUGA scans) and cardiology consultations performed on 
subjects who experience a >10% decrease in LVEF from baseline and whose cardiac 
ejection fraction is <institution’s LLN will be required by [CONTACT_301172].  
Instructions for submitting qualifying ECHOs (or MUGA scans) are provided in the 
SRM.
Section 7 .2.4 Valvular Toxicity Stoppi[INVESTIGATOR_2121] (NEW SECTION)
NEW TEXT
Subjects who have a new asymptomatic, moderate regurgitation or stenosis by 
[CONTACT_123550] (Grade 2 mitral/tricuspid/aortic valvular toxicity per 
CTCAE v4.[ADDRESS_367930] 
a repeat evaluation by [CONTACT_301174] 1 week.  An ECHO (or MUGA scan) should be 
repeated every 1 to 2 weeks for 4 weeks or until valve recovery to baseline.
If the valve recovers to baseline any time during the next [ADDRESS_367931] may be 
restarted on [COMPANY_004]2636771 at a reduced dose(s).  For such subjects, 
monitoring of the valve via ECHO (or MUGA scan) will then be performed 
2 and 4 weeks after re -challenge, and eve ry 4 weeks thereafter for 8 weeks 
and then per protocol.
If repeat ECHO (or MUGA scan) does not reveal valve recovery to baseline 
within [ADDRESS_367932] should permanently discontinue 
[COMPANY_004]2636771.  The valve should continue to be monitored via ECH O (or 
MUGA scan) every 4 weeks for 8 weeks or until resolution.
Subjects with a Grade 3 or 4 (symptomatic, severe regurgitation/stenosis by [CONTACT_301210]) valvular toxicity must 
discontinue [COMPANY_004]2636771.  Valvular t oxicity should continue to be monitored every 
4weeks for 8 weeks or until resolution.  If recovery occurs (return to baseline via 
2013N172718_04 CONFIDENTIA L
200331
183imaging AND symptom resolution) within [ADDRESS_367933] may restart 
[COMPANY_004]2636771 at a reduced dose after consultation and a pproval of the [COMPANY_004] Medical 
Monitor.
ECHO (or MUGA scan) must be performed within 28 days of Day -1 and at the End 
of Study visit (see Time and Events Tables in Section 8.1).  Copi[INVESTIGATOR_301081](s) 
(or MUGA scan) and cardiology consultations performed on su bjects who 
experience valvular toxicity will be required by [CONTACT_301172].  Instructions for 
submitting qualifying ECHOs (or MUGA scans) are provided in the SRM.
Section 7.3 Management Guidelines for Specific Events Associated with 
[COMPANY_004]2636771 (NEW SECTION )
NEW TEXT
If a subject experiences an AE during the Enzalutamide Run -In Period resulting in 
a dose interruption that precludes the subject from completing the run -in period 
within [ADDRESS_367934] to continue in the study (refer 
to the SRM).  
Section 7.3.1 Renal Insufficiency or Other Renal Events –Table 10
REVISED TEXT
Table 10  Management and Dose Modification of Renal Events
Assessment Action and Dose Modification
Urine dipstick protein 2+ Monitor for concomitant medications (e.g., NSAIDs) or medical 
conditions (e.g., menstruation, urinary tract infection) associated 
with positive urinary protein dipstick test (see SRM for further 
details)
 Assess BP and ensure it is well -controlled (<140/90 mmHg)
 Obtain a random UPC ratio ( see Appendix  5 )
Serum creatinine 
0.5mg/dL ( 44.2 µmol/L) 
increase from baselineRepeat serum creatinine level within 24 hrs of previous result
If repeat value confirms s erum creatinine 0.5 mg/dL 
(44.2 µmol/L) increase from baseline:
Immediately interrupt treatment with [COMPANY_004]2636771
Evaluate and treat possible causes for elevated serum 
creatinine (e.g., renal outflow obstruction, sepsis, dehydration, 
hypotension, GI bleed, medications [e.g., trimethoprim, 
ketoconazole or cimetidine] that increase serum creatinine 
level)
Obtain blood sample for PK analysis, if requested (see 
SRM),  within [ADDRESS_367935] dose ( refer to Section 
[IP_ADDRESS] for details on PK sample colle ction)
Consider oral or IV hydration, if clinically indicated
Repeat serum creatinine level every 7 days or more frequently 
if clinically indicated
2013N172718_04 CONFIDENTIA L
200331
184Assessment Action and Dose Modification
If serum creatinine fails to improve ( 0.5 mg/dL [ 44.2 µmol/L] 
increase persists) within 14 days following dose interruption:
Permanently discontinue treatment with [COMPANY_004]2636771
Consult with [COMPANY_004] Medical Monitor
If serum creatinine improves (<0.5 mg/dL [<44.2 µmol/L] increase 
from baseline) within 14 days following dose interruption:
Restart treatment with [COMPANY_004]2636 771 with dose reduced by [CONTACT_23615]
Repeat serum creatinine level every 4 weeks or more 
frequently if clinically indicated
If elevated serum creatinine recurs after one dose reduction 
(0.5mg/dL [ 44.2 µmol/L] increase from baseline):
Repeat serum cre atinine within 24 hrs to confirm result
If repeat serum creatinine confirms increase, withdraw 
subject from treatment/study unless there is agreement 
between investigator and [COMPANY_004] Medical Monitor that 
subject will benefit from continued treatment following 
recovery of serum creatinine ( 0.5 mg/dL [<44.2 µmol/L] 
increase from baseline)
If repeat serum creatinine fails to confirm increase, 
continue treatment with [COMPANY_004]2636771 at same dose level 
without interruption
Hypocalcemia
(serum calcium Grade 2)
or
Hypop hosphatemia
(serum phosphate Grade 3 
or symptomatic Grade 2)Repeat serum calcium or phosphate level within 24 hrs of previous 
result
If repeat value confirms Grade 2 serum calcium, or 
symptomatic Grade 2 serum phosphate.
Immediately interrupt treatment w ith [COMPANY_004]2636771
Treat as clinically indicated by [CONTACT_301211]
Obtain serum PTH level
Obtain blood sample for PK analysis, if requested (see 
SRM),  within [ADDRESS_367936] dose ( refer to Section 
[IP_ADDRESS] for details on PK sample coll ection)
Obtain urine samples for urine creatinine, calcium, phosphate, 
and protein at treatment interruption; repeat every 7 days
Repeat serum calcium or phosphate level every 7 days or more 
frequently if clinically indicated
If serum calcium fails to impr ove to Grade 1 or if serum phosphate 
fails to improve to asymptomatic Grade 2 within 14 days following 
dose interruption:
Permanently discontinue treatment with [COMPANY_004]2636771
Consult with [COMPANY_004] Medical Monitor
If serum calcium improves to Grade 1 or serum phosp hate 
improves to asymptomatic Grade 2 or baseline, whichever is more 
improved within 14 days following dose interruption:
Restart treatment with [COMPANY_004]2636771 with dose reduced by [CONTACT_23615]
Repeat serum calcium or phosphate level per Time and Events 
Tables (Section 8.1) or more frequently if clinically indicated
If decreased serum calcium or phosphate levels reoccurs after one 
dose reduction :
2013N172718_04 CONFIDENTIA L
200331
185Assessment Action and Dose Modification
Repeat serum calcium or phosphate levels within 24 hrs to 
confirm result
If repeat serum calcium or phosphate lev els confirm 
decrease, withdraw subject from treatment/study unless 
there is agreement between investigator and [COMPANY_004] Medical 
Monitor that subject will benefit from continued treatment 
following recovery of serum calcium or phosphate to 
baseline with dose of [COMPANY_004]2636771 further reduced one 
dose level.
If repeat serum calcium or phosphate fails to confirm a decrease, 
continue treatment with [COMPANY_004]2636771 at same dose level without 
interruption
Abbreviations:  BP, blood pressure; GI, gastrointestinal; [COMPANY_004], GlaxoSmi thKline; IV, intravenous; mmHg, millimeters of 
mercury; NSAIDs, non -steroidal anti -inflammatory drugs; PK, pharmacokinetics ; PTH, parathyroid hormone ; RBC, 
red blood cell; SRM, Study Reference Manual; UPC, urine/protein/creatinine ratio
Section [IP_ADDRESS]. ( New Section)
NEW TEXT
Serum parathyroid hormone (PTH) level will be assessed on the first day of 
combination treatment (Week 1, Day 1 of Combination Treatment Period).  
Subsequently a serum PTH level should be obtained for any subject who 
experiences Grade 2 or greater hypocalcemia or hypophosphatemia while on study 
(refer to Table 10).
Section 7.3.2  Cardiac -related Toxicities
REVISED TEXT
Reversible increases in mean arterial pressure and decreases in heart rate and cardiac 
contractility  that were conside red secondary  to an elevation in blood pressure were 
observed in a single dose safet y pharmacology study  in dogs administered 300 mg/kg of 
[COMPANY_004]2636771.   In the ongoing FTIH stud y, no Grade [ADDRESS_367937] ory of uncontrolled hy pertension, heart failure, or 
known significant coronary  artery  disease are excluded from this study .  Cardiac 
monitoring, including assessment of blood pressure and heart rate, along with 12 -lead 
ECGs, will be performed.
Section 7.3. 2.1  Hypertension
REVISED TEXT 
Table 6 Management and Dose Modification for Hypertension
2013N172718_04 CONFIDENTIA L
200331
186Section 7.3.3 Rash
REVISED TEXT
Table 7 Management and Dose Modification for Rash
Section 7.3.4  Diarrhea (NEW SECTION)
NEW TEXT
Epi[INVESTIGATOR_301082]2636771 
monotherapy. Other frequent causes for diarrhea, including concomitant 
medications (e.g., stool softeners, laxatives, antacids, etc.), infections by C. difficile or 
other pathogens, partial bowel obstruction, should be cli nically excluded.
Standardized and universal guidelines have been developed by [CONTACT_301212] (ASCO) panel for treating chemotherapy -induced diarrhea 
[Benson, 2004].  Presented in the sections below are the recommended guidelines for 
the management of diarrhea in subjects receiving [COMPANY_004]2636771.  These guidelines 
were derived from the recommendations published by [CONTACT_114477] [Benson, 
2004].
Early identification and intervention is critical for the optimal management of 
diarrhea.  A subject’s baseline bowel patterns should be established so that changes 
in patterns can be identified while subject is on treatment.
An assessment of frequency, consistency and duration as well as knowledge of other 
symptoms such as fever, crampi[INVESTIGATOR_007], pain , nausea, vomiting, dizziness and thirst 
should be taken at baseline.  Consequently subjects at high risk of diarrhea can be 
identified.  Subjects should be educated on signs and symptoms of diarrhea with 
instructions to report any changes in bowel pattern s to the physician.
It is recommended that subjects keep a diary and record the number of diarrhea 
epi[INVESTIGATOR_301123].  They should also include information on any 
dietary changes or other observations that may be useful in the evaluation of their 
diarrhea history.
If subjects present with diarrhea of any grade, check they are receiving the study 
treatment correctly (i.e., single dose, rather than splitting it through the day).  
Obtain information on food (solid and liquid) and over -the-counte r (OTC) 
medication(s), including herbal supplements, taken during the treatment period.
Guidelines regarding management and dose reduction for diarrhea considered to be 
related to study treatments by [CONTACT_301178] 13.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367938] epi[INVESTIGATOR_76337] 
(i.e., unformed stool) and contact t he 
investigator.
Administer loperamide: Initial dose: 4 mg. 
Subsequent doses: 2 mg after each 
unformed stool
19.Re-evaluate after 24 hrs:
20.If diarrhea is resolving: continue 
loperamide treatment at 2 mg dose after 
each unformed stool until diarrhea -free 
(i.e., bowel patterns return to baseline) for 
12hrs.  If diarrhea recurs, re -initiate 
loperamide as need edto maintain normal 
bowel pattern.
21.If diarrhea is NOT resolving:
continue loperamide 2 mg every 4 hrs for 
the next 24 hrs; re -evaluate after 24 hrs.  
If no t resolving, administer loperamide 2 
mg after each unformed stool until 
diarrhea free (i.e., bowel patterns return 
to baseline) for 12 hrs.  If diarrhea is not 
resolving, continue loperamide 2 mg 
every 4 hrs and re -evaluate every 24 hrs.
2.Dietary modificati ons:
22.Stop all lactose containing products and 
eat small meals
23.Avoid spi[INVESTIGATOR_70329], fried and fatty foods, raw 
vegetables and other foods high in fiber
24.Avoid caffeine and alcohol (can irritate 
bowel and increase motility)
25.Hydration:  Drink 8 to 10 large glasses of 
clear liquids (e.g., water, electrolyte drink) 
daily.  Avoid acidic drinks such as tomato 
juice and fizzy soft drinks
26.Supplement diet to include food rich in 
potassium (e.g., bananas, potatoes, 
apricots; evaluate their impact on 
diarrhea due to fiber conte nt 
(e.g., apricots)Continue study 
treatments at current 
dose.
Continue supportive care 
until diarrhea resolves 
(diarrhea free for 12 hrs 
and bowel pattern 
returns to baseline)
If diarrhea recurs after 
stoppi[INVESTIGATOR_301084], resume 
loperamide treat ment, 
re-introduce diet 
modifications, and 
continue study 
treatments at current 
dose.
3.If Grade 1 diarrhea persists for >1 week with 
loperamide treatment, consider treatment with 
second -line agents (i.e., octreotide, 
2013N172718_04 CONFIDENTIA L
200331
188Grade Management Action and Dose Modification
budesonide or tincture of opi[INVESTIGATOR_1890]).
4.If Grade 1 diarrhea persists for ≥2 weeks, refer 
to Persistent Grade 2 diarrhea management 
guidelines.
Uncomplicated 
Diarrhea –
Grade 21.Instruct subject to start supportive care 
immediately at the first epi[INVESTIGATOR_76337] 
(i.e., unformed stool) and contact [CONTACT_1275].
27.Administer loperamide: Initial dose: 4 mg.  
Subsequent doses: 2 mg every 4 hrs or 
after each unformed stool
28.Re-evaluate after 24 hrs:
29. If diarrhea is resolving: continue 
loperamide treatment at 2 mg dose after 
each unformed stool until dia rrhea free 
(i.e., bowel patterns return to baseline) for 
12 hrs.  If diarrhea recurs, re -initiate 
loperamide as need edto maintain normal 
bowel pattern.
30. If diarrhea is NOT resolving:
consider loperamide 2 mg every 2 hrs for 
the next 24 hrs.  If Grade 2 dia rrhea 
persists after 48 hrs of loperamide 
treatment, start treatment with second -
line agents (i.e., octreotide, budesonide 
or tincture of opi[INVESTIGATOR_1890]).  Consider 
performing stool work -up, CBC, 
electrolytes and other tests as 
appropriate.
2.Dietary modifications:
31.Stop all lactose containing products and 
eat small meals
32.Avoid spi[INVESTIGATOR_70329], fried and fatty foods, bran, 
raw vegetables and other foods high in 
fiber.  Eat foods low in fiber (i.e., lean 
meat, rice, skinless chicken or turkey, 
fish, eggs, canned or cooked skinles s 
fruits, cooked/pureed vegetables)
33.Avoid caffeine and alcohol (can irritate 
bowel and increase motility)
34.Hydration:  Drink 8 to 10 large glasses of 
clear liquids (e.g., water, electrolyte drink) 
daily.  Avoid acidic drinks such as tomato 
juice and fizzy s oft drinksContinue study 
treatments at current 
dose.
Continue supportive care 
until diarrhea resolves 
(diarrhea free for 12 hrs / 
bowel pattern returns to 
baseline)
Once diarrhea has 
resolved, subject may 
gradually re -introduce 
foods from their normal 
diet.
If diarrhea recurs after 
stoppi[INVESTIGATOR_301084], resume 
loperamide treatment, re -
introduce diet 
modifications, and 
continue study 
treatments at current 
dose.
2013N172718_04 CONFIDENTIA L
200331
189Grade Management Action and Dose Modification
35.Supplement diet to include food rich in 
potassium (e.g., bananas, potatoes, 
apricots );evaluate their impact on 
diarrhea due to fiber content 
(e.g., apricots) 
36.If diarrhea recurs, refer to Recurrent 
Diarrhea management guidelines.
Persistent  
(≥3days/ 
72hrs) 
Diarrhea –
Grade 21.If Grade 2 diarrhea persists for ≥[ADDRESS_367939].Hold treatment with 
[COMPANY_004]2636771 and 
enzalutamide until 
symptoms have resolved 
to Grade 1 or baseline 
bowel pattern.
Once diarrhea has 
resolved, continue 
treatment with 
[COMPANY_004]2636771 and 
enzalutamide at reduced 
dose.
Recurrent 
Diarrhea (>1 
occurrence) -
(Grade 2)If second occurrence of Grade 2 diarrhea recurs, 
resume loperamide treatment and re -introduce 
diet modifications.Once diarrhea resolves 
to Grade 1 or baseline, 
consider re -starting 
study treatments 
([COMPANY_004]2636771 +  
enzalutamide) at a 
reduced dose
Complicated 
Diarrhea2–
Grade [ADDRESS_367940] c all 
investigator immediately for any complicated 
severe diarrhea event.
2.If loperamide has not been initiated, initiate 
loperamide immediately.  Initial dose: 4 mg.  
Subsequent doses: 2 mg every 2 hrs or after 
each unformed stool.
3.Refer to the dietary modif ications for Grade 1 
and 2 uncomplicated diarrhea (above).
4.For dehydration use IV fluids as appropriate.  
If subject presents with severe dehydration, 
administer octreotide.
5.Perform stool work -up, complete blood count, 
electrolytes and other tests as appro priate
6.Administer antibiotics (i.e., fluoroquinolones) 
as needed, especially if diarrhea is persistent 
beyond [ADDRESS_367941] at risk for life threatening Hold treatment with 
[COMPANY_004]2636771 and 
enzalutamide until 
symptoms have resolved 
to Grade 1 or baseline 
bowel pattern and 
without complicating 
factors present.
Once diarrhea resolves 
to Grade 1 or baseline, 
consider re -starting 
study treatments 
([COMPANY_004]2636771 
+enzalutamide) at a 
reduced dose 
Continue supportive care 
until diarrhea resolves 
(diarrhea free for 24 hrs 
and bowel pattern 
returns to baseline)
2013N172718_04 CONFIDENTIA L
200331
190Grade Management Action and Dose Modification
complications.
Complicated 
Diarrhea –
Grade 41.Instruct subject that they must call 
investigator immediately fo r any complicated 
Grade 4 diarrhea event.
2.If loperamide has not been initiated, initiate 
loperamide immediately.  Initial dose: 4 mg.  
Subsequent doses: [ADDRESS_367942].
6.Administer antibiotics (i.e., fluoroquinolones) 
as needed, especially if diarrhea i s persistent 
beyond [ADDRESS_367943] at risk for life threatening 
complications.Hold treatment with 
[COMPANY_004]2636771 and 
enzalutamide
Consult with [COMPANY_004] 
Medical Mo nitor to 
discuss subject’s event 
history, re -initiation of 
study treatments, and 
dose modifications, once 
symptoms have resolved 
to Grade 1 or baseline 
bowel pattern
Continue supportive care 
until diarrhea resolves 
(diarrhea free for 24 hrs 
and bowel patte rn 
returns to baseline)
Abbreviations: CBC, complete blood count; GI, gastrointestinal; hrs, hours; IV, intravenous; mg, milligram(s)
Section 7.3.5 Vomiting (NEW SECTION)
NEW TEXT
Table 14 Management and Dose Modification for Events of Vomiting
Grade Action and Dose Modification
≤Grade 1 Continue study treatments at current dose.
Grade 2Hold until ≤Grade 1.  Resume study treatments at same dose 
level.
Grade 3Hold1until <Grade 2.  Resume study treatments at one dose 
level lower, if indicated.2
Grade 4 Withdraw study treatment s.
1Subjects requiring a delay of >14 days should be withdrawn from treatment and/or study.
2Subjects requiring >2 dose reductions should be withdrawn from treatment and/or study.
It is recommended that any event of vomiting should be managed with the u se of 
antiemetics.
2013N172718_04 CONFIDENTIA L
[ADDRESS_367944] i s eligible for pre -screening b y reviewing the eligibility  criteria and completing all 
of The pre-screening assessments outlined in the Time and Events Tables (Section 8.1) 
are performed.
Section 8.2.[ADDRESS_367945] is eligible for enrollment in the study b y reviewing 
the eligibility  criteria and completing all of the Screening assessments outlined in the 
applicable Time and Events Tables in Section 8.1.
Section 8.3.1  Pre -Screening: Determinati on of PTEN Deficiency Status, 2nd
paragraph
REVISED TEXT
After written informed consent is provided by  [CONTACT_301213]’s tumor.  If archived 
tumor tissue is not available, fresh tumor tissue should be obtained by  [CONTACT_094]-treatment
biopsy  to determine PTEN deficiency .  The PTEN testing will be performed at a [COMPANY_004] 
selected laboratory  and the tumor specimen should be provided to that laboratory .  The 
PTEN status will be communicated to sites by  [CONTACT_301214].
Section 8.3.[ADDRESS_367946] provide written informed 
consent for screening will be eligible to undergo specific screening assessments to 
determine eligibi lity for the study .
Section 8.4 Demographics and Medical History
REVISED TEXT
Demographic data will include gender, date year of birth, race, height, weight, ethnicity  
and geographic ancestry .
Medical, surgical, and treatment history  including date (month and year)of first 
diagnosis, histology , current sites of disease as well as cardiovascular risk factors, alcohol 
2013N172718_04 CONFIDENTIA L
200331
192and tobacco history , plus family  history  will be taken as part of the medical history  and 
disease status.
Section 8.6 Safety 
REVISED TEXT
Measurements used to evaluate safet y will include physical examinations, vital sign (BP, 
temperature and pulse heart rate) measurements, ECOG performance status, 12 -lead 
ECGs, ECHO/MUGA, clinical laboratory  tests and monitoring for AEs.  Planned time 
points f or all safet y assessments are listed in the applicable Time and Events Tables 
(Section 8.1).
Section 8.6.2 Vital Signs
REVISED TEXT
Vital sign measurements will include BP, temperature, and pulse heart rate.  Vital signs 
may be measured as indicated in the Time and Event Tables (Section 8.1) or more 
frequentl y if warranted by [CONTACT_301215].  Refer to the SRM for details 
regarding measurement of vital signs.
Section 8.6.5 Echocardiogram and/or Multi -gated Acquisition (MUGA) Scans 
(NEW SECT ION)
NEW TEXT
Echocardiograms (ECHOs) or MUGA scans will be performed at baseline to assess 
cardiac ejection fraction and cardiac valve morphology for the purpose of study 
eligibility, as specified in the Time and Events Tables (Section 8.1).  Additional 
ECHO assessments may be performed if clinically warranted.  The evaluation of the 
echocardiographer should include an evaluation for LVEF and both right and left -
sided valvular lesions.
Copi[INVESTIGATOR_301124] >10% in LVEF compared to baseline concurrent with LVEF < 
institutional LLN may be required by [CONTACT_301172].
Refer to the SRM for further details on submission of ECHOs or MUGA scans.
Section 8.6.6. Laboratory Assessments, 1st, 2nd, 3rdparagraphs
REVISED TEXT
Laboratory  tests may  be done up to [ADDRESS_367947] dose of study  treatment.
Liver function tests and urine tests for UPC protei n/creatinine may be performed up to 
72hrs prior to the scheduled visit in order to have results available for review by  
[CONTACT_301216].
2013N172718_04 CONFIDENTIA L
[ADDRESS_367948] with a value outside the normal range may  be repeated during 
Screen ing (prior to the first dose) at the discretion of the investigator.  A subject with a 
laboratory  value outside the reference range(s) may  be included onl y if the investigator 
and [COMPANY_004] Medical Monitor agree that it is unlikely  to introduce additional risk f actors and 
will not interfere with study  procedures.
Table 17  Laboratory Assessments
Other tests
PSA 
Serum Testosterone
Coagulation Tests: PT/PTT/INR
Serum Parathyroid Hormone (PTH)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminot ransferase; BUN, blood urea nitrogen; INR, 
international normalization ratio; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume; PSA, prostate -
specific antigen; PT, prothrombin time; PTH, parathyroid hormone ; PTT, partial thromboplastin time; RBC, red blood 
cell; ULN, upper limit of normal; UPC, urine/protein/creatinine ratio; WBC, white blood cell
1. Direct bilirubin is required only if the total bilirubin is elevated ( [ADDRESS_367949])
2. Chemistry evaluation of chloride or uric acid is not required wh ere there are logistical constraints.
3. See Appendix 5
Section 8.7.1 PK Assessments: Dose Escalation Phase
REVISED TEXT
Blood Plasma samples for PK anal ysis of enzalutamide and N -desmethyl 
enzalutamide will be collected from all subjects on Day [ADDRESS_367950] of [COMPANY_004]2636771 on 
the PK of enzalutamide and to quantify  the s ystemic exposure to [COMPANY_004]2636771, 
enzalutamide and N -desmethyl enzalutamide. 
Section 8.7.2  PK Assessments: Dose Expansion Phase
REVISE D TEXT
A sparse reduced PK sampling strategy  will be used for subjects in the Dose Expansion 
Phase (on Day 29, Week 5 and during Weeks 8 and 12) to quantify  the sy stemic 
exposure to study  treatments [COMPANY_004]2636771, enzalutamide and N -desmethyl 
enzalutamide.
Section 8.7.3 PK Blood Sample Collection
REVISED TEXT
Serial Blood and/or plasma samples for PK anal ysis of [COMPANY_004]2636771 and/or
enzalutamide and N -desmethy l enzalutamide will be collected at the time points indicated 
2013N172718_04 CONFIDENTIA L
200331
194in the Time and Events Tables (see Section 8.1).  Whenever possible, blood for PK 
samples should be drawn from the peripheral arm vein or from a central IV port.  Each 
PK sample should be collected as close as possible to the planned time relative to the 
dose (i.e., time zero) administered to the s ubject on serial PK day s.  Once preliminary  PK 
data have been reviewed, the planned sample collection times or study  day may  be 
revised based on newl y available data (i.e., to obtain data closer to the time of peak 
plasma concentration) to ensure appropria te monitoring.  These changes must be 
approved and documented by  [CONTACT_23983], but will not constitute a protocol amendment.  
For Dose -Escalation Phase:  Blood samples for analy sis of enzalutamide and 
N-desmeth yl enzalutamide will be collected pre-dose and 0.5, 1, 2, 3, 4, and [ADDRESS_367951] dose of [COMPANY_004]2636771 (Day -1).
Blood samples for the analy sis of [COMPANY_004]2636771 + enzalutamide should be collected on 
Day [ADDRESS_367952] -dose.Blood and/or plasma 
samples for analysis of [COMPANY_004]2636771 and/or enzalutamide and N -desmethyl 
enzalutamide will be collected according to a serial sampling scheme in the Dose 
Escalation Phase.  
Day 14 (Enzalutamide Run -In Period): the day prior to administration of the 
first dose of [COMPANY_004]2636771:  Subjects will be instructed to fast overnight (at 
least 8 hrs) and withhold their dose of enzalutamide prior to the study visit 
on Day 14.  Study treatments will be administered in the clinic after the pre -
dose blood draw is completed.  Subjects will continue to fast for [ADDRESS_367953] -dose 
of enzalutamide (total of 7 samples).
Day 29, W eek 5 (Treatment Continuation Period): Subjects will be instructed 
to fast overnight (at least 8 hrs) and withhold the doses of study treatment 
prior to the study visit. Study treatments will be administered in the clinic 
after the pre -dose blood draws are completed. Subjects will continue to fast 
for [ADDRESS_367954] -dose (total of 14 samples) .
Weeks 8 and 12 (Treatment Continuation Period):  Subjects will be 
instructed to withhold the doses of study treatment prior to the study visit 
(no overnight fast is necessary). Study treatments will be administered in the 
clinic after the pre -dose blood draws are completed, either 1 hr before or 
2hrs after a meal. Blood and plasma samples for the analysis of 
[COMPANY_004]2636771, enzalutamide and N -desmethyl enzalutamide will be collected 
pre-dose only (total of 2 samples per visit).
For Dose Expansion Phase:  Blood samples for analy sis of enzalutamide and 
N-desmeth yl enzalutamide will be collected according to a sparse sampling scheme in 
subjects in the Dose Expansion Phase.  Subjects with morning clinic visits will be 
instructed to withhold the doses of study  treatment prior to the Week [ADDRESS_367955] is not necessary for any of these PK days. Study treatments should be 
administered either 1 hr before or 2 hrs after a meal.  
Day 29, Week 5 (Treatment Continuation Period):  
oSubjects scheduled for a morning clinic visit will be instructed to 
withhold the doses of study treatments prior to the study visit.  Study 
treatments will be administered in the clinic after the pre -dose blood 
draws are completed (either 1 hr before or 2 hrs after a meal). Blood
and plasma samples for analysis of [COMPANY_004]2636771, enzalutamide and 
N-desmethyl enzalutamide will be collected at pre -dose and 1, 2, and 
3hrs post -dose (total of 8 samples).
oSubjects scheduled for an afternoon clinic visit will take their doses of 
study trea tments at the usual time in the morning (either 1 hr before 
or 2 hrs after a meal) .  Blood and plasma samples for analysis of 
[COMPANY_004]2636771, enzalutamide and N -desmethyl enzalutamide will be 
collected approximately [ADDRESS_367956] -dose (to tal of 
6samples).
Weeks 8 and 12 (Treatment Continuation Period):  Subjects will be 
instructed to withhold the doses of study treatments prior to the study visit. 
Study treatments will be administered in the clinic after the pre -dose blood 
draw is complet ed (either 1 hr before or 2 hrs after a meal). Blood and 
plasma samples for the analysis of [COMPANY_004]2636771, enzalutamide and N -
desmethyl enzalutamide will be collected pre -dose only (total of 2 samples 
per visit). 
Details of PK blood and plasma sample collect ion (including volume to be 
collected), processing, storage and shippi[INVESTIGATOR_42232] .
Section [IP_ADDRESS]  Additional PK Blood Sample Collection
NEW TEXT
Blood and plasma samples for PK analysis will also be collected within [ADDRESS_367957] dose of study treatment(s) at the time of a treatment -emergent AE of 
special interest unless the event occurs on the same day that the Day 14 
(Enzalutamide Run -In Period) and/or Week 5, Day 29 (Treatment Continuation 
Period) PK samples are obt ained.
2013N172718_04 CONFIDENTIA L
200331
196The date/time of the PK blood and plasma sample draw and the date/time of the last 
dose of study treatments prior to the PK blood and plasma sample draws will be 
recorded on the eCRF.  If the date or time of the last dose of study treatment is 
uncle ar, provide the subject’s best approximation.  If the date/time of the last dose 
of study treatment cannot be approximated OR PK blood or plasma samples cannot 
be collected in the time period indicated above, do not obtain a PK samples.  Refer 
to the SRM f or instructions on sample handling and shippi[INVESTIGATOR_301089].
Section 8.7.4 Pharmacokinetic Sample Analysis
REVISED TEXT
Blood and plasma analysis will be performed under the control of [COMPANY_004] Platform 
Technology  and Science -Drug Metabolism and Pharmacok inetics (PTS -DMPK)/Scinovo, 
the details of which will be included in the SRM. Concentrations of [COMPANY_004]2636771, 
enzalutamide and N -desmethy l enzalutamide will be determined in blood and plasma 
samples using the currently  approved bioanal ytical methodology .Raw data will be 
archived at the bioanal ytical site (detailed in the SRM).
Once the blood and plasma has been anal yzed for [COMPANY_004]2636771, enzalutamide and N -
desmethy l enzalutamide any  remaining blood or plasma may be analy zed for other 
compound -related metabol ites and the results reported under a separate [COMPANY_004] PTS -DMPK 
protocol.
Section 8.7.[ADDRESS_367958] 1 hr before or 2 hrs after 
a meal unless otherwise instructed due to PK, CTC, and/or urine electrolyte 
sampling (see Section 6.3 for details).
Tobacco
Subjects who use tobacco products w ill be instructed that use of nicotine -containing 
products (including nicotine patches) will not be permitted while they  are in the clinical 
unit.
Smoking while in the clinical unit will not be permitted. Subjects who use tobacco 
products may use nicotine patches while they are in the clinical unit.
Section 8.[ADDRESS_367959] dose of [COMPANY_004]2636771 on Week 1, Day 1 of the 
Combination Treatment Period.  The remaining tumor tissue submitted for the PTEN 
testing may  be utilized for retrospective analy sis as detailed below predictive biomarker 
analysis .  Additional archival or pre -dose biopsy  tumor tissue samples will also be 
requested for the enrolled subjec ts to complete the intended analy sis.  .  If additional 
tumor tissue is not available, no new biopsy procedure is required in order to obtain 
tumor tissue for predictive biomarker analysis.  
Genetic changes known to alter or regulate PTEN function includi ng mutation, loss of 
heterozy gosit y (LOH), silencing due to promoter methylation may  also be assessed.  
Additional proteins, DNA, RNA, or microRNA, related to activity of [COMPANY_004]2636771and 
enzalutamide or prostate cancer may  also be anal yzed.  Any remaining tu mor tissue may  
also be utilized to further develop a PTEN diagnostic assay .
Section 8.9.3  Circulating Tumor Cells
NEW TEXT
Additional blood samples will be collected at the time points indicated in the Time 
and Events Tables (Section 8.1) to isolate CTCs using an EPIC Biosciences 
platform.  The isolated CTCs will be analyzed for AR variants or other protein 
markers and potential genomic alterations (e.g., PTEN allele loss, AR 
amplifications, etc.).
If subject withdraws consent for further treatment and dat a collection, all samples 
collected for the biomarker analysis at the time of withdrawal will still proceed for 
analysis to meet the intended objectives defined in this protocol.
Details on sample collection, processing, storage and shippi[INVESTIGATOR_301125].
Section [IP_ADDRESS]  CTC Conversion Rate
REVISED TEXT
CTC enumeration will be performed at a central laboratory  using the anal ytically  valid 
CellSearch s ystem (Veridex LL C).  For subjects with baseline CTC counts of 5 cells per 
7.5 mL  of blood, a conversion is defined as a decline in the CTC count to <5 cells per 
2013N172718_04 CONFIDENTIA L
[PHONE_6264].5mL of blood.  Genetic analysis of CTCs may also be performed by [CONTACT_301217].
Section 8.9.4  Circulating Free Tumor DNA and Soluble Mar kers
REVISED TEXT
Assessment of gene mutations in circulating free tumor DNA (cfDNA) and other soluble 
markers will be performed to better understand clonal evolution and other predictive 
circulating biomarkers.  Soluble markers may  include cy tokines or ot her immune 
response markers.  DNA anal ysis includes mutation anal ysis of genes implicated in the 
PI3K/Ras/Raf or AR pathway .
Tumor -specific cfDNA levels detected in plasma or serum have been found to 
correlate with increasing tumor burden and decline follo wing therapy.  
Furthermore, cfDNA in cancer subjects can harbor many genetic alterations 
(mutations, microsatellite alterations, aberrant methylation), which are generally 
consistent with the tumor. Thus, tumor -specific circulating cfDNA has the potential 
to be a useful biomarker of therapeutic response as well as offering a less invasive 
blood based technique for identifying predictive biomarkers.
Plasma samples for analysis of cfDNA and soluble markers will be collected at the time 
points provided in the Time and Events Tables in Section 8.1. during Screening, at 
Week 4 (pre -dose) and at time of disease progression for soluble markers and DNA 
analysis for all subjects enrolled in the study  (see Time and Event Tables in Section 8.1) .  
Section 8.10  Appendix 8:  Genetic Research
NEW TEXT
Information regarding genetic research is included in Appendix 8.
Section 9.5 Time Period and Frequency of Detecting AEs and SAEs
REVISED TEXT
2ndparagraph: AEs will be collected from the time the first dose of enzalutamide is 
administered on Week 1, Day [ADDRESS_367960] been taken within 4 weeks prior to Screening.  Subjects will be instructed to 
inform the investigator prior to sta rting any new medication(s), including herbal 
preparations and OTC products, taken from the time of the first dose of study  treatment
enzalutamide monotherapy on Day 1 of the Enzalutamide Run -In Period until the 
2013N172718_04 CONFIDENTIA L
200331
199end of the study (i.e. through the final post-treatment follow -up visit).  Any 
concomitant medication(s), including OTC and herbal product(s), taken during the 
study will be recorded in the eCRF. At a minimum, the drug name, dose and the 
dates of administration are to be recorded.   Additionally , a complete list of all prior 
cancer therapi[INVESTIGATOR_42214].
Questions regarding concomitant medications should be directed to the [COMPANY_004] Medical 
Monitor for clarification.
If future changes to the list of permitted or prohibited medications are m ade as a result of 
emerging data, formal documentation will be provided to the investigative site by  [CONTACT_23983].
Any such changes will be communicated to the investigative sites in the form of a letter, 
which should be stored in the study file .Sites may  also r efer to the SRM for updates 
regarding changes to the list of permitted or prohibited medications.
Section 10.1 Permitted Medications, 3rdand 4thparagraphs
REVISED TEXT
Steroids:  Use of steroids is discouraged while subject is undergoing treatment on thi s 
study.  However, steroids (up to a maximum of 10 mg of prednisone or equivalent) are 
permitted provided that the subject has been on a stable dose for at least [ADDRESS_367961] dose of study  treatments .
Anticoagulants:  Prophy lactic doses of anticoagulants (i.e., heparin, warfarin) are 
permitted provided that the subject meets the PTT/I NR entry  criteria (see Section 4.1.2) 
and INR is monitored in accordance with local institutional practice.  Therapeutic doses 
of warfarin (defined as a dos e resulting in INR >1.5) are prohibited within [ADDRESS_367962]-treatment follow -up visit.  Caution should be exercised if aspi[INVESTIGATOR_301096]2636771 .
Section 10.2  Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_301126]
AR antagonists (e.g., bicalutamide, flutamide, nilutamide)
Section [IP_ADDRESS] [COMPANY_004]2636771 as Perpetrator of Drug -Drug Interactions (section 
header added)
DELETED TEXT
A preliminary  study suggested the potential of CYP3A4 inhibition; however, subsequent 
studies did not confirm this.  Use of medications that have a narrow therapeutic index and 
are substrates of CYP3A4 should be avoided within 7 day s or 5 half-lives (whichever is 
longer) p rior to the first dose of study  treatment and for the duration of study  treatment 
through the post -treatment follow -up visit.
2013N172718_04 CONFIDENTIA L
200331
200Drug(s) that are strong inducers of CYPs and UGTs as they  may  decrease the 
concentration of [COMPANY_004]2636771 (see Table 11).  CYP3A4 sub strates with a narrow 
therapeutic index, strong inducers of CYP3A4 and UGTs, and anti -platelet agents to 
avoid include, but are not limited to, those listed in Table 11 below.  Consider therapeutic 
substitutions for these medications.
NEW TEXT
A preliminar y study suggested the potential of CYP3A4 inhibition by [CONTACT_23983]2636771; 
however, subsequent studies using human recombinant CYP3A4 and pooled human 
liver microsomes did not confirm this at concentrations tested (up to 100 M). The 
preliminary study indicated G SK2636771 did not inhibit CYP1A2, 2C8, 2C9, 2C19 
and 2D6 at up to 25 µM (10.8 g/mL), the risk is low but was not fully discharged at 
higher concentrations.  Medications that have a narrow therapeutic index and are 
substrates of CYP3A4 should be used with caution within 7 days or 5 half-lives 
(whichever is longer) prior to the first dose of [COMPANY_004]2636771 (Week 1, Day 1 of the 
Combination Treatment Period) and for the duration of study treatment through 
the post -treatment follow -up visit (Table 18).  Medication s that have a narrow 
therapeutic index and are substrates of CYP1A2, CYP2C8, 2C9 and 2C19, CYP2D6 
and CYP2B6 should be used with caution.  [COMPANY_004]2636771 did not inhibit transporters 
OATP1B1, OATP1B3, BCRP and P -gp up to 23 -30 µM in vitro.  Due to high 
[COMPANY_004]2636 771 concentrations (up to 100 M) observed in the FTIH study 
(P3B115717), there is a risk for renal transporter inhibition; however, in vitro data 
to discharge this risk is pending.  Therefore, medications that are sensitive 
substrates of renal transporter s OAT and OCT2 should be used with caution when 
administered with [COMPANY_004]2636771 (example drugs are listed in Table 18).
Table 18 Drugs Potentially Affected by [CONTACT_23983]2636771: Avoid Usewith Caution
Drugs/Agents Therapeutic Area
CYP3A4 Substrates
dihydroergota mine, ergonovine, ergotamine, methylergonovine Ergot derivatives
pi[INVESTIGATOR_301098], flecainide, lidocaine, mexilitine, amiodarone, quinidine, 
propafenoneAntiarrhythmics
tacrolimus, sirolimus Immune modulators
quetiapi[INVESTIGATOR_050], risperidone, cloz api[INVESTIGATOR_050], atomoxetine Miscellaneous
CYP Inducers and/or UGT enzymes
rifamycin class agents (e.g., rifampin, rifabutin, rifapentine) Antibiotics
carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin, s -mephenytoin Antiepi[INVESTIGATOR_301127], prasugrel or ticagrelor Antiplatelet
Renal Transporter (OAT, OCT2) Substrates 
methotrexate Antineoplastic
dofetilde, pi[INVESTIGATOR_14959], procainamide Antiarrhythmic
metformin Antidiabetic
2013N172718_04 CONFIDENTIA L
200331
201Section [IP_ADDRESS]  [COMPANY_004]2636771 as Victim of Drug -Drug Interactions ( section header 
added)
REVISED TEXT
Based on pre -clinical and in vitro data, CYP enzymes do not appear to mediate the 
metabolism of [COMPANY_004]2636771.  However, strong inhibitors or inducers of CYP enzy mes 
should be used with caution in the case that they  may  alter the PKof [COMPANY_004]2636771 
(Table 12 ).
Based on pre -clinical and in vitro data [COMPANY_004]2636771 is a substrate for UDP -
glucuronosy ltransferase (UGT) enz ymes.  Therefore, drugs that are inhibitors of UGT 
enzy mes should be used with caution ( Table 12 ).
Based on pre -clinical and in vitro data, [COMPANY_004]2636771 is an in vitro substrate for 
UDP -glucuronosyltransferase (UGT) enzymes, while CYP enzymes did not appear 
to be the major pathways for metabolism of [COMPANY_004]2636771. Therefore, d rug(s) that 
are strong inhibitors or inducers o f CYPs and UGTs may increase or decrease the 
concentration of [COMPANY_004]2636771.  Medications that are strong inhibitor/inducers of 
CYP3A4 and UGTs, including, but not limited to, those listed in Table 19, should be 
used with caution.  Consider therapeutic substi tutions for these medications.
Table [ADDRESS_367963] [COMPANY_004]2636771: Use with Caution
Generic Drug Name [CONTACT_301228] (e.g., rifampin, rifabutin, rifapentine) Antibiotics
carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin, s -mephenytoin Antiepi[INVESTIGATOR_301128], telithromycin, troleandomycin Antibiotics
itraconazole, ketoconazole, posaconazole, voriconazole Antifungals
nefazodone Antidepressants
gemfibrozil Hyperlipi [INVESTIGATOR_301129], mibefranil, conivaptan Miscellaneous
cyclosporine Immunosuppressive agents
Inhibitors of UGTenzymes i nhibitors
fluconazole Antifungal
cisapride, probenecid, ranitidine, cyclosporine, diflunisal, sertraline, valproic 
acid, atavaquone, methadone, methsuximide, olanzapi[INVESTIGATOR_050], retigabineMiscellaneous
Caution is also recommended when [COMPANY_004]2636771 and aspi[INVESTIGATOR_301130].
Section 10.2.2 Potential Drug Interactions with Enzalutamide
2013N172718_04 CONFIDENTIA L
200331
202NEW TEXT
The following information is provided a s an initial reference, however, please refer 
to the approved US FDA prescribing information [Xtandi, 2013] or the Xtandi 
Prescribing Information for the area where it is approved for the most current 
drug -drug interaction (DDI) information and contraindic ated medications .
Section 11.1 Contraception Requirements
REVISED TEXT
Abstinence:  Male subjects may  also elect abstinence, defined as sexual inactivity  
consistent with the preferred and usual lifest yle of the subject.  Periodic abstinence 
(e.g. calendar, ovulation, sy mptothermal, post -ovulation methods) and withdrawal are not
acceptable methods of contraception.  Complete abstinence from sexual intercourse must 
occur for [ADDRESS_367964] dose of study  treatments.
Sperm Donation:  Subjects must not donate sperm from the time day of the first dose of 
study  treatment enzalutamide monotherapy on Day [ADDRESS_367965] dose of study  treatments.
Section [IP_ADDRESS] Pharmacokinetic Analyses
REVISED TEXT
Pharmacokinetic anal ysis will be the responsibility of the Clinical Pharmacology  
Modeling and Simulation Depar tment, [COMPANY_004].  Statistical anal yses of the PK parameter 
data will be the responsibility  of [COMPANY_004] Discovery  Biometrics and Clinical Statistics.
Non-compartmental analy sis will be conducted on Concentration -time data for 
[COMPANY_004]2636771, enzalutamide and N -desmethyl enzalutamide from the Dose -Escalation 
Phase will be analyzed via standard non -compartmental methods .  Parameters 
calculated include the area under the concentration -time curve from [ADDRESS_367966] 
quantifiable blood or plasma concentration (AUC(0 -t)), the ma ximum plasma or blood 
concentration (Cmax), and the time of the maximum concentration (tmax) if data permit.  
Population PK parameters for [COMPANY_004]2636771 including oral clearance (CL/F), oral 
volume of distribution (V/F), and absorption rate constant (ka) will be estimated pooling 
all data from this study  with historical data , if data permit.  Dependent on the final 
structural PK model, additional PK parameters may also be estimated. Sources of 
variability  in PK parameters will be investigated during population modeling.  
Section 14.2 Regulatory and Ethical Considerations, Including the Informed 
Consent Process
2013N172718_04 CONFIDENTIA L
200331
203NEW TEXT
In approving the clinical protocol the IEC/IRB and, where required, the applicable 
regulatory agency are also approving the optional assessme nts, e.g. genetic research 
described in Appendix 7, unless otherwise indicated.  Where permitted by 
[CONTACT_12721], approval of the optional assessments can occur after 
approval is obtained for the rest of the study.  If so, then the written approv al will 
clearly indicate approval of the optional assessments is being deferred and the 
study, except for the optional assessments, can be initiated.  When the optional 
assessments are not approved, then the approval for the rest of the study will clearly 
indicate this and therefore, the optional assessments will not be conducted.
Section 16.1  Appendix 1: ECOG Performance Status
REVISED TEXT
5 Death
Section 16.4  Appendix 4: Disease Assessment per RECIST 1.1
NEW TEXT
Assessment Guidelines –CT and MRI:
NOT E: If CT contrast is contraindicated, acquire and submit a contrast -
enhanced MRI of the abdomen/pelvis and an unenhanced CT of the chest in 
place of the enhanced CT for complete lesion assessment.
REVISED TEXT
Baseline Assessments –CT and MRI:
NOTE: Although CT scan is preferred, MRI may be used as an alternative method of 
baseline disease assessment for abdomen/pelvis , especiall y for those subjects where a 
CT scan is contraindicated due to allergy  to contrast, provided that the method used to 
document ba seline status is used consistently  throughout study  treatment to facilitate 
direct comparison.  An unenhanced CT of the chest can replace the enhanced CT of 
the chest, but MRI of the chest is not recommended.
Confirmation of CR and PR are required per prot ocol.  Confirmation assessments must be 
performed no less than 4 weeks (±3 days) after the criteria for response have initially  
been met and may  be performed at the next protocol scheduled assessment.  If a 
confirmation assessment is performed prior to the next protocol schedule assessment, the 
next protocol scheduled evaluation is still required (e.g. evaluations must occur at each 
protocol scheduled time point regardless of unscheduled assessments).
Baseline Assessments
The following baseline disease (les ion) assessments must be performed within 28 day s 
prior to enrollment (or within 35 day s if disease assessment is assessed by  [CONTACT_9268] ) prior to 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367967] dose of enzalutamide (Day 1 of Enzalutamide Run -In Period) to identify  
target and non -target lesions:
Base line documentation of target and non -target lesions 
All baseline lesion assessments must be performed within 28 day s prior to 
enrollment ( or within 35 day s if disease assessment is assessed by  [CONTACT_9268]) prior to the 
first dose of enzalutamide (Day 1 of Enzalut amide Run -In Period) .
Confirmation Criteria:
To be assigned a status of PR or CR, a confirmatory  disease assessment should be 
performed no less than 4 weeks (±3 days) after the criteria for response are first 
met.
Confirmation of Response per RECIST 1.[ADDRESS_367968] 4 weeks (±3 days) after the criteria for response have initially  been 
met and may  be performed at the next protocol scheduled assessment.  If a confirma tion 
assessment is performed prior to the next protocol -specified assessment, the next 
protocol -specified evaluation is still required (e.g., evaluations must occur at each 
protocol scheduled time point regardless of unscheduled assessments).
Brain metasta ses:  To confirm a CR in a solid tumor subject with brain metastases at 
baseline, brain imaging that is obtained before the response assessment indicating a CR 
must have been obtained no earlier than [ADDRESS_367969] be done no more 
than 4 weeks (±3 days) after the next protocol specified assessment in order to confirm a 
CR.
Section 16.6  Appendix 6: Liver Safety Required Actions and Follow -up 
Assessments (Section deleted; subsequent sections renumbered)
DELETED TEXT
Phase I liver chemistry stoppi[INVESTIGATOR_301131] y and eval uate liver event etiology  (in alignment with the 
FDA premarketing clinical liver safet y guidance).  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
Phase I Oncology Liver Chemistry Increased Monitoring C riteria with continued therapy –
Liver Monitoring Event
Criteria Actions
ALT [ADDRESS_367970] but <[ADDRESS_367971] 
andbilirubin <[ADDRESS_367972], 
without symptoms believed 
to be related to liver injury or Notify the [COMPANY_004] Medical Monitor within [ADDRESS_367973] safety
Subject can continue study treatment
2013N172718_04 CONFIDENTIA L
200331
205hypersensitivity andwho can 
be monitored weekly for 4 
weeksSubject must return weekly for repeat liver chemistries (ALT, AST, 
alkaline phosphatase, bilirubin) until they resolve, stabilis e or return to 
within baseline
If at any time subject meets the liver chemistry stoppi[INVESTIGATOR_3418], 
proceed as described above
If, after 4 weeks of monitoring, ALT <[ADDRESS_367974] and bilirubin <[ADDRESS_367975] with documented
liver metastases/tumor 
infiltration at baseline AND 
entry criteria ALT>2.[ADDRESS_367976] but ≤[ADDRESS_367977]
ALT ≥[ADDRESS_367978] and 1.5 x 
baseline value butALT <[ADDRESS_367979] and 2 x baseline value
andbilirubin <[ADDRESS_367980] , 
without symptoms believed 
to be related to liver injury, o r 
hypersensitivity andwho can 
be monitored weekly for 4 
weeksFor subjects with documented liver metastases/tumor infiltration at 
baseline AND entry criteria ALT>2.[ADDRESS_367981] but ≤[ADDRESS_367982]
If, after 4 weeks of monitoring, ALT <[ADDRESS_367983] and <1.5 x baseline 
value, and bilirubin <[ADDRESS_367984], monitor subjects twice monthly until liver 
chemistries normalize or return to within baseline
References:
James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Protein Adducts in Adults with 
Acetaminophen Overdose and Acute L iver Failure. Drug Metab Dispos.
2009;37(8):1779 -1784. 
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény  P, Gault E.  Quantification 
of Hepatitis Delta Virus RNA in Serum by  [CONTACT_301218] -Time PCR I ndicates 
Different Patterns of Virological Response to Interferon Therap y in Chronically  Infected 
Patients.  J Clin Microbiol . 2005;43(5):2363 –2369.
Section 16.6  Appendix 6: Liver Safety Drug Restart/Rechallenge Guidelines
REVISED TEXT
1.Rechallenge Following Liver Stoppi[INVESTIGATOR_301132] (third bullet)
subject currently  exhibits severe liver injury  defined by : [CONTACT_14427] 
(ALT) >≥3xULN, bilirubin ≥>2xULN (direct bilirubin >35% of total), or 
international normalization ratio (INR) >1.5
Section 16.7  Appendix 7: Genetic Research (new section; subsequent sections were 
renumbered)
2013N172718_04 CONFIDENTIA L
200331
206NEW TEXT
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between 
genetic variants and: 
Response to medicine, including any treatment regimens under investigation in 
this study or any concomitant medicines;
Cancer susceptibility, severity, an d progression and related conditions
Genetic data may be generated while the study is underway or following completion 
of the study.  Genetic evaluations may include focused candidate gene approaches 
and/or examination of a large number of genetic variant s throughout the genome 
(whole genome analyses). Genetic analyses will utilize data collected in the study and 
will be limited to understanding the objectives highlighted above.  Analyses may be 
performed using data from multiple clinical studies to invest igate these research 
objectives.
Appropriate descriptive and/or statistical analysis methods will be used. A detailed 
description of any planned analyses will be documented in a Reporting and Analysis 
Plan (RAP) prior to initiation of the analysis. Planned analyses and results of 
genetic investigations will be reported either as part of the clinical RAP and study 
report, or in a separate genetics RAP and report, as appropriate.
Study Population
Any subject who is enrolled in the study can participate in gen etic research.  Any 
subject who has received an allogeneic bone marrow transplant must be excluded 
from the genetic research.
Study Assessments and Procedures
A key component of successful genetic research is the collection of samples during 
clinical studi es. Collection of samples, even when no a priori hypothesis has been 
identified, may enable future genetic analyses to be conducted to help understand 
variability in disease and medicine response.  
A 6-mLblood sample will be taken for deoxyribonucleic ac id (DNA) extraction. 
A blood sample is collected at the baseline visit (Day 1 preferably for this study) , 
after the subject has been randomized and provided informed consent for 
genetic research. If a subject initially declines to participate in genetic r esearch 
and then changes their mind, a sample should be obtained at the earliest 
opportunity.   Instructions for collection and shippi[INVESTIGATOR_301133]. The DNA from the blood sample may 
undergo quality control analyses to confirm the integrity of the sample. If there 
are concerns regarding the quality of the sample, then the sample may be 
destroyed. The blood sample is taken on a single occasion unless a duplicate 
sample is required due to an inability to utiliz e the original sample.  
2013N172718_04 CONFIDENTIA L
200331
207The genetic sample is labelled (or “coded”) with the same study specific number 
used to label other samples and data in the study.   This number can be traced or 
linked back to the subject by [CONTACT_132018]. Coded s amples do not 
carry personal identifiers (such as name [CONTACT_78207]). 
Samples will be stored securely and may be kept for up to [ADDRESS_367985] completes the study, or GlaxoSmithKline ([COMPANY_004]) may destroy the samples 
sooner.  [COMPANY_004] or those working with [COMPANY_004] (for example, other researchers) will only 
use samples collected from the study for the purpose stated in this protocol and in 
the informed consent form.  Samples may be used as part of the development of a 
companion diagnostic t o support the [COMPANY_004] medicinal product.
Subjects can request their sample to be destroyed at any time.
Informed Consent
Subjects who do not wish to participate in the genetic research may still participate 
in the clinical study.  Genetic informed consent must be obtained prior to any blood 
being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research withdraws from the 
clinical study for any reason other than being lost to follow -up, the subject will be 
given a ch oice of one of the following options concerning the genetic sample, if 
already collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy the gen etic DNA 
sample 
If a subject withdraws consent for genetic research or requests sample destruction 
for any reason, the investigator must complete the appropriate documentation to 
request sample destruction within the timeframe specified by [CONTACT_301219] n the 
documentation in the site study records . 
Genotype data may be generated during the study or after completion of the study 
and may be analyzed during the study or stored for future analysis. 
If a subject withdraws consent for genetic research and ge notype data has not 
been analyzed, it will not be analyzed or used for future research.  
Genetic data that has been analyzed at the time of withdrawn consent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample fo r genetic research has been collected and it is determined that the 
subject does not meet the entry criteria for participation in the study, then the 
2013N172718_04 CONFIDENTIA L
[ADDRESS_367986]’s Genetic Data
[COMPANY_004] may summarize the genetic research results in the clinical study report, or 
separately and may publish the results in scientific journals. 
[COMPANY_004] may share genetic research data with other scientists to further scientific 
understand ing in alignment with the informed consent. [COMPANY_004] does not inform the 
subject, family members, insurers, or employers of individual genotypi[INVESTIGATOR_301134]’s medical care at the time of the 
study, unless required b y law. This is due to the fact that the information generated 
from genetic studies is generally preliminary in nature, and therefore the 
significance and scientific validity of the results are undetermined.  Further, data 
generated in a research laboratory may not meet regulatory requirements for 
inclusion in clinical care.
16.9.3. Protocol changes for A mendment 3 (24 -Jun-2016) from Protocol 
Amendment 2 (26 -Feb-2015)
Where the A mendment A pplies
This amendment applies to all sites and countries.
Summary  of A mendment Changes with Rationale
Amendment [ADDRESS_367987] of Specific Changes:
Throughout this section, added text has been bolded and deleted text had been shown 
with strikethrough.  The remaining text has been shown to provide context for the 
changes.
Changes associated with renal assessments:
Section [IP_ADDRESS], Risk assessment for [COMPANY_004]2636771 :
Renal : Degenerative changes were observed in the kidney s of rats and dogs at 
100mg/kg/day  or 1000 mg/kg/day , including cellular and tubular changes, with 
chemistry  and urinal ysis findings.  Grade 3, treatment -related h ypophosphatemia and 
hypocalcaemia have been observed in the FTIH study  P3B115717.  There have been 2 
reports of acute kidney injury (grade 2 and 3) in subjects who received [COMPANY_004]2636771 
in Study 200331.   Since it is possible that [COMPANY_004]2636771 may contribute to acute 
kidney injury, renal events should be closely monitored .  Medical history  will be 
colle cted and, ph ysical examination and clinical laboratory  tests will be measured 
frequentl y during therap y to monitor for potential toxicity .  Guidelines will be 
implemented including dose modification and discontinuation (Section 7.3.1) for the 
management of renal insufficiency  or renal -related events considered to be related to 
study  treatment, will be implemented .  It is recommended that patients be well 
hydrated and avoid the use of NSAIDs.
Section 4.1.2, Inclusion Criterion 11 :
Changes to requirements for adequate baseline organ function at time of Screening to 
include serum phosphate within normal limits , rather than Grade 1; and to require 
the use of the CKD -EPI [INVESTIGATOR_301135] b y the Cockcroft -Gault formula when 
estimating serum creatinine cleara nce. 
Section 7.3.1, Management Guidelines for Renal Insufficiency:
Management guidelines for renal insufficiency  or other renal events are to be followed 
when serum creatinine 0.3 mg/dL ( 26.5 µmol/L) rather than when serum creatinine 
0.5 mg/dL ( 44.2 µmol/L ), and are to include an assessment of 24-hour urine 
creatinine clearance, where feasible.   
In addition,
If repeat serum creatinine fails to confirm increase, c ontinue treatment with [COMPANY_004]2636771
at same dose level without interruption and o btain bloo d sample for PK analysis , 
within [ADDRESS_367988] dose ( refer to Section [IP_ADDRESS] for details on PK sample 
collection)
Section 7.3.4 and Section 7.3.5, Management Guidelines for Diarrhea and Vomiting
A cross reference to Section 11.3 on hy dration was added to this section on the 
management of diarrhea and the section on vomiting.
2013N172718_04 CONFIDENTIA L
200331
210Section 10.1, Permitted Medications:
Concomitant medication and non -drug therapi[INVESTIGATOR_301136], Use of NSAIDs 
should be avoided during the study.
Section 11.3 Othe r Lifestyle Restrictions:
Lifesty le restrictions was updated to include the addition, Subjects are to be instructed 
to avoid dehydration while participating in the study.  Subjects who have 
inadequate oral intake or who have difficulty maintaining hydratio n should 
discontinue treatment with [COMPANY_004]2636771 until adequate oral intake can be 
maintained.  If the subject must discontinue treatment for more than [ADDRESS_367989] should be withdrawn from the study.
Appendix 3:
Update d to remove the Cockcroft -Gault Formula and to add the web address for the 
CKD -EPI [INVESTIGATOR_10908].
Change associated with clarification of the distinction between disease 
progression as and endpoint and as a criterion for the discontinuation of 
treatment
Section 5.2, Permanent Discontination of Study Treatment:
Study  treatment(s) will be permanently  discontinued for any  of the following reasons:
Disease progression defined with regards to termination of study 
treatment as: Radiographic progression in soft tissue or bone by 
[CONTACT_393] 1.1 for subjects with measurable disease, OR
Bone progression on bone scan according to the criteria (Section [IP_ADDRESS]), 
OR
When it is determined in the opi[INVESTIGATOR_301137] i s no longer clinically 
benefitting (NLCB) from treatment.
NOTE: Subjects who are tolerating therapy and meet criteria for disease 
progression solely on the basis of rising PSA or for the worsening of an 
isolated disease site that is not clinically signific ant will NOT be required to 
discontinue treatment and can continue treatment until they are NLCB 
from treatment [ Scher , 2016].
NOTE:  Subjects must meet the PCWG2 guidelines for disease progression to 
avoid premature discontinuation of study  treatment(s).
Treatment Discontinuation due to PSA rise:   Following PCWG2 
guidelines, subjects should not be discontinued from study  treatment(s) 
solely  due to PSA rise during the first 12 weeks of treatment 
(Section [IP_ADDRESS]).
2013N172718_04 CONFIDENTIA L
200331
211Treatment Discontinuation due to Bone Scan changes:  Subjects should 
not be discontinued from study  treatment(s) due to the occurrence of 
bone scan changes in the first 12 weeks that do not meet PCWG2 
guidelines for progression (Section [IP_ADDRESS]).
Section 5.3, Subject Completion:
A subject will be c onsidered to have completed the study  if the subject dies or 
discontinues treatment due to disease progression otherwise progre sses during the 
study  treatment or post -treatment follow -up period. All other subjects will be considered 
to have withdrawn from the study .
Section 8.1, Change in the column heading for Table 15 Time and Event Table for 
the Dose Escalation Phase and Table 16 Time and Event Table for the Dose 
Expansion Phase and addition of explanatory footnote 31 :
Time ofDiscontinuation of Treatme nt due to Disease Progression31
31. Subjects are not required to discontinue treatment on the basis of PSA 
progression alone or for the worsening of an isolated disease site that is not clinically 
significant (see Section 5.2).
Section 8.8.1, Clinical Acti vity Endpoint:
The secondary  endpoint to evaluate the clinical activity  of oral [COMPANY_004]2636771 + 
enzalutamide will be assessed using the disease progression endpoint (see Section 
[IP_ADDRESS]) which differs from the disease progression criteria that lead to 
discont inuation of treatment (see Section 5.2 ).  is the PSA and RECI ST response rate 
as per PCWG2 guidelines.   CTC response will also be determined and reported as an 
exploratory  endpoint.
Section [IP_ADDRESS], Disease Progression Endpoint:
The disease progression endpoint is defined by  1 or more of the following criteria:
PSA progression according to the PCWG2 criteria (Section [IP_ADDRESS])
Radiographic progression in soft tissue or bone by [CONTACT_23603] 1.1 for subjects with 
measurable disease
Bone progression on bone scan acco rding to the PCWG2 criteria 
(Section [IP_ADDRESS]).
Subjects are not required to discontinue treatment on the basis of meeting PSA 
progression alone or for the worsening of an isolated disease site that is not clinically 
significant (see Section 5.2) 
2013N172718_04 CONFIDENTIA L
200331
212Referenc es:
Citation for the Prostate Cancer Clinical Trials Working Group 3 [Scher, 2016] was 
added. 
Other minor changes:
To conform to changes added in Section 5.2 regarding when treatment is to be 
discontinued
A cross reference to Section 5.[ADDRESS_367990] ion 3.2.3 and Section 3.3, and
Clarifications were added to Section 3.5 and Section 8.1 (Time and Events Table 
15 and Table 16). 
Changes associated with the addition of o ptional paired biopsies for  
pharmacody namics analy sis as well as clarifications arou nd biomarkers, 
including assessments added to the Time and Events tables for the Dose 
Escalation and Dose Expansion Phases.  
Section 2.2 Objective and Endpoints:
Addition of the following stud y objective and endpoint:
To determine pharmacodynamic effects of 
drug treatmentRNA/protein analysis of pre/post 
treatment tumor biopsies 
Section 3.0, Investigational Plan:
Biomarker Assessments:  Planned biomarker assessments include:  1) I dentify  potential 
predictive biomarkers (protein, DNA, ribonucleic acid [R NA] based) in archived tumor 
tissue/pre -treatment biopsies; 2) enumeration of CTCs in circulation and evaluation of 
genetic alterations or expression of inAR,orPTEN or other genes (or other genomic 
markers) in isolated CTCs; 3) Assessment of gene mutations incirculating free
DNA/ RNA (cfDNA) and other soluble markers in plasma to better understand clonal 
evolution and other predictive circulating biomarkers; and 4) understand the mechanism 
of resistance in tumor tissues biopsies (optional) at time of progres sion 5) assess 
pharmacodynamic effects by [CONTACT_301220]/post treatment tumor biopsies
Section 3.4 Dose Escalation Plan
If the combination doses in Cohort 1 are not tolerable, lower doses as defined in the de -
escalation cohort (Cohort -1) will be evaluate d.  If the de -escalation cohort (Cohort -1) is 
not tolerable, further dose escalation using a continuous daily  dosing schedule for both 
compounds simultaneously  will be terminated. additional dose levels of [COMPANY_004]2636771 or 
alternative dosing schedules may  be explored based upon ongoing assessment of safet y, 
2013N172718_04 CONFIDENTIA L
200331
213PDand PK.  Dose modification decisions will be made utilizing all available data at the 
end of each DLT reporting period (the first 28 days of combination treatment).
Section 8.1, Time and Events Tables:
Additional unplanned blood, plasma and/or optional tumor samples may be requested 
with patient consent and investigator agreement as needed to better characterize safet y 
and response(s) in subjects.
Table 15 Time and Events Table for the Dose Escalation Ph ase and Table 16 Time 
and Events Table for the Dose Expansion Phase :
cfDNA/RNA/Soluble Marker updated to include plasma samples collected pre -dose at 
Weeks 1, 8, 16, 24, and 32 .
Footnote 24:
24. Tumor Biopsies for PD and progression :These biopsies are opt ional and may be 
undertaken in select cases upon agreement with the investigator and when consent is 
provided by [CONTACT_423]. For pharmacodynamic biomarker analyses, fresh tissue 
biopsies would be collected between Day 12 of the Enzalutamide Run -in Period and 
Week 1/Day 1, prior to any treatment with [COMPANY_004]2636771, and [ADDRESS_367991] dose 
between Days 8 and 15 of the Combination Treatment Period (post -treatment).   For 
subjects who consent to the optional progression biopsy, a fresh tumor biopsy 
should be compl eted if the subject initially responded to combination treatment and 
then progressed.   
LDH assessments added, along with a footnote [ADDRESS_367992], LDH will be 
reported.
Section 8.9.2, Tumor Sam ple Biopsies:
If consent is provided b y the subject, optional fresh tumor biopsies may be collected 
prior to combination treatment and [ADDRESS_367993] treatment effects. For subjects who initially  responded to combination 
therap y and then progressed, an optional progression tumor biopsy is requested in order 
to better understand the mechanism of resistance.  I t is preferable to obtain this biopsy  
from a new lesion or a lesion which had previously  responded and then progressed.  
Biopsy  samples from other lesions will be accepted as well.  Both soft tissue and bone 
biopsies will be accepted.
2013N172718_04 CONFIDENTIA L
200331
214Section 8.9.4, Circulating Cell Free Tumor DNA, RNA and Soluble Markers :
Furthermore, cfDNA in cancer subjects can harbor many genetic alterations (mutations, 
copy number changes microsatellite alterations , aberrant methy lation), which are 
generall y consistent with the tumor of origin .
Section 8.11, Explorator PK and PD Analysis:
Evaluation of pre and post treatment tumor tissue may also be explored to determine 
pharmacodynamic effects and the mechanism of resistance to combina tion therapy  in 
subjects who have progressed after initiall y responding to the combination therap y.
Section [IP_ADDRESS], Translational Research Analyses:
Plasma collection at baseline, post -treatment and at time of disease progression will be 
used to anal yze cfDNA, RNA and other soluble markers to understand clonal evolution, 
monitor response and explore and other predictive circulating biomarkers.  Archival 
tissue/pre -dose or fresh biopy  tissue may  be utilized to identify  potential predictive 
biomarkers (pro tein, DNA and RNA based markers).  Optional PDand progression 
biopsies for subjects who have progressed from initially  responding to the combination 
therap y ma y also be requested to understand pharmacodynamic effects and
mechanism(s) of resistance.
Change s associated with the futility  criterion for the Dose Expansion Phase
Section 3.6.1, Evaluation of Futility
All available data will be considered in making enrollment decisions.
The decision to terminate the Dose Expansion Phase will not depend solely on t he 
results of the statistical methodology, but will take all factors into account. These 
factors include the representation of predictive biomarkers, such as Androgen 
receptors, in the subjects treated at the time of interim analysis; and the totality of 
the safety, tolerability, PK, and PD data. Additional subjects targeting a specific 
biomarker profile may be enrolled in the cohort at the discretion of the team even if 
the predictive probability suggests a low likelihood of clinical activity in this coh ort
Section 13.2.2, Dose Expansion Phase
However, the decision to terminate the Dose Expansion Phase will not depend solely 
on the results of the statistical methodology, but will take all factors into account. 
Additional subjects in a cohort may be enroll ed even if the predictive probability 
suggests a low likelihood of activity in the Expansion Cohort (see Section 3.6.1).
2013N172718_04 CONFIDENTIA L
[ADDRESS_367994] inadvertent 
errors in previous versions of the protocol:
Section 1.2.1 , Introduction:
Updated status of stud y P3B115717 to note the study is completed and enrolled [ADDRESS_367995]-Extended Follow -Up/EOS Visit performed.
Section 3.4.1, Cohort Expansion:
Subjects may  be enrolled at previously  completed dose levels for the purpose of 
obtaining additional PK and/or PD data
Section 3.[ADDRESS_367996] been determined in the Dose Escalation Phas e.  Up to 20 additional subjects 
may be enrolled to better characterize the safet y profile, PK, and clinical activity  of the 
recommended doses of the combination of [COMPANY_004]2636771 + enzalutamide for future 
studies. One or more combination doses may be explored in the Dose Expansion 
Phase based the MTD and RP2D identified in the Dose Escalation Phase of the 
study.
Section 4.1.3, Exclusion Criteria 1:
Added clarification that treatment with abiraterone during the study  is exclusionary  to 
enrollment. 
Section 7.3. 3 Management Guidelines for Rash:
An error in previous versions of the protocol was corrected in the rash management 
guidelines to indicate that treatment can be restarted following rash events when rash 
returns to Grade 1 , rather than < Grade 1. 
A note was also added to include PK samples for Grade 3 and Grade 4 dose limiting 
toxicity  rash events. 
2013N172718_04 CONFIDENTIA L
200331
216Section 8.1, Time and Events Tables:
Table 15 Time and Events Table for the Dose Escalation Phase and Table 16 Time 
and Events Table for the Dose Expansion Phase :
CTC -Janssen
Section 8.6.6, Table 17, Laboratory Assessments:
Added Hematocrit to the list of laboratory  assessments.
Section [IP_ADDRESS] and Section [IP_ADDRESS]:
Clarification was added to note that PSA response and response in bone is to be assessed 
follo wing 12 weeks of combination treatment with enzalutamide plus [COMPANY_004]2636771.
16.9.4. Protocol changes for A mendment 4 ( 27-Jan-2017 ) from Protocol 
Amendment 3 (24 -Jun-2016)
Where the A mendment A pplies
This amendment applies to all sites and countries.
Summary  of A mend ment Changes with Rationale
Amendment 4 was completed to include additional requirements for monitoring of events 
related to calcium results , including revisions to the Table & Events to clarify  additional 
laboratory  testing requirements ; clarification of secondary  clinical activity  endpoints and 
update to associated statistical section(s) ; revision of clinical activit y population allowing 
the combination of dose escalation and dose expansion populations ; revision of dose 
escalation and dose expansion wordi ng to allow multiple dose levels in dose expansion to 
establish RP2D after dose expansion phase; a djustment to Week 12 visit window and 
clarification for Week 12 assessment timing; revision to reflect current indication for 
enzalutamide throughout; clarifi cation of stud y populations ; clarification of bone 
progression definition . 
Other minor clarifications and corrections of inadvertent errors were also added.   
List of Specific Changes:
Throughout this section, added text has been bolded and deleted text had been shown 
with strikethrough.  The remaining text has been added to provide context for changes.
Synopsis –Study Rationale: 
Rationale for Change: 
Revision to reflect currently  approved indication for enzalutamide.
2013N172718_04 CONFIDENTIA L
200331
217Previous text:
Therapeutic approa ches that simultaneously inhibit both the androgen receptor (AR) pathway and 
the PI3K pathway may be more effective than inhibition of either pathway alone in mCRPC.  
Enzalutamide is an AR inhibitor indicated for the treatment of patients with mCRPC who ha ve 
previously received docetaxel.  The proposed Phase I study will evaluate the safety and tolerability, 
pharmacokinetics (PK), and clinical activity to determine the recommended Phase II dose (RP2D) 
and regimen of [COMPANY_004]2636771 in combination with enzalutami de given orally in adult male subjects 
with mCRPC.
Revised text: 
Therapeutic approaches that simultaneously inhibit both the androgen receptor (AR) pathway and 
the PI3K pathway may be more effective than inhibition of either pathway alone in mCRPC.  
Enza lutamide is an AR inhibitor indicated for the treatment of patients with mCRPC who have 
previously received docetaxel .  The proposed Phase I study will evaluate the safety and tolerability, 
pharmacokinetics (PK), and clinical activity to determine the reco mmended Phase II dose (RP2D) 
and regimen of [COMPANY_004]2636771 in combination with enzalutamide given orally in adult male subjects 
with mCRPC.
Synopsis –Secondary Hypothesis: 
Rationale for Change: 
Update of stud y population in hy pothesis wording
Previous text:
Secondary Hypothesis:   The addition of a targeted PI3K pathway inhibitor ([COMPANY_004]2636771) to 
enzalutamide can limit mCPRC progression in a clinically meaningful way for at least 12 weeks.  
The null hypothesis is that the 12 -week non -progressive disease (PD) rate is not attractive ( ≤5%).  
The alternative hypothesis is that the rate is clinically meaningful and, therefore, the compound 
warrants further development ( ≥30%).  This hypothesis will be tested for Part 2 of the study only. 
Revised text: 
Secondary Hy pothesis:   The addition of a targeted PI3K pathway inhibitor ([COMPANY_004]2636771) to 
enzalutamide can limit mCPRC progression in a clinically meaningful way for at least 12 weeks.  
The null hypothesis is that the 12 -week non -progressive disease (PD) rate is not at tractive ( ≤5%).  
The alternative hypothesis is that the rate is clinically meaningful and, therefore, the compound 
warrants further development ( ≥30%).  This hypothesis will be tested for Part 2 of the study, only 
combining eligible subjects from Part 1.
Syno psis –Primary Objectives: 
Rationale for Change: 
Changes to the abbreviations used in this section, by  [CONTACT_301221] s first 
instance in the s ynopsis. These included writing out AE (Adverse Events), SAEs (Serious 
2013N172718_04 CONFIDENTIA L
200331
218Adverse Events), DLTs (Do se Limiting Toxicities, ECGs (Electrocardiograms) and BP 
(Blood Pressure). Adjustment to efficacy  endpoint wording. 
Previous text:
Non-PD rate for 12 weeks according to 2PCWG2 criteria (either by [CONTACT_393] 1.1, PSA 
progression, and/or progression in bone).
Revised text: 
Non-PD rate for 12 weeks according to 2PCWG2 criteria (either by R esponse Evaluation
Criteria In SolidTumors [ RECIST ]1.1, or progression in bone orProstate Specific
Antigen [PSA]progression with accompanying progression by [CONTACT_393] 1.1 or b one 
scan when baseline radiological or bone disease present or PSA progression if no 
other baseline disease ).
Synopsis –Secondary Objectives: 
Rationale for Change: 
Deletion of wording associated with how additional clinical activity  was to be measured 
with less defined endpoints. Addition new secondary  objective and endpoints. 
Previous text: 
To evaluate the clinical activity of oral 
[COMPANY_004]2636771 + enzalutamide in the 
treatment of mCRPC (PTEN deficient)PSA as defined in PCWG2 guidelines 
and RECIST 1.1 re sponse.
Revised text: 
To evaluate the clinical activity of oral 
[COMPANY_004]2636771 + enzalutamide in the 
treatment of mCRPC (PTEN deficient)PSA50 response rate defined as the 
percent of subjects achieving PSA50 
at 12 weeks or thereafter (PSA50 is 
≥50% decrease in PSA from baseline)
Objective Response Rate (ORR) 
defined as complete response (CR) 
rate plus partial response (PR) rate 
per RECIST 1.1 
Time to PSA progression according 
to PCWG2 criteria
Time to radiologica l progression 
according to PCWG2 criteria (either 
by [CONTACT_393] 1.1, and/or progression in 
bone)
Radiological progression free 
survival (rPFS) per RECIST1.1 and/or 
bone scans
PSA as defined in PCWG2 guidelines 
and RECIST 1.1 response.
2013N172718_04 CONFIDENTIA L
200331
219Synopsis –Dose escal ation Cohort Expansion: 
Rationale for Change: 
Due to possibility of multiple doses being explored in dose expansion, updated wording 
to clarify  dose escalation population and how maximum tolerated dose will be defined. 
Previous text: 
Cohort Expansion: Selected dose levels may enroll up to 12 additional subjects to ensure a 
sufficient number of subjects enrolled to assess PK and/or safety.  The MTD will be the 
recommended dose combination for future Phase II studies unless there is a lower dose of 
[COMPANY_004]26 [ZIP_CODE] that provides adequate PK exposure and biologic activity with superior tolerability.
Revised text: 
Cohort Expansion:  Selected dose levels may enroll up to 12 additional subjects to ensure a 
sufficient number of subjects enrolled to assess PK and/or safety.  The MTD may willbe the 
recommended dose combination for future Phase II studies unless there is a lower dose of 
[COMPANY_004]2636771 that provides adequate PK exposure and biologic activity with superior tolerability. 
The final decision will be based on t he totality of data.   
Synopsis –Dose Expansion Phase: 
Rationale for Change: 
Clarification that multiple doses may  be explored in the dose expansion phase. 
Previous text: 
This phase of the study will evaluate the long term safety of the combination tr eatment as well as 
the 12 -week non -progressive disease (PD) rate of the combination treatment in subjects with 
mCPRC.  Approximately [ADDRESS_367997] assigned to receive 
[COMPANY_004]2636771 in combination with enzalutamide.
Revised tex t: 
This phase of the study will evaluate the long term safety of the combination treatment as well as 
the 12 -week non -progressive disease (PD) rate of the combination treatment in subjects with 
mCPRC.  Approximately [ADDRESS_367998] assigned to receive 
[COMPANY_004]2636771 in combination with enzalutamide. To confirm dose(s) identified during dose 
escalation, multiple dose levels of [COMPANY_004]2636771 in combination with enzalutamide may be 
examined during dose expansion, with each dose level co hort enrolling up to 20 subjects. 
Using the totality of safety, PK and clinical activity data, the RP2D will be confirmed from 
the dose level(s) which are examined in the dose expansion phase.
Synopsis –Number of Subjects Study Design: 
2013N172718_04 CONFIDENTIA L
200331
220Rationale for Cha nge: 
Updated of the potential number of subjects due to possibility  of multiple dose expansion 
cohorts and clarification of wording due to combination of dose escalation and expansion 
populations.
Previous text: 
A total of approximately [ADDRESS_367999] completed 12 weeks of treatment. The sample 
size planned for the Dose Expansion Phase is not driven by [CONTACT_301222].  
Revised text:
A total of approximately [ADDRESS_368000] s to combination therapy for an 
extended period of time.  
Synopsis –Inclusion Criteria 11: 
Rationale for Change: 
Due to updated changes for calcium and bone markers adjusted the Other section of the 
tests in this criteria and updated footnote, b y addi ng footnote 6.
2013N172718_04 CONFIDENTIA L
200331
221Previous text:
Other
Serum Phosphate6 WNL
Serum Calcium (corrected) WNL
6.Per CTCAE v4.0, Grade 1 hypophosphatemia is <LLN –2.5 mg/dL (<LLN -0.8 mmol/L
Revised text: 
Other
Serum Phosphate6 WNL
Serum Calcium6(corrected)
Ionized Calcium6
Vitamin D6: 25-OH D and 
1,25-OH2 DWNL
WNL
WNL
6. Per CTCAE v4.0, Grade 1 hypophosphatemia is <LLN –2.5 mg/dL (<LLN   0.8 mmol/ Vitamin D 
supplementation may be added to achieve values WNL. Calcium supplements should be added for 
subjects with calci um values near the lower normal limit. 
Synopsis –Safety Assessments: 
Rationale for change: 
Clarification of labs required for stud y based on emerging safet y data. 
Previous text:
Clinical chemistry: blood urea nitrogen, creatinine, glucose (fasting), s odium, potassium, chloride, 
carbon dioxide, calcium, aspartate aminotransferase (AST), ALT, alkaline phosphatase, total 
protein, albumin, uric acid and total/direct bilirubin, phosphorus, and magnesium.
Revised text: 
Clinical chemistry: blood urea nitrog en, creatinine, glucose (fasting), sodium, potassium, chloride, 
carbon dioxide, calcium (serum and ionized), vitamin D , aspartate aminotransferase (AST), ALT, 
alkaline phosphatase, total protein, albumin, uric acid and total/direct bilirubin, phosphorus, a nd 
magnesium.
Synopsis –Statistical Methods: 
Rationale for change: 
Revis ion of hypotheses to allow anal yses on combined dose escalation and expansion 
cohorts. 
Previous text:
Hypothesis:  No formal statistical hypotheses will be tested in the Dose Escal ation Phase.  All 
analyses will be descriptive and exploratory for this phase.
A targeted PI3K pathway inhibitor ([COMPANY_004]2636771) added to enzalutamide will be tested to see if 
mCPRC progression can be limited in a clinically meaningful way for at least 12 weeks.  The null 
2013N172718_04 CONFIDENTIA L
200331
222hypothesis is that the 12 -week non -PD ra te is not attractive ( ≤5%).  The alternative hypothesis is 
that the rate is clinically meaningful and therefore, the compound warrants further development 
(≥30%). 
For the Dose Expansion Phase, utilizing a null and alternative hypothesis of 5% and 30% 
respectively, a maximum of 20 subjects will be enrolled, with a minimum enrollment of 10 subjects. 
With an actual type I error rate (α) of 0.065 and 94.2% power, the design has stoppi[INVESTIGATOR_301138].  
Number of Subjects 
EnrolledThis Number of  
Responses1to Stop Early 
for Futility
10 0
11 0
12 0
13 0
14 0
15 0
16 1
17 1
18 1
19 1
20 2
Abbreviation: PCWG2, Prostate Cancer Working Group 2
1. Response for the purpose of futility is defined as lack of disease progression at 12 weeks ac cording to 
PCWG2 criteria.
Revised text: 
Hypothesis:  No formal statistical hypotheses will be tested in the Dose Escalation Phase.  All 
analyses will be descriptive and exploratory for this phase.
A targeted PI3K pathway inhibitor ([COMPANY_004]2636771) added to enzalutamide will be tested to see if 
mCPRC progression can be limited in a clinically meaningful way for at least 12 weeks.  The null 
hypothesis is that the 12 -week non -PD rate is not attractive ( ≤5%).  The alternative hypothesis is 
that the rate is clini cally meaningful and therefore, the compound warrants further development 
(≥30%). 
For the Dose Expansion Phase, clinical activity will be evaluated per dose level if more than 
one dose is examined. A targeted PI3K pathway inhibitor ([COMPANY_004]2636771) added to 
enzalutamide will be tested to see if mCPRC progression can be limited in a clinically 
meaningful way for at least 12 weeks.  The null hypothesis is that the 12 -week non -PD rate 
is not attractive ( ≤5%).  The alternative hypothesis is that the rate is clinic ally meaningful 
and therefore, the compound warrants further development ( ≥30%). All evaluable subjects 
treated during dose escalation and in the dose expansion Phase will be included in 
analyses. utilizing a null and alternative hypothesis of 5% and 30% r espectively, a A maximum of 
20 subjects per dose level will may be enrolled, with a minimum enrollment of 10 subjects. With an 
actual type I error rate (α) of 0.065 and 94.2% power, the design has stoppi[INVESTIGATOR_301139] .  
2013N172718_04 CONFIDENTIA L
200331
223Number of Subjects 
EnrolledThis Number of  
Responses1to Stop Early 
for Futility
10 0
11 0
12 0
13 0
14 0
15 0
16 1
17 1
18 1
19 1
20 2
Abbreviation: PCWG2, Prostate Cancer Working Group [ADDRESS_368001] or bone progression in addition to PSA progression to be determined a disease progressor.
Synopsis –Statistical Methods Study Populations: 
Rationale for change: 
Revised and added population to clarify  between safet y and clinical activit y populations 
and to define the evaluable population for endpoint analy ses. 
Previous text: 
The All Treated Populatio nis defined as all subjects who receive at least one dose of 
[COMPANY_004]2636771.  Safety, clinical activity, and evaluation of non -PD rate in the Dose Expansion Phase 
will be evaluated based on this analysis population. 
The PK Population will consist of all subj ects from the All Treated Population for whom at least 
one PK sample is obtained and analyzed.
The All Screened Population is defined as all subjects for whom pre -screening consent is 
obtained.
Efficacy Analyses:   The All Treated Population will be used fo r the analysis of efficacy data, and 
summarized separately for each part of the study.  Response data per 2PCWG2 and RECIST 1.1 
guidelines will be reported.  Further details about efficacy analyses will be outlined in detail in the 
RAP.
Safety Analyses:   The All Treated Population will be used for the analysis of safety data. All 
serially collected safety endpoints (e.g., laboratory tests, vital signs, ECGs) will be summarized 
according to the scheduled, nominal visit at which they were collected and across all on -treatment 
time points using a “worst -case” analysis. 
2013N172718_04 CONFIDENTIA L
200331
224Revised text: 
The All Treated Safety Population is defined as all subjects who receive at least one dose of 
[COMPANY_004]2636771 or Enzalutamide .  Safety, clinical activity, and evaluation of non PD rat e in the Dose 
Expansion Phase will be evaluated based on this analysis population. 
The All Treated Clinical Activity Population is defined as all subjects who received at least 
one dose of [COMPANY_004]2636771. Clinical activity and evaluation of non -PD rate will be based on 
this analysis population.  This will include subjects from both dose escalation and dose 
expansion. 
The All Evaluable Population is defined as all subjects from All Treated Clinical Activity 
Population who have at least one post -dose disease assessment and have been exposed to 
study drug for at least [ADDRESS_368002] one 
PK sample is obtained and analyzed.
The All Screened Population is defined as all subjects for whom pre -screening consent is 
obtained.
Efficacy Analyses:  The All Treated Clinical Activity Population will be used for the analysis of 
efficacy data, and will be summarized separately for each part of the study per dose level . 
Response data per 2PCWG2 and RECIST 1.1 guidelines will be reported.  Further details about 
efficacy analyses will be outli ned in detail in the RAP.
Safety Analyses:  TheAll Treated Safety Population will be used for the analysis of safety data. 
All serially collected safety endpoints (e.g., laboratory tests, vital signs, ECGs) will be summarized 
according to the scheduled, n ominal visit at which they were collected and across all on -treatment 
time points using a “worst -case” analysis.
Section 1.3 –Enzalutamide (Xtandi): 
Rationale for change: 
Updated section to reflect currentl y approved indication for enzalutamide. Update d 
citation in the body  of the text and added the citation in the Reference section. 
Previous text: 
Enzalutamide (Xtandi) is an orall y bioavailable, AR signalling inhibitor approved in the 
[LOCATION_002] (US) and the European Union for the treatment of pat ients with mCRPC 
who have previously  received treatment with docetaxel [ Xtandi , 2013].  Enzalutamide 
acts on several steps in the AR signaling pathway , including competitive inhibition of 
androgen binding to ARs and inhibition of AR nuclear translocation a nd its interaction 
with deox yribonucleic acid (DNA).  A major metabolite, N -desmeth yl enzalutamide, 
exhibited similar in vitro activity  to enzalutamide.
2013N172718_04 CONFIDENTIA L
200331
225Refer to to the approved US Food and Drug Administration (FDA) prescribing 
information [ Xtandi , 2013] o r the Xtandi Prescribing Information for the area where it is 
approved for further details. ].
Revised text: 
Enzalutamide (Xtandi) is an orall y bioavailable, AR signalling inhibitor approved in the 
[LOCATION_002] (US) and the European Union for the treatmen t of patients with mCRPC 
who have previously  received treatment with docetaxel [Xtandi , 201 36].  Enzalutamide 
acts on several steps in the AR signaling pathway , including competitive inhibition of 
androgen binding to ARs and inhibition of AR nuclear transl ocation and its interaction 
with deox yribonucleic acid (DNA).  A major metabolite, N -desmeth yl enzalutamide, 
exhibited similar in vitro activity  to enzalutamide.
Refer to to the approved US Food and Drug Administration (FDA) prescribing 
information [ Xtandi , 201 36] or the Xtandi Prescribing Information for the area where it is 
approved for further details. ].
Section 1.3.1 –Clinical Safety, Pharmacokinetic Data, and Clinical Activity of 
Enzalutamide: 
Rationale for change: 
Updated citation in the body  of th e text and added the citation in the Reference section. 
Previous text: 
Clinical Response.  In a randomized, double -blinded, Phase III clinical trial comparing 
enzalutamide with placebo in subjects with mCRPC who had progressed following 
docetaxel -based c hemotherapy , enzalutamide prolonged overall survival b y 5 months 
(median survival of 18.4 months with enzalutamide [n=800] compared to 13.6 months 
with placebo [N=399])  which is statistically  and clinically  significant [ Xtandi , 2013].  
Enzalutamide is app roved in the US, Canada, the European Union and others (refer to 
Xtandi Prescribing Information in the relevant jurisdiction).  Recently , enzalutamide has 
also been shown to improve survival (32.4 months vs. 30.2 months) in chemotherap y-
naïve subjects with advanced prostate cancer in a separate Phase III, randomized, 
placebo -controlled study  [Beer, 2014].
Refer to the approved US FDA prescribing information [ Xtandi , 2013] or the Xtandi 
Prescribing Information for the area where it is approved for further de tails.
Revised text: 
Clinical Response.  In a randomized, double -blinded, Phase III clinical trial comparing 
enzalutamide with placebo in subjects with mCRPC who had progressed following 
docetaxel -based chemotherap y, enzalutamide prolonged overall surviva l by 5 months 
(median survival of 18.4 months with enzalutamide [n=800] compared to 13.6 months 
with placebo [N=399])  which is statistically  and clinically  significant [ Xtandi , 201 36].  
Enzalutamide is approved in the US, Canada, the European Union and ot hers (refer to 
2013N172718_04 CONFIDENTIA L
200331
226Xtandi Prescribing Information in the relevant jurisdiction).  Recently , enzalutamide has 
also been shown to improve survival (32.4 months vs. 30.2 months) in chemotherap y-
naïve subjects with advanced prostate cancer in a separate Phase III, randomized, 
placebo -controlled study  [Beer, 2014].
Refer to the approved US FDA prescribing information [ Xtandi , 201 36] or the Xtandi 
Prescribing Information for the area where it is approved for further details.
Section 1.4 –Summary of Risk Management: 
Rationale for change: 
Updated citation in the body  of the text and added the citation in the Reference section. 
Previous text: 
Refer to the [COMPANY_004]2636771 IB [GlaxoSmithKline Document Number 2011N117133_01 ] 
for detailed information concerning the biology , pharmacology , PK and safety .  Refer to 
approved US FDA prescribing information [ Xtandi , 2013] or the Xtandi Prescribing 
Information for the area where it is approved for additional information.
Revised text: 
Refer to the [COMPANY_004]2636771 IB [GlaxoSmithKline Doc ument Number 2011N117133_01 ] 
for detailed information concerning the biology , pharmacology , PK and safety .  Refer to 
approved US FDA prescribing information [ Xtandi , 201 36] or the Xtandi Prescribing 
Information for the area where it is approved for additio nal information.
Section [IP_ADDRESS] Risk Assessment -[COMPANY_004]2636771: 
Rationale for change: 
Section was updated to reflect updated information and to reflect changes in the core 
information sheet. 
Previous text: 
Renal : Degenerative changes were observed in th e kidney s of rats and dogs at 
100mg/kg/day  or 1000 mg/kg/day , including cellular and tubular changes, with 
chemistry  and urinal ysis findings.  Grade 3, treatment -related h ypophosphatemia and 
hypocalcaemia have been observed in the FTIH study  P3B115717.  T here have been 2 
reports of acute kidney  injury  (grade 2 and 3) in subjects who received [COMPANY_004]2636771 in 
Study  200331.  Since it is possible that [COMPANY_004]2636771 may  contribute to acute kidney  
injury , renal events should be closel y monitored.  Medical history  will be collected and, 
physical examination and clinical laboratory  tests will be measured frequently  during 
therap y to monitor for potential toxicity .  Guidelines will be implemented including dose 
modification and discontinuation (Section 7.3.1 ) for the man agement of renal 
insufficiency  or renal -related events considered to be related to stud y treatment.  I t is 
recommended that patients be well hy drated and avoid the use of NSAIDs.
2013N172718_04 CONFIDENTIA L
200331
227Revised text: 
Renal and electrolytes : Degenerative changes were observed in the kidneys of rats and 
dogs at 100 mg/kg/day  or 1000 mg/kg/day , including cellular and tubular changes, with 
chemistry  and urinal ysis findings.  There have been serious, treatment -related reports 
of acute kidney injury, hypophosphatemia and hypocalcaemia in [COMPANY_004]2636771 
clinical trials.  Renal events should be closely monitored.  It is recommended that 
patients be well -hydrated and avoid the use of NSAIDs.  Calcium and Vitamin D 
levels will be monitored.  Consider supplements in those with calcium levels at or 
near the lower normal limit and those with low Vitamin D levels.  Grade 3, treatment -
related h ypophosphatemia and h ypocalcaemia have been observed in the FTIH study 
P3B115717.  There have been 2 reports of acute kidney  injury  (grade 2 and 3) in subjects
who received [COMPANY_004]2636771 in Study  200331.  Since it is possible that [COMPANY_004]2636771 may  
contribute to acute kidney injury , renal events should be closely  monitored. Medical 
history  will be collected and, phy sical examination and clinical laboratory  tests will be 
measured frequently  during therapy  to monitor for potential toxicity .  Guidelines will be 
implemented including dose modification and discontinuation (Section 7.3.1 ) for the 
management of renal insufficiency ,orrenal -related events or electrolyte abnor malities
considered to be related to study  treatment. It is recommended that patients be well 
hydrated and avoid the use of NSAIDs.
Section 1.5.1 –Rationale for Study
Rationale for change: 
Updated citation in the body  of the text and added the citation in the Reference section. 
Previous text: 
Despi[INVESTIGATOR_301054], relapses are 
inevitable and mCRPC carries considerable morbidity  along with shortened survival.  
Previous studies have indicated the importance of the PI 3K pathway  in prostate cancer.  
Therapeutic approaches that simultaneously  inhibit both the AR and PI 3K pathway s may  
be more effective than inhibition of either pathway  alone in mCRPC.  Enzalutamide is an 
AR inhibitor indicated for the treatment of patients with mCRPC who have previously  
received docetaxel.  This study  is designed to investigate whether the PI3K pathway  
inhibitor can be co -administered safely  with enzalutamide, thus allowing further 
investigation of their ability  to reverse resist ance to this AR inhibitor.  Future studies may  
also assess whether the combination can delay  the onset of resistance in enzalutamide -
naïve CRPC or increase the response rate to enzalutamide.
Revised text: 
Despi[INVESTIGATOR_301140], relapses are 
inevitable and mCRPC carries considerable morbidity  along with shortened survival.  
Previous studies have indicated the importance of the PI 3K pathway  in prostate cancer.  
Therapeutic approaches that simultaneously  inhibit both the AR and PI 3K pathway s may  
be more effective than inhibition of either pathway  alone in mCRPC.  Enzalutamide is an 
AR inhibitor indicated for the treatment of patients with mCRPC who have previously 
2013N172718_04 CONFIDENTIA L
[ADDRESS_368003]  
inhibitor can be co -administered safely  with enzalutamide, thus allowing further 
investigation of their ability  to reverse resistance to this AR inhibitor.  Future studies may  
also assess whether the combination can delay  the onset of resistance in enzalutamide -
naïve CRPC or increase the response rate to enzalutamide.
Section 2.1 –Hypothesis; Secondary Hypothesis: 
Rationale for Change: 
Update of stud y population in hy pothesis wording
Previous text: 
Secondary  Hypothesis:   The addition of a targeted PI 3K pathway  inhibitor 
([COMPANY_004]2636771) to enzalutamide can limit mCPRC progression in a clinically meaningful 
way for at least 12 weeks.  The null hy pothesis is that the 12 -week non PD rate is not 
attractive ( ≤5%).  The alternativ e hypothesis is that the rate is clinicall y meaningful and, 
therefore, the compound warrants further development ( ≥30%).  This h ypothesis will be 
tested for Part 2 of the study  only. 
Revised text: 
Secondary  Hypothesis:   The addition of a targeted PI 3K pa thway  inhibitor 
([COMPANY_004]2636771) to enzalutamide can limit mCPRC progression in a clinically meaningful 
way for at least 12 weeks.  The null hy pothesis is that the 12 -week non PD rate is not 
attractive ( ≤5%).  The alternative hy pothesis is that the rate is cli nicall y meaningful and, 
therefore, the compound warrants further development ( ≥30%).  This h ypothesis will be 
tested for Part 2 of the study  onlyusing a combination of data provided in both the 
dose escalation and dose expansion phases. 
Section 2.2 Objec tives and Endpoints –Primary Objectives: 
Rationale for Change: 
Adjustment to efficacy  endpoint wording. 
Previous text:
Non-PD rat e for 12 weeks according to PCWG2 criteria (either by  [CONTACT_23603] 1.1, 
PSA progression, and/or progression in bone).
Revised tex t: 
Non-PD rate for 12 weeks according to PCWG2 criteria (either b y RECIST 1.1, 
or progression in bone orPSAprogression with accompanying progression by 
[CONTACT_393] 1.1 or bone scan when baseline radiological or bone disease present 
or PSA progression if no o ther baseline disease ).
2013N172718_04 CONFIDENTIA L
200331
229Section 2.2 Objectives and Endpoints –Secondary Objectives: 
Rationale for Change: 
Deletion of wording associated with how additional clinical activity  was to be measured 
with less defined endpoints. Addition new secondary  object ive and endpoints. 
Previous text: 
To evaluate the clinical activity of oral 
[COMPANY_004]2636771 + enzalutamide in the 
treatment of mCRPC (PTEN deficient)PSA as defined in PCWG2 guidelines 
and RECIST 1.1 response.
Revised text: 
To evaluate the clinical activit y of oral 
[COMPANY_004]2636771 + enzalutamide in the 
treatment of mCRPC (PTEN deficient)PSA50 response rate defined as the 
percent of subjects achieving PSA50 
at 12 weeks or thereafter (PSA50 is 
≥50% decrease in PSA from baseline)
Objective Response Rate (ORR) 
defined as complete response (CR) 
rate plus partial response (PR) rate 
per RECIST 1.1 
Time to PSA progression according 
to PCWG2 criteria
Time to radiological progression 
according to PCWG2 criteria (either 
by [CONTACT_393] 1.1, and/or progression in 
bone)
Radiologi cal progression free 
survival (rPFS) per RECIST1.1 and/or 
bone scans
PSA as defined in PCWG2 guidelines 
and RECIST 1.1 response.
Section 3 –Investigation Plan : 
Rationale for Change: 
Due to possibility of multiple doses being explored in dose expansi on, updated wording 
to clarify  dose escalation population and how maximum tolerated dose will be defined. 
Previous text: 
In the Dose Escalation Phase, subjects will be enrolled into dose -finding cohorts to 
evaluate the safet y and PK to guide the selectio n of the RP2D of [COMPANY_004]2636771.  Dosing 
decisions will be based on all available data at the end of each DLT reporting period (the 
first 28 day s of combination treatment).  Decisions for dose determination for subsequent 
2013N172718_04 CONFIDENTIA L
200331
230cohorts will be documented and maintai ned b y each site and in the [COMPANY_004] Trial Master 
Files (TMF).
In the Dose Expansion Phase, subjects will be assigned to receive [COMPANY_004]2636771 at doses 
identified at or below the MTD in the Dose Escalation Phase while continuing treatment 
with enzalutamide to eval uate the long -term safety  of the combination as well as the 12 -
week non -PD rate.
Clinical Response Assessments: The determination of clinical response, including 
disease progression, will be assessed b ythe PCWG2 criteria (see Section 8.8.2 ).  The 
assessme nt of the 12 week non -PD-rate in the Dose Expansion Phase will also be 
determined b y 2PCWG2 criteria (either b y RECIST 1.1, PSA progression, and/or 
progression in bone).
Revised text: 
In the Dose Escalation Phase, subjects will be enrolled into dose -findi ng cohorts to 
evaluate the safet y and PK to guide the selection of the MTD RP2D of [COMPANY_004]2636771.  
Dosing decisions will be based on all available data at the end of each DLT reporting 
period (the first 28 day s of combination treatment).  Decisions for dose d etermination for 
subsequent cohorts will be documented and maintained b y each site and in the [COMPANY_004] Trial 
Master Files (TMF).
In the Dose Expansion Phase, subjects will be assigned to receive [COMPANY_004]2636771 at doses 
identified at or below the MTD in the Dose Esc alation Phase while continuing treatment 
with enzalutamide to evaluate the long -term safety  of the combination as well as the 12 -
week non -PD rate. This may include multiple dose levels in order to establish the 
RP2D of the combination treatment at the conc lusion of combination treatment in 
any dose level. 
Clinical Response Assessments: The determination of clinical response, including 
disease progression, will be assessed b ythe PCWG2 criteria (see Section 8.8.2 ).  The 
assessment of the 12 week non -PD-ratein the Dose Expansion Phase will also be 
determined b y 2PCWG2 criteria (either by  [CONTACT_393] 1.1, PSA progression, and/or 
progression in bone).
Section 3.3 –Discussion of Study Design: 
Rationale for change: 
Updated citation in the body  of the text and added the citation in the Reference section. 
Previous text:
The dosing of enzalutamide will be administered at the US FDA approved dose (refer to 
the Prescribing Information for enzalutamide [ Xtandi , 2013].  Study  treatment will 
continue until there is no long er clinical benefit (see Section 5.2), in the opi[INVESTIGATOR_1070], or until an unacceptable AE (including stoppi[INVESTIGATOR_873] 
7.2), withdrawal of consent, permanent discontinuation of study  treatment, or death 
occurs.  Investigato rs will use the PCWG2 criteria to determine clinical response to each 
treatment.
2013N172718_04 CONFIDENTIA L
200331
231Revised text: 
The dosing of enzalutamide will be administered at the US FDA approved dose (refer to 
the Prescribing Information for enzalutamide [ Xtandi , 201 36].  Study  treatment will 
continue until there is no longer clinical benefit (see Section 5.2), in the opi[INVESTIGATOR_1070], or until an unacceptable AE (including stoppi[INVESTIGATOR_873] 
7.2), withdrawal of consent, permanent discontinuation of stud y treatment, or death 
occurs.  Investigators will use the PCWG2 criteria to determine clinical response to each 
treatment.
Section 3.4 Dose Escalation Phase: 
Rationale for Change: 
Due to possibility of multiple doses being explored in dose expansion, upd ated wording 
to clarify  dose escalation population and how maximum tolerated dose will be defined. 
Previous text:
In the Dose Escalation Phase, the dose of [COMPANY_004]2636771 will follow a modified 3+3 dose 
escalation procedure to evaluate the safet y and PK for e ach combination dose level and to 
guide selection of the RP2D of the combination.  
Revised text: 
In the Dose Escalation Phase, the dose of [COMPANY_004]2636771 will follow a modified 3+3 dose 
escalation procedure to evaluate the safet y and PK for each combination dose level and to 
guide selection of the RP2D of the combination dose for dose expansion .  
Sections 3.4.5, 3.5 and Section 3.6 (new section) –Recommended Phase II dose/Dose 
Expansion Phase: 
Rationale for change: 
Due to possibility of multiple doses bei ng explored in dose expansion, updated wording 
to clarify  dose escalation population and how maximum tolerated dose will be defined. 
Movement of Section 3.4.5. under new section 3.6, thereb y updated all remaining Section 
3 heading numbers. 
Previous text: 
Section 3.4.[ADDRESS_368004] dose of [COMPANY_004]2636771 explored (at or below 
MTD) in the Dose Escalation Phase that provides adequate PK exposure and biologic 
activity  with a superior tolerability  profile.
2013N172718_04 CONFIDENTIA L
[ADDRESS_368005] been determined in the Dose Escalation Phase.  Up to 20 additional subjects 
may be enrolled to better characterize the safet y profile, PK, and clinical activity  of the 
recommended doses of the combination of [COMPANY_004]2636771 + enzalutamide for future 
studies. One or more combination doses may  be explored in the Dose Expansion Phase 
based the MTD and RP2D identified in the Dose Escalation Phase of the study .
In the Dose Expansion Phase, final anal yses will occur [ADDRESS_368006] 
not completed the treatment phase of the stud y (see Section 5.2)at the time of the final 
analysis may  be transferred to a continued access study , if available.
Revised text: 
Section 3.4.[ADDRESS_368007] dose of [COMPANY_004]2636771 explored (at or below 
MTD) in the Dose Escalat ion Phase that provides adequate PK exposure and biologic 
activity  with a superior tolerability  profile.
Section 3.5 Dose Expansion Phase
Enrollment in the Dose Expansion Phase of the study  may  begin once a suspected the
MTD and RP2D hasvebeen determined in the Dose Escalation Phase. Up to 20 
additional subjects per dose level may be enrolled to better characterize the safet y 
profile, PK, and clinical activity  of the recommended doses of the combination of 
[COMPANY_004]2636771 + enzalutamide for future studies. One or more combination doses may  be 
explored in the Dose Expansion Phase based onthe MTD and RP2D identified in the 
Dose Escalation Phase of the study . To fully evaluate additional combination doses, 
up to [ADDRESS_368008] 
not completed the treatment phase of the stud y (see Section 5.2) at the time of the final 
analysis may  be transferred to a continued access study , if available.
Section 3.[ADDRESS_368009] dose of [COMPANY_004]2636771 explored (at or below 
MTD) in the Dose Escalation Phase that provides adequate PK exposure and biologic 
activity  with a superior tolerability  profile. If multiple dose levels are explored in dose 
expansion, the RP2D will be based on the totality of data . 
2013N172718_04 CONFIDENTIA L
200331
233Section 3.7.1 –Evaluation of Futility: 
Rationale for Change: 
Upda te of timing of futility  analy sis to occur when adequate subjects are enrolled. Update 
to the efficacy  endpoint wording used for futility  predictive probability  design. 
Previous text: 
Futility  will be evaluated in the Dose Expansion Phase of the study .  The methodology  is 
based on the predictive probability  of success if enrollment continues to 20 subjects [ Lee, 
2008] . The predictive probability  design is similar to a Green -Dahlberg design in that it 
allows for earl y stoppi[INVESTIGATOR_16589]. The differences are that the predictive probability  
design allows for evaluation of stoppi[INVESTIGATOR_301113], rather than at only  two 
stages, once a minimum number of subjects are evaluable. In this particular study , we 
will stop only  for futility . While the two designs have similar ty pe I and t ype II error 
rates, the probability  of early  termination is greater with the predictive probability  design.
Number of Subjects 
EnrolledThis Number of  
Responses1to Stop Early 
for Futility
10 0
11 0
12 0
13 0
14 0
15 0
16 1
17 1
18 1
19 1
20 2
Abbreviation: PCWG2, Prostate Cancer Working Group 2; PSA, prostate -specific antigen; RECIST, Response 
Evaluation Criteria in Solid Tumors
1. Response for the purpose of futility is defined as lack of disease progression a t 12 weeks according to 
PCWG2 criteria (either by [CONTACT_393] 1.1, PSA progression and/or progression in bone).
Revised text: 
Futility  will be evaluated when there is adequate enrollment in the Dose Expansion 
Phase of the stud y.  The methodology  for evaluation of futility is based on the predictive 
probability  of success if enrollment continues to 20 subjects per dose level [Lee, 2008] 
per dose level . The predictive probability  design is similar to a Green -Dahlberg design in 
that it allows for earl y stoppi[INVESTIGATOR_43240] r futility . The differences are that the predictive 
probability  design allows for evaluation of stoppi[INVESTIGATOR_301113], rather than at 
only two stages, once a minimum number of subjects are evaluable. In this particular 
study , we will stop only  for futility . While the two designs have similar ty pe I and ty pe II 
error rates, the probability of earl y termination is greater with the predictive probability 
design.
2013N172718_04 CONFIDENTIA L
200331
234Number of Subjects 
EnrolledThis Number of  
Responses1to Stop Early 
for Futility
10 0
11 0
12 0
13 0
14 0
15 0
16 1
17 1
18 1
19 1
20 2
Abbreviations: PCWG2, Prostate Cancer Working Group 2; PSA, prostate -
specific antigen; RECIST, Response Evaluation Criteria in Solid Tumors
1. Response for the purpose of futility is defined as l ack of disease 
progression at 12 weeks according to PCWG2 criteria. (either by 
[CONTACT_393] 1.1, PSA progression and/or progression in bone ).PSA 
progression in subjects with baseline radiological or bone 
disease will require RECIST or bone progression in additio n to 
PSA progression to be determined a disease progressor.
Section 4.1.1.  –Number of Subjects : 
Rationale for Change: 
Updated of the potential number of subjects due to possibility  of multiple dose expansion 
cohorts and clarification of wording due to combination of dose escalation and expansion 
populations.
Previous text: 
A total of approximately  44 subjects will be enrolled in this study .  
Dose Expansion Phase:  In the Dose Expansion Phase, it is estimated that approximately  
[ADDRESS_368010] 
completed 12 weeks of treatment (see Section 3.7.1 ). 
The sample size planned for the Dose Expansion Phase is not driven b y statistical 
considerations as the cohort is meant to further un derstand the safet y implications of 
enrolling subjects to combination therap y for an extended period of time.  See 
Section 13.2 for sample size assumptions.
2013N172718_04 CONFIDENTIA L
200331
235Revised text:
A total of between approximately  44and 64subjects will be enrolled in this study .  
Dose Expansion Phase:  In the Dose Expansion Phase, it is estimated that approximately  
[ADDRESS_368011] 
completed 12 weeks of treatment (see Section 3.7.1 ). This analysis may oc cur using the 
combination of the dose escalation and dose expansion population. If multiple dose 
levels of [COMPANY_004]2636771 are examined during dose expansion to establish the RP2D, 
each dose level cohort will enrol approximately 20 subjects, increasing the over all 
number of subjects targeted for enrolment in thisstudy.
The sample size planned for the Dose Expansion Phase is not driven b y statistical 
considerations as the cohort is meant to further understand the safet y implications of 
enrolling subjects to comb ination therap y for an extended period of time.  See 
Section 13.2 for sample size assumptions.
Section 4.1.2. -Inclusion Criteria
Rationale for change: 
Updated citation in the body  of the text and added the citation in the Reference section. 
Previous te xt:
Specific information regarding warnings, precautions, contraindications, AEs, and other 
pertinent information on [COMPANY_004]2636771 or enzalutamide that may  impact subject 
eligibility  is provided in the IB for [COMPANY_004]2636771 [GlaxoSmithKline Document Number 
2011N1 17133_01 ] and the Prescribing Information for enzalutamide [ Xtandi , 2013].
Revised text: 
Specific information regarding warnings, precautions, contraindications, AEs, and other 
pertinent information on [COMPANY_004]2636771 or enzalutamide that may  impact subject 
eligibility  is provided in the IB for [COMPANY_004]2636771 [GlaxoSmithKline Document Number 
2011N117133_01 ] and the Prescribing Information for enzalutamide [ Xtandi , 201 36].
Section 4.1.2. -Inclusion Criteria 11: 
Rationale for Change: 
Due to updated changes for cal cium and bone markers adjusted the Other section of the 
tests in this criteria and updated footnote, b y adding footnote 6.
Previous text:
Other
Serum Phosphate6 WNL
Serum Calcium (corrected) WNL
6.Per CTCAE v4.0, Grade 1 hypophosphatemia is <LLN –2.5 mg/dL (<LLN -0.8 mmol/L
2013N172718_04 CONFIDENTIA L
200331
236Revised text: 
Other
Serum Phosphate6 WNL
Serum Calcium6(corrected)
Ionized Calcium6
Vitamin D6: 25-OH D and 
1,25-OH2 DWNL
WNL
WNL
6.   Per CTCAE v4.0, Grade 1 hypophosphatemia is <LLN –2.5 mg/dL (<LLN   0.8 mmol/L Vitamin D 
supplementation may be added to achieve values WNL. Calcium supplements should be added for 
subjects with calcium values near the lower normal limit. 
Section 6.1 –[COMPANY_004]2636771 [COMPANY_004] Investigational Product
Rationale for Change:
In the event that there are legal changes to the way that [COMPANY_004]2636771 is interpreted, 
added additional wording to include this possibility. 
Previous text: 
The contents of the label will be in accordance with all applicable regulatory  
requirements.
Revised text: 
The contents of the label will be in accordance with all applicable regulatory  and/or legal
requirements.
Section 6.3.2. –Enzalutamide
Rationale for Change: 
Updated citation in the body  of the text and added the citation in the Reference section. 
Previous text: 
Per the p roduct prescribing information for enzalutamide [ Xtandi , 2013], the 
recommended dose of enzalutamide 160 mg (four 40 mg capsules) taken orally  once 
daily  will be administered during this study .  
Revised text: 
Per the product prescribing information for e nzalutamide [ Xtandi , 201 36], the 
recommended dose of enzalutamide 160 mg (four 40 mg capsules) taken orally  once 
daily  will be administered during this study .  
2013N172718_04 CONFIDENTIA L
200331
237Section 7.3.1 –Renal Insufficiency or Other Renal Events
Rationale for Change: 
Based on eme rging data and additional internal review, section adjusted and revised to 
adjust calcium management. 
Previous text: 
Prior to start of study  treatment, concomitant medications should be reviewed for the 
potential risk of inducing nephrotoxicity  and conco mitant medications should be 
modified if clinically  possible.
Close monitoring of serum creatinine, calcium and phosphate and treatment interruption 
for increased serum creatinine >2 mg/dL (or >0.5 mg/dL above baseline), hypocalcemia, 
and hy pophosphatemia, respectivel y, should occur.  Nephrology  consultation should also 
be considered.
Guidelines regarding the management of renal insufficiency  or renal -related events 
considered to be related to study  treatment are provided in Table 10.
Table 10 Management an d Dose Modifications for Renal Events
Hypocalcemia
(serum calcium 
Grade 2)
or
Hypophosphatemia
(serum phosphate 
Grade 3 or 
symptomatic 
Grade 2)Repeat serum calcium or phosphate level within 24 hrs of previous result
If repeat value confirms Grade 2 seru m calcium, or symptomatic Grade 
2 serum phosphate.
Immediately interrupt t reatment with [COMPANY_004]2636771
Treat as clinically indicated by [CONTACT_301211]
Obtain serum PTH level
Obtain blood sample for PK analysis, if requested (see SRM), within 
24-[ADDRESS_368012] dose (refer to Section [IP_ADDRESS] for details on PK 
sample collection)
Obtain urine samples for urine creatinine, calcium, phosphate, and 
protein at treatment interruption; repeat every 7 days
Repeat serum calcium or phosphate level ever y 7 days or more 
frequently if clinically indicated
If serum calcium fails to improve to Grade 1 or if serum phosphate fails to 
improve to asymptomatic Grade 2 within 14 days following dose 
interruption:
Permanently discontinue treatment with [COMPANY_004]2636771
Consult with [COMPANY_004] Medical Monitor
If serum calcium improves to Grade 1 or serum phosphate improves to 
asymptomatic Grade 2 or baseline, whichever is more improved within 14 
days following dose interruption:
Restart treatment with [COMPANY_004]2636771 with dose reduced by [CONTACT_37387]
Repeat serum calcium or phosphate level per Time and Events Tables 
(Section 8.1) or more frequently if clinically indicated
If decreased serum calcium or phosphate levels reoccurs after one dose 
reduction :
Repeat serum calcium or phospha te levels within 24 hrs to confirm 
2013N172718_04 CONFIDENTIA L
200331
238result
If repeat serum calcium or phosphate levels confirm decrease, 
withdraw subject from treatment/study unless there is agreement 
between investigator and [COMPANY_004] Medical Monitor that subject will 
benefit from continued tr eatment following recovery of serum 
calcium or phosphate to baseline with dose of [COMPANY_004]2636771 
further reduced one dose level.
If repeat serum calcium or phosphate fails to confirm a decrease, c ontinue 
treatment with [COMPANY_004]2636771 at same dose level without int erruption
Revised text: 
Prior to start of study  treatment, concomitant medications should be reviewed for the 
potential risk of inducing nephrotoxicity  and concomitant medications should be 
modified if clinically  possible.
Close monitoring of serum crea tinine, calcium and phosphate and treatment interruption 
for increased serum creatinine >2 mg/dL (or >0.5 mg/dL above baseline), hypocalcemia, 
and hy pophosphatemia, respectivel y, should occur.  Nephrology  consultation should also 
be considered.
Calcium sho uld be carefully managed in all subjects and especially in subjects with 
bone lesions/metastases and in those on treatments that are associated with 
hypocalcemia, including but not limited to, bisphosphanates (e.g., zoledronic acid) 
or denosumab (RANK -L inhibitor). Subjects with baseline calcium levels at or near 
the lower normal limit and those with Vitamin D below the normal limit should be 
treated with supplements.  Subjects who develop hypocalcemia should be closely 
monitored and managed per Table 10. 
Guidelines regarding the management of renal insufficiency  or renal -related events 
considered to be related to study  treatment are provided in Table 10.
Management and Dose Modifications for Renal Events
Hypocalcemia
(serum calcium 
Grade 21)
or
Hypophosph atemia
(serum phosphate 
Grade 3 or 
symptomatic 
Grade 2)Administration of oral calcium supplements to subjects with calcium 
levels at or near the lower limit of normal should be considered
For subjects with Grade1 hypocalcemia, administer oral calcium 
supplements and evaluate the need for Vitamin D supplementation.
For hypocalcemia > Grade 1, Rrepeat serum calcium and Vitamin D,and or
phosphate level within 24 hrs of previous result
If repeat value confirms >Grade 21serum calcium, or symptomatic 
Grade 2 serum phosphate.
Immediately interrupt t reatment with [COMPANY_004]2636771
Treat as clinically indicated by [CONTACT_301176] i.v. calcium gluconate (1 g/10 ml) and evaluate the 
need for Vitamin D supplementation.
Obtain serum PTH level
Obtain blood sample for PK analysis, if requested (see SRM), within 
24-[ADDRESS_368013] dose (refer to Section [IP_ADDRESS] for details on PK 
sample collection)
2013N172718_04 CONFIDENTIA L
200331
239Obtain urine samples for urine creatinine, calcium, phosphate, and 
protein at treatment interrupti on; repeat every 7 days
Repeat serum calcium or phosphate level every 7 days or more 
frequently if clinically indicated
If serum calcium fails to improve to Grade 1 WNL or if serum phosphate 
fails to improve to asymptomatic Grade 2 within 14 days following dose 
interruption:
Permanently discontinue treatment with [COMPANY_004]2636771
Consult with [COMPANY_004] Medical Monitor
If serum calcium improves to Grade 1 WNL or serum phosphate improves 
to asymptomatic Grade 2 or baseline, whichever is more improved within 
14 days follo wing dose interruption:
Restart treatment with [COMPANY_004]2636771 with dose reduced by [CONTACT_37387]
Repeat serum calcium or phosphate level per Time and Events Tables 
(Section 8.1) or more frequently if clinically indicated
If decreased serum calcium or phosphat e levels reoccurs after one dose 
reduction :
Repeat serum calcium or phosphate levels within 24 hrs to confirm 
result
If repeat serum calcium or phosphate levels confirm decrease, 
withdraw subject from treatment/study unless there is agreement 
between inve stigator and [COMPANY_004] Medical Monitor that subject will 
benefit from continued treatment following recovery of serum 
calcium or phosphate to baseline with dose of [COMPANY_004]2636771 
further reduced one dose level.
If repeat serum calcium or phosphate fails to confirm a decrease, c ontinue 
treatment with [COMPANY_004]2636771 at same dose level without interruption
Section 8.1 –Time and Events Tables
Rationale for Changes: 
Visit window clarifications at Week 1, Day  1and Week 12 to clarify  that assessments are 
to occur onl y after that visit timeframe has passed; updates to laboratory  assessments 
section including additional footnotes 33, 34 and 35 ; update to footnotes 12 and 15. 
2013N172718_04 CONFIDENTIA L
200331
240Previous text: 
Table 15 Time and Events Table for Dose Escalation Phase
Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window 1 
day1 
day1
day1
day1
day3 days
for each visit+1
day-2/+7 
days14 
days3 
days
Clinical Assessments
Informed Consent X3 X4
Demographics X
Medical History X
Determination of 
PTEN Deficiency 
StatusM5
Safety Assessments
ECO G PS X X X X X Week 8 and then 
Q8wksX X X
Physical Exam X X Week 8 and then 
Q8wksX X
Height8 X
Weight X X Week 8 and then 
Q8wksX X
Vital Signs9 X X X X X X X X X
12-Lead ECG10 X6 X Week 8 and then 
Q8wksX X
ECHO/MUGA X6,7 As clinically indicated
AE Monitoring Continuous X11 X11
2013N172718_04 CONFIDENTIA L
200331
241Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window 1 
day1 
day1
day1
day1
day3 days
for each visit+1
day-2/+7 
days14 
days3 
days
Concomitant 
MedicationsX Continuous X
Laboratory Assessments12
Hematology/
Clinical ChemistryX6 X X X X X X X X
Coagulation: 
PT, PTT, INRX6 X X
Liver Function 
TestsX6 X X X X X X X X
Urinalysis13
Urine Microscopy13
UPC14X6 X X X X X
Urine Electrolytes15 X6 X X X Week 8 and then 
Q8wksX
Parathyroid 
HormoneX As clinically indicated16
Laboratory Assess ments continued
PSA and LDH32 X6 X X X X X
Serum 
TestosteroneX6 X X
PK Assessments
PK Blood 
Sampling17X X Weeks 8 and 12
Disease Assessments18
2013N172718_04 CONFIDENTIA L
200331
242Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window 1 
day1 
day1
day1
day1
day3 days
for each visit+1
day-2/+7 
days14 
days[ADDRESS_368014] Scan or MRI19 X6,7 Week 8 and then 
Q8wks to Week 
48; then Q12 wksX X
Chest X -Ray or 
Chest CT ScanX6,7
Bone Scan20 X6,7 Week 12 and 
then Q12wksX X
Biomarker Assessments
CTC –-Janssen21 X X X Weeks 8, 16, 24, 
and 32X
CTC –EPIC22 X Week 8 only X
Biomarker Assessme nts continued
Predictive 
Biomarker: Tumor 
Tissue23X
Progression Tumor 
yBiopsy24X
Tumor Biopsies for 
Pharmaco -
dynamics24X X24
cfDNA/RNA/Soluble 
Markers25X X X Weeks 8, 16, 24, 
and 32X
Blood Sample f or 
Genetic Research26X
2013N172718_04 CONFIDENTIA L
200331
243Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window 1 
day1 
day1
day1
day1
day3 days
for each visit+1
day-2/+7 
days14 
days3 
days
Study Treatments27
Enzalutamide Continuous Continuous
[COMPANY_004]2636771 Continuous
12. Laboratory Assessments: Refer to Section 8.6.[ADDRESS_368015] of specific laboratory tests to be performed.  Assessments may b e performed within 24 hrs prior to scheduled visit 
(liver function tests and urine tests for UPC may be performed up to 72 hrs prior to a scheduled visit) to ensure availabilit y of results.
15. Urine Electrolytes:   Urine samples will be obtained at Screeni ng, pre -dose on Day 1 (Week 1), Day 15 (Week 3), Day 22 (Week 4) of the Combination Treatment Period, 
Week 8 and then every 8 weeks ( 3 days) thereafter during the Treatment Continuation Period, and at the post -treatment follow -up visit to determine urine electrolytes 
(magnesium, phosphorus and calcium) and urine creatinine.
2013N172718_04 CONFIDENTIA L
200331
244Revised text: 
Table 15 Time and Events Table for Dose Escalation Phase
Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Repo rting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window +1 
day1 
day1
day1
day1
day+5 days Week 
12 only; 3 days
for al lother 
visits
for each visit+1
day-2/+7 
days14
days3 
days
Clinical Assessments
Informed Consent X3 X4
Demographics X
Medical History X
Determination of 
PTEN Deficiency 
StatusM5
Safety Assessments
ECOG PS X X X X X Week 8 and then 
Q8wksX X X
Physical Exam X X Week 8 and then 
Q8wksX X
Height8 X
Weight X X Week 8 and then 
Q8wksX X
Vital Signs9 X X X X X X X X X
12-Lead ECG10 X6 X Week 8 and then X X
2013N172718_04 CONFIDENTIA L
200331
245Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Repo rting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window +1 
day1 
day1
day1
day1
day+5 days Week 
12 only; 3 days
for al lother 
visits
for each visit+1
day-2/+7 
days14
days3 
days
Q8wks
ECHO/MUGA X6,7 As clinicall y indicated
AE Monitoring Continuous X11 X11
Concomitant 
MedicationsX Continuous X
Laboratory Assessments12    
Hematology/
Clinical ChemistryX6 X33 X X X X X X X
Ionized Calcium X6 X X X X X X X X
Vitamin D34 X6 X X X
Coagulation: 
PT, PTT, INRX6 X X
Liver Function 
TestsX6 X X X X X X X X
Urinalysis13
Urine Microscopy13
UPC14X6 X X X X X
Urine Electrolytes15 X6 X33 X X X Week 8 and then 
Q8wksX
Parathyroid 
HormoneX As cli nically indicated16
2013N172718_04 CONFIDENTIA L
200331
246Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Repo rting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window +1 
day1 
day1
day1
day1
day+5 days Week 
12 only; 3 days
for al lother 
visits
for each visit+1
day-2/+7 
days14
days[ADDRESS_368016] Scan or MRI19 X6,7 Week 8 and then 
Q8wks to Week 
48; then Q12wksX X
Chest X -Ray or 
Chest CT ScanX6,7
Bone Scan20 X6,7 Week 12 and 
then Q12wksX X
Biomarker Assessments
CTC –-Janssen21 X X X Weeks 8, 16, 24, 
and 32X
CTC –EPIC22 X Week 8 only X
2013N172718_04 CONFIDENTIA L
200331
247Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Repo rting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window +1 
day1 
day1
day1
day1
day+5 days Week 
12 only; 3 days
for al lother 
visits
for each visit+1
day-2/+7 
days14
days3 
days
Biomarker Assessments continued
Predictive 
Biomarker: Tumor 
Tissue23X
Progression Tumor 
Biopsy24X
Tumor Biopsies for 
Pharmaco -
dynamics24X X24
cfDNA/RNA/Soluble 
Markers25X X X Weeks 8, 16, 24, 
and 32X
Blood Sample for 
Genetic Research26X
Study Treatments27
Enzalutamide Continuous Continuous
[COMPANY_004]2636771 Continuous
12. Laboratory Assessments: Refe r to Section 8.6.6 8.6.5 (Table 17 ) for list of specific laboratory tests to be performed.  Assessments may be performed within 24 hrs prior to 
scheduled visit (liver function tests and urine tests for UPC may be performed up to 72 hrs prior to a scheduled visit) to ensure availability of results.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].Urine Electrolytes:   Urine samples will be obtained at Screening, pre -dose on Day 1 (Week 1), Day 3 OR Day 4, Day 15 (Week 3), Day 22 (Week 4) of the Combination 
Treatment Period, Week 8 and then every 8 weeks ( 3 days) thereafter during the Treatment Continuation Period, and at the post -treatment follow -up visit to determine urine 
electrolytes (magnesium, phosphorus and calcium) and urine creatinine.
33.Complete clinical chemistries laboratory assessments at We ek1/Day 1 and again on either Day 3 or Day 4.  The Day 3 or Day 4 assessments can be completed at a 
local laboratory and does not require a clinic visit.  The hematology panel does NOT need to be collected on Day 3/ Day 4. Re view of these labs must occur b efore 
Week 2, Day 1 visit. 
34.Includes assessments for 25-OH D and 1,25 -OH2 D . 
35.Includes urine and blood and/or serum samples.  Must be collected at the same time of day ( 1 hour) to eliminate diurnal effects, and after fasting.  See SRM for 
additional details on the specific assessments and sample collection.  
Previous text: 
Table 16 Time and Events Table for Dose Expansion Phase
Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Perio d)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 1 to Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window 1 
day1 
day1
day1
day1
day3 days
for each visit+1
day-2/+7 
days14 
days3 
days
Clinical Assessments
Informed Consen t X3 X4
Demographics X
Medical History X
Determination of 
PTEN Deficiency 
StatusM5
Safety Assessments
ECOG PS X X X X X Week 8 and 
then Q8wksX X X
2013N172718_04 CONFIDENTIA L
200331
249Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Perio d)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 1 to Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window 1 
day1 
day1
day1
day1
day3 days
for each visit+1
day-2/+7 
days14 
days3 
days
Physical Exam X X Week 8 and 
then Q8wksX X
Height8 X
Weight X X Week 8 and 
then Q8wksX X
Vital Signs9 X X X X X X X X X
12-Lead ECG10 X6 X Week 8 and 
then Q8wksX X
ECHO/MUGA X6,7 As clinically indicated
AE Monitoring Continuous X11 X11
Concomitan t 
MedicationsX Continuous X
Laboratory Assessments12
Hematology/
Clinical ChemistryX6 X X X X X X X X
Coagulation: 
PT, PTT, INRX6 X X
Liver Function 
TestsX6 X X X X X X X X
Urinalysis13
Urine Microscopy13
UPC14X6 X X X X X
Urine Electrolytes15 X6 X X X Week 8 and 
then Q8wksX
2013N172718_04 CONFIDENTIA L
200331
250Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Perio d)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 1 to Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window 1 
day1 
day1
day1
day1
day3 days
for each visit+1
day-2/+7 
days14 
days[ADDRESS_368017] Scan or MRI19 X6,7 Week 8 and 
then Q8wks to 
Week 48; then 
Q12wksX X
Chest X -Ray or 
Chest CT ScanX6,7
Bone Scan20 X6,7 Week 12 and 
then Q12wksX X
Biomarker Assessments
CTC –-Janssen21 X X X Weeks 8, 16, 
24, and 32X
CTC –EPIC22 X Week 8 only X
Biomarker Assessments continued
Predictive X
2013N172718_04 CONFIDENTIA L
200331
251Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Perio d)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 1 to Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window 1 
day1 
day1
day1
day1
day3 days
for each visit+1
day-2/+7 
days14 
days3 
days
Biomarker: Tumor 
Tissue23
Progression Tumor 
yBiopsy24X
Tumor Biopsies for 
Pharmaco -
dynamics24X (Day 14) X24
cfDNA/RNA/Soluble 
Markers25X X X Weeks 8, 16, 
24, and 32X
Blood Sample for 
Genetic Research26X
Study Treatments27
Enzalutamide Continuous Continuous
[COMPANY_004]2636771 Continuous
12.Laboratory Assessments: Refer to Section 8.6.[ADDRESS_368018] of specific laboratory tests to be performed.  Assessments may be performed within 24 hrs prior to scheduled visit 
(liver function tests and urine tests for UPC may be performed up t o 72 hrs prior to a scheduled visit) to ensure availability of results.
15.Urine Electrolytes:   Urine samples will be obtained at Screening, pre -dose on Day 1 (Week 1), Day 15 (Week 3), Day 22 (Week 4) of the Combination Treatment Period, 
Week 8 and then e very 8 weeks ( 3 days) thereafter during the Treatment Continuation Period, and at the post -treatment follow -up visit to determine urine electrolytes 
(magnesium, phosphorus and calcium) and urine creatinine.
2013N172718_04 CONFIDENTIA L
200331
252Revised text: 
Table 16 Time and Events Table f or Dose Expansion Phase
Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window +1 
day1 
day1
day1
day1
day+5 days Week 
12 only; 3 days
for all other 
visits
for each visit+1
day-2/+7 
days14 
days3 
days
Clinical Assessments
Informed Consent X3 X4
Demographics X
Medical History X
Determination of 
PTEN Deficiency 
StatusM5
Safety Assessments
ECOG PS X X X X X Week 8 and then 
Q8wksX X X
Physical Exam X X Week 8 and then 
Q8wksX X
Height8 X
Weight X X Week 8 and then 
Q8wksX X
Vital Signs9 X X X X X X X X X
12-Lead ECG10 X6 X Week 8 and then X X
2013N172718_04 CONFIDENTIA L
200331
253Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window +1 
day1 
day1
day1
day1
day+5 days Week 
12 only; 3 days
for all other 
visits
for each visit+1
day-2/+7 
days14 
days3 
days
Q8wks
ECHO/MUGA X6,7 As clinically indicated
AE Monitoring Continuous X11 X11
Concomitant 
MedicationsX Continuous X
Laboratory Assessment s12    
Hematology/
Clinical ChemistryX6 X33 X X X X X X X
Ionized Calcium X6 X X X X X X X X
Vitamin D34 X6 X X X
Coagulation: 
PT, PTT, INRX6 X X
Liver Function 
TestsX6 X X X X X X X X
Urinalysis13
Urine Micr oscopy13
UPC14X6 X X X X X
Urine Electrolytes15 X6 X33 X X X Week 8 and then 
Q8wksX
Parathyroid 
HormoneX X As clinically indicated16 X
2013N172718_04 CONFIDENTIA L
200331
254Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window +1 
day1 
day1
day1
day1
day+5 days Week 
12 only; 3 days
for all other 
visits
for each visit+1
day-2/+7 
days14 
days[ADDRESS_368019] Scan or MRI19 X6,7 Week 8 and then 
Q8wks to Week 
48; then Q12wksX X
Chest X -Ray or 
Chest CT ScanX6,7
Bone Scan20 X6,7 Week 12 and 
then Q12wksX X
Biomarker Assessments
CTC –-Janssen21 X X X Weeks 8, 16, 24, 
and 32X
CTC –EPIC22 X Week 8 only X
2013N172718_04 CONFIDENTIA L
200331
255Study 
Assessments1,2
Pre-Screening
ScreeningEnzalutamide 
Run-In 
PeriodCombination Treatment Period 
(DLT Reporting Period)Treatment Continuation 
Period
Time of Discontinuation of 
Treatment due to Disease 
Progression31
Post-Treatment
Follow-Up Visit28Extended
Follow -
Up  
Visits29Post -
Extended 
Follow -
Up
/EOS 
Visit30Day 
-14 
to
Day 
-1Day 
1 to
Day 
13Day 
14Wk 
1, 
Day 
1Wk 2, 
Day 8Wk 3, 
Day 15Wk 4, Day 
22Wk 5, Day 
29Week 8 and 
every 4 weeks 
thereafterEvery 3 
months
Visit Window +1 
day1 
day1
day1
day1
day+5 days Week 
12 only; 3 days
for all other 
visits
for each visit+1
day-2/+7 
days14 
days3 
days
Biomarker Assessments continued
Predictive 
Biomarker: Tumor 
Tissue23X
Progression Tumor 
Biopsy24X
Tumor Biopsies for 
Pharmaco -
dynamics24X X24
cfDNA/RNA/Soluble 
Markers25X X X Weeks 8, 16, 24, 
and 32X
Blood Sample for 
Genetic Research26X
Study Treatments27
Enzalutamide Continuous Continuous
[COMPANY_004]2636771 Continuous
12.Laboratory Assessments: Refer to Section 8.6.6 8.6.5 (Table 17) for list of specific laboratory tests to be performed.  Assessments may be performed within 24 hrs prior to 
scheduled visit (liver function tests and urine tests for UPC may be performed up to 72 hrs prior to a scheduled visit) to en sure availability of results.
2013N172718_04 CONFIDENTIA L
200331
[ZIP_CODE].Urine Electrolytes:   Urine samples will be obtained at Screening, pre -dose on Day 1 (Week 1), Day 3 OR Day 4, Day 15 (Week 3), Day 22 (Week 4) of the Combination 
Treatment Period, Week 8 and then every 8 weeks ( 3 days) thereafter during the Treatment Continuation Period, and at the post -treatment follow -up visit to determine ur ine 
electrolytes (magnesium, phosphorus and calcium) and urine creatinine.
33.Complete clinical chemistries laboratory assessments at Week1/Day 1 and again on either Day 3 or Day 4.  The Day 3 or Day 4 a ssessments can be completed at a 
local laboratory and does not require a clinic visit.  The hematology panel does NOT need to be collected on Day 3/ Day 4. Review of these labs mu st occur before 
Week 2, Day 1 visit. 
34.Includes assessments for 25-OH D and 1,25 -OH2 D . 
35.Includes urine and blood and/or seru m samples.  Must be collected at the same time of day ( 1 hour) to eliminate diurnal effects, and after fasting.  See SRM for 
additional details on the specific assessments and sample collection.  
2013N172718_04 CONFIDENTIA L
200331
257Section 8.6.6. –Laboratory Assessments
Rationale for Ch ange: 
Addition to Table of Laboratory  Assessments of the new tests added to Other tests 
section of this amendment. 
Previous text: 
Other tests
PSA 
Serum Testosterone
Coagulation Tests: PT/PTT/INR
Serum Parathyroid Hormone (PTH)
Revised text:
Other tests
PSA 
Serum Testosterone
Coagulation Tests: PT/PTT/INR
Serum Parathyroid Hormone (PTH)
Ionized Calcium
25-OH D and 1,25 -OH2 D
Bone Markers5
5..Refer to SRM
Section 8.8.2. –Disease Assessment
Rationale for Change: 
Added text to clarify  the im portance of completing these Week 12 assessments at the 
appropriate time after the start of combination treatment. 
Previous text: 
The primary  endpoint is to evaluate the 12 week non -PD rate of oral [COMPANY_004]2636771 + 
enzalutamide according to PCWG2 guidelines (either b y RECI ST 1.1, PSA progression, 
and/or progression in bone).
Revised text: 
The primary  endpoint is to evaluate the 12 week non -PD rate of oral [COMPANY_004]2636771 + 
enzalutamide according to PCWG2 guidelines (either b y RECI ST 1.1, PSA progression, 
and/or p rogression in bone). These assessments at Week [ADDRESS_368020] 12
weeks (+5 day window) after start of combination treatment.
Section [IP_ADDRESS]. –PSA Response per PCWG2 Criteria
Rationale for Change: 
2013N172718_04 CONFIDENTIA L
200331
258Adjusted the rate of PSA to include that PSA de crease can be equal to 50%. 
Previous text:
PSA Response Rate is defined as proportion of subjects with a decrease of >50% in the 
PSA concentration from the baseline PSA value determined at least 12 weeks after start 
of treatment and confirmed after ≥4weeks by  [CONTACT_301223].
Revised text:
PSA Response Rate is defined as proportion of subjects with a decrease of ≥>50% in the 
PSA concentration from the baseline PSA value determined at least 12 weeks after start 
of treatment and confirmed after ≥4weeks b y an additional PSA evaluation.
Section [IP_ADDRESS]. –Radiographic Response per PCWG2 Criteria
Rationale for Change: 
Revisions and additional wording to further clarify the bone progression definition. 
Previous text:
Bone progression [Scher , 2008 ] is defined as the appearance of ≥[ADDRESS_368021] scan that 
indicates the chang e.  Subjects should not be discontinued from study  treatment(s) due to 
the occurrence of bone scan changes in the first 12 weeks of combination treatment that 
do not meet PCWG2 guidelines for progression.
Revised text: 
Bone progression [Scher , 2008] is de fined as the appearance of ≥[ADDRESS_368022]-treatment bone scan (Week 12) wi ll be used as the baseline scan with which all 
future bone scans are compared. The date of progression is the date of the first scan 
that shows a minimum of 2 additional new lesions indicates the change .  Subjects 
should not be discontinued from study  treatment(s) due to the occurrence of bone scan 
changes in the first 12 weeks of combination treatment that do not meet PCWG2 
guidelines for progression.
Section [IP_ADDRESS]. –Disease Progression Endpoint 
Rationale for Change: 
Revisions to clarify  update to PSA progression assessment for inclusion in disease 
progression anal ysis.  
Previous text:
PSA progression according to the PCWG2 criteria (Section [IP_ADDRESS] )
2013N172718_04 CONFIDENTIA L
200331
259Revised text: 
PSA progression according to the PCWG2 criteria (Section [IP_ADDRESS] ) with 
accompanying pro gression by [CONTACT_393] 1.1 or bone scan for subjects with 
measeurable baseline disease OR PSA progression if no measurable baseline 
disease
Section 10.1 –Permitted Medications
Rationale for Change: 
Revised Supportive Care section to allow the use of calcium supplements and Vitamin D 
supplements due to changes to inclusion minimums and management guidelines.
Previous text:
Supportive Care:  Subjects should receive full supportive care during the study , 
including transfusions of blood and blood products, and tr eatment with antibiotics, 
antiemetics, antidiarrheals, and analgesics, and other care as deemed appropriate, and in 
accordance with local institutional guidelines.
Revised text: 
Supportive Care:  Subjects should receive full supportive care during the stu dy, 
including transfusions of blood and blood products, and treatment with antibiotics, 
antiemetics, antidiarrheals, calcium supplements, Vitamin D supplements, and 
analgesics, and other care as deemed appropriate, and in accordance with local 
institutiona l guidelines.
Section 10.2.2. –Potential Drug Interactions with Enzalutamide
Rationale for Change: 
Updated citation in the body  of the text and added the citation in the Reference section. 
Previous text: 
The following information is provided as an init ial reference, however, please refer to the 
approved US FDA prescribing information [ Xtandi , 2013] or the Xtandi Prescribing 
Information for the area where it is approved for the most current DDI information and 
contraindicated medications .
Revised text: 
The following information is provided as an initial reference, however, please refer to the 
approved US FDA prescribing information [ Xtandi , 201 36] or the Xtandi Prescribing 
Information for the area where it is approved for the most current DDI information and 
contraindicated medications .
Section 13.1.2. –Dose Expansion Phase: 
Rationale for Change: 
2013N172718_04 CONFIDENTIA L
200331
260Clarification s to Dose Expansion phase section to clarify  that multiple doses may  be 
examined . 
Previous text: 
For the Dose Expansion Phase, the h ypothesize d non -PD rate is provided in 
Section 13.2.[ADDRESS_368023] that non -PD rate is less than or equal to the null 
hypothesis rate versus the non -PD rate is greater than or equal to the alternative rate is 
being performed using the stoppi[INVESTIGATOR_301141] 13.2.2 .  Descriptive 
statistics will be used to describe the response data at the RP2D dose used in the 
expanded cohort.
Revised text: 
For the Dose Expansion Phase, t The hy pothesized non -PD rate is provided in 
Section 13.2.[ADDRESS_368024] that non -PD rate is less than or equal to the null 
hypothesis rate versus the non -PD rate is greater than or equal to the alternative rate is 
being performed using the stoppi[INVESTIGATOR_301142] 13.2.2 .  Descriptive 
statistics will be used t o describe the response data at the RP2D dose(s)used in the 
expanded cohort (s).
Section 13.2.2.  –Dose Expansion Phase: 
Rationale for Change: 
Clarifications to Dose Expansion phase section to clarify  that multiple doses may  be 
examined. 
Previous text:
An initial dose finding will be used to establish the RP2D for the combination arm.  Once 
the final dose is confirmed, at least 10 subjects will be enrolled at the appropriate RP2D, 
using decision rules defined in Table 3.  The sample size and stoppi[INVESTIGATOR_301143] [ Lee, 2008].
Revised text: 
An initial dose finding will be used to establish the RP2D MTD for the combination arm.  
Once the final dose is confirmed, at least 10 subjects will be enrolled at the appropriate 
dose lev el RP2D , using decision rules defined in Table 3.  The sample size and stoppi[INVESTIGATOR_301144] [ Lee, 2008].
Section 13.3.1 –Analysis Populations
Rationale for Change: 
Revised and added population to clarify  between safet y and c linical activit y populations 
and to define the evaluable population for endpoint analy ses. 
Previous text: 
2013N172718_04 CONFIDENTIA L
200331
261All Treated Population :  The All Treated Population is defined as all subjects who 
receive at least one dose of [COMPANY_004]2636771. This will be the main po pulation for all 
analyses.  
Pharmacokinetic (PK) Population : The PK Population will consist of all subjects from 
the All Treated Population for whom at least one PK sample is obtained and anal yzed.
All Screened Population: The All Screened Population is d efined as all subjects for 
whom pre -screening consent is obtained.
Revised text: 
All Treated Population:   The All Treated Safety Population is defined as all subjects 
who receive at least one dose of [COMPANY_004]2636771 or Enzalutamide . This will be the main 
popul ation for all anal yses.  Safety will be evaluated based on this analysis population.
The All Treated Clinical Activity Population is defined as all subjects who received 
at least one dose of [COMPANY_004]2636771. Clinical activity and evaluation of non -PD rate 
will be based on this analysis population.  This will include subjects from both dose 
escalation and dose expansion 
The All Evaluable Population is defined as all subjects from All Treated Clinical
Activity Population who have at least one post -dose disease assessment and have 
been exposed to study drug for at least [ADDRESS_368025] withdrawn from the study for any reason. Dose Expansion futility analyses will 
be based on this population.
Pharmacokinetic (PK) Population:  The PK Population will consist of all subjects from 
the All Treated Population for whom a PK sample is obtained and anal yzed.
All Screened Population: The All Screened Population is defined as all subjects for 
whom pre -screening consent is obtained.
Section 13 .3.3.2. –Dose Expansion Phase
Rationale for Change: 
Clarification on futility  analy sis timeframe and population for this analy sis. 
Previous text:
After the initial [ADDRESS_368026] enrolled at the RP2D dose, 12 -week non -PD rate will be 
reviewed on an on going basis and the number of responses observed will be compared 
with the stoppi[INVESTIGATOR_301142] 13.2.2 .
Revised text: 
After the initial [ADDRESS_368027] enrolled at the RP2D become evaluable at a dose level 
using a combination of dose escala tion and dose expansion subjects , 12-week non -PD 
2013N172718_04 CONFIDENTIA L
200331
262rate will be reviewed on an ongoing basis and the number of responses observed will be 
compared with the stoppi[INVESTIGATOR_301142] 13.2.2 .
Section [IP_ADDRESS] –Efficacy Analyses
Rationale for Change: 
Updated of population to be used for anal yses; added and revised secondary  analy ses.
Previous text: 
TheAll Treated Population will be used for the analy sis of efficacy  data.  Efficacy  
analyses will be provided separately  for each cohort.
Primary Analyse s
The primary  anal ysis is to determine whether the 12 -week non PD rate is greater than or 
equal to 5%.  The 12 -week non PD rate is defined as the percentage of subjects without 
progression at Week 12. Subjects with unknown or missing response will not be t reated 
as not having PD (i.e., subjects with NE will be included in the denominator when 
calculating the percentage of non -PD). Non -PD rate will be provided along with 
corresponding exact 95% CI s.
Secondary Analyses
PSA and RECI ST response data will be rep orted.  Subjects with unknown or missing 
response data, including those who withdraw from the study  without an assessment, will 
be treated as non -responders (i.e., they  will be included in the denominator when 
calculating the percentage). No imputation wil l be performed for missing lesion 
assessment or tumor response data.  An exact 95% CI  will be computed for the PSA and 
RECI ST response rate.
Revised text: 
TheAll Treated Clinical Activity Population will be used for the anal ysis of efficacy  
data, and wil l be summarized separately for each dose level combining data from 
both dose escalation and does expan sion.  Efficacy analyses will be provided separatel y 
for each dose level cohort .
Primary Analyses
The primary  anal ysis is to determine whether the 12 -week non PD rate is greater than or 
equal to 5%.  The [ADDRESS_368028] 1.1 or bone scan 
when baseline disease present or PSA progression solely if no other baseline disease.
Subjects with unknown or missing response will not be treated as not having PD (i.e., 
subjects with NE will be included in the denominator when cal culating the percentage of 
non-PD). Non -PD rate will be provided along with corresponding exact 95% CI s.
Secondary Analyses
2013N172718_04 CONFIDENTIA L
[ADDRESS_368029] 1.1response data will be reported.  Subjects with unknown or missing 
response data, including those who withdraw fro m the study  without an assessment, will 
be treated as non -responders (i.e., they  will be included in the denominator when 
calculating the percentage). No imputation will be performed for missing lesion 
assessment or tumor response data.  An exact 95% CI  will be computed for the PSA [ADDRESS_368030] 1.1 confirmed response rate.
New text: 
PSA Response Rate
PSA Response rate (RR) is defined as proportion of subjects with a decrease of 
50% in the PSA concentration from the baseline PSA value determi ned at least 12 
weeks after start of treatment and confirmed after ≥4weeks by [CONTACT_301224] 95% confidence 
interval. Waterfall plots will be presented that show the maximum percentage of 
change in PSA reduction f rom baseline.
Objective Response Rate
The objective response (ORR) rate is defined as the percentage of subjects with a 
confirmed complete response (CR) or a partial response (PR) at any time as per 
PCWG3 -modified RECIST 1.1 (Appendix 5). Subjects with unk nown or missing 
response will be treated as non -responders, i.e. these subjects will be included in the 
denominator when calculating the percentage. The number and types of responses, 
as outlined in PCWG3 -modified RECIST 1.1, will be listed and summarized 
separately, as appropriate. The observed ORR, observed confirmed and 
unconfirmed ORR will be reported at the interim and final analysis for each cohort 
specified in treated dose, if data warrant. The estimates along with 95% exact 
confidence interval (CI) will be provided.
Radiographic Progression -free survival (rPFS) will be defined as the time from 
combination study treatment start until the first date of either disease progression 
or death due to any cause. The date of disease progression will be defined as the 
earliest date of disease progression as assessed by [CONTACT_301225] 1.[ADDRESS_368031] adequate disease assessment (e.g. assessment where 
visit le vel response is CR, PR, or stable disease [SD]) prior to the extended loss to 
follow -up or start of new anti -cancer therapy, respectively. Further details on rules 
for censoring will be provided in the RAP. rPFS will be summarized by [CONTACT_301226] i n expansion cohort using Kaplan -Meier quantile estimates along with 2 -
sided 95% CIs 
Time to PSA progression 
If there has been a decline from baseline : time from start of combination 
treatment to first PSA increase that is 25% and 2  ng/mL in absolute v alue 
from the nadir, and which is confirmed by a second value 3 or more weeks later 
(i.e., a confirmed rising trend) at least 12 weeks after the start of treatment.
2013N172718_04 CONFIDENTIA L
200331
264If there has NOT been a decline from baseline : time from start of therapy to first
PSA incr ease that is 25% and 2  ng/mL in absolute value from the baseline 
value, determined at least [ADDRESS_368032] 1.1 and/ or 
confirmed bone progression as defined in Section [IP_ADDRESS] .  Time to radiological 
progression will be summarised using Kaplan -Meier meth ods by [CONTACT_15994].
Section [IP_ADDRESS] –Safety Analyses
Rationale for Change: 
Clarification of the population used for safet y analyses.
Previous text:
TheAll Treated Population will be used for the analy sis of safet y data. All serially 
collected safet y end points (e.g., laboratory  tests, vital signs, ECGs) will be summarized 
according to the scheduled, nominal visit at which they  were collected and across all on -
treatment time points using a “worst -case” analy sis.Complete details of the safet y 
analyses will be provided in the RAP.
Revised text: 
TheAll Treated Safety Population will be used for the anal ysis of safet y data. All serially 
collected safet y endpoints (e.g., laboratory  tests, vital signs, ECGs) will be summarized 
according to the scheduled, nomin al visit at which they  were collected and across all on -
treatment time points using a “worst -case” analy sis.Complete details of the safet y 
analyses will be provided in the RAP . 
2013N172718_04 CONFIDENTIA L
[ADDRESS_368033] inadvertent 
errors in previous versions of the protocol:
Title Page: 
Updated author list to include new authors:  and 
and remove . 
Table of Contents: 
Revision to Table of Contents to reflect changes to Section [ADDRESS_368034] of Abbreviations: 
Addition of new abbreviations to table: ORR – Objective Response Rate, PSA50 –
Prostate -specific antigen decrease from baseline ≥50%, rPFS –Radi ological progression 
free survival, and RR –Response rate
Protocol Synopsis and Section 3:
In multiple locations, revised an error in the abbreviation for PCWG2 guidelines, which 
was previousl y 2PCWG2 to PCWG2. 
Section 4.1.1. – Number of Subjects: 
Updat ed link for Section related to futility from 3.6.1 to 3.7.1.
Section 13.2.2 – Dose Expansion Phase: 
Updated link for Section related to futility  from 3.6.1 to 3.7.1.
Section 15 – References: 
Updated date of most recent prescribing information reference f or Xtandi (enzalutamide).
Appendix 9 – Protocol Amendment Changes:
For each Amendment, updated the section to provide heading numbers and dates of all 
protocol amendments. 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]